CLINICAL INVESTIGATION PROGRAM

30 September 1990

DEPARTMENT OF CLINICAL INVESTIGATION

Fitzsimons Army Medical Center
Aurora, Colorado 80045-5001
**Report Documentation Page**

1. **Report Number**
   - 26

2. **GOVT Accession No.**
   - 

3. **Recipient's Catalog No.**
   - 

4. **Title (and Subtitle)**
   - Annual Research Progress Report (U)

5. **Type of Report & Period Covered**
   - Annual FY 90

6. **Performing Org. Report Number**
   - 

7. **Author(s)**
   - SHANNON M. HARRISON, LTC, MC

8. **Contract or Grant Number(s)**
   - 

9. **Performing Organization Name and Address**
   - Department of Clinical Investigation
   - Fitzsimons Army Medical Center
   - Aurora, Colorado 80045-5001

10. **Controlling Office Name and Address**
    - Office of Deputy Commander (HSHG-ZB)

11. **Report Date**
    - 30 September 1990

12. **Number of Pages**
    - 

13. **Security Class. (of this Report)**
    - Unclassified

14. **Distribution Statement (of report)**
    - Approved for public release, distribution unlimited

15. **Distribution Statement (of the abstract entered in Block 20, if different from report)**
    - NA

16. **Supplementary Notes**
    - The findings in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

17. **Key Words**
    - Unit summary; research protocols (objective, technical approach, progress); publications; presentations.

18. **Abstract**
    - Subject report identifies these individuals who are conducting investigative protocols at Fitzsimons Army Medical Center. An abstract of each protocol giving abbreviated technical approach, objectives, and progress is presented.
REPORTS CONTROL SYMBOL MED-300

ANNUAL PROGRESS REPORT

30 SEPTEMBER 1990

DEPARTMENT OF CLINICAL INVESTIGATION
FITZSIMONS ARMY MEDICAL CENTER
AURORA, COLORADO 80045-5001

THE FINDINGS IN THIS REPORT ARE NOT TO BE CONSTRUED AS AN OFFICIAL DEPARTMENT OF THE ARMY POSITION UNLESS SO DESIGNATED BY OTHER AUTHORIZED DOCUMENTS.

DESTROY THIS REPORT WHEN NO LONGER NEEDED.
DO NOT RETURN IT TO THE ORIGINATOR.

APPROVED FOR PUBLIC RELEASE

DISTRIBUTION UNLIMITED

(b)
This report identifies the research activities conducted by Fitzsimons Army Medical Center investigators through protocols approved by the Institutional Review Committee and registered with the Department of Clinical Investigation during Fiscal Year 1990 along with other known presentations and publications by FAMC professional staff.

The research protocols described in this report were conducted under the provisions of AR 40-38, Clinical Investigation Program, AR 40-7, Use of Investigational Drugs in Humans, AR 40-23, as amended, Management of Clinical Investigation Protocols and Reports, to insure the medical safety, well being, preservation of rights and dignity of human subjects who participated in these investigations. In conducting the research described in this report, the investigator(s) adhered to AR 70-18, Laboratory Animals, Procurement, Transportation, Use, Care, and Public Affairs and the "Guide for Laboratory Animal Facilities and Care", as promulgated by the Committee or the Guide for Laboratory Animal Resources, National Academy of Sciences, National Research Council.

The Department of Clinical Investigation is grateful to the Center's Commander, BG Thomas E. Bowen and all of the professional and administrative staff for departments and directorates who have furthered the mission of Clinical Investigation Department at Fitzsimons through their cooperation and extra effort as reflected in this report. I should like to particularly recognize the outstanding work and dedication and wholehearted corroboration of all of the Services' within Clinical Investigation Department, the Deputy Chief, LTC Leo A. Andron, the Research Protocol Specialist, Ms. Marcia Bilak, and Ms. Chris Montoya, Secretary, without whose assistance and support beyond the call of duty this year's progress and its report would not have been possible.

SHANNON M. HARRISON  
LTC, MC  
Chief, Department of  
Clinical Investigation
TABLE OF CONTENTS

REPORT NO. 26

Page

Report Documentation Page .................................. (a)
Reports Control Symbol Med-300 ................................ (b)
Foreword ................................................................ (c)
Table of Contents ................................................ (d-bb)
Unit Summary + HMLAC Report + Service Report .......... i-ix
Publications FY 90 ............................................. 1-14
Presentations FY 90 ............................................ 15-30
Detail Summary Sheets .......................................... 31-442
Investigator's index ............................................. 443
Key Word Index .................................................. 451
Distribution ...................................................... 459

DEPARTMENT OF MEDICINE

<table>
<thead>
<tr>
<th>No.</th>
<th>Status</th>
<th>Description and Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>80/120</td>
<td>O</td>
<td>Evaluation of Carbohydrate Metabolism in Thyrotoxicosis: Investigations into the Frequency, Type and Mechanisms of Carbohydrate Tolerance ................................................. 32</td>
</tr>
<tr>
<td>81/117</td>
<td>O</td>
<td>The Role of Calcitonin in Osteoporosis (PR)(P) ................................................. 34</td>
</tr>
<tr>
<td>81/118</td>
<td>O</td>
<td>Hypothalamic Pituitary Gonadal Function in Hypothyroidism ................................................. 36</td>
</tr>
<tr>
<td>81/119</td>
<td>C</td>
<td>The Effect of Thyrotropin Releasing Hormone on Gonadotropin Releasing Hormone Stimulated Gonadotropin Secretion (P) ................................................. 37</td>
</tr>
<tr>
<td>82/114A</td>
<td>T</td>
<td>Growth of Basal Cell Carcinoma Cells in Defined Medium and Study of their Growth and Immunological Characteristics ................................................. 39</td>
</tr>
<tr>
<td>83/107</td>
<td>O</td>
<td>Use of Isotretinoin in Prevention of Basal Cell Carcinoma (PR)(P) ................................................. 40</td>
</tr>
<tr>
<td>83/113A</td>
<td>O</td>
<td>Growth of Human Keratinocyte (P) ................................................. 42</td>
</tr>
<tr>
<td>83/122</td>
<td>O</td>
<td>The Role of Food Allergy in the Pathogenesis of Migraine Headaches (PR)(P) ................................................. 44</td>
</tr>
<tr>
<td>83/126</td>
<td>O</td>
<td>The Role of Altered Prostaglandin Synthesis in the Impaired Water Excretion and Abnormal Renin-Aldosterone Axis of Hypothyroidism .... 46</td>
</tr>
<tr>
<td>84/100</td>
<td>O</td>
<td>The Effect of Abnormal Thyroid States on the Metabolism of Theophylline and Methylprednisolone (PR) ................................................. 48</td>
</tr>
<tr>
<td>84/115A</td>
<td>C</td>
<td>Heterotransplantation of Basal cell Carcinomas to Nude Mice (P)(PR) ................................................. 50</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).

(d)
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>84/119 O Treatment of Graves' Ophthalmopathy with Cyclosporin</td>
</tr>
<tr>
<td>85/100 O SWOG #7804 - Adjuvant Chemotherapy with 5-Fluorouracil, Adriamycin and Mitomycin-C (FAM) vs. Surgery Alone for Patients with Locally Advanced Gastric Adenocarcinoma, Phase III</td>
</tr>
<tr>
<td>85/102 C SWOG 7827 - Combined Modality Therapy for Breast Carcinoma, Phase III</td>
</tr>
<tr>
<td>85/122 C SWOG 8221 - Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy vs. Radical Cystectomy Alone, Phase III</td>
</tr>
<tr>
<td>85/132 C SWOG #8294 - Evaluation of Adjuvant Therapy and Biological Parameters in Node Negative Operable Female Breast Cancer, Intergroup Study</td>
</tr>
<tr>
<td>85/133 C SWOG #8300 - Treatment of Limited Non-Small Cell Lung Cancer: Radiation Versus Radiation Plus Chemotherap (FOMi/CAP), Phase III</td>
</tr>
<tr>
<td>85/136 C SWOG #8313 - Multiple Drug Adjuvant Chemotherapy for Patients with ER Negative Stage II Carcinoma of the Breast, Phase III</td>
</tr>
<tr>
<td>85/139 O SWOG 8393 - National Intergroup Protocol for Intermediate Thickness Melanoma 1.0-4.0 mm. Evaluation of Optimal Surgical Margins (2 vs 4cm) Around the Melanoma and Evaluation of Elective Regional Lymph Node Dissection</td>
</tr>
<tr>
<td>85/141 C SWOG 8411 - Evaluation of DTIC in Metastatic Carcinoid, Phase II</td>
</tr>
<tr>
<td>85/142 C SWOG 8415 - Evaluation of Tamoxifen in Unresectable and Refractory Meningiomas, Phase II</td>
</tr>
<tr>
<td>85/147 C HLA and Gm Genes in Systemic Lupus Erythematosus Antibody Expression</td>
</tr>
<tr>
<td>85/157 C SWOG 8590 - Phase III Study to Determine the Effect of Combining Chemotherapy with Surgery and Radiotherapy for Resectable Squamous Cell Carcinoma of the Head and Neck</td>
</tr>
<tr>
<td>85/158 C SWOG #8591 - NCI Intergroup #0035, An Evaluation of Levamisole Alone or Levamisole Plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon, Phase III-Intergroup</td>
</tr>
<tr>
<td>85/163 C The Effect of Theophylline and Nifedipine on Hormone Secretion</td>
</tr>
<tr>
<td>85/165A O An Evaluation of Cross Allergenicity Among Pollen Extracts of Members of the Chenopodiaceae and Amaranthaceae Pollens and Poll Spores of the Same or Related Botanical Families</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated, (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
85/166  C Colon Inflammation in Reiter's Syndrome: Response to Sulfasalazine. Results in a Controlled Study (P)(PR) ......................... 69
85/167  O The Effect of Age on Thyroid Function Studies: The Perchlorate Discharge Test ...................... 71
85/174  C SWOG #8326/27 - Evaluation of Combination Chemotherapy Using High Dose ARA-C in Adult Acute Leukemia and Chronic Granulocytic Leukemia in Blastic Crisis, Phase III ..................... 72
86/10X  T - Feasibility Study to Determine if Estrogen and Progesterone Affect In-vitro Growth of Cultured Malignant Melanoma (MM) Cell Lines .............. 73
86/103  C SWOG #8592 - Evaluation of Low Dose Ara-C versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (E25G EST 4483) .... 74
86/107A O In-Vitro Drug Sensitivity Utilizing the Guinea Pig Airway Smooth Muscle Model (PR)(P) ............ 75
86/109  O The Effect of INH and Combination INH-Rifampin Therapy on Calcium and Vitamin D Metabolism .... 77
86/114  O Natural History of HTLV-III Infection and Disease in a United States Military Community (PR) .................................. 78
86/118  C SWOG #8507 - Maintenance vs. No Maintenance BCG Immunotherapy of Superficial Bladder Cancer (P-PR) ........................................ 79
86/119  C SWOG #8514 - Randomized Comparison of Cisplatin + 5-Fluorouracil vs. CBDCA + 5+Fluorouracil vs. Methotrexate in Advance Squamous Cell Carcinoma of the Head and Neck, Phase III ...... 80
86/120  O SWOG #8516 - A Phase II Comparison of CHOP versus m-BACOD versus ProMaCE-CytaBOM versus MACOP-B in Patients with Intermediate or High Grade Non-Hodgkins' Lymphoma .......................... 81
86/123  C SWOG #8519 - Phase II Evaluation of Methyl-Glyoxal Bis-Guanylhydrazone (MGBG) in Patients with Advanced Bladder Cancer ...................... 82
86/124  C SWOG #8573 - Treatment of Limited Small Cell Lung Cancer with Concurrent Chemotherapy, Radiotherapy and Intensification with High Dose Cyclophosphamide .............................................. 83
86/126  T LCSG #832 - A Prospective Randomized Trial to Determine the Benefit of Surgical Resection of Residual Disease Following Response of Small Cell Lung Cancer to Combination Chemotherapy ........ 84

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
LCSG #853 - A Clinical Trial in Patients with Stage II and III Completely Resected Non-Small Cancer of the Lung Comparing Chemotherapy vs. no Therapy Following Surgery
The Effect of Theophylline on Calcium and Vitamin D Metabolism (P)(PR)
Anti-Histone Antibody Production in Procainamide Associated Drug-Induced Lupus Erythematosus: Association of Serologic Patterns and Lymphocyte Subsets
Identification of Those at Risk for Osteoporotic Hip Fractures, by an Noninvasive Measurement (P)(PR)
SWOG 8600 - A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-Lymphocytic Leukemia, Phase III
Pre-operative Cimetidine Therapy in Patients Undergoing Parathyroid Exploration: Efficacy and Mechanisms of Action
A Prospective Double Blind Study of Retrovir in Early HIV Infection (PR)(P)
SWOG 8598 -(RTOG-85-01) Prospective Trial for Localize Cancer of the Esophagus: Comparing Radiation as a Single Modality to the Combination of Radiation Therapy and Chemotherapy, Phase III Intergroup
SWOG 8624 - A Phase II Randomized Trial of Combination Therapy for Multiple Myeloma: Comparison of (1) VMCP/VBAP to VAD or VMCPP/VBAPP for Induction, (2) Alpha-2b Interferon or No Therapy for Maintenance; and (3) Alpha -2b Interferon + Dexamethasone for Incomplete or No Responders
Patient Evaluation of Physicians' Humanistic Qualities (P)(PR)
A Double-Blind, Multicenter, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of HA-1A Human Monoclonal Antibody in Patients with Gram-Negative Sepsis
Effect of Iodine Containing Water Purification Tablets on Thyroid Function in Man (PR) Analysis of von Willebrand Factor Multimers Before and After Cardiopulmonary Bypass

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Code</th>
<th>Type</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>88/101</td>
<td>T</td>
<td>LCSG 871 Centralized Non-Small Cell Lung Cancer Specimen Repository and DNA/RNA Bank</td>
</tr>
<tr>
<td>88/102</td>
<td>C</td>
<td>Effect of Chronic Coumadin Therapy on Cortical and Trabecular Bone Density in Man</td>
</tr>
<tr>
<td>88/103</td>
<td>C</td>
<td>Clinical Efficacy of Phenindamine as Determined by Skin Test Suppression</td>
</tr>
<tr>
<td>88/104</td>
<td>O</td>
<td>Descriptive Study of Pastoral Care Interventions Designed to Assist HIV+/AIDS Patients in Achieving Their Maximum Quality of Life (P) (PR)</td>
</tr>
<tr>
<td>88/106</td>
<td>C</td>
<td>Use of Nifedipine (Gastrointestinal Therapeutic System) in the Treatment of Hypertension (PR)</td>
</tr>
<tr>
<td>88/109</td>
<td>O</td>
<td>Methotrexate in the Treatment of Steroid Dependent Asthmatics (PR)</td>
</tr>
<tr>
<td>88/110A</td>
<td>O</td>
<td>Biological Investigation of Cutaneous Lupus Employing Athymic Mice as Skin Heterotransplant Recipients</td>
</tr>
<tr>
<td>88/111</td>
<td>C</td>
<td>The Use of Fibrin Monomer and D-Dimer in the Evaluation of Patients with Chest Pain (PR)</td>
</tr>
<tr>
<td>88/112</td>
<td>C</td>
<td>Long-Term 5-Fluorouracil Infusion for Recurrent Head and Neck Cancer. A Phase II Pilot Study</td>
</tr>
<tr>
<td>88/113</td>
<td>O</td>
<td>Methotrexate vs D-Penicillamine in Rheumatoid Arthritis: A Randomized Comparative Study</td>
</tr>
<tr>
<td>88/115</td>
<td>O</td>
<td>The Impact of an Ambulatory Care Rotation on Interns' Psychosocial Attitudes</td>
</tr>
<tr>
<td>88/116A</td>
<td>O</td>
<td>Mouse Anti-Chenopod/Amaranth Pollen Monoclonal Antibody Production (PR)</td>
</tr>
<tr>
<td>88/117</td>
<td>C</td>
<td>A Comparison of Amitriptyline vs. Trazodone vs. Placebo as Adjuvant to Opiate Analgesics in the Management of Pain in Cancer Patients</td>
</tr>
<tr>
<td>88/118</td>
<td>C</td>
<td>(CAP Study 12-21-87) Use of Nifedipine (Gastrointestinal Therapeutic System) in the Treatment of Angina Pectoris (PR)</td>
</tr>
<tr>
<td>88/120</td>
<td>O</td>
<td>Ventilatory Effects of Transtracheal Oxygenation</td>
</tr>
<tr>
<td>88/121</td>
<td>O</td>
<td>Bone Density in Thyroid Extract Treated Patients (PR)</td>
</tr>
<tr>
<td>88/122</td>
<td>T</td>
<td>LCSG 881 - A Randomized Phase II Study of Preoperative Therapy for Patients with Technically Unresectable Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td>88/124</td>
<td>O</td>
<td>Corticosteroids in the Treatment of Stable Chronic Obstructive Pulmonary Disease</td>
</tr>
<tr>
<td>89/100</td>
<td>O</td>
<td>The Application of Orem's Self-Care Model in Type II Diabetes: An Outcome Study of Diabetic Self-Care Classes and Self-Care Contracting Comparing Self-Care Knowledge, Health Care Benefits, Weight Loss and Metabolic Control</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>128</td>
<td>Factors Determining Peak Bone Mass and Subsequent Bone Loss</td>
</tr>
<tr>
<td>129</td>
<td>Transient Hypoxia During Sedated Endoscopic Procedures</td>
</tr>
<tr>
<td>130</td>
<td>Efficacy of Corticosteroids in the Acute Treatment of Asthma: Is Duration of Symptoms Important?</td>
</tr>
<tr>
<td>131</td>
<td>Role of Blood Pressure Control in Progression of Diabetic Nephropathy and Other Microangiopathies</td>
</tr>
<tr>
<td>132</td>
<td>Immunologic Criteria for the Cessation of Immunotherapy</td>
</tr>
<tr>
<td>133</td>
<td>A Multicentric Observer-Blind, Randomized Study of the Safety, Efficacy and Tolerance of Cefpirome (HR-810) Versus Ceftazidime in the Treatment of Pneumonia</td>
</tr>
<tr>
<td>134</td>
<td>Efficacy of Pentoxifylline in Treating Diabetic Impotence</td>
</tr>
<tr>
<td>135</td>
<td>The Effect of Percutaneous Endoscopic Gastrostomy Tube Place on Gastric Emptying</td>
</tr>
<tr>
<td>136</td>
<td>Cyclic Oxygen Therapy at Rest and During Exercise</td>
</tr>
<tr>
<td>137</td>
<td>Multicenter Clinical Evaluation of Penicillin Skin Testing Materials</td>
</tr>
<tr>
<td>138</td>
<td>The Use of Megestrol Acetate to Treat Cachexia in Patients with Chronic Obstructive Pulmonary Disease and the Possible Improvement of Pulmonary Function</td>
</tr>
<tr>
<td>139</td>
<td>LCSG NC 3 Natural History Registry for Patients with Stage II Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td>140</td>
<td>Response of Arthritis and Microscopic Colitis to Sulfasalazine in Rheumatoid Arthritis Patients</td>
</tr>
<tr>
<td>141</td>
<td>The Effect of Congestive Heart Failure (CHF) on the Erythrocyte Sedimentation Rate (ESR)</td>
</tr>
<tr>
<td>142</td>
<td>Atrial Natriuretic Peptide (ANP) Levels in Patients With VVI Pacing With and Without Ventriculoatrial (VA) Conduction Versus Dual Chamber Pacing</td>
</tr>
<tr>
<td>143</td>
<td>Evaluation of Thermography in the Delineation of Late Phase Skin Tests (PR)(P)</td>
</tr>
<tr>
<td>144</td>
<td>Bronchoalveolar Lavage in Intubated Patients with the Adult Respiratory Syndrome for the Evaluation of Fat Emulsion Induced Changes in Alveolar Characteristics</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>145</td>
<td>Development of a Cardiopulmonary Resuscitation (CPR) Information Sheet and Assessment of Patient and Staff Exposure</td>
</tr>
<tr>
<td>146</td>
<td>Mediastinal Tamponade Due to Closed Thoracostomy in a Goat</td>
</tr>
<tr>
<td>147</td>
<td>Platelet Thromboxane, Aggregation and Whole Blood Prostacyclin Synthesis in Human Thyroid Disease</td>
</tr>
<tr>
<td>148</td>
<td>Study of the Efficacy of Influenza Vaccine in Chronic Lung Disease - Serologic Response and Disease Prevention</td>
</tr>
<tr>
<td>149</td>
<td>Effect of Prolonged Administration of Iodine Containing Water Purification Tables in Man</td>
</tr>
<tr>
<td>150</td>
<td>The Limulus Amoebocyte Lysate Assay for the Diagnosis of Spontaneous Bacterial Peritonitis in Ascitic Fluid</td>
</tr>
<tr>
<td>151</td>
<td>Group C/Treatment Protocol: Levamisole (NSC 177023) Plus 5-Fluorouracil as an Adjuvant to Surgery for Resectable Adenocarcinoma of the Colon. (NCI Protocol 89-0017)</td>
</tr>
<tr>
<td>152</td>
<td>Incidence and Prevalence of Hematuria in Patients on Long-Term Anticoagulation</td>
</tr>
<tr>
<td>153</td>
<td>Self-Treatment of Anaphylaxis in an Outpatient Population</td>
</tr>
<tr>
<td>154</td>
<td>A Double-Blind, Placebo-Controlled Randomized Trial of the Clinical and Hemodynamic Effects of Vasopressin in Patients with Cirrhosis and Acute Variceal Hemorrhage --- A Multi-Center Study</td>
</tr>
<tr>
<td>155</td>
<td>Comparison of Impedance Plethysmography, Venogram and Doppler Ultrasound in Diagnosing Deep Vein Thrombosis</td>
</tr>
<tr>
<td>156</td>
<td>Altitude Effects on Oxygen Kinetics During Exercise in Acclimatized Fit Troops</td>
</tr>
<tr>
<td>157</td>
<td>Effects of Altered Calcium on BloodPressure</td>
</tr>
<tr>
<td>158</td>
<td>Prevention of Pseudomonas Colonization by Saccharomyces boulardii or Lactobacillus acidophilus in Antibiotic Treated Mice</td>
</tr>
<tr>
<td>159</td>
<td>Laboratory Screening to Detect Biochemical Evidence of Hemochromatosis Among Patients with Non-Insulin Dependent Diabetes Mellitus</td>
</tr>
<tr>
<td>160</td>
<td>Effect of Cold Remedies on Metabolic Control of Noninsulin Dependent Diabetes Mellitus</td>
</tr>
<tr>
<td>161</td>
<td>Assessment of Patient Utilities for Health Outcomes: Influence on Aspirin Prophylaxis to Prevent Myocardial Infarction</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
90/130 O SWOG 8899 A Prospective, Randomized Trial of Low-Dose Leucovorin + 5-FU, High-Dose Leucovorin + 5-FU, Levamisole + 5-FU, or Low-Dose Leucovorin + 5-FU + Levamisole Following Curative Resection in Selected Patients with Dukes' B or C Colon Cancer ........ 177

90/131 O VA Cooperative Study No. 316: Efficacy of Passive Immunization in the Prevention of Infection Due to Klebsiella Penumoniae and Pseudomonas Aeruginosa ......................... 178

90/132 O Prevention and Treatment of Steroid Induced Osteoporosis ........................................... 179

90/133 O The Effect of Terfenadine on Urination ........ 180

90/134 O Fibrinolytic and Thrombotic Activity in Unstable Coronary Disease ...................................... 181

90/135 O Comparison of Liver Biopsy Versus Noninvasive Testing Using Hepatic Ultrasound, Radionuclide Scanning, Erythrocyte Folate Levels and Methotrexate Levels for the Determination of Methotrexate-Induced Hepatotoxicity ............ 182

90/136 O SWOG 8921 A Phase II Trial of Cyclophosphamide/IL-2, DTIC/IL-2 and DTIC/Cisplatin/Tamoxifen in Stage IV Melanoma .................. 183

90/137 O SWOG 8312 Megestrol Acetate and Aminoglutethimide/Hydrocortisone in Sequence or in Combination as Second-Line Endocrine Therapy of Estrogen Receptor Positive Metastatic Breast Cancer, Phase III ........................................... 184

90/138 O SWOG 8520 Cis-Diamminedichloroplatinum (II), Methotrexate and Bleomycin in the Treatment of Advanced Epidermoid Carcinoma of the Penis, Phase II .................................................. 185

90/139 O SWOG 8621 Chemo-Hormonal Therapy of Postmenopausal Receptor-Positive Breast Cancer, Phase III ............................................. 186

90/140 O SWOG 8692 Therapy in Premenopausal Women with Advanced ER Positive or PgR Positive Breast Cancer: Surgical Oophorectomy vs the LH-RH Analog, Zoladex Phase III Intergroup .............. 187

90/141 O SWOG 8711 A Study of Reproductive Function in Patients with Testicular Cancer ...................... 188

90/142 O SWOG 8736 Treatment Treatment of Localized Non-Hodgkin's Lymphoma: Comparison of Chemotherapy (CHOP) to Chemotherapy Plus Radiation Therapy .... 189

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>90/143</td>
</tr>
<tr>
<td>90/144</td>
</tr>
<tr>
<td>90/145</td>
</tr>
<tr>
<td>90/146</td>
</tr>
<tr>
<td>90/147</td>
</tr>
<tr>
<td>90/148</td>
</tr>
<tr>
<td>90/149</td>
</tr>
<tr>
<td>90/150</td>
</tr>
<tr>
<td>90/151</td>
</tr>
<tr>
<td>90/152</td>
</tr>
<tr>
<td>90/153</td>
</tr>
<tr>
<td>90/154</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
90/155  O  SWOG 8810 Six Courses of 5-Fluorouracil and Cisplatinum with Correlation of Clinical and Cellular DNA Parameters in Patients with Advanced, Untreated and Unresectable Squamous Cell Carcinoma of the Head and Neck, Phase II Pilot Study .......................... 202

90/156  O  SWOG 8812 Treatment of Limited Small Cell Lung Cancer with Concurrent Chemotherapy, Radiotherapy, with or without GM-CSF and Subsequent Randomization to Maintenance Interferon or No Maintenance .......................... 203

90/157  O  SWOG 8828 A Phase II Trial of Carboplatin (CBDCA) in Relapsed or Refractory Acute Myeloid Leukemia ........................................ 204

90/158  O  SWOG 8851 A Phase III Comparison of Combination Chemotherapy (CAF) and Chemohormonal Therapy (CAF + Zoladex or CAF + Coladex and Tamoxifen) in Premenopausal Women with Axillary Node-Positive, Receptor-Positive Breast Cancer. 205

90/159  O  SWOG 8892 A Study of Radiotherapy with or without Concurrent Cisplatin in Patients with Nasopharyngeal Cancer, Phase III ............. 206

90/160  O  SWOG 8897 Phase III Comparison of Adjutant Chemotherapy with or without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients and a Natural History Followup Study in Low-Risk, Node Negative Patients .......................... 207

90/161  O  SWOG 8910 Evaluation of Low Dose Continuous 5-Fluorouracil (F-FU) and Weekly Cisplatinum (CDDP) in Advanced Adenocarcinoma of the Stomach, Phase II Pilot ...................................... 208

90/162  O  SWOG 8915 A Phase II Study of 6-Thioguanine Administered as 120 Hour Continuous Infusion for Refractory or Recurrent Small Cell Carcinoma ........................................ 209

90/163  O  SWOG 8916 Evaluation of Merbarone in Pancreatic Adenocarcinoma, Phase II ........................................ 210

90/164  O  SWOG 8952 Treatment of Advanced Hodgkin's Disease - A Randomized Phase III Study Comparing ABVD vs MOPP/ABV Hybrid ..................... 211

90/165  O  SWOG 8997 A Phase III Chemotherapy of Disseminated Advanced Stage Testicular Cancer with Cisplatin Plus Etoposide with Either Bleomycin or Ifosfamide ..................... 212

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>90/166A</td>
</tr>
<tr>
<td>90/167A</td>
</tr>
<tr>
<td>90/168A</td>
</tr>
<tr>
<td>90/169</td>
</tr>
<tr>
<td>90/170</td>
</tr>
<tr>
<td>90/171</td>
</tr>
<tr>
<td>90/172</td>
</tr>
<tr>
<td>90/173</td>
</tr>
<tr>
<td>90/174</td>
</tr>
<tr>
<td>90/175</td>
</tr>
<tr>
<td>90/176</td>
</tr>
<tr>
<td>90/177</td>
</tr>
<tr>
<td>90/178</td>
</tr>
<tr>
<td>90/179</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Project Code</th>
<th>Status</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>78/20X</td>
<td>O</td>
<td>1-Repair of Femoral Artery by Microvascular Technique in Rabbits and Rats</td>
</tr>
<tr>
<td>78/20X</td>
<td>O</td>
<td>2-Repair of Femoral Artery by Microvascular Technique in Rabbits and the Rat</td>
</tr>
<tr>
<td>78/20X</td>
<td>O</td>
<td>3-Microsurgical Training in Free Flap Transfer and Vessel and Nerve Repair Utilizing the Rabbit and Rat</td>
</tr>
<tr>
<td>78/201</td>
<td>O</td>
<td>Clinical Study for Intraocular Lenses, General Leonard Wood Army Community Hospital</td>
</tr>
<tr>
<td>78/201</td>
<td>O</td>
<td>Clinical Study for Intraocular Lenses, Fitzsimons Army Medical Center (PR)</td>
</tr>
<tr>
<td>78/201A</td>
<td>O</td>
<td>Clinical Study for Intraocular Lenses, Munson Army Community Hospital</td>
</tr>
<tr>
<td>78/201C</td>
<td>O</td>
<td>Clinical Study for Intraocular Lenses, Ft. Riley, KS</td>
</tr>
<tr>
<td>78/201D</td>
<td>O</td>
<td>Clinical Study for Intraocular Lenses, Ft. Sill, OK</td>
</tr>
<tr>
<td>78/201E</td>
<td>O</td>
<td>Clinical Study for Intraocular Lenses, Ft. Carson, Co</td>
</tr>
<tr>
<td>84/20X</td>
<td>O</td>
<td>Microvascular Arterial and Venous Anastomosis in Laboratory Rats</td>
</tr>
<tr>
<td>86/200A</td>
<td>O</td>
<td>Treatment of Urinary Tract Trauma in the Porcine Animal Model</td>
</tr>
<tr>
<td>86/209A</td>
<td>T</td>
<td>Effects of Nonsteroidal Anti-inflammatory Agents on Tendon Healing</td>
</tr>
<tr>
<td>87/202</td>
<td>O</td>
<td>Improving Cancer Management Through the Tumor Conference</td>
</tr>
<tr>
<td>87/203</td>
<td>O</td>
<td>Comparison of Thermography and Standard Techniques for Detection, Diagnosis and Tracing of Disorders Marked by Altered Patterns of Peripheral Blood Flow (PR)</td>
</tr>
<tr>
<td>87/204</td>
<td>O</td>
<td>Mechanism Based Treatment of Phantom Limb Pain (P)(PR)</td>
</tr>
<tr>
<td>87/205</td>
<td>O</td>
<td>Etiology of Low Back Pain Due to Muscle Tension (P)(PR)</td>
</tr>
<tr>
<td>87/206</td>
<td>O</td>
<td>Evaluation of Psychophysiological Ways to Assess Chronic Low Back Pain (P)(PR)</td>
</tr>
<tr>
<td>87/207</td>
<td>O</td>
<td>Determination of Mechanisms of Phantom Limb Pain: Phase 2 (P)(PR)</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
88/20X  O  003-Evaluation of the Goat as a Model for Bone Grafting ........................................... 252
88/20X  O  004-Development of an Animal Model for the Study of Anterior Cruciate Ligament Repairs ... 253
88/200  O  Alcon Surgical Intraocular Lenses Study ........ 254
88/201A O  Use of Goats for Training in Advanced Trauma Life Support ........................................ 255
88/202  O  A Comparison of Clinical Features of Ulnar Nerve Compression at the Elbow Before and After Medial Epicondylectomy ................................. 256
88/203  O  Evaluation of Current Nasal Surgical Techniques Used to Improve Nasal Obstruction (Subjective and Objective), Utilizing Anterior Rhinometric Techniques ........................................ 257
88/206A T  An Analysis of the Effect of Nonsteroidal Anti-inflammatory Medications on Regeneration of Articular Cartilage in New Zealand White Rabbits Treated by Intermittent Active Motion and Continuous Passive Motion .......................... 259
88/208  C  A Retrospective Analysis of the Incidence of Pseudoarthrosis in Posterior Spine Fusion Done Between 1971 and 1986 at St. Anthony's Hospital and Denver Children's Hospital .......... 260
88/209  O  A Comparison of Percutaneous Repair vs Open Repair of Achilles' Tendon Ruptures (PR)(SP) ... 261
88/210A C  Delayed Repair of Traumatic Intratemporal Facial Nerve Palsy in the Pig (PR) ................... 263
88/211 T  Double Blind Crossover Study of Cyclobenzaprine versus Placebo in Patients with Primary Fibrositis: Correlation of Symptomatic versus Thermographic Criteria of Improvement ................ 264
88/212  T  Prevention of Nosocomial Pneumonia and Gastro-duodenal Ulcer Prevention in Mechanically-Ventilated Patients ...................... 265
88/213  O  Investigational Plan for the Clinical Study of Silicone Intraocular Lenses Sponsored by Allergan Medical Optics ................................. 266
88/214  O  Clinical Investigation of Intraocular Lenses in Minors Sponsored by COBURN Optical IND, Inc/Storz Ophthalmics Inc. ............................ 267
88/215  O  Plot Study For: Continuous Environmental Recording Activity, Headache, and Muscle Contraction Level Among Subjects with Tension, Migraine or No Headache (PR) ............ 268

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
| 89/20X | O | 001-Microsurgical Training in Free Flap Transfer, and Vessel and Nerve Repair Utilizing the Rat | 270 |
| 89/202 | O | The Effect of Harvesting the Central One-Third of the Patellar Tendon and Reapproximating the Medial and Lateral Edges of Patellofemoral Joint Mechanics in Cadavers | 271 |
| 89/203 | O | Rates of Occurrence of Simultaneous and Independent Low Back Pain and Headache Among Patients with and without Chronic Pain | 272 |
| 89/204 | C | Incidence of Multiresistance in Serial Gram-Negative Isolates from ICU's | 273 |
| 89/205A | O | Correlation of the Vocal Fold Vibratory Pattern to the Post Operative Surgical Wound in the Porcine Model | 274 |
| 89/206A | C | The Effect of Liposuction of Mycutaneous Flaps in the Yucata Micro Pig | 275 |
| 89/207 | O | Etiology and Progression of Acute Muscle Tension Related Low Back Pain Occurring During Sustained Activity Including Combat Training Exercises | 276 |
| 89/209 | T | Clinical Investigation of the Synthes Spinal Internal Fixator | 277 |
| 89/210 | O | Use of Body Surface Heat Patterns for Predicting and Evaluating Acute Lower Extremity Pain Among Soldiers | 278 |
| 89/211 | O | Randomization Study of Transurethral Resection of the Prostate vs Balloon Dilatation of the Prostate for Symptomatic Benign Prostatic Hyperplasia in Men | 279 |
| 90/20X | O | 001-Evaluation of the Goat as a Model for ACL Reconstruction Fixation Studies | 280 |
| 90/200A | O | Comparison of ACL Graft Fixation Techniques in a Goat Model | 281 |
| 90/201A | O | Use of Retrograde Cardioplegia in the Pig Model | 282 |
| 90/202 | O | Non-Surgical Treatment of Morton's Neuroma with Injection of Vitamin B-12/Lidocaine/Solumedral Combination (PR) | 283 |
| 90/203 | O | Synovial and Serum Keratan Sulfate Levels and Their Correlation with Arthoscopically Determined Articular Damaged Chronically Deficient Cruciate Ligament Knees | 284 |
| 90/204 | O | A Clinical Comparison of a Hydroxylapatite Coated versus Porous Coated Total Hip Implant for Use in Arthritic Human Hips | 285 |

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
90/205  C  Investigation of the Radiology and Anatomy of the Origin of the Anterior Cruciate Ligament .. 286
90/206  O  Pilot Trial of Potentiating Normal Healing of Stress Fractures Using Pulsing Electromagnetic Fields ......................... 287
90/207A  O  Patellar Tendon Healing and Strength Following Patellar Tendon Autograft Harvest in Goats .... 288
90/208A  O  Development of an Implanted, Hydroxyapatite Coated, Titanium Limb Prosthetic Through Tests in Tissue Culture, Then in Goats, and Finally in Humans ........................................ 289
90/209  O  Reliability of Psychophysiological Measures Used to Evaluate Pain ................................. 290
90/210  O  Effectiveness of Treatments for Reflex Sympathetic Dystrophy ........................................ 291
90/211A  O  Effects of Coumadin and Methotrexate on Bone Ingrowth and Fixation in Hydroxyl Apatite Coated Porous Implants in a Goat .............................. 292
90/212A  O  The Evaluation of Bone Ingrowth in Hydroxyl Apatite and in Non-Hydroxylapatite Porous Implants in a Goat .................................................. 293
90/213  O  Eaton Trapezial Implant Long-Term Follow-Up .... 294

DEPARTMENT OF CLINICAL INVESTIGATION

77/300  O  Immunologic Disorders in Children and Adults. I. Correlation of Immune Function in the Immuno-deficiency State. II. Correlation of Immune Function of Leukemia and other Childhood Malignancies (PR) .................. 296
82/302  O  The Evaluation of Recently Introduced, Commercially Available Clinical Microbiology Products for Possible Use in the FAMC Diagnostic Microbiology Laboratory (P)(PR) .... 298
86/300  O  Early Identification of Borrelia burgdorferi Antibody in Human Sera ................................. 300
88/30X  O  Veterinarian & Veterinary Support Personnel Training in Emergency Care Procedures for Lab Animals .................................................. 301
89/300A  C  The Effect of the Topical Application of Minoxidil on Hair Growth in the "Nude" Mouse .. 302
89/301  O  Biology of Cutaneous Lupus: I Skin Lesion Examination (P)(PR) ..................................... 303
89/302  O  Biology of Cutaneous Lupus: II Characterization of Autoantigens and Autoantibodies in Lupus ................................. 305

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
Evaluation of the Protofluor-Z as a Screening Tool for Lead Intoxification in Children (P)(PR)307
Videx (2',3'dideoxyinosine, ddI) Treatment IND Protocol No. 454-999-001. (Bristol-Myers Co.) . 308
Videx (2',3'dideoxyinosine, ddI) Open Label Study Protocol No. 454-999-001. (Bristol-Myers Co.) ................. 309

Training Support Summary ..................... 310

DEPARTMENT OF OB-GYN

GOG #26 - Section A: Master Protocol for Phase II Drug Studies in the Treatment of Advanced Recurrent Pelvic Malignancies .......... 313
GOG #26 - Section C: A Phse II Trial of Cis-Platinum ........................................ 314
GOG #26 - Section S: A Phase II Trial of VM26. 315
GOG #72 - Ovarian Tumors of Low Malignant Potential A Study of the Natural History and a Phase II Trial of Melphalan and Secondary treatment with Cisplatin in Patients with Progressive Disease ......................... 316
GOG#74 - Early Stage I Vulvar Cancer Treated with Ipsilateral Superficial Inguinal Lymphadenectomy and Modified Radical Hemivulvectomy (Phase III) .................... 317
GOG #73 - A Clinical Pathologic Study of Primary Malignant Melanoma of the Vulva Treated by Modified Radical Hemivulvectomy ...................... 318
-001 - Repair of Femoral Artery and Fallopian Tube of Rabbit and Rat ................. 319
Danazol in the Treatment of Premenstrual Syndrome ........................................ 320
GOG 85 - Comparison of Hydroxyurea versus Cisplatin and 5FU as an Adjunct to Radiation Therapy in Patients with Advanced Carcinoma of The Cervix ............................... 321
GOG 90 - Evaluation of Cisplatin, Etopuside, and Bleomycin Induction Followed by Vincristine, Dactinomycin and Cyclophosphamide Consolidation in Advanced Ovarian Germ Cell Tumors (O) .... 322
<table>
<thead>
<tr>
<th>Page</th>
<th>Study Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>87/354</td>
<td>O  GOG 95 - Randomized Clinical Trial for the Treatment of Women with Selected Stage IAi &amp; IAii &amp; IBii Ovarian Cancer (Phase III) .......... 323</td>
</tr>
<tr>
<td>87/356</td>
<td>C  GOG 97 - A Phase III Randomized Study of Cyclophosphamide and Cisplatin in Patients with Suboptimal Stage III and Stage IV Epithelial Ovarian Carcinoma Comparing Intensive and Non-Intensive Schedules ......................... 324</td>
</tr>
<tr>
<td>87/358</td>
<td>O  GOG 93 Evaluation of Intraperitoneal Chromic Phosphate After Negative Second-Look Laparotomy in Ovarian Carcinoma ................................. 325</td>
</tr>
<tr>
<td>87/359</td>
<td>O  GOG 99 Adjunctive Radiation Therapy in Intermediate Risk Endometrial Carcinoma .......... 326</td>
</tr>
<tr>
<td>88/350</td>
<td>O  GOG 92 Radiation Therapy vs No Further Therapy in Selected Patients with Stage IB Invasive Carcinoma of the Cervix ........................................ 327</td>
</tr>
<tr>
<td>88/351</td>
<td>O  GOG 94 A Phase II Study of the Treatment of Stage III and IV Disease of Advanced Endometrial Carcinoma and All Stages of Papillary Serious Carcinoma and Clear Cell Carcinoma of the Endometrium with Total Abdominal Radiation Therapy ....................... 328</td>
</tr>
<tr>
<td>88/355</td>
<td>O  GOG 104 Intraperitoneal (SWOG 8501) Intraperitoneal Cis-Platinum and Cyclophosphamide IV vs Intravenous Cis-Platinum and Cyclophosphamide IV in Patients with Optimal Stage III Ovarian Cancer ................................. 329</td>
</tr>
<tr>
<td>88/359</td>
<td>O  GOG 100 Monoclonal Antibody Against Free Beta HCG to Predict Developmen of PGTD in Patients with Hydatidiform Mole ............................. 330</td>
</tr>
<tr>
<td>88/360</td>
<td>O  GOG 87C A Phase II Trial of Hydroxurea, DTIC and VP16 in Patients With Advanced Uterine Sarcomas ........................................ 332</td>
</tr>
<tr>
<td>89/350</td>
<td>C  GOG 76H A Phase II Trial of Echinomycin (NSC#E526417) in Patients with Advanced Squamous Cell Carcinoma of the Cervix ...................... 333</td>
</tr>
<tr>
<td>89/351</td>
<td>O  GOG 87D A Phase II Trial of VP-16 in Patients with Advanced or Recurrent Uterine Sarcoma .... 334</td>
</tr>
<tr>
<td>89/352</td>
<td>O  GOG 101 A Phase II Evaluation of Preoperative Chemoradiation for Patients with Advanced Vulvar Cancer ........................................ 335</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
89/353  C  GOG 102C A Phase II Study of Intraperitoneal Administration of Cisplatin (NSC#119875) and Recombinant Alpha 2 Interferon in Residual Ovarian Carcinoma ............................ 336

89/354  O  GOG 107 A Randomized Study of Doxorubicin vs Doxorubicin Plus Cisplatin in Recurrent Endometrial Adenocarcinoma Previously Diagnosed as Primary Stage III or IV (Phase III) .......... 337

89/355  O  GOG 102E Intraperitoneal Administration of Cisplatin (NSC#119875) and Etoposide (VP-16) (NSC#141540) in Patients with Residual Ovarian Carcinoma (Phase II) .......................... 338

89/356  O  GOG 102F Intraperitoneal Administration of Alpha Recombinant Interferon (aIFN) in Residual Ovarian Carcinoma (Phase II) .... 339

90/350  O  GOG 108 Ifosfamide and the Uroprotector Mesna, With or Without Cisplatin, in Patients With Advanced or Recurrent Mixed Mesodermal Tumors of the Uterus .............................. 340

90/351  O  GOG 109 A Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy VS Radiation Therapy Alone in Selected Patients with Stage 1A-2, 1B or 2A Carcinoma of the Cervix Following Radical Hysterectomy and Node Dissection ......................... 341

90/352  O  GOG 26EE: A Phase II Trial of Didemnin B in Patients with Advanced Pelvic Malignancies .... 342

90/353  O  GOG 26GG: A Phase II Trial of Fazarabine (NSC#281272) in Patients with Advanced/Recurrent Pelvic Malignancies .................... 343

90/354  O  GOG 26HH: A Phase II Trial of 5-Fluorouracil and Leucovorin in Advanced Metastatic or Recurrent Pelvic Malignancies ............... 344

90/355  O  GOG 102G: Intraperitoneal Administration of Cisplatin (NSC#119875) and Thiotepa in Residual Ovarian Carcinoma .......................... 345

90/356  O  GOG 111: A Randomized Phase III Study of Cisplatin and Cyclophosphamide Versus Cisplatin and Taxol in Patients with Suboptimal Stage III and Stage IV Epithelial Ovarian Carcinoma ...... 346

DEPARTMENT OF PEDIATRICS

78/40X  O  -001 - Use of Laboratory Animals (Cats) to Teach Medical Skills .......................... 348

Ongoing (O), Completed (C), Terminated (T), Published (P) or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>82/403</td>
</tr>
<tr>
<td>82/414</td>
</tr>
<tr>
<td>82/420</td>
</tr>
<tr>
<td>83/401</td>
</tr>
<tr>
<td>86/403</td>
</tr>
<tr>
<td>86/408</td>
</tr>
<tr>
<td>86/410</td>
</tr>
<tr>
<td>87/401</td>
</tr>
<tr>
<td>87/403</td>
</tr>
<tr>
<td>87/404</td>
</tr>
<tr>
<td>87/405</td>
</tr>
<tr>
<td>87/406</td>
</tr>
<tr>
<td>87/408</td>
</tr>
<tr>
<td>88/400</td>
</tr>
<tr>
<td>88/401</td>
</tr>
<tr>
<td>88/402</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (F), or Submitted for Publication (SP), Presentations (PP).
88/403  C  POG 8763 Evaluation of Response and Toxicity of Ifosfamide and VP-16-213 in Children with Resistant Malignant Tumors .................... 367
88/404  O  Ceftriaxone vs Anoxicillin/Clavulanate for Initial Empirical Therapy of Occult Bacteremia. 368
88/405A  O  Macromolecular Absorption in the Post-Asphixiated Small Intestines of the Adult Rat ........... 369
88/408A  O  Effect of Human/Animal Interaction on Stress Levels During Outpatient Pediatric Oncology Visits ........................................... 371
88/409  T  The Correlation of Perinatal Events with Neonatal Morbidity: A Scoring System ............. 372
89/400  O  POG 8710 Protocol for Second Induction and Maintenance in Childhood Acute Lymphoblastic Leukemia (SIMAL #5) ..................... 373
89/401A  O  An Observational Study on the Response of Children to the Presence of a Stuffed Animal VS a Live Animal During a Neuromuscular Exam (PR) ........................................... 374
89/402  C  Newborn Informed Consent Study ........................ 375
89/403A  O  Effect of Inflammation in Chronic Pneumonia in Rats Due to Pseudomonas Aeruginosa ---Medication by Bacterial Exoproducts ....... 376
89/404  O  POG 8725 Randomized Study of Intensive Chemotherapy (MOPP/ABVD) + or - Low Dose Total Radiation Therapy in the Treatment of Stages IIB, IIIA-2, IIIB, IV Hodgkin's Disease in Pediatric Patients .............................. 377
89/405  O  Clonidine Treatment of Constitutional Delay of Growth and Puberty--A Prospective Double Blind Study ................................. 378
89/406  C  POG 8495 A Phase I Study of Hyperfractionation in Brain Stem Glioma in Children .................. 379
89/407  O  Baby Development Follow-up Network Project .... 380
89/408  O  Comparison of Cotinine Hair and Saliva Analysis in the Determination of Passive and Active Cigarette Smoking Exposure in Adolescents ..... 381
90/400  T  A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients with HIV Disease (TX 304-IND-33,760) .................. 382
90/401  O  Experience with Multiple Doses of Survanta in Premature Infants ............................... 383
90/402A  O  Training for Pediatricians in Emergency Procedures ..................................................... 384
90/403A  O  Studies of the Hemodynamic Consequences of Partial Cardiopulmonary Bypass in the Lamb .... 385

Ongoing (O), Completed (C), Terminated (T), Published (P), or Submitted for Publication (SP), Presentations (PR).
<table>
<thead>
<tr>
<th>No.</th>
<th>Status</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>90/404</td>
<td>C</td>
<td>Revision of Bayley Scales of Infant Development</td>
</tr>
<tr>
<td>90/405</td>
<td>O</td>
<td>Followup of the NICU Graduate in Military Medical Facilities</td>
</tr>
<tr>
<td>90/406</td>
<td>O</td>
<td>POG 8788 Intergroup Ghabdomyosarcoma Study I: A Pilot Study for Clinical Group III Disease</td>
</tr>
<tr>
<td>90/407</td>
<td>O</td>
<td>POG 8821 AML#3: Intensive Multagent Therapy vs Autologous Bone Marrow Transplant Early in 1st CR for Children with Acute Myelocytic Leukemia</td>
</tr>
<tr>
<td>90/408</td>
<td>O</td>
<td>POG 8823/24 Recomginant Alpha Interferon in Childhood Chronic Myelogenous Leukemia</td>
</tr>
<tr>
<td>90/409</td>
<td>O</td>
<td>POG 8827 Treatment of Children with Prostate Disease in Relapse - Phase I</td>
</tr>
<tr>
<td>90/410</td>
<td>O</td>
<td>POG 8829 A Protocol for a Case-Control Study Hodgkin's Disease in Childhood - A New Therapeutic Study</td>
</tr>
<tr>
<td>90/411</td>
<td>O</td>
<td>POG 8832 Pre-XRT Cisplatin and Ara-C Treafor Malignant Brain Tumors with Incompletely Resected Glioma</td>
</tr>
<tr>
<td>90/412</td>
<td>O</td>
<td>POG 8850 Evaluation of Vincristine, Cyclophosphamide, and Dactinomycin, the Addition of Ifosfamide and Etoposide in the Treatment of Patients with Metastatic Sarcoma or Primitive Neuroectodermal Bone</td>
</tr>
<tr>
<td>90/413</td>
<td>O</td>
<td>POG 8899 Intergroup Phhardomyosarcoma Pilot Study for Clinical Group IV Disease</td>
</tr>
<tr>
<td>90/414</td>
<td>O</td>
<td>POG 8828 Late Effects of Treatment of Acute Lymphoblastic Leukemia Disease: A Pediatric Oncology Cooperative Therapeutic Study</td>
</tr>
<tr>
<td>90/415</td>
<td>O</td>
<td>POG 8650 National Wilms' Tumor Study (NWTS-4), A Pediatric Hemato-oncology Cooperative III Study</td>
</tr>
</tbody>
</table>

DEPARTMENT OF PATHOLOGY

<table>
<thead>
<tr>
<th>No.</th>
<th>Status</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>89/450</td>
<td>C</td>
<td>Evaluation of the Available Magnitude Normal Tubes for Storage of Patient Specimens</td>
</tr>
</tbody>
</table>

DEPARTMENT OF RADIOLOGY

<table>
<thead>
<tr>
<th>No.</th>
<th>Status</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>80/602</td>
<td>O</td>
<td>I.V. Administration of 131I-norcholesterol (NP-59) for Adrenal Evaluation and Imaging</td>
</tr>
</tbody>
</table>

Ongoing (O), Completed (C), Terminated (T), Published (P), Submitted for Publication (SP), Presented (Pr).
a. The Usefulness of Magnetic Resonance Imaging and Transrectal Ultrasound in the Staging of Prostatic Cancer: Comparison to 1mm Whole Gland Mounts.

b. Artifacts and Variants of the Normal Prostate Seen by MRI and Transrectal Ultrasound: Comparison to 1mm Whole Gland Mounts

Body Fat Determination by Dual Photon Absorptiometry

The Comparative Renal Clearances of Disofenin and Mebrofenin

The Utility of the Bard "Biopty" Gun in the Breast: Correlation with Surgical Excisional Specimens

The Ontogenesis of Hemoglobin in the American Opossum (Didelphis Virginia) (P)

Clonal Fidelity of Erythroid Lineage in Dyserythropoiesis: An Inquiry Into Ultrastructure

Introduction to Suturing Techniques Using Outbred Adult Rats

A Study of the Clinical Nurse Specialist in the AMEDD (PR) (P)

A Pilot Study: A Comparison of Subarachnoid Block Anesthesia with Tetracaine and Epidural Anesthesia with Lidocaine and the Effects on the Umbilical Artery Acid-Base Results and Five Minute Apgar Scores of Neonates Following Uncomplicated Cesarean Section

Assessment of Post Myocardial Infarction Patients Learning Needs During Hospitalization and Post Discharge

The Impact of Practice at Fitzsimons Army Medical Center Upon Registered Nurses Professional Role Conception
PHYSICAL MEDICINE

90/750 O Onset-to-Onset Difference Between the Median Motor Nerve and the Anterior Interosseous Nerve Using a Common Stimulation at the Antebubital Fossae ........................................ 419

90/751 C The Frequency That Physicians Recommend Aerobic Exercise in the Management of Patients with Rheumatoid Arthritis ........................................ 420

MEDDAC

83/902A O Use of Goats for Training in Emergency Medical Procedures .................................................. 422

88/900 O IOLAB Investigational Plan for the Clinical Study of Intraocular Lenses ......................... 423

88/901 O COBURN IOL at GLWACH, Ft. Leonard Wood, MO ... 424

89/900 O Evaluation of a Phase I Coxiella burnetii Vaccine (IND 610) for Immunization Against Q Fever .... 425

89/901 O Continued Evaluation of the Safety and Effectiveness of Venezuelan Equine Encephalomyelitis Vaccine, TC-83 Live, Attenuated, NDBR-102, Lot 4 in At-Risk Personnel IND 142 ........................................ 426

89/902 O Evaluation of New Lots of Tularemia Vaccine Protocol B: Comparative Assessment of Francis tularensis Vaccine, Live, NDBR 101, IND 157 427

89/903 O Evaluation of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated. Protocol B: Continued Assessment of the Safety and Effectiveness of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Lot C-84-6, TSI-GSD 205 As a Booster in At-Risk Personnel, IND 914 .......... 428

89/904 O Use of the Sixteen Personality Factor Questionaire to Predict Susceptibility to Occupational Stresses Among US Army Recruits ........................................ 429

89/905 C Comparative Evaluation of Jet Injected PPD Based on the Mantoux Response in Initial Entry Training Soldiers .................................................. 430

90/900 O Iron Deficiency Anemia in 11-14 Month Old Infants at 6,000 Feet, (1830m) Elevation. A Study to Evaluate the Response to a Therapeutic Trial of Iron .................................................. 431

90/950A O Postgraduate Course on Obstetric, Neonatal, and Gynecologic Care. Resuscitation of the Newborn Utilizing Young Cats ................................. 432

Ongoing (O), Completed (C), Terminated (T), Published (P), or Submitted for Publication (SP), Presentations (PR).
## EMERGENCY USE PROTOCOLS

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU-89-1</td>
<td>C</td>
<td>POG 8633/34 Treatment of Children Less Than Three Years of Age with Malignant Brain Tumors Using Postoperative Chemotherapy and Delayed Irradiation</td>
</tr>
<tr>
<td>EU-89-2</td>
<td>O</td>
<td>POG 8743</td>
</tr>
<tr>
<td>---------</td>
<td>C</td>
<td>Compassionate Enrollment in POG 8696/97</td>
</tr>
<tr>
<td>One</td>
<td>C</td>
<td>Compassionate/One Time Use Protocol - Ribovirin (2-wk course)</td>
</tr>
<tr>
<td>Two</td>
<td>C</td>
<td>Tc99m Antimony - Trisulfide Colloid</td>
</tr>
<tr>
<td>Three</td>
<td>T</td>
<td>Itraconazole</td>
</tr>
<tr>
<td>Four</td>
<td>T</td>
<td>POG 8751</td>
</tr>
<tr>
<td>Five</td>
<td>C</td>
<td>Intravenous Ciprofloxacin</td>
</tr>
<tr>
<td>Six</td>
<td>C</td>
<td>Strontium Chloride Sr-89</td>
</tr>
</tbody>
</table>

(bb)
UNIT SUMMARY

Clinical Investigation efforts by FAMC personnel in FY 90 culminated in the publication of 148 articles and 159 presentations and lectures at national, international, and regional scientific meetings. As of 30 September 1990, there were 347 research protocols on the DCI register. Of these, 263 projects were ongoing, 57 projects completed, 27 projects terminated, and for this FY there were 127 new registrations.

Objectives:

To encourage the performance of clinically-oriented investigation by personnel assigned to the Fitzsimons Army Medical Center (FAMC). To aid in the planning, development, support, and execution of experimental clinical studies, both in patients and by directly related laboratory work, into the clinical problems of significant concern in the health care of members of the military community. To provide physician experience in research and investigative procedures by furnishing a highly educated and trained staff of specialists, laboratory facilities, administrative services and funding for: supplies, equipment, consultants, publications and reprints. To achieve continuous improvement in the quality of patient care by providing an atmosphere of inquiry, maintaining high professional standing and accreditation of advanced health programs.

The Clinical Investigation Program differs from Medical Research and Development in that the emphasis is on the health care problems existing in our patient populations, i.e., active duty, retired, and dependents and not solely on medical problems affecting combat readiness and the fighting strength. It is, by its nature, an integral part of the triad of patient care and medicine. It promotes and supports the finest ideals and traditions of Military Medicine and enhances the vitality of the teaching programs which in turn elevates the standard of medical care. The research program operates on the premise that all approved protocols will be supported to the fullest extent allowed by current funding. This concept allows for a larger number of physicians and ancillary personnel to participate in research rather than as in the grant system used elsewhere. This means that virtually every investigator is given a chance to pursue his research without having to compete for funds with "established" names in the field.

Technical Approach:

This support is carried out under the aegis of AR 40-38, Clinical Investigation Program; AR 40-7, Use of Investigational Drugs in Humans; AR 70-25, Use of Volunteers as Subjects in Research; AR 70-18, Laboratory Animals, Procurement, Transportation, Use, Care, and Public Affairs; HSC Reg 40-23, Management of Clinical Investigation Protocols and Reports, as amended; FAMC Reg 40-18,
Institutional Review Committee. This Department provides guidance, assistance, and coordinates the PAMC program with higher headquarters.

Manpower: current authorized strength is outlined.

<table>
<thead>
<tr>
<th>Description</th>
<th>Grade</th>
<th>MOS</th>
<th>Br</th>
<th>Auth</th>
<th>Req</th>
<th>Act</th>
<th>Name</th>
<th>Rank</th>
</tr>
</thead>
<tbody>
<tr>
<td>C, Dept Clin Inv</td>
<td>05</td>
<td>60P9B</td>
<td>MC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>HARRISON</td>
<td>LTC</td>
</tr>
<tr>
<td>C, Micro Svc</td>
<td>05</td>
<td>68A00</td>
<td>MSC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Andron</td>
<td>LTC</td>
</tr>
<tr>
<td>C, Biomet &amp; Resh</td>
<td>04</td>
<td>68T00</td>
<td>MSC</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>Sherman</td>
<td>MAJ</td>
</tr>
<tr>
<td>C, Biochem Svc</td>
<td>04</td>
<td>68C9C</td>
<td>MSC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>White</td>
<td>MAJ</td>
</tr>
<tr>
<td>C, Immunol Svc</td>
<td>04</td>
<td>68E00</td>
<td>MSC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Stewart</td>
<td>MAJ</td>
</tr>
<tr>
<td>C, Cell Phys Svc</td>
<td>03</td>
<td>68J00</td>
<td>MSC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Jackson</td>
<td>CPT</td>
</tr>
<tr>
<td>C, Animal Res Svc</td>
<td>04</td>
<td>64C9B</td>
<td>VC</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Banks</td>
<td>MAJ</td>
</tr>
<tr>
<td>NCOIC-Med Lab</td>
<td>E6</td>
<td>92B30M</td>
<td></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>Remmick</td>
<td>SSG</td>
</tr>
<tr>
<td>Operating Rm Sp</td>
<td>E5</td>
<td>91D2R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Haynes</td>
<td>SGT</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E6</td>
<td>01H3R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>Brady</td>
<td>SSG</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E7</td>
<td>92B4RM</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Dalton</td>
<td>SFC</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E5</td>
<td>01H3R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Sanders</td>
<td>SGT</td>
</tr>
<tr>
<td>Vet Sp</td>
<td>E6</td>
<td>91T3R</td>
<td></td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>Barrett</td>
<td>SSG</td>
</tr>
<tr>
<td>Vet Sp</td>
<td>E5</td>
<td>91T2R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Wendt</td>
<td>SGT</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>01H1R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Cruz-Saez</td>
<td>SPC</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>01H1R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Williams</td>
<td>SPC</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>01H1R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Sipple</td>
<td>SPC</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E4</td>
<td>01H1R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>Schaphorst</td>
<td>SPC</td>
</tr>
<tr>
<td>Bio Sci Asst</td>
<td>E6</td>
<td>01H1R</td>
<td></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>Stinnett</td>
<td>SSG</td>
</tr>
<tr>
<td>Supv Res Chem</td>
<td>13</td>
<td>1320</td>
<td>GS</td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>Gutierrez</td>
<td></td>
</tr>
<tr>
<td>Microbiologist</td>
<td>11</td>
<td>0403</td>
<td>GS</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>Lima</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Paine</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hoyt</td>
<td></td>
</tr>
<tr>
<td>Description</td>
<td>Grade</td>
<td>MOS</td>
<td>Br</td>
<td>Auth Req</td>
<td>Act</td>
<td>Name</td>
<td>Rank</td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td>-------</td>
<td>------</td>
<td>-----</td>
<td>----------</td>
<td>-----</td>
<td>-----------------------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>Microbiologist</td>
<td>09</td>
<td>0403</td>
<td>GS</td>
<td>3</td>
<td>6</td>
<td>3 Morse</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Petring</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Muehlbauer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Med Technologist</td>
<td>11</td>
<td>0644</td>
<td>GS</td>
<td>0</td>
<td>1</td>
<td>1 Rush</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Med Technologist</td>
<td>09</td>
<td>0644</td>
<td>GS</td>
<td>0</td>
<td>6</td>
<td>5 Ramirez (Term)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pinney (Term)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Goodgion (Term)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sachanandani (Term)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Med Technician</td>
<td>07</td>
<td>0645</td>
<td>GS</td>
<td>1</td>
<td>1</td>
<td>1 Nelson</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Research Chem</td>
<td>11</td>
<td>1320</td>
<td>GS</td>
<td>4</td>
<td>3</td>
<td>3 Noble</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>O'Brien</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bio Lab Tech</td>
<td>09</td>
<td>0404</td>
<td>GS</td>
<td>1</td>
<td>1</td>
<td>1 Mercill</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Animal) Animal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caretaker (Foreman)</td>
<td>04</td>
<td>5048</td>
<td>WS</td>
<td>1</td>
<td>1</td>
<td>1 Jones</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Research Prot Sp</td>
<td>09</td>
<td>0301</td>
<td>GS</td>
<td>1</td>
<td>1</td>
<td>1 Bilak</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Animal Caretaker</td>
<td>05</td>
<td>5408</td>
<td>WG</td>
<td>1</td>
<td>3</td>
<td>2 Chase (overhire)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hitchcock</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secretary</td>
<td>06</td>
<td>0318</td>
<td>GS</td>
<td>1</td>
<td>1</td>
<td>1 Montoya</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Funding**

The OMA costs have not been itemized by protocol number because it is not feasible or practical to do so.

<table>
<thead>
<tr>
<th></th>
<th>FY 88</th>
<th>FY89</th>
<th>FY 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>OMA Civilian Personnel</td>
<td>668,953.</td>
<td>1,260,000.</td>
<td>834,529.</td>
</tr>
<tr>
<td>Contracts/Supplies</td>
<td>259,514.</td>
<td>218,800.</td>
<td>453,777.</td>
</tr>
<tr>
<td>Cee; Equipment</td>
<td>28,599.</td>
<td>4,350.</td>
<td>64,424.</td>
</tr>
<tr>
<td>Travel</td>
<td>6,552.</td>
<td>6,031.</td>
<td>9,978.</td>
</tr>
<tr>
<td>Military Personnel</td>
<td></td>
<td>1,260,000.</td>
<td>754,499.</td>
</tr>
</tbody>
</table>

**OPA MEDCASE**

<table>
<thead>
<tr>
<th></th>
<th>FY 88</th>
<th>FY89</th>
<th>FY 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>OPA MEDCASE</td>
<td>282,809.</td>
<td>579,122.</td>
<td>740,811.</td>
</tr>
</tbody>
</table>

Civilian Consultants FY 90 - $828.00
Publication Costs FY 90 - $9,081.00
Personnel

<table>
<thead>
<tr>
<th></th>
<th>Authorized</th>
<th>Required</th>
<th>Assigned</th>
</tr>
</thead>
<tbody>
<tr>
<td>Officers</td>
<td>6</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Enlisted</td>
<td>12</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Civilian</td>
<td>15</td>
<td>34</td>
<td>26</td>
</tr>
<tr>
<td>VA Civilian</td>
<td>2</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>

GRANTS

USAMRDC

Prospective Double Blind Study of Zidovudine (AZT) in Early Stage HIV Infection. $84,000

A Double Blind, Multicenter, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of HA-1A Human Monoclonal Antibody in Patients with Gram-Negative Sepsis/Gram Negative Septic Shock.

Veterans Administration (VA)

VA Funds (Sherman) $29,800

USAMRDC Grants Total: 205,000
This student research award was established in 1950 and honors the late Colonel Hugh W. Mahon, MC, USA, Retired, who was Chief, Department of Pathology, Fitzsimons Army Medical Center, for 12 years. The lectureship consists of the presentation of papers judged best from among those submitted by officers in training status at FAMC.

The Hugh Mahon Lectureship Award Competition is divided into the categories of retrospective or prospective clinical studies, basic laboratory investigations, and literature reviews/case reports. This year there were a total of 36 submissions; 6 manuscripts in the laboratory category, 13 in clinical studies, and 17 case reports/literature reviews. Last year's submission was the largest with 41, while in 1988 there were 23 papers submitted and in 1987, 18.

Judging was done by the members of the FAMC clinical teaching staff and a panel of distinguished university and community professors. Manuscripts were scored on originality and medical significance, experimental design, presentation and interpretation of data, and literary quality.

A Grand Prize Winner was chosen from among the five finalists in all three categories based on the presentation and question-and-answer period during the Hugh Mahon Lectureship Conference. The finalists receive Army Achievement Medals, and the Grand Prize Winner is awarded the Army Commendation Award. The finalists for 1990 are as follows:

**Clinical Studies**


Grand Prize Winner and 2nd Place: Kids and Guns: A Five Year Analysis of Firearm Deaths in Colorado Children. Sivanthini Hines, CPT, MC, Pediatrics

**Laboratory Studies**


2nd Place: A Comparison of Patellar Tendon Graft Fixation Techniques in Anterior Cruciate Ligament Reconstruction Using a Goat Model. R. Todd Hockenbury, CPT, MC, Orthopedic Surgery

**Case Reports/Literature Reviews**

One Prize Only: Covert Hypothyroidism Presenting as a Cardiovascular Event. Homer J. LeMar, MAJ, MC, Endocrine.
An air-operated box stapler and a hot glue applicator gun were
procured to facilitate packaging of live animals for shipment. New
cleaning utensils of metal and plastic construction were bought for
the animal facility to replace wooden handled tools. Two infant
anatomical models were purchased to assist in the training of
Newborn Service staff members in the resuscitation of newborn and
premature infants. Foamed alcohol hand degemers were installed
throughout the animal facility to aid in the elimination of cross-
contamination between animal rooms. A high pressure washer was
purchased to aid in cleaning animal rooms. A new blanket purchase
agreement was obtained for the purchase of conditioned goats and
sheep.

Two computer-based training programs were purchased in the text-
only version, one to assist in the training of investigators in the
use of laboratory animals and the other to assist technicians in
preparing for certification and to maintain proficiency. The
accompanying graphics programs will be sought when hardware is
available, i.e., a VGA board and monitor.

Work was begun in September installing suspended ceiling in the
corridor and animal areas where it was omitted during original
construction. Installation of stainless steel wall protectors on
exposed walls in the large animal enclosures was also started at
that time.

MAJ Trahan passed the Colorado State licensing examination given
by the State Board of Veterinary Medicine, and was accredited for
the State of Colorado by the USDA, APHIS, Veterinary Services. MAJ
Trahan and Mr. Jones attended the national AALAS meeting, held in

Biochemistry Service - FY 90

The Biochemistry Service has a new look for 1990. We have a new
medical technologist and a molecular geneticist. We are renovating
lab space for their work now. We hope to bring this exciting area
of DNA and RNA research on line soon.

We completed work on our blood lead protocol and presented results
at the March 1990 meeting of the Society of Armed Forces Laboratory
Scientists in Baltimore, Maryland. The current blood lead project
involves screening pediatric populations close to smelters and
mines. This is a collaborative effort between Colorado Department
of Health and our lab. The Biochemistry Service is one of only two
labs in Colorado that is OSHA certified to perform blood lead
analysis.

We completed work developing an assay for cotinine (the major
stable metabolite of nicotine) in hair. This assay supports a
protocol that assesses passive smoking exposure.
The amino acid laboratory provides physiological amino acids for Army physicians in long term civilian training at University of Colorado Health Sciences Center, Perinatal Division.

We completed one collaborative research project with Denver University Endocrine Department. We also support many FAMC endocrine protocols with binding and other specialized assays.

Our Service has an active HPLC lab that specializes in the assay of red blood cell metabolites. We are expanding and improving our HPLC capabilities in this area which has an excellent record of publishing its research.

**Cell Physiology Service - FY 90**

Cell Physiology Service (CPS) provides clinical research support for FAMC in a number of scientific areas. These include: histochemistry, immunocytochemistry, electron microscopy, tissue culture, and animal modeling in tumor growth and treatment.

CPS received a new chief in January 1990. Although CPS's basic mission support remains the same, CPS collaborated on new projects with a somewhat different emphasis. CPS and Pulmonary Disease Service (PDS) are studying physiologic factors contributing to long-term acclimatization in newcomers to intermediate altitude as measured by physical performance (2 mile run time on AFPT). Biochemical and metabolic indicators relating to improved oxygen delivery were determined on a group of soldiers both at low and after assignment to intermediate altitude in order to evaluate the time course of acclimatization. Results suggest that even relatively mild hypoxic environments elicit physiological responses that indicate tissue hypoxia. This investigation is supported by the Command group and the Physical Fitness School, Ft. Benjamin Harrison, Indians. Preliminary findings will be presented at The American Thoracic Society meeting May 1991.

Polytetrafluoroethlene (Gortex) patches of different porosities were cultured in epithelial cells in vitro. Results demonstrated that cells successfully attached to and infiltrated the gortex especially with 30 and 60 micron pores. Subsequently, patches were utilized as a soft tissue grafts in rabbits. Dr. Walton, an Ophthalmology resident, will present his findings at a conference this Spring. CPS cell culture lab also is actively involved in an orthopedic study which will determine whether human fibroblasts will grow to titanium rods with or without hydroxyapatite coating with prospect of improving biocompatibility of implanted prosthetic devices. Culturing is complete and the rods were sent to New Orleans for sectioning. Other research conducted in tissue culturing involve: improvement sin keratinocyte growth and isolation for collaborative work with Dermatology Service; and successful culturing of osteoblasts for possible use in studying
different drug treatment modalities for bone or joint disorders. Evidence was provided through autoradiography and histology for cell viability in different surgical procedures utilized for skin-flap repair. The results are being incorporated into a publication.

CPS and FAMC's Dermatology Service are evaluating new strains of immunodeficient mice for use as a recipient of human skin grafts in order to study the etiology of subcutaneous lupus erythematosus (SCLE). Beige nude Xid (X-linked mutation) mice have rendered promising results demonstrating a greater potential for skin graft acceptance.

Clinical Biometrics and Research Design Service - FY 90

During this fiscal year two major research programs were initiated with funding from MRDC. They concern (1) evaluation and prediction of lower limb injuries during basic combat training at Ft. Sill and during normal work at FAMC and (2) determination of etiology of low back pain during combat exercises at Ft. Carson and normal work at FAMC. The Service continues to run entirely from grant funds. With the exception of the Chief, none of the five and half full time equivalent positions are paid from HSC funds. MRDC has funded an experimental surgery program set to begin in October which will provide an additional 1/1/2 slots to the Service and virtually all other orthopedic research programs are now fully or mostly funded by grants. Significant changes in staffing patterns at FAMC have resulted in the assignment of many new staff who are strongly oriented toward participation in long term, complex, frequently multicenter, very expensive research projects rather than sporadic participation by students in minor, inexpensive, local projects. This has resulted in an explosion in the number, complexity, and cost of research protocols.

Immunology Service - FY 90

The Immunology Service continues to maintain its premiere reputation in flow cytometry amongst the military medical centers. Work with immunophenotyping, DNA analysis of both fresh and preserved tissues, and antigen specificity studies will soon be expanded to include intracellular calcium analysis in the UV excitation wavelengths. A second argon laser will replace the unused krypton laser on the EPICS V to provide dedicated support to this endocrinology research. The HIV Natural History Protocol continues to constitute more than 60% of the Service's workload. The Allergy Therapy protocol continues with antigen analysis of the investigated pollens and many soon include binding studies. A presentation was made at the 1990 SAFMLS Annual Meeting in Baltimore on capabilities of the Vanguard radioisotope imaging scanner now in routine use in lymphocyte transformation studies. New instrumentation installed in the third and fourth quarters include a peptide sequencer, a peptide synthesizer, and a research grade video densitometer. The first two systems will provide core level capabilities on par with any research center in the country.
and will be used in antigen-analysis, antigen-antibody binding studies, and structural comparisons of bacterial and HLA antigens. The video densitometer will greatly enhance our capabilities in gel and advanced image analysis. Still due into the Service (but held up in contracting due to vendor failure) is an advanced systems upgrade to the Department's graphics handling system which will include optical character recognition hardware and software, a color image scanner, a color printer, and color video imaging software and firmware (Targa board).

**Microbiology Service - FY 90**

The Mycobacteriology Section demonstrated excellent performance on CAP proficiency surveys and maintains its CAP accreditation. Cycloserine, Amikacin, and Ciprofloxacine will be added to the standard 8 drug susceptibility panel. A seven drug panel including Amikacin, Trimethoprim/Sulfa-Methoxazole, Kanamycin, Doxycycline, Minocycline, Cefoxitin, and Ciprofloxacine was instituted to test the rapid growing mycobacteria. These additions will greatly improve the ability of physicians to treat infected patients.

Two new diagnostic tests for hepatitis C (non-A, non-B hepatitis) were evaluated and used to survey HIV patients who had indications of liver cell damage unexplained by other tests. The commercial ELISA test for Hepatitis C was used for screening and positives were confirmed by recombinant immuno-blot assay (RIBA).

New protocols involving Limulus testing of human ascites fluid and investigation of pollen samples for microbiological contamination were developed. Three abstracts were accepted for presentation at the HIV International Congress and manuscripts are in preparation describing results of the early treatment with Zidovudine of HIV infection. A new multi-center protocol involving IV immunoglobulin treatment for endotoxic shock was initiated. New studies are underway with laboratories in Boston and Maryland to survey sera obtained from Reservists training at Ft. McCoy, Wisconsin for antibodies to tick saliva products and to quantitate Borrelia burgdorferi antigenemia.
PUBLICATIONS

C = Protocol Related
Allergy Service


Cardiology Service - No Report
Dermatology Service - No Report

Endocrinology Service


Fortenbery EJ, McDermott MT, Duncan WE: The Effect of Theophylline on Calcium Metabolism and Circulating Vitamin D Metabolites. J Bone Min Res, 5:321-324, 1990. (C)

Georgitis WJ, McDermott MT, Kidd GS: An Iodine Load from Water Purification Tablets Alters Thyroid Function in Man. Submitted for publication, 1990. (C)


Leidy J, McDermott MT, Robbins RJ: Effect of Hypophysectomy and Growth Hormone Administration on Hypothalamic Growth Hormone-Releasing Hormone and Somatostatin Content: Relationship to Age-Related Growth Rate. Neuroendocrinology, 51:400-405, 1990. (C)

LeMar HJ Jr, West S, Garrett CR, Hofeldt FD: Covert Hypothyroidism Presenting as a Cardiovascular Event. Submitted for publication, 1990. (C)


McDermott MT, Georgitis WJ, Kidd GS: Angiotensin-Converting Enzyme Activity is Unchanged by Excess Growth Hormone Administration (in press, 1990). (C)


McDermott MT: Nodular Thyroid Disease. Submitted or publication, 1990. (C)

Merenich JA, McDermott MT, Hobart TP, Kidd GS: Elevated T3 Antibodies in an Euthyroid Patient. Submitted for publication, 1990. (C)


Merenich JA, Pfander NA, Georgitis WJ: Addition of Bedtime Ultralente Insulin to NIDDM Patients Suboptimally Controlled with Oral Agents. Diabetes (Suppl 1), 1990. (C)


Simcic KJ, McDermott MT, White JC, Kidd GS: Crossover Comparison of Maximum Dose Glyburide and Glipizide in NIDDM. Submitted for publication, 1990. (C)


Gastroenterology Service


McNally PR, Herrera JL, Brewer TG, Visvesvara GS, Engelkirk PG: Immunofluorescent Antibody (IFA) Testing in Microscopically Proven Giardiasis. (submitted for publication) 1990. (C)

McNally PR, Theoharides AD, Peggins JO, Schuster BG, Brewer TG: Pharmacokinetics of Anteether in the Isolated Perfused Rat Liver (IPRL) Model. (submitted for publication) 1990. (C)


General Medicine Service


Infectious Disease Service


Internal Medicine Service - No Report

Nephrology Service - No Report

Neurology Service - Negative Report

Hematology/Oncology Service - No Report
Pulmonary Disease Service


Kollef MH: Chronic Pleural Effusion Following Coronary Artery Revascularization with the Internal Mammary Artery. CHEST, 97:750-751, 1990.


Rheumatology Service - No Report
General Surgery Service


Ophthalmology Service


Neurology Service - No Report

Orthopedic Service


Gillogly SD, Hockenbury RT: Assessment and Primary Management of the Acutely Injured Knee. Accepted for publication in Modern Medicine, 1990. (C)

Ginther JR: Development of an Ambulatory Recorder for Evaluation of Muscle Tension Related Low Back Pain and Fatigue in Soldier's Normal Environments. Accepted for publication in Military Medicine, 1990. (C)

Ginther JR, Eilert RE: Missed Monteggia Fractures Treated with the Bell Tawse Procedure. Accepted for publication in Orthopaedic Transactions, 1990. (C)


Pruitt A, Friermood TG: Tibia Fractures Treated with Reamed Intramedullary Nails: A Clinical and Biomechanical Analysis. (C)

Rak KM, Gillogly SD, Schaefer RA, Yakes WF, Liljedahl RR: anterior Cruciate Ligament Reconstruction: Evaluation with MR. Accepted for publication in Radiology, 1990. (C)


Otolaryngology Head and Neck Surgery Service


Plastic Surgery Service - No Report

Thoracic Surgery - No Report

Urology Service - No Report

DEPARTMENT OF CLINICAL INVESTIGATION


Chedester AL, Bakarich AC, Rabin BM, Banks RE, Hadick CL: Preparation and Care of the Area Postrema Lesioned Cat. J Invest Surg, 2:3, Fall 89. (C)


Sherman KA, Freeman S, Harrison S, Andron L: Prevalence of Antibody to Hepatitis C Virus in Patients Infected with the Human Immunodeficiency Virus (submitted to Ann Int Med) 1990. (C)


DEPARTMENT OF PEDIATRICS

Adolescent Medicine Service


Neonatology Service


General Pediatric Service - Negative Report

No Report

DEPARTMENT OF PATHOLOGY AND ALS

PHYSICAL MEDICINE SERVICE


DEPARTMENT OF NURSING


DEPARTMENT OF PRIMARY CARE AND COMMUNITY MEDICINE


DEPARTMENT OF RADIOLOGY


Yavorski RT, Hallgren SE, Blue PW: The Effects of Verapamil and Diltiazem on Gastric Emptying in Normal Subjects. Dig Dis Sci, 1990. (C)

Radiation Therapy Service

PRESENTATIONS

(C) = Protocol Related
DEPARTMENT OF MEDICINE

Allergy Service

Brown JS, Green EW: Evaluation of Thermography in Delineation of Late Phase Skin Tests: Presented: Harold S. Nelson Allergy Symposium, FAMC, February 1990 and the American Academy of Allergy and Immunology, Baltimore, MD, March 1990. (C)


Goodman DL: Pediatric Food Allergy: Presented: XVIth Scientific Assembly of the Uniformed Services Academy of Family Practice, Richmond VA, March 1990. (C)

Goodman DL: Pediatric Allergy: Treat or Refer: Presented: XVIth Scientific Assembly of the Uniformed Services Academy of Family Practice, Richmond VA, March 1990. (C)


Cardiology Service - No Report

Endocrinology Service


Georgitis WJ, Abrams LF, Dolbow A, Bunker DM: Bone Densitometry in Patient Taking Thyroid Extract: Accepted for presentation 6th Annual Army Regional ACP Meeting, October 1989, San Francisco, Ca. (C)

Georgitis WJ, McDermott MT: Iodine Water Purification Tablets Alter Thyroid Function in Man: Accepted for presentation 6th Annual Army Regional ACP Meeting, October 1989, San Francisco, Ca. (C)


Simcic KJ, McDermott MT, White JC, Kidd GS: Crossover Comparison of Maximum Dose Glyburide and Glipizide: Accepted for presentation 6th Annual Army Regional ACP Meeting, October 1989, San Francisco, Ca. (C)


Gastroenterology Service


McNally PR, Peggins JO, Brewer TG, Schuster BG, Theoharides AD: Pharmacokinetics and Metabolism of Arteether in the Isolated Perfused Rat Liver Model: Presented: American Society of Tropical Medicine and Hygiene, Honolulu, HI, December 1989. (C)

General Medicine Service

Weaver MJ, Ow CL, Walker DJ, Degenhardt EF: Evaluation of Residents Humanistic Qualities by Patients and Attending Physicians: Presented: 5th Biannual Symposium for Teaching Internal Medicine, Boston, MA, Nov 1989. (C)

Hematology/Oncology Service - No Report

Internal Medicine Service - No Report

Pulmonary Disease Service


Meyer JI: Transtracheal Oxygen (TTO) and Weight Gain in Chronic Obstructive Pulmonary Disease (COPD) Patients: Presented: Annual Meeting of the American Thoracic Society, Boston, MA, May 1990. (C)


Nephrology Service - No Report
Neurology Service - No Report

Rheumatology Service - No Report

DEPARTMENT OF SURGERY

General Surgery Service


Freeman IHG, Clark JR: The Fitzsimons Experience with Thyroid Cancer: A Twenty Year Review: Presented: Gary P. Wratten Surgical Symposium, Washington, DC, April 1990. (C)


Ophthalmology Service


Orthopedic Service


Otolarvngology Service - Speech Language Rehabilitation Section


Ferrer-Vincent ST: Audiology/Audiologist in the Care of Children with Otitis Media, Part of a University of Northern Colorado, Greeley, CO continuing education course, October 1989.


Otolarvngology Head and Neck Surgery Service


Plastic Surgery Service - No Report

Thoracic Surgery - No Report

Urology Service - No Report

DEPARTMENT OF CLINICAL INVESTIGATION


Banks RE: Care and Management of Laboratory Animals: Presented: Walter Reed Army Institute of Research Military Medical Research Fellowship, July 1990.


Harrison SM, et al: Ability to Distinguish Between 800mg ZDV/Day and Placebo by Walter Reed/DOD Classification Scheme of Progression in a Double Blind Study of DoD 2-5 with <500 CD4/mcL: Presented: 5th International HIV Conference, San Francisco, Ca., 1990. (C)


DEPARTMENT OF OB-GYN


DEPARTMENT OF PEDIATRICS

General Pediatric Service - Negative Report

Neonatal Service


26.
No Report - - - DEPARTMENT OF PATHOLOGY AND ALS

PHYSICAL MEDICINE SERVICE

Bavaro, S: Occupational Therapy Assessment and Treatment of Affective Disorders and Neurotic Disorders: Presented: Colorado State University; Fort Logan, Colorado, May 1990.

DEPARTMENT OF NURSING

Degenhardt EF: Health Locus of Control and Health Maintaining Activities of the Type II Diabetic: Presented: Army Nurse Research Symposium, Quade Center, Fitzsimons Army Medical Center, March 1990.


DEPARTMENT OF PRIMARY CARE AND COMMUNITY MEDICINE

Negative Report

No Report - - - - DEPARTMENT OF PSYCHIATRY

DEPARTMENT OF RADIOLOGY


SOCIAL WORK SERVICE


(1) Date: 30 Sep 90  (2) Protocol #: 80/120  (3) Status: Ongoing

(4) Title: Evaluation of Carbohydrate Metabolism in Thyrotoxicosis: Investigations into the Frequency, Type and Mechanisms of Carbohydrate Tolerance

(5) Start Date: 1981  (6) Est Compl Date: 1991

(7) Principal Investigator: Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrinology

(10) Associate Investigators:
    Fred D. Hofeldt, COL, (Ret)
    Robert J. Sjoberg, MAJ, MC

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(15) Study Objective: The first objective of the study is to determine the frequency and reversibility of carbohydrate intolerance in thyrotoxicosis and to determine the importance of gut factors by doing oral and intravenous glucose tolerance test. The second objective is to study the mechanisms of carbohydrate intolerance. This objective will be approached by measuring glucose, insulin, glucagon and free fatty acids, basally and after oral intravenous glucose and by measuring the responses to exogenous insulin.

(16) Technical Approach: Ten non-diabetic patients who are taking no medications, are less than age 45, are less than 120% of ideal body weight, will be studied while thyrotoxic and after recovery. Each
patient will have an oral and an intravenous glucose tolerance test. Each patient will have an insulin tolerance test basally and following glucose infusion.

(17) Progress: No patients have been enrolled in this study during the past academic year. The research study is still entirely valid and worthwhile in purpose. The principal investigator has not had adequate time to pursue this project as it is very complex. However, it is still hoped that a new Endocrine Fellow will pick up this project and complete it within the next year to a year and a half. A tremendous amount of effort has already been expended on this study, and it is requested that the protocol be continued in hopes of mobilizing associate investigators to pursue the project.

Publications and Presentations: None
(1) Date: 30 Sep 90 (2) Protocol #: 81/117 (3) Status: Ongoing

(4) Title: The Role of Calcitonin in Osteoporosis

(5) Start Date: Reactivate 1987 (6) Est Compl Date:

(7) Principal Investigator: Michael T. McDermott, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators: Gerald S. Kidd, COL, MC

(11) Key Words:
    osteoporosis
    bone density
    calcitonin deficiency
    thyroid hormone

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Aug 90 b. Review Results: ongoing
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date: 35
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine if, longitudinally, thyroid cancer patients who have calcitonin deficiency and are on suppressive doses of thyroid hormone, loose radial bone more rapidly than goiter patients, who are also on suppressive doses of thyroid hormone but are not calcitonin deficient, and than normal controls. Also to compare these 3 groups, cross-sectionally, for bone density of the spine and hip.

(16) Technical Approach: 3 Groups: (a) thyroid cancer patients - calcitonin deficient and on thyroid hormone; (b) goiter patients - not calcitonin deficient but are on thyroid hormone, and (b) normal

(17) Progress: Thyroidectomized patients had lower bone density in the forearm in the first cross-sectional analysis but after 2 years did not lose bone at a greater rate than goiter or control patients. 6-8 year longitudinal data in the forearm and cross-sectional data in the spine and hips have been collected in most patients but the data have not yet been analyzed. (FY 90) Many of the initial subjects have had their followup single photon absorptiometry and their initial dual photon absorptiometry, but not all have been restudied as of yet. Subjects benefit from knowledge of their bone density value but have no other benefit.

Publications:


Presentations:

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 81/118  (3) Status: Ongoing

(4) Title: Hypothalamic Pituitary Gonadal Function in Hypothyroidism

(5) Start Date: 1981  (6) Est Compl Date: Indefinite

(7) Principal Investigator:  Michael T. McDermott, LTC, MC
(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators: Gerald S. Kidd, LTC, MC

(11) Key Words: hypothyroidism
gonadal dysgenesis
gonadotropins, pituitary

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date: 1 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: The objectives of this protocol are to define more clearly the mechanisms of gonadal dysfunction occurring in hypothyroidism and to see if these abnormalities resolve after treatment of the hypothyroid state.

(16) Technical Approach: A prospective study to assess in a pair manner results of alterations in HPG axis as a consequence of hypothyroidism when evaluated with GnRH infusion and TRH testing, clinical stimulation and HCG testing in males and females.

(17) Progress: No progress in the past year.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 81/119  (3) Status: Completed

(4) Title: The Effect of Thyrotropin Releasing Hormone on Gonadotropin Releasing Hormone Stimulated Gonadotropin Secretion

(5) Start Date: 1981  (6) Est Compl Date: 

(7) Principal Investigator: Michael T. McDermott, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine  (10) Associate Investigators: Gerald S. Kidd, LTC, MC

(11) Key Words:
    hypothyroidism
    gonadal dysgenesis

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 6/90 b. Review Results: Comp.  c. Number of Subjects Enrolled During Reporting Period: 6 d. Total Number of Subjects Enrolled to Date: 16 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: In order to gain a better insight into the mechanism of gonadal dysfunction in hypothyroidism, the objective of this protocol is to study the effect of a thyrotropin releasing hormone (TRH) infusion on basal and gonadotropin releasing hormone (GnRH) stimulated gonadotropins in normal subjects.

(16) Technical Approach: Sixteen normal males will be studied with either a normal saline infusion or a TRH infusion. During these infusions, GnRH will be given as a bolus with measurement of appropriate hormone to determine interaction between releasing hormones.

(17) Progress: Sixteen subjects have been studied and the data analysis is complete. The TRH infusion produced a statistically significant
augmentation of the FSH response (both peak and total integrated response) to GnRH, while the LH response was unaffected.


Presentations: None
Date: 30 Sep 90  Protocol #: 82/114A  Status: Terminated

Title: Growth of Basal Cell Carcinoma Cells in Defined Medium and Study of their Growth and Immunological Characteristics

Start Date: 1982  Est Compl Date: 1990

Principal Investigator: Charles F. Ferris, MAJ, MS

Facility: FAMC

Dept/Svc: DCT

Associate Investigators:

Key Words: basal cell, carcinoma

Accumulative MEDCASE:*  Est Accum OMA Cost:*

Refer to Unit Summary Sheet of this Report.

Study Objective: Growth and study of basal cell carcinoma cells in culture.

Technical Approach: The approach to culturing of basal cells has, and will be the use of the media formulated by Dr. Ham's lab at the University of Colorado in Boulder termed MCDB 153. We have been successful to date in culturing normal cell carcinomas. This has included an attempt utilizing fibronectin coated plates. We next will be attempting growth utilizing basal cell tumors that we have successfully grown in nude mice.

Progress: The Dermatology Service is unable to continue support. No further progress occurred.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 83/107  Status: Ongoing

Title: Use of Isotretinoin in Prevention of Basal Cell Carcinoma

Start Date: 1984  Est Compl Date: 1991

Principal Investigator:  Facility: FAMC
M. James Schleve, LTC, MC  FAMC

Dept/Svc: MED/Dermatology  Associate Investigators:
(10) Scott Bennion, LTC, MC
Key Words:
retinoids  Richard Gentry, LTC, MC
basal cell carcinoma  Kathy David, MAJ, MC

Accumulative MEDCASE:*  Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  NA  
d. Total Number of Subjects Enrolled to Date:  98  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". Dry skin, chapped lips, myalgias.

Study Objective: To evaluate the effectiveness of low dosage levels of Isotretinoin in reducing the incidence of basal cell carcinomas in high risk population; to examine possible side effects with long term administration of isotretinoin.

Technical Approach: The study is a double-blind study with participants randomly assigned to the medication. Patients will take the medication for three years and will be followed for a total of four-five years. Compliance side-effects and basal cells are very closely monitored.

Progress: Total 98 patients randomized. 84 remain on the study. Five patients are deceased: Four have transferred to other sites: Five other are off the study for misc reasons. All patients have completed the three years on the medication and have been notified as to whether or not they were on isotretinoin or the placebo. All patients have opted to stay on the program until closure which will be 30 Sept 1991.
Publications:


Presentations:


Helpful Hints for Dermatological Surgery - Thirteenth Annual Tri-Services Dermatology Symposium, San Antonio, Texas.
Date: 30 Sep 90  Protocol #: 83/113A  Status: Ongoing

Title: Growth of Human Keratinocytes

Start Date: 1983  Est Compl Date:

Principal Investigator: Ronald L. Jackson, CPT, MS

Facility: FAMC

Dept/Svc: DCI  Associate Investigators: Scott D. Bennion, LTC, MC
Jose A. CruzSaez, SPC
Rodncy F. Williams, SPC

Key Words: keratin

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Study Objective: Growth and study of human keratinocytes in culture and subsequent studies using athymic mice as an in vivo culture system.

Technical Approach: The technical approach has been to grow keratinocytes obtained from newborn foreskins using serum-free media. A more successful approach has been to culture the cells in complete MCDB 153 media. A new mechanism of freezing the cells has commenced. The final phase of the study will include identifying specific proteins expressed by these cells and the presence of protein hormone receptors on the cell surfaces.

Progress: Improved growth of cultures, new principal investigator on this study.
Publications:

Grimwood RE, Clark RAF, Baskin JB, Nielson LD, Ferris CF: Fibronectin is Deposited by Keratinocytes in the Basement Membrane Zone during Tissue Organization. Accepted for publication in Journal of Investigative Dermatology.


Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 83/122  (3) Status: Ongoing

(4) Title: The Role of Food Allergy in the Pathogenesis of Migraine Headaches

(5) Start Date: 1983  (6) Est Compl Date: 1990

(7) Principal Investigator: Thurman R. Vaughan, MAJ, MC
(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy  (10) Associate Investigators:

(11) Key Words:
migraine
food hypersensitivity
mediators

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
    b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period: 12
    d. Total Number of Subjects Enrolled to Date: 104
    e. Note any adverse drug reactions reported to the FDA or sponsor for
    studies conducted under an FDA-awarded IND. May be continued on a
    separate sheet, and designated as "(14)e": None

(15) Study Objective: To study the value of allergy food skin test in
directing and defining a diet which will cause a decrease in the
frequency of migraine headaches in affected patients. To determine if
immunological mediators can be detected in positive responders.

(16) Technical Approach: Approximately 100 patients with dx of migraine
headaches who suffered 3 or more MAs/month will keep a 1 month food
diary/st diary. They will then be skin tested to 83 common foods and
undergo an additional 1 mo diet eliminating suspected food, and skin
test positive foods. Positive regimens will be studied with open chall.
and double blind food challenge with immunologic mediators precursors.
CONTINUATION SHEET, FY 90, ANNUAL PROGRESS REPORT  Protocol #: 83/122

(17) Progress: 104 patients completed the protocol. 37% report a 50% reduction in migraine frequency; 17 patients with positive double-blind food challenge. Five patient: studied with histamine, PGD2 determinations during DBPCFC's. No problems encountered. Results of immunol. studies show initial increase in histamine and PGD2 and late rise of PGD2 alone during active challenge. Source of late PGD2 is unclear. Request one year extension to study additional patients with addition of serotonin assay. This will allow cell source of PGD2 to be determined (basophil vs platelet).

Presentations:


Publications:


(4) Title: The Role of Altered Prostaglandin Synthesis in the Impaired Water Excretion and Abnormal Renin-Aldosterone Axis of Hypothyroidism

(15) Study Objective: The objective of this study is to determine in an indirect manner i.e., with prostaglandin synthesis inhibition, if the abnormal suppressibility of vasopressin and/or altered renal sensitivity to vasopressin seen in hypothyroid patients is caused by altered prostaglandin levels. This will be done by measuring serum vasopressin levels and urinary water excretion in response to a water load, as well as the renal response to exogenous vasopressin, in hypothyroid patients with and without prostaglandin synthesis inhibition, both before and after treatment with thyroid hormone to the point of euthyroidism. In the same way, the influence of altered prostaglandin levels on the renin-aldosterone axis of hypothyroidism will be studied by measuring plasma renin activity and aldosterone levels in these patients while in
a relatively volume depleted state, that is before the water loading is performed. Altered renal prostaglandin synthesis in hypothyroidism will also be assessed directly by measuring urinary PGE-2 excretion in the hypothyroid and euthyroid states. (Urinary PGE-2 excretion is thought to reflect primarily renal PGE-2 production.)

(16) Technical Approach: By measuring urinary prostaglandin E and water loading responses in hypothyroid patients before and after indomethacin administration as well as measuring plasma, aldosterone, and plasma renin activity we will evaluate the effects of prostaglandin synthesis inhibition on water metabolism.

(17) Progress: Because of competing priorities, no subjects have yet been studied. A new fellow will be assigned to complete the study, protocol is still worthwhile and should be continued.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-2J as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 84/100  (3) Status: Ongoing

(4) Title: The Effect of Abnormal Thyroid State on the Metabolism of Theophylline and Methylprednisolone

(5) Start Date: 1984  (6) Est Compl Date: 1990

(7) Principal Investigator: Michael T. McDermott, LTC, MC
    Ray Vaughan, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators:
     Stanley J. Szefler, MD
     Harold S. Nelson, MD

(11) Key Words:
     theophylline
     methylprednisolone
     hyperthyroidism
     hypothyroidism

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:
    b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period: 0
    d. Total Number of Subjects Enrolled to Date: 7
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e" None

(15) Study Objective: To determine whether hyperthyroidism and hypothyroidism result in alterations of theophylline and methylprednisolone metabolism.

(16) Technical Approach: Hypo- and hyperthyroid subjects are studied when thyroid function is abnormal and again when it is normal by studying the disappearance rate of theophylline and methylprednisolone from serum after bolus injections.

(17) Progress: No further patient enrollment. A manuscript is being prepared.

Publications: None
**Date:** 30 Sep 90  
**Protocol #:** 84/115  
**Status:** Completed

**Title:** Heterotransplantation of Basal Cell Carcinomas to Nude Mice

**Start Date:** 1984  
**Est Compl Date:** 1990

**Principal Investigator:** Charles F. Ferris, MAJ, MS

**Facility:** FAMC

**Dept/Svc:** DCI

**Key Words:** carcinoma, basal cell transplantation mice, nude

**Study Objective:** To develop an in-vivo model of human basal cell carcinoma in the athymic mouse.

**Technical Approach:** Basal cell carcinoma tissue obtained from excess tissue obtained from Moh's surgery is transplanted to a subcutaneous pocket created by a linear incision on the abdomen of the nude mouse. The mouse will have been splenectomized and transplantation is followed by weekly intraperitoneal injections of antilymphocyte serum. Tumor weight is taken before implantation and measurements of tumor size taken at weekly intervals. Autoradiography and immunofluorescent studies are performed at the time of tumor harvest as well as routine histology and tumor weight.

**Progress:** No progress this year. Dermatology Service is unable to continue support.
Presentations:


Publications:


FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 84/119 (3) Status: Ongoing

(4) Title: Treatment of Graves' Ophthalmopathy with Cyclosporin

(5) Start Date: 1984 (6) Est Compl Date: 1992

(7) Principal Investigator:
   Michael T. McDermott, LTC, MC
   Leonard Wartofsky, COL, MC

(8) Facility: FAMC
   WRAMC
   MAMC
   BAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators
      Anthony Truxal, CPT, MC

(11) Key Words:
      eye disease
      cyclosporin
      prednisone

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
      *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date: 5
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". Cyclosporine - Acne (1 pt.) Prednisone - Acne, swelling (1 pt.) Arthralgia on withdrawal (1 pt.)

(15) Study Objective: To determine the effectiveness of cyclosporin in the treatment of Graves' eye disease.

(16) Technical Approach: Patients with Graves' eye disease will receive a 3-week course of cyclosporine or prednisone, then have a 3-week rest. Then, 3 weeks of prednisone or cyclosporine (crossover). They will be followed by complete eye examination and CT scan of the orbits before and after each drug period, and twice weekly with CBC, SMA-18, urinalysis and B-2 microglobulin (urine).

(17) Progress: No new patients enlisted from FAMC in the past year. Two patients added from other medical centers. Results in patients evaluated thus far as a group are kept at Walter Reed and have not yet been analyzed.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 85/100  (3) Status: Ongoing

(4) Title: Adjuvant Chemotherapy with 5-Fluorouracil, Adriamycin and Mitomycin-C (FAM) vs. Surgery Alone for Patients with Locally Advanced Gastric Adenocarcinoma, Phase III SWOG #7804

(5) Start Date: 1978  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 85/102  Status: Completed

Title: Combined Modality Therapy for Breast Carcinoma, Phase III SWOG #7827

Start Date: 1979  Est Compl Date: 1990

Principal Investigator: Thomas Cosgriff, COL, MC

Dept/Svc: MED/Hema/Oncol

Associate Investigators

Key Words:
  drug therapy

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date: 1

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Closed to patient accrual.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 85/122 (3) Status: Completed

(4) Title: Treatment of Advanced Bladder Cancer with Preoperative Irradiation and Radical Cystectomy vs. Radical Cystectomy Alone, Phase III
SWOG #8221

(5) Start Date: 1982 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Daniel Tell, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Completed.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 85/132  Status: Completed

Title: Evaluation of Adjuvant Therapy and Biological Parameters in Node Negative Operable Female Breast Cancer, Intergroup Study

Start Date: 1982  Est Compl Date: 1990

Principal Investigator: Thomas Cosgriff, COL, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators

Key Words: drug therapy

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 9 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Closed to patient accrual.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 85/133  Status: Completed

Title: Treatment of Limited Non-Small Cell Lung Cancer: Radiation Versus Radiation Plus Chemotherapy (FOMi/CAP), Phase III SWOG #8300

Start Date: 1984  Est Compl Date: Indefinite

Principal Investigator: Daniel Tell, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators

Key Words: drug therapy

Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Completed.

Publications and Presentations: None
(1) Date: 30 Sep 90 (2) Protocol #: 85/136 (3) Status: Completed

(4) Title: Multiple Drug Adjuvant Chemotherapy for Patients with ER Negative Stage II Carcinoma of the Breast, Phase III SWOG #8313

(5) Start Date: 1974 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: AMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 
   b. Review Results: 
   c. Number of Subjects Enrolled During Reporting Period: 
   d. Total Number of Subjects Enrolled to Date: 0
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Closed.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 85/139  (3) Status: Ongoing

(4) Title: National Intergroup Protocol for Intermediate Thickness Melanoma 1.0-4.0 mm. Evaluation of Optimal Surgical Margins (2 vs 4 cm) Around the Primary Melanoma and Evaluation of Elective Regional Lymph Node Dissection
SWOG #8393

(5) Start Date: 1983  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Thomas Cosgriff, COL, MC
(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing
Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 85/141  Status: Completed

Title: Evaluation of DTIC in Metastatic Carcinoid, Phase II SWOG #8411

Start Date: 1984  Est Compl Date: Indefinite

Principal Investigator: Thomas Cosgriff, COL, MC

Dept/Svc: MED/Hema/Oncol

Key Words:
- drug therapy

Accumulative MEDCASE:*

*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:
Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date: 0

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Closed.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 85/142  Status: Completed

Title: Evaluation of Tamoxifen in Unresectable and Refractory Meningiomas, Phase II  SWOG #8415

Start Date: 1984  Est Compl Date: Indefinite

Principal Investigator:  Thomas Cosgriff, COL, MC

Dept/Svc: MED/Hema/Oncol  Associate Investigators

Key Words:  drug therapy

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:  Total Number of Subjects Enrolled to Date:  Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Closed to patient accrual.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 85/147  Status: Completed

Title: HLA and Gm Genes in Systemic Lupus Erythematosus Antibody Expression

Start Date: 1985  Est Compl Date: 1988

Principal Investigator: Christopher LeSueur, MD Sterling West, MD

Facility: FAMC

Dept/Svc: MED/Rheumatology

Associate Investigators

Key Words: lupus erythematosus, systemic HLA antigens

Study Objective: To see if patients with systemic lupus erythematosus have increased prevalence of any HLA and Gm genes as it relates to their autoantibody expression compared to a control group.

Technical Approach: After patient education and consent form is signed, the patient has eight tubes of heparinized blood drawn for HLA and Gm typing. The patient's clinical symptoms, signs and other laboratory parameters are collected according to protocol and correlated with the patient's HLA and Gm typing.

Progress: A total of 150 patients have been HLA and Gm typed. Data collected from this protocol is presently being compiled for publication.

Publications and Presentations: More
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 85/157 (3) Status: Completed

(4) Title: Phase III Study to Determine the Effect of Combining Chemotherapy with Surgery and Radiotherapy for Resectable Squamous Cell Carcinoma of the Head and Neck SWOG #8590

(5) Start Date: 1985 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words: chemotherapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Closed.

Publications and Presentations: None

63
(1) Date: 30 Sep 90  
(2) Protocol #: 85/158  
(3) Status: Completed

(4) Title: NCI Intergroup #0035, An Evaluation of Levamisole Alone or Levamisole Plus 5-Fluorouracil as Surgical Adjuvant Treatment for Resectable Adenocarcinoma of the Colon, Phase III-Intergroup  
SWOG #8591

(5) Start Date: 1985  
(6) Est Compl Date: 1990

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(10) Associate Investigators

(11) Key Words:  
drug therapy

(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 2  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach:  See Protocol

(17) Progress: Closed to patient accrual.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90   (2) Protocol #: 85/163   (3) Status: Completed

(4) Title: The Effect of Theophylline and Nifedipine on Hormone Secretion

(5) Start Date: Reactivate 1987   (6) Est Compl Date:

(7) Principal Investigator: Michael McDermott, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators
     Gerald S. Kidd, COL, MC

(11) Key Words:
     theophylline
     nifedipine

(12) Accumulative MEDCASE:*   (13) Est Accum OMA Cost:*
     *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
     b. Review Results:
     c. Number of Subjects Enrolled During Reporting Period:
     d. Total Number of Subjects Enrolled to Date: 10
     e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objectives of this protocol are to study the effect of theophylline and nifedipine on hormone secretion patterns in order to probe the intracellular mechanisms of hormone secretion and to better understand the effects of these medications on endocrine function tests.

(16) Technical Approach: Subjects will have a combined pituitary stimulation study (TRH, GnRH and ACTH) on 3 occasions: control period, during a theophylline infusion, after 2 days of taking nifedipine. Basal and peak hormone responses to the stimulating hormones will be compared among the 3 periods.
CONTINUATION SHEET, FY 90, ANNUAL PROGRESS REPORT  Protocol #: 85/163

(17) Progress: 10 subjects have been studied. Theophylline enhanced the cortisol response to ACTH but no other hormone responses. Nifedipine had no significant effect on any hormone response.


Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 89  (2) Protocol #: 85/165A  (3) Status: Ongoing

(4) Title: An Evaluation of Cross Allergenicity Among Pollen Extracts of Members of the Chenopodiaceae and Amaranthaceae

(5) Start Date: 1985  (6) Est Compl Date: 1990

(7) Principal Investigator:
David Goodman, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy  (10) Associate Investigators

(11) Key Words: R. Ledoux
pollen
hypersensitivity
allergens
Bernard L. Crosby, MAJ, MC

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate patterns of cross allergenicity among pollens of the weed families, Chenopodiaceae and Amaranthaceae.


(17) Progress: Comparison of Adjuvant Preparations. We are presently completing the immunoassays (CIE, ELISA, SDS-PAGE, and immunoblots) necessary to define quantitative and qualitative antibody production (in the rabbit model) utilizing the four adjuvant systems: Freund's adjuvant, RIBI adjuvant system, Aluminum hydroxide. Assessments of Antigenicity will be completed during the first 6 months of the calendar year 1990. These are presently under way and include SDS-PAGE and IEF separation of allergenic extract proteins, and subsequent characterization of antigenicity by crossed-immunoelectrophoretic assays. Assessments of allergenicity and cross-reactivity will similarly be completed during FY 90. Presently, we are comparing cross-
specific rabbit antipollen antibody (IgG) production, and specific human antipollen antibody (IgE, IgG) production. Additionally, we are developing an enzyme-linked crossed-immunoelectrophoretic assay that may offer additional evidence of allergenic similarities amongst these weed pollen family members. This protocol using polyvalent antisera from the rabbit model will represent an important foundation step for the work of MAJ Larsen from this Service utilizing monoclonal antibodies. The delineation of the specific allergenic epitopes of these pollen families is realistically achievable.

Presentations:


Publications: Two publications expected to be completed this FY.
(4) Title: Colon Inflammation in Reiter's Syndrome: Response to Sulfasalazine. Results in a Controlled Study

(9) Dept/Svc: MED/Rheumatology

(10) Associate Investigators:

(14) a. Date, Latest IRC Review: 
   b. Review Results: 
   c. Number of Subjects Enrolled During Reporting Period: 10
   d. Total Number of Subjects Enrolled to Date: 0
   e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: To see if patients with idiopathic Reiter's syndrome have colon inflammation and to see (in double-blinded fashion) if this responds to Sulfasalazine.

(16) Technical Approach: Colonoscopy with biopsy is performed on Reiter's patients and controls (patients with inflammatory arthritis that is not Reiter's).

(17) Progress: Completed, manuscript in preparation. Patients and controls continue to be added to the protocol. Although numbers are still small, patients with Reiter's seem to have a favorable response to Sulfasalazine, and their microscopic inflammation improves as well. A small number of new patients (10) have been added this FY and patients treated with Sulfasalazine continue to be followed closely for 6-8 months.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 85/167  (3) Status: Ongoing

(4) Title: The Effect of Age on Thyroid Function Studies: The Perchlorate Discharge Test

(5) Start Date: 1985  (6) Est Compl Date: 1991

(7) Principal Investigator: Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators

William J. Georgitis, MAJ, MC
Michael T. McDermott, MAJ, MC
Peter Blue, LTC, MC
Stephen M. Manier, MAJ, MC
Tony L. Walden, CPT, MC

(11) Key Words:
thyroid diseases
thyroid function tests
thyroid gland

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date: 12
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective of this study is to determine the effect of age on the perchlorate discharge test in individuals with thyroid disease.

(16) Technical Approach: Patients over the age of 60 years without thyroid disease by history, physical examination and lab evaluation will be studied. A perchlorate test will be performed in Nuclear Medicine.

(17) Progress: No progress has been made due to inadequate time of principal investigator; however, the study is thought to still be valid and worthwhile. A new Endocrine Fellow will pick up this protocol and complete it.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 85/174  (3) Status: Completed

(4) Title: Evaluation of Combination Chemotherapy Using High Dose ARA-C in Adult Acute Leukemia and Chronic Granulocytic Leukemia in Blastic Crisis, Phase III
SWOG 8326/27

(5) Start Date: 1983  (6) Est Compl Date: 1990

(7) Principal Investigator:
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words:
drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:________ b. Review Results:________
c. Number of Subjects Enrolled During Reporting Period: 0 d. Total Number of Subjects Enrolled to Date: 1
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Closed to patient accrual

Publications and Presentations: None

72
Date: 30 Sep 90  Protocol #: 86/10X-001  Status: Terminated

Title: Feasibility Study to Determine if Estrogen and Progesterone Affect in-vitro Growth of Cultured Malignant Melanoma (MM) Cell Lines

Start Date: 1986  Est Compl Date: 1990

Principal Investigator: Charles F. Ferris, MAJ, MS

Facility: FAMC

Dept/Svc: MED/Dermatology

Associate Investigators:
Donald B. Mercill, DAC
Thomas P. O'Barr, DAC
Charles F. Ferris, CPT, MS

Key Words:
malignant melanoma receptors estrogen progesterone

Study Objective: To determine whether malignant melanoma cell lines previously obtained and stored (frozen) have estrogen and progesterone receptors. If receptors can be identified, then a full scale protocol can be undertaken to determine if estrogen and progesterone have an effect on cell growth.

Technical Approach: Malignant melanoma cells lines currently stored in the Cell Physiology Service will be grown to confluence. Specific binding will be characterized utilizing a dextran-coated charcoal technique.

Progress: The feasibility study did not support the original hypothesis.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 86/103  (3) Status: Completed

(4) Title: Evaluation of Low Dose Ara-C versus Supportive Therapy Alone in the Treatment of Myelodysplastic Syndromes (ECOG EST 4483)
   SWOG #8592

(5) Start Date: 1985  (6) Est Compl Date: Indefinite

(7) Principal Investigator:  (8) Facility: FAMC
   Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words:  
   drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
   *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Closed to patient accrual.

Publications and Presentations: None

74
In-Vitro Drug Sensitivity Utilizing the Guinea Pig Airway Smooth Muscle Model

Study Objective: We have previously demonstrated in the guinea pig tracheal model the development of subsensitivity to beta-adrenergic agonists. It would now be useful to have an animal model in which we can safely study the pharmacodynamic interactions involved in beta-adrenergic blocker induced bronchoconstriction. Specifically, it will be important to determine the direct effects of beta-adrenergic blockers on tracheal smooth muscle prior to histamine-induced tracheal constriction. Then, it will be important to determine the effects of beta-adrenergic agonists and anticholinergics on beta-adrenergic blocker induced tracheal constriction.

Technical Approach: In-vitro blockade of beta-adrenergic receptors of the guinea pig tracheal model will be achieved after the guinea pig tracheas have been excised, divided into segments, and placed into tissue chambers under physiologic conditions. Subsequently, the effects of beta-adrenergic blockers will be studied before and after the induction of tracheal smooth muscle contraction by histamine. Finally, the effects of beta-adrenergic agonists and anticholinergics on the beta-adrenergic blocker induced tracheal smooth muscle constriction will be studied.
(17) Progress: (a) Propranolol (10-4M) causes no significant tracheal smooth muscle contraction. (b) Pretreatment with propranolol potentiates histamine-induced tracheal smooth muscle contraction. (c) Pretreatment with propranolol attenuates albuterol reversal of histamine-induced smooth muscle contraction. (d) We have established an in-vitro model with which we can safely study the pharmacodynamic interactions involved in beta-blocker potentiated bronchoconstriction. (e) Atropine methylnitrate causes no significant reversal of the histamine-induced tracheal smooth muscle contraction during the observation period (5-10 minutes). (f) Atropine sulfate causes reversal of the histamine-induced tracheal smooth muscle contraction. (g) Propranolol (10-6M) causes no significant tracheal smooth muscle contraction. (h) Pretreatment with propranolol (10-6M) appears to potentiate histamine-induced tracheal smooth muscle contraction. (i) Both g & h are important because of 10-6M propranolol reflects reported tissue concentrations of propranolol in the lung.


FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 86/109  (3) Status: Ongoing

(4) Title: The Effect of INH and Combination INH-Rifampin Therapy on Calcium and Vitamin D Metabolism

(5) Start Date: 1986  (6) Est Compl Date: 1991

(7) Principal Investigator: John Merenich, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators
    Gerald S. Kidd, LTC, MC
    Michael E. Perry, COL, MC
    Michael T. McDermott, MAJ, MC
    Fred Negron, CPT, MC
    Peter Blue, LTC, MC

(11) Key Words: calcium
    vitamin D
    rifampin
    vitamin D deficiency

(12) Accumulative MEDCASE:* Refer to Unit Summary Sheet of this Report.

(13) Est Accum OMA Cost:*

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 0 d. Total Number of Subjects Enrolled to Date: 7 e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: The purpose of this study is to see if INH therapy alters vitamin D and/or calcium metabolism in a significant manner. This may then lead to further evaluation to determine if patients would benefit from vit D or calcium supplementation while receiving INH therapy.

(16) Technical Approach: Ten to 20 patients will be begun on INH therapy for their recent PPD conversion. Determinations of Vit D (25-OH, 1,25-OH), serum calcium, PTH, 24-hour urine calcium and SMA-18 are drawn at baseline, 2 weeks, 6 and 9 months. Bone densitometry is obtained before and after therapy.

(17) Progress: Seven patients have been entered in the study as of this date. No progress made concerning patients. The following events and progress has been made: 1) Protocol approved in November at Eisenhower AMC (Dr. Asp); 2) A plan has been set up with LTC Criswell, Preventive Medicine, for recruiting patients.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 86/114  Status: Ongoing

Title: Natural History of HTLV-I Infection and Disease in a United States Military Community

Start Date: 1986  Est Compl Date: 1996

Principal Investigator: Gates, Robert H. LTC, MC

Facility: FAMC

Dept/Svc: DCI

Associate Investigators
Leo A. Andron, LTC, MS
Roland N. Hannon, PA-C, CW3(Ret)
Jefferey Casserly, PA-C, CW3(Ret)
Shannon M. Harrison, LTC, MC
William R. Byrne, LTC, MC

Key Words: HIV virus

Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: Jan 90  Review Results: Ongoing
Number of Subjects Enrolled During Reporting Period: 100
Total Number of Subjects Enrolled to Date: 550

Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

Study Objective: To develop an accurate, thorough understanding of the pattern of disease progression and clinical course in individuals with documented HIV infection within the general military population including active duty, dependents, and retirees. This will provide critical information for clinical and administrative management of patients.

Technical Approach: Collect data on all patients who are required to be staged by DA directives and any who request staging.

Progress: No changes except as noted for amendments in the protocol.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 86/118  (3) Status: Completed

(4) Title: Maintenance vs. No Maintenance BCG Immunotherapy of Superficial Bladder Cancer
          SWOG #8507

(5) Start Date: 1985  (6) Est Compl Date: 1990

(7) Principal Investigator:
    Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words:
    chemotherapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ________  b. Review Results: ________
     c. Number of Subjects Enrolled During Reporting Period: ________
     d. Total Number of Subjects Enrolled to Date: ________
     e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Closed to patient accrual.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 86/119  (3) Status: Completed

(4) Title: Randomized Comparison of Cisplatin + 5-Fluorouracil vs CBDCA + 5-Fluorouracil vs. Methotrexate in Advanced Squamous Cell Carcinoma of the Head and Neck, Phase III SWOG #8514

(5) Start Date: 1986  (6) Est Compl Date: 1990

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: _________  b. Review Results: _________
    c. Number of Subjects Enrolled During Reporting Period: _________
    d. Total Number of Subjects Enrolled to Date: _________
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See protocol.

(17) Progress: Closed to patient accrual.

Publications and Presentations: None
(1) Date: 30 Sep 90 (2) Protocol #: 86/120 (3) Status: Ongoing

(4) Title: A Phase II Comparison of CHOP versus m-BACOD versus ProMaCE-CytaBOM versus MACOP-B in Patients with Intermediate or High Grade Non-Hodgkin's Lymphoma SWOG #8516

(5) Start Date: 1986 (6) Est Compl Date: Indefinite

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
   *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date: 2
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 86/123  (3) Status: Completed

(4) Title: Phase II Evaluation of Methyl-Glyoxal Bis-Guanylhydrazone (MGBG) in Patients with Advanced Bladder Cancer  
SWOG #8519

(5) Start Date:  (6) Est Compl Date: 1990

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC

(8) Facility:  

(10) Associate Investigators

(11) Key Words:  
drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the SWOG study in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Closed to accrual.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 86/124  Status: Complete

Title: Treatment of Limited Small Cell Lung Cancer with Concurrent Chemotherapy, Radiotherapy and Intensification with High Dose Cyclophosphamide  SWOG #8573

Start Date: 1985  Est Compl Date: 1990

Principal Investigator: Thomas Cosgriff, COL, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol  Associate Investigators

Key Words: drug therapy

Accumulative MEDCASE:* Est Accum OMA Cost:

*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the SWOG group in the study of adult oncological malignancies.

Technical Approach: See Protocol

Progress: Closed to accrual.

Publications and Presentations: None
(1) Date: 30 Sep 90 (2) Protocol #: 86/126

(4) Title: A Prospective Randomized Trial to Determine the Effect of Surgical Resection of Residual Disease Followed by Response of Small Cell Lung Cancer to Combination Chemotherapy
   LCSG #832

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigator:

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Actual FDA Cmt
   *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
    b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or in Memo
       sheet, and designated as "(14)e".

(15) Study Objective: To participate in the FAMC

(16) Technical Approach: See Protocol

(17) Progress: Terminated

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 86/128 (3) Status: Terminated

(4) Title: A Clinical Trial in Patients with Stage II and III Completely Resected Non-Small Cancer of the Lung Comparing Chemotherapy vs. No Therapy Following Surgery
LCSG #853

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC
Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators

(11) Key Words:
drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the LCSG group protocols.

(16) Technical Approach: See Protocol

(17) Progress: Terminated

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 86/132A  Status: completed

Title: The Effect of Theophylline on Calcium and Vitamin D Metabolism in Male Sprague-Dawley Rats

Start Date:

Principal Investigator: Edwin J. Fortenberry, CPT, MC
Michael T. McDermott, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Endocrinology

Associate Investigators
Gerald S. Kidd, COL, MC

Key Words: theophylline, vitamin D, calcium

Accumulative MEDCASE:

Study Objective: The objectives of the study were to determine the effect of chronic theophylline administration on calcium and vitamin D metabolism and bone mineral content in rats.

Technical Approach: Theophylline (250 mg of saline/kg) was administered by continuous infusion with an Abbott pump for a period of 4 weeks. After 2 1/2 weeks, new groups are made of 34 bone calcium intake, urine calcium, and fecal calcium excretion and overall calcium balance is calculated. After 4 weeks, the rats are sacrificed and serum calcium PTH, 25 (OH) vitamin D and 1,25 (OH)2 vitamin D are measured. The rats are ashed for determination of total body calcium.
CONTINUATION SHEET, FY 90, ANNUAL PROGRESS REPORT  Protocol #: 86/132A

(17) Progress: All animals have been studied. Chronic theophylline increased urinary calcium excretion and decreased 25 (OH) vitamin D levels.

Presentations:


Publications:

(1) McDermott MT, Fortenbery EJ, Duncan WE: Theophylline alters vitamin D and calcium metabolism in rats. J Bone Min Res 3(Suppl. 1): 5115 (188A)

(1) Date: 30 Sep 90  (2) Protocol #: 87/102  (3) Status: Terminated

(4) Title: Anti-Histone Antibody Production in Procainamide Associated Drug-Induced Lupus Erythematosus: Association of Serologic Patterns and Lymphocyte Subsets

(5) Start Date: 1987  (6) Est Compl Date: 1989

(7) Principal Investigator: James D. Singleton, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Rheumatology  (10) Associate Investigators

(11) Key Words: procainamide  Peter A. Andersen, LTC, MC
drug-induced lupus  West, Sterling, LTC, MC
histones

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 19  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: There are two study objectives: a) to survey the population of patients receiving procainamide to determine baseline data and b) to evaluate a subgroup of patients chosen randomly from patient populations determined by amount of drug administered, serologic status, and the presence of symptomatology.

(16) Technical Approach: Autoantibodies are one of the hallmarks of SLE yet mechanisms of their production and their pathogenetic import remain unclear. Drug-induced lupus makes feasible the investigation of potential early immunologic abnormalities which would lead to autoantibody production. Demographic, clinical and serologic data will be obtained on patients taking procainamide. Selected patients will, additionally, have T-cell and B-cell lymphocyte studies and be followed serially to
discover correlates, if any, in studied parameters.

(17) Progress: Although only 19 patients have been enrolled in the study and baseline data obtained, approximately 110 individuals receiving procainamide have been identified. Very few patients could be contacted; an inordinate number of those enrolled were lost to followup due to death or unwillingness to continue in the study.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 87/103  (3) Status: Ongoing

(4) Title: Identification of Those at Risk for Osteoporotic Fractures by a Non-Invasive Measurement

(5) Start Date: 1987  (6) Est Compl Date: June 1990

(7) Principal Investigator: Michael T. McDermott, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine  (10) Associate Investigators

Gerald Kidd, COL, MC

(11) Key Words:
osteoporosis
hip fractures

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:          b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 25
d. Total Number of Subjects Enrolled to Date: 70
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate possible risk factors for osteoporosis by comparing hip fracture patients and matched controls for bone density, calcium intake, smoking, medications, mental status, visual acuity, vitamin D levels and exercise history.

(16) Technical Approach: Hip fracture patients, within 5 days of fracture, and normal matched controls will have measurement of bone density at 3 sites in the unaffected hip and in the spine by dual photon absorptiometry and in the non-dominat midradius by single photon absorptiometry. All subjects will have a history and physical examination to include dietary and exercise history. Twenty subjects from each group will have visual acuity and 25-hydroxy vitamin D levels evaluated.
(17) Progress: Patients with hip fractures had significantly reduced bone density in the hip and lumbar spine and significantly lower calcium intakes. No further progress. The manuscript has been submitted for publication.

Presentations:


Publications:


(1) Date: 30 Sep 90  (2) Protocol #: 87/104  (3) Status: Ongoing

(4) Title: A Randomized Investigation of High-Dose Versus Standard Dose Cytosine Arabinoside with Daunorubicin in Patients with Acute Non-Lymphocytic Leukemia, Phase III

SWOG 8600

(5) Start Date:

(6) Est Compl Date: 1990

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words:
    drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
     b. Review Results:
     c. Number of Subjects Enrolled During Reporting Period:
     d. Total Number of Subjects Enrolled to Date: 0
     e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing

Publications and Presentations: None
Date: 30 Sep 90  
Protocol #: 87/105  
Status: Completed

Title: Pre-operative Cimetidine Therapy in Patients Undergoing Parathyroid Exploration: Efficacy and Mechanisms of Action

Start Date: 1987  
Est Compl Date: 1989

Principal Investigator:  
John A. Merenich CPT, MC  
Jeffrey R. Clark, COL, MC

Facility: FAMC

Dept/Svc: MED/Endocrine Svc

Associate Investigators  
Michael T. McDermott, MC  
William J. Georgitis, MAJ, MC  
Arnold A. Asp, MAJ, MC  
Gerald S. Kidd, COL, MC

Key Words:  
hyperparathyroidism  
postoperative hypocalcemia

Accumulative MEDCASE:*  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 20  
d. Total Number of Subjects Enrolled to Date: 20  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".----Last year one patient developed moderate elevations of liver function tests. She was completely asymptomatic, but her parathyroid surgery was postponed (until her tests returned to normal) and she was dropped from the study. She has subsequently undergone surgery without complications and LFT's remain normal. This year, none of the new patients experienced any complications.

Study Objective: To determine whether or not pre-operative cimetidine therapy can reduce the incidence of post-operative hypocalcemia in patients undergoing parathyroid explorative surgery.

Technical Approach: Patients are given placebo or cimetidine for 10 days prior to their surgery in a double-blind fashion. Calcium and its regulatory hormones are monitored before and after surgery to see if cimetidine favorably alters calcium homeostasis.

Progress: Completed. All but one subject undergoing parathyroid exploration agreed to participate.


Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 87/111  (3) Status: Ongoing

(4) Title: A Prospective Double Blind Study of Zidovudine in Early HIV Infection

(5) Start Date: 31 Oct 87  (6) Est Compl Date: 1991, Oct

(7) Principal Investigator: Shannon Harrison, LTC, MC
(8) Facility: FAMC Denver Health & Hospitals

(9) Dept/Svc: DCI
(10) Associate Investigators

(11) Key Words: R.N. Hannon, PA-C
ZDV
asymptomatic HIV
Leo Andron, LTC, MS
Robert H. Gates, MAJ, MC

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report. (Fenced HSC/HIV monies & P6 MED R&D Grant renewed for FY 90 & 91

(14) a. Date, Latest IRC Review: Feb 90  b. Review Results: Ongoing __
c. Number of Subjects Enrolled During Reporting Period: __none___
d. Total Number of Subjects Enrolled to Date: __66 & 1500 DH&H__
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". (1 RBC aplasia; 4 granulocytopenia; 6 thrombocytopenia; 1 severe nausea and vomiting; none off study).

(15) Study Objective: To look for efficacy and toxicity in terms of difference in natural history of DoD class 2 through early 5, HIV infected individuals given zidovudine at 200mg every 6 hours, 1/2 started 87, 88, 1/2 started 15 Aug 90.

(16) Technical Approach: 16 study endpoints/78 withdrawals: misentries, 1 for toxicity.

(17) Progress: Protocol was closed 1 February 1989. 110 patients still on study.

Publications and Presentations: (a) 3 abstracts; International HIV Meeting, San Francisco, CA, Jun 90; (b) 2 presentations; WRAIR Retrovirology Seminar, Sep 88, Sep 89; (c) 1 presentation; US Army HIV symposium, Dallas, TX 28 Jan 90 - 2 Feb 90.
(1) Date: 30 Sep 90       (2) Protocol #: 87/112       (3) Status: Ongoing

(4) Title: (PTOG-85-01) Prospective Trial for Localized Cancer of The Esophasgus: Comparing Radiation as a Single Modality to the Combination of Radiation Therapy and Chemotherapy, Phase III Intergroup

SWOG-8598

(5) Start Date:       (6) Est Compl Date: 1990

(7) Principal Investigator:       (8) Facility: FAMC
Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol       (10) Associate Investigators

(11) Key Words:
    drug therapy

(12) Accumulative MEDCASE:*       (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 87/113  (3) Status: Completed

(4) Title: A Phase II Randomized Trial of Combination Therapy for Multiple Myeloma: Comparison of (1) VMCP/VBAP to VAD or VMcpp/VBAPP for Induction, (2) Alpha-2b Interferon or No Therapy for Maintenance; and (3) Alpha -2b Interferon + Dexamethasone for Incomplete or Nonresponders

SWOG 8624

(5) Start Date:  (6) Est Compl Date: Indefinite

(7) Principal Investigator:  Thomas Cosgriff, COL, MC

(8) Facility:  FAMC

(9) Dept/Svc:  MED/Hema/Oncol  (10) Associate Investigators

(11) Key Words:
    drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:__________  b. Review Results:__________
    c. Number of Subjects Enrolled During Reporting Period:__________ 1
    d. Total Number of Subjects Enrolled to Date:_____________________
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the SWOG group in the study of adult oncological malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Completed

Publications and Presentations: None
Title: Patient Evaluation of Physicians' Humanistic Qualities

Start Date: 30 Sep 90
Est Compl Date: 1992

Principal Investigator: Michael J. Weaver, COL, MC


Associate Investigators: Cathy L. Ow, CPT, MC

Key Words: humanistic qualities, medical residents

Accumulative MEDCASE:* Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: 6/90
Review Results: 
Number of Subjects Enrolled During Reporting Period: 
Total Number of Subjects Enrolled to Date: 12

Study Objective:

a) to determine what behaviors are considered by patients to be important markers of humanistic qualities in their physicians;
b) to develop and test a questionnaire for a patient to rate the humanistic qualities of their own physician, and (c) to determine whether feedback, based on their own patients' ratings, can result in a change in physicians' humanistic behaviors.

Technical Approach: The study consists of three phases: (a) open-ended interviews with patients to elicit important physicians' humanistic behaviors; (b) development and testing of a questionnaire from the responses generated in Phase a, and (c) we will give back feedback to physicians, based on their own patients' evaluation of their humanistic behaviors, using the questionnaire developed, and measure whether there is any change on a repeat questionnaire, post-feedback.

Progress: Data analysis completed for 1st version of questionnaire. Questionnaire is being revised for 2nd version to be tested on larger number of interns and residents.
Publications:

Weaver MJ, Ow CL, Walker DJ and Degenhardt EF: Evaluation of Residents Humanistic Qualities by Patients and Attending Physicians (Abstract Submitted)

Presentations:

Ow C, Weaver M, Walker D, Degenhardt E: Patient Evaluation of Physicians Humanistic Qualities. (Accepted for presentation at Army Regional LAP meeting, October 1989).

Date: 30 Sep 90  Protocol #: 87/115  Status: Terminated

Title: Double Blind, Multicenter, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of HA-1A Human Monoclonal Antibody in Patients with Severe Gram-Negative Sepsis/Gram-Negative Septic Shock

Start Date:  Est Compl Date: 1990

Principal Investigator: Richard Winn, LTC, USAF, MC

Facility: FAMC

Dept/Svc: MED/Pul Dis Svc.

Associate Investigators: Shannon M. Harrison, LTC, MC
           Robert H. Gates, MAJ, MC

Key Words: gram negative shock
           gram negative spesis
           monoclonal antibody
           HA-1A monoclonal antibody

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 4

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Objective: To determine the efficacy of HA-1A monoclonal antibody in reducing the mortality and/or direct morbidity of gram-negative sepsis as compared to a placebo treated control group. To determine the impact that HA-1A has on patient benefit. To determine the impact that HA-1A has on laboratory parameters/clinical signs associated with sepsis. To determine the safety and potential for immunogenicity of HA-1A monoclonal antibody administration in patients presenting with clinical syndrome of gram-negative sepsis.

Technical Approach: Patients with the clinical diagnosis of septic shock or sepsis suspected of being secondary to gram-negative organisms will be treated with one dose of either placebo or HA-1A monoclonal antibody. A comparison of morbidity and mortality between the placebo and HA-1A group will be made to determine efficacy and safety of the drug.

Progress: Enrollment of patients at FAMC is complete. Additional study on specimens and samples will be performed. Terminate study.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 87/116  (3) Status: Ongoing

(4) Title: Effect of Iodine Containing Water Purification Tablets on Thyroid Function in Man

(5) Start Date: Aug 87  (6) Est Compl Date:

(7) Principal Investigator: Michael T. McDermott, LTC, MC
    Gerald S. Kidd, COL, MC

(9) Dept/Svc: MED/Endocrinology

(11) Key Words:
    iodine
    water purification tablets
    thyroid function tests

(12) Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 6/90  b. Review Results: Ongoing  c. Number of Subjects Enrolled During Reporting Period:  d. Total Number of Subjects Enrolled to Date: 14  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objectives of this study are to investigate the effects of iodine containing water purification tablets on thyroid function and job performance in soldiers in a field environment.

(16) Technical Approach: See Protocol

(17) Progress: No progress has been since last FY. The manuscript has been submitted for publication and the reviewers have asked that we measure serum iodine levels. We have been working with Biochemistry Service, DCI, since then to try to develop an assay for serum iodine but have so far been unsuccessful. Alternately we may eventually send them to a commercial lab. We are still trying to get serum iodide measurements.


Publications: None
Date: 30 Sep 90  Protocol #: 67/117  Status: Terminated

Title: Analysis of von Willebrand Factor Multimers Before and After Cardiopulmonary Bypass

Start Date: 1987  Est Compl Date: 1990

Principal Investigator: B. Vishnu V. Reddy, LTC, MC

Facility: FAMC

Dept/Svc: Pathology

Associate Investigators

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: Nov b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 25 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To determine the effect of the cardiopulmonary bypass machine on the multimeric structure of von Willebrand's factor and to provide clinical research experience for FAMC residents and staff.

Technical Approach: See Protocol

Progress: Since the PCS of the original principal investigator no new subjects have been enrolled. Efforts to establish a laboratory method to analyze the multimeric structure of von Willebrand's factor have failed.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/101  (3) Status: Terminated

(4) Title: Centralized Non-Small Cell Lung Cancer Specimen Repository and DNA/RNA Bank
LCSG 871

(5) Start Date: ______________________________ (6) Est Compl Date: ______________________________

(7) Principal Investigator: Thomas Cosgriff, COL, MC
(8) Facility: FAMC

(9) Dept/Svc: MED/Hemo/Oncol Svc  (10) Associate Investigators: ______________________________

(11) Key Words: ______________________________

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: __________ b. Review Results: __________
c. Number of Subjects Enrolled During Reporting Period: __________
d. Total Number of Subjects Enrolled to Date: 22

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the LCSG group protocol.

(16) Technical Approach: See protocol.

(17) Progress: Terminated

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 88/102  (3) Status: Completed

(4) Title: Effect of Chronic Coumadin Therapy on Cortical and Trabecular Bone Density in Man

(5) Start Date:  (6) Est Compl Date: 1989

(7) Principal Investigator: Michael McDermott, LTC, MC
(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine Svc.  (10) Associate Investigators
    Gerald S. Kidd, COL, MC
    Peter Blue, LTC, MC

(11) Key Words:
    bone density
    coumadin
    osteocalcin

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: _________ b. Review Results: _________
    c. Number of Subjects Enrolled During Reporting Period: 0
    d. Total Number of Subjects Enrolled to Date: 20
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective of this study is to investigate the bone density of cortical and trabecular bone in patients on chronic coumadin therapy and in age-matched controls.

(16) Technical Approach: See protocol.

(17) Progress: Coumadin patients do not have lower bone density than matched controls.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 88/103  Status: Completed

Title: Clinical Efficacy of Phenindamine as Determined by Skin Test Suppression

Start Date:  Est Compl Date:

Principal Investigator: Thurman R. Vaughan, MAJ, MC

Facility:  FAMC

Dept/Svc: MED/Allergy Svc  Associate Investigators

Edward W. Green COL, MC
Paul R. Sklarew, CPT, MC

Key Words:  antihistamine
phenindamine

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Study Objective: To examine the null hypotheses that there is no difference in skin test suppression and side effects produced by phenindamine 25mg qid, chlorpheniramine 8mg tid, and placebo in 2 week trials in normal subjects.

Technical Approach: Twenty subjects will take part in a placebo controlled crossover study of the skin test suppression produced by phenindamine, chlorpheniramine, and placebo. Results will be used to evaluate the efficacy, as determined by skin test suppression, of phenindamine compared to chlorpheniramine and placebo.

Progress: Investigators are now available. However, as phenindamine is being marketed as a non-sedating antihistamine, we feel the more appropriate comparison would be with terfenadine (seldane). An amendment to this protocol is being prepared. FY 90 - 12 completed study, results statistically significant in that phenindamine was less potent and produced more drowsiness than terfenadine.

Publications and Presentations: Nelson HS: Allergy-Immunology Symposium, Feb 90; Am. College of Allergy-Immunology, San Francisco, CA Nov 90.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/104  (3) Status: Ongoing

(4) Title: A Descriptive Study of Pastoral Care Interventions Designed to Assist HIV+/AIDS Patients in Achieving Their Maximum Quality of Life

(5) Start Date: 1988  (6) Est Compl Date: 1990

(7) Principal Investigator:  F. William Miles, LTC, USAR (Chaplain)

(8) Facility:  FAMC

(9) Dept/Svc:  Minis. & Past. Care

(10) Associate Investigators

(11) Key Words:  psycho-social-spiritual
cognitive, moral and faith development

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period: Tst 47/Intr 7 d. Total Number of Subjects Enrolled to Date: Tst 397/Intr 96  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". NA

(15) Study Objective:  (a) To observe and document the continuity of pastoral care with a traumatically stressed patient population (FAMC and beyond). (b) To conduct a longitudinal descriptive study that shows process from the point of view of patient, family member, supervisor and pastoral care giver. (c) To encourage personal processing of issues that impact on a sense of well being, decision making, psycho-social-spiritual growth through the use of an intentional and prescribed series of pastoral interventions. To provide the patient personal gain from telling his/her own "story." (d) To look at life histories, values, moral/faith development, personality types as they inform the pastoral care giver for ministry.

(16) Technical Approach: We have developed a pastoral data base of information relative to providing pastoral care to HIV+/AIDS patients. This was accomplished through regular personality inventories and interviews every six months during the HIV staging process, as well as follow-up questionnaires and support visits/calls to determine continuity of pastoral care and individuals functioning at unit/home.
(17) Progress: The protocol ended the data gathering phase in May 1990. We cut off new data gathering, except for followup testing and interviews, and prisoners and women, by 30 May 90. Coordination with HSC, FORSCOM, and Ft. Carson to obtain a control group, a random sample of soldiers by age, MOS, and rank, with whom to compare our patient group was not successful. An inadequate (not randomized, etc.) control group is used which consists mostly of soldiers and dependents from the FAMC area (or who cam through the I.D.S. for other reasons), as well as spouses of patients. During the last two years, the following testing was completed in the HIV Pastoral Research Project (since began testing o/a 1 Oct 87). Totals for the current year, 16 Dec 89-30 Jun 90, are included to the right in [bold] parentheses.

a. Patients tested/interviewed - 397[47](Black=136, White=156, Others=36)
b. Second testings - 115 [18] (Prisoners=30)
d. Fourth testings - 12 [6]
e. Fifth testings - 6 [6]
d. Values inventories - 302 [26] (includes 43 HIV-)
e. Second values Inv.- 6 [2]
f. D.I.T. - 290 [16] (includes 47 HIV-)
g. MBTI - 335 [27]
h. TJTA - 493 [66] (253+, 63-)
i. MPD - 212 [27] (includes 33 HIV-)
j. MPD #2 - 18 [5]
k. Fowler Interviews - 96 [0]
l. 2nd Interviews - 51 [7]

Publications:

(1) For the General Convention of the Episcopal Church, Detroit, Michigan, July 1988, Short article describing the research projects being conducted in Infectious Disease Service/DMPC at FAMC.


Presentations:


FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCK 40-23 as amended)

(1) Date: 30 Sep 90   (2) Protocol #: 88/106   (3) Status: Completed

(4) Title: Use of Nifedipine Gastrointestinal Therapeutic System in the Treatment of Hypertension

(5) Start Date: Sep 1988   (6) Est Compl Date: 1989

(7) Principal Investigator: J. Hasbargen, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Nephrology Svc.  (10) Associate Investigators V. Bray

(11) Key Words:
nifedipine
hypertension

(12) Accumulative MEDCASE:*   (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:________   b. Review Results:________
c. Number of Subjects Enrolled During Reporting Period: 8
d. Total Number of Subjects Enrolled to Date: 21
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To assess the efficacy of the gastrointestinal therapeutic system utilizing nifedipine in the control of hypertension.

(16) Technical Approach: Study with baseline, titration, and efficacy phases study. Blood studies and baseline and after 12 week efficacy period.

(17) Progress: Twenty-one patients enrolled, 9 completed entire study. Eight patients did not meet required BP measurements during baseline. One patient withdrew for personal reasons. Three withdrawn for protocol violations.

(1) Date: 30 Sep 90  (2) Protocol #: 88/109  (3) Status: Ongoing

(4) Title: Methotrexate in the Treatment of Steroid Dependent Asthmatics

(5) Start Date: 1989  (6) Est Compl Date: 1992

(7) Principal Investigator: Thurman R. Vaughan, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy Svc.

(10) Associate Investigators

(11) Key Words: asthma, steroid dependent methotrexate

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 4 d. Total Number of Subjects Enrolled to Date: 15 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate the effectiveness of weekly methotrexate in reducing the steroid requirements of steroid dependent asthmatics. The purpose is to demonstrate a statically significant reduction in the steroid dose over the placebo control, without involvement of the other parameters.

(16) Technical Approach: Double blind crossover design with methotrexate and placebo following pulmonary function tests, symptom scores with attempt to taper corticosteroids.

(17) Progress: Twelve patients have completed the study, and eight have benefited judged by increase in PFTs and decrease in total steroid use.

Presentations:


American College of Allergy & Immunology Annual Scientific Meeting, Orlando, FL, Nov, 89.

Publications: None

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 88/116A (3) Status: Pending

(4) Title: Biological Investigation of Cutaneous Lupus Employing Athymic Mice as Skin Heterotransplant Recipients

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Scott Bennion, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Dermatology Svc. (10) Associate Investigators
Larry Urry, MW, MC
Don Mercilli, DAC
Silvija Coulter, UCHSC
James Fitzpatrick, LTC, C
William Weston, MD, UCHSC

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: _________ b. Review Results: _________
c. Number of Subjects Enrolled During Reporting Period: _________
d. Total Number of Subjects Enrolled to Date: _________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To develop an in vivo model demonstrating cutaneous lupus as manifested in humans and to use such model to sequentially study the biological causes of the diseases.


(17) Progress: Recently we did an experiment to determine the ability of the Hsd:Athymic Nude-nu AF mice which are currently in our mouse colony to accept human skin grafts. That experiment is not yet completed but the necessity of finding a better immunocompromised mouse for human skin grafting is apparent from the current results.

Publications and Presentations: None
Title: The Use of Fibrin Monomer and D-Dimer in the Evaluation of Patients with Chest Pain

Start Date: April 1988

Principal Investigator:
Mark E. Dorosy, CPT, MC
Robert W. Hull, CPT, MC

Key Words:
fibrin monomer
D-dimer
unstable coronary artery disease

Study Objective: To determine the diagnostic usefulness of fibrin monomer and D-dimer in patients presenting with chest pain requiring evaluation for unstable coronary disease. To determine the prognostic value of these levels in patients with unstable angina and acute myocardial infarction.

Technical Approach: Patients admitted to the CCU for evaluation of chest pain are divided into two groups - those with unstable coronary disease (MI, unstable angina), and those determined to have noncardiac chest pain based on initial history and physical, EKG, serial CK determinations and additional workup (TMST, cardiac cath, etc.). Blood is drawn at the time of admission for determination of fibrin monomer and D-dimer levels.

Progress: The sensitivity and specificity of the initial D-dimer study were found to be 90% each for detecting unstable coronary disease. An unexpected finding of markedly elevated D-dimer levels were found in the patients with unstable angina. We are looking at plasminogen activator inhibitors levels in these patients in an attempt to explain this observation. Patient enrollment complete, awaiting results of PAJ-1 levels.
Publications and Presentations: Information is to be presented in abstract form at the 1988 Army ACP meetings, Cardiology section by Dr. Hull.

1989 Colorado Regional ACP meeting presentation.

October 1989 Army ACP Meeting, San Francisco. Abstract accepted and published. Meeting cancelled due to earthquake.
Date: 30 Sep 90  Protocol #: 88/112  Status: Completed  

Title: Long Term 5-Fluorouracil Infusion for Recurrent Head and Neck Cancer  

Start Date: 1988  Est Compl Date: 1990  

Principal Investigator: Thomas Cosgriff, COL, MC  

Department: MED/Hem/Oncol Svc  

Facility: FAMC  

Associate Investigators:  
Frank Ward, MAJ, MC  
Denis Lanier, LTC, MC  
Patrick W. Cobb, CPT, MC  

Key Words:  

Accumulative MEDCASE:* (Refer to Unit Summary Sheet of this Report.)  

Est Accum OMA Cost:*  

Date, Latest IRC Review:  
Review Results:  
Number of Subjects Enrolled During Reporting Period:  
Total Number of Subjects Enrolled to Date:  
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". 

Study Objective: The study is designed to assess the effectiveness of a continuous infusion of 5-FU on patients with recurrent head and neck cancer. Tumor response, toxicity and survival will be monitored. 


Progress: No patients entered at FAMC. Patient accrual completed. FAMC inactive in SWOG when protocol was active. 

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 68/113  (3) Status: Ongoing

(4) Title: Methotrexate versus D-penicillamine in Rheumatoid Arthritis: A Randomized Comparative Study

(5) Start Date: 1988  (6) Est Compl Date: 1991

(7) Principal Investigator: James D. Singleton, MAJ, MC
(8) Facility: FAMC

(9) Dept/Svc: MEL/Rheumatology Svc  (10) Associate Investigators
Sterling G. West, LTC, MC

(11) Key Words:
methotrexate
D-penicillamine
rheumatoid arthritis

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 1
d. Total Number of Subjects Enrolled to Date: 28
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To compare clinical efficacy, toxicity and radiographic progression of joint disease in patients receiving methotrexate or D-penicillamine.

(16) Technical Approach: Patients with rheumatoid arthritis will be randomly assigned to receive either methotrexate or D-penicillamine. Clinical assessment will be performed every 3 months and radiographic assessment every year.

(7) Progress: A total of 28 pts have now been in enrolled in study. Very few patients have dropped out of the study; several have been continued on the protocol on the "other" medication. MTX patients have responded more quickly overall; D-PCM patients are responding but more slowly.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 88/115  Status: Ongoing

Title: The Impact of an Ambulatory Care Rotation on Interns Psychosocial Attitudes

Start Date:  Est Compl Date:

Principal Investigator: Michael J. Weaver, COL, MC

Facility: FAMC

Dept/Svc: MED/Int. Med. Svc.  Associate Investigators

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

da. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 8 d. Total Number of Subjects Enrolled to Date: 16 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: We propose to test the hypotheses that this ambulatory care rotation will result in increased awareness of psychosocial problems and the increase in awareness will be correlate with an increase in knowledge of psychosocial content.

Technical Approach: Each intern who does a one month ambulatory care rotation in the internal medicine clinic is given a cognitive knowledge test and a psychosocial attitudes questionnaire at the beginning of the rotation, and again at the end of the rotation.

Progress: We have completed testing 8 interns during the training 1989-90. We will continue testing the next 8 interns who are scheduled to have the ambulatory care rotation through June 1991.

Publications and Presentations: None
Date: 30 Sep 89  Protocol #: 88/116A  Status: Ongoing

Title: Mouse Anti-Chenopod/Amaranth Pollen Monoclonal Antibody Production

Start Date:  Est Compl Date:

Principal Investigator: Thurman R. Vaughan, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Allergy Svc.

Associate Investigators

Key Words: Lawrence V. Larsen, CPT, MC

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:

Number of Subjects Enrolled During Reporting Period:

Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To develop mouse monoclonal antibodies to chenopod-amaranth pollen antigens. The purpose is to use these antibodies to study the crossreactivity of chenopod-amaranth pollen antigens. The importance of the latter is the eventual improvement of allergen extracts for diagnostic and therapeutic utilizations.

Technical Approach: Stage I: Characterization of allergen extracts by PAGE and Western Blot. Stage II: Monoclonal antibody production and characterization by injecting mice with allergen extract, screen for antibody with ELISA, and develop hybridomas.

Progress: Have obtained monoclonal antibody against three antigenic determinants to the weed russian thistle; have shown by Western Blot that two determinants occur in several molecular weight protein species; have shown that limited crossreactivity exists for the monoclonal antibodies between russian thistle and kochia; have polyclonal sera for redroot pigweed, kochia. Protocol on hold until return of Dr. Larsen.
Publications: None

Presentations:


**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td><strong>Date:</strong> 30 Sep 90</td>
<td>(2) <strong>Protocol #:</strong> 88/117</td>
</tr>
<tr>
<td>(4)</td>
<td><strong>Title:</strong> A Comparison of Amitriptyline vs. Trazodone vs. Placebo as Adjuvants to Opiate Analgesics in the Management of Pain in Cancer Patients</td>
<td></td>
</tr>
<tr>
<td>(5)</td>
<td><strong>Start Date:</strong> 1988</td>
<td>(6) <strong>Est Compl Date:</strong> 1991</td>
</tr>
<tr>
<td>(7)</td>
<td><strong>Principal Investigator:</strong> Thomas Cosgriff, COL, MC</td>
<td></td>
</tr>
<tr>
<td>(8)</td>
<td><strong>Facility:</strong> FAMC</td>
<td></td>
</tr>
<tr>
<td>(9)</td>
<td><strong>Dept/Svc:</strong> MED/Hemo/Oncol Svc</td>
<td></td>
</tr>
<tr>
<td>(10)</td>
<td><strong>Associate Investigators</strong> Rose A. Gates, MAJ, ANC</td>
<td></td>
</tr>
<tr>
<td>(11)</td>
<td><strong>Key Words:</strong> drug therapy</td>
<td></td>
</tr>
<tr>
<td>(12)</td>
<td><strong>Accumulative MEDCASE:</strong> Refer to Unit Summary Sheet of this Report.</td>
<td></td>
</tr>
<tr>
<td>(13)</td>
<td><strong>Est Accum OMA Cost:</strong> Refer to Unit Summary Sheet of this Report.</td>
<td></td>
</tr>
</tbody>
</table>
| (14) | a. **Date, Latest IRC Review:** May 90  
|   | b. **Review Results:**   
|   | c. **Number of Subjects Enrolled During Reporting Period:**   
|   | d. **Total Number of Subjects Enrolled to Date:** 3  
|   | e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". NONE |
| (15) | **Study Objective:** a. To compare the relative effectiveness of amitriptyline and trazodone as adjuvants to opiate analgesics for the management of pain of malignant diseases; b. Quantify the "opiate sparing" effect of these two agents when used in conjunction with morphine sulfate; c. Evaluate the cost-efficiency/effectiveness of trazodone and amitriptyline, as adjuvants to opiate analgesics in the treatment of pain associated with malignant disease. |
| (16) | **Technical Approach:** See protocol. |

**Progress:** Three subjects at Fitzsimons. One of our patients receiving an antidepressant noted a difference in pain control when the study medication was withdrawn. Problems encountered was obtaining patients who meet the criteria and getting patients who are willing to complete the pain diary.

**Publications and Presentations:** None
Date: 30 Sep 90  Protocol #: 88/118  Status: Completed

Title: CAP Study 12-21-87 - Use of Nifedipine (Gastrointestinal Therapeutic System) in the Treatment of Angina Pectoris

Start Date: 1988  Est Compl Date: 1990

Principal Investigator: Richard C. Davis, Jr., COL, MC

Facility: FAMC

Dept/Svc: MED/Cardiology Svc

Associate Investigators

Key Words:
nifedipine GITS
angina pectoris
silent ischemia

Accumulative MEDCASE:*

Est Accum OMA Cost:*

Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: 5/90  b. Review Results: 

c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 8  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

Study Objective: To establish the efficacy of Nifedipine GITS as monotherapy or combined therapy with beta blockers in angina pectoris. Secondly, to try to clarify some of the issues regarding mechanism of action of a new delivery system, Nifedipine GITS compared to other antianginal therapies.

Technical Approach: Qualified patients will be placed on Nifedipine GITS placebo in a single blind fashion after all other antianginal therapy except beta blockers are discontinued. They will then undergo Holter monitoring. Those with objective evidence of ischemia will be placed on Nifedipine GITS and dose titrated over 7-12 weeks to maximum efficacy with Holter monitoring performed at the completion of the efficacy phase. A single blind placebo control period will then be repeated with Holter monitoring at the completion.
(7) Progress: To date, eight patients have been enrolled in the study, five patients have been dropped after the first placebo control period due to lack of ST changes on Holter monitoring. One patient has been dropped from the study due to significant resting ST segment depression. Two patients have completed the study. These two individuals responded well to the study drug with marked improvement in frequency of angina. They are currently on chronic long term drug therapy and doing well. Holter monitoring did not reveal significant change in the frequency of silent ischemia in these two individuals. No problems encountered. No new patients entered during the last year. In November 1989 Nifedipine GITS was approved by the FAMC formulary committee after FDA approval. The two patients on chronic therapy are now on the commercially available form of the drug.

Publications and Presentations: Abstract accepted for Army ACP Meeting, Cardiology Section, San Francisco, CA October 1989. Abstract title: "The Use of Nifedipine GITS in the Treatment of Angina Pectoris" ACP meeting was cancelled.
Date: 30 Sep 90  Protocol #: 88/120  Status: Ongoing

Title: Ventilatory Effects of Transtracheal Oxygenation

Start Date:  Est Compl Date:

Principal Investigator:  Facility: FAMC
Michael Perry, COL, MC  Peter Blue, COL, MC

Dept/Svc: MED/Pulmonary Dis.  Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results: 1
c. Number of Subjects Enrolled During Reporting Period: 1
d. Total Number of Subjects Enrolled to Date: 10
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To demonstrate the ventilatory effects of transtracheal oxygen therapy.

Technical Approach: A group of 10 COPD patients will have their resp. parameters measured while receiving supplemental oxygen through a nasal cannula and then again while receiving transtracheal oxygen at a flow rate equivalent to that of the nasal cannula. The 2nd part of the study will examine the effects of transtracheal oxygen on radioactive xenon wash.

Progress: Computer program modified as per amendment. One new patient enrolled since modification.

Publications and Presentations: HMLAC, Oct 88; Army ACP meeting; An. Thoracic Soc. May 89; Abstract: Review of Am. Respiratory, Apr 89.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/121  (3) Status: Ongoing

(4) Title: Bone Densitometry in Thyroid Extract Treated Patients

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
William J. Georgitis, LTC,MC

(9) Dept/Svc: MED/Endocrine Svc  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Aug 89  b. Review Results:Approved  c. Number of Subjects Enrolled During Reporting Period: 27 controls  d. Total Number of Subjects Enrolled to Date: 47  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine whether thyroid extract has greater adverse effects on bone density and calcium metabolism than synthetic 1-thyroxine. The second is to assess the reversibility of any documented effect.

(16) Technical Approach: The effects of thyroid extract treatment on bone densitometry will be investigated. Subjects taking thyroid extract treatment matched with a thyroxine controlled group will have assessments of thyroid replacement therapy status, mineral metabolism and bone density. Thyroid extract subjects found to be subclinically hyperthyroid may enter a longitudinal assessment of bone density after crossing over to euthyroid thyroxine replacement.

(17) Progress: From eighty-five refill prescriptions for thyroid extract, seventy-one patients were sent letters. Twenty-eight potential subjects were counseled about the study and twenty have been studied.
TRH tests and 24hr urine collections have been completed on the controls who are all awaiting bone densitometry measurements through the Nuclear Medicine Service.

Publications and Presentations:


Date: 30 Sep 90  Protocol #: 88/122  Status: Terminated

Title: LCSG 881 - A Randomized Phase II Study of Preoperative Therapy for Patients with Technically Unresectable Non Small Cell Lung Cancer

Start Date:  Est Compl Date:

Principal Investigator:  Facility: FAMC
Thomas Cosgriff, COL, MC

Dept/Svc: Med/Hem-Onc  Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in the LCSG group protocol.

Technical Approach: See Protocol

Progress: Terminate.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/124  (3) Status: Ongoing

(4) Title: Corticosteroids in the Treatment of Stable Chronic Obstructive Pulmonary Disease

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Thurman R. Vaughan, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy Svc  (10) Associate Investigators:

David L. Goodman, LTC, MC

(11) Key Words: COPD, obstructive lung disease, corticosteroids

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:  
d. Total Number of Subjects Enrolled to Date: 7 - 4 complete
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e" None

(15) Study Objective: To determine if subjects with severe obstruction lung disease would benefit from extended therapy with corticosteroids.

(16) Technical Approach: Approximately 10 subjects who have COPD that is not responsive to maximal beta-agonist therapy will be enrolled (elevated FEC, <10%) they will then be randomized to receive either 32mg methylprednisolone per day or placebo for 4 weeks followed by a washout period of 4 weeks and finally crossover to receive the alternate drug. Spirometry and body plethysmography will be performed prior to beginning the study and at 2 week intervals throughout the study period.

(18) Progress: Four subjects enrolled; 2 in the final 4-week period. Patient recruitment is somewhat difficult in that most "irreversible" COPD subjects have demonstrated a >10% response to Q2 therapy. Q2 therapy still remains a problem.

Publications and Presentations: None
**Title:** The Application of Orem's Self-Care Model in Type II Diabetes: An Outcome Study of Diabetic Self-Care Classes and Self-Care Contracting Comparing Self-Care Knowledge, Health Care Beliefs, Weight Loss and Metabolic Control

**Start Date:** Aug 88  
**Est Compl Date:** Aug 90

**Principal Investigator:** Ann Marie Bianchi, MAJ, An  
**Facility:** FAMC

**Key Words:** noninsulin dependent diabetes  
Orem's self-care model  
locus of control  
contract vs noncontract

**Study Objective:** To examine whether Type II (NIDDM) clients who attend diabetic self-care classes and also contract for specific self-care activities will significantly gain in self-care knowledge and activities as measure by knowledge questionnaire, Locus of control tool, wt. control, and metabolic control (FBS, HgbA1c, chol, TG), relative to those who do not contract for self-care behaviors.

**Technical Approach:** Subjects were randomly selected from type II diabetic clients referred for diabetic education. They were given a pretest questionnaire. The locus of control tool was also given to elicit information about subjects' health beliefs. Metabolic data (FBS, HgbA1c, chol, TG) was also obtained. The clients were then randomly assigned to the contract or noncontract group. The above data will be collected again at 3 mo., 6 mo., and at 12 months.

**Progress:** 20 clients have completed the study. One more will complete it by 31 Aug 90. Then all that remains is the analysis of the data.

**Publications and Presentations:** None
Date: 30 Sep 90  
Protocol #: 89/102  
Status: Ongoing

Title: Factors Determining Peak Bone Mass and Subsequent Bone Loss

Start Date:  
Est Compl Date:  

Principal Investigator:  
Michael T. McDermott, LTC, MC  
Gerald S. Kidd, COL, MC  
Peter W. Blue, COL, MC  
Harry N. Tyler, Jr., DAC

Facility: FAMC

Dept/Svc: MED/Endocrinology

Key Words:  
bone density  
peak bone mass

Study Objective: To determine factors associated with the development of peak bone mass and subsequent bone loss.

Technical Approach: Bone density of the radius (single photon absorptiometry) and of the hip and spine (dual photon absorptiometry) will be done in a large group of male and female volunteers, who will also, on another protocol, be having total body fat and lean mass measured by dual photon absorptiometry. Questionnaire concerning present and past calcium intake, exercise and other habits will also be administered.

Progress: No progress this FY.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 89/103  (3) Status: Ongoing

(4) Title: Transient Hypoxia During Sedated Endoscopy

(5) Start Date: Dec 88  (6) Est Compl Date: Jun 92

(7) Principal Investigator: Steven P. Lawrence, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Gastroent

(10) Associate Investigators:
    Stephen Freeman, LTC, MC
    Scott Hallgren, MAJ, MC
    Jeffrey Dunkelberg, MAJ, MC
    John Van Deren, CPT, MC

(11) Key Words: endoscopy hypoxia

(12) Accumulative MEDCASE:*

(13) Est Accum OMA Cost:*

    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the incidence of transient hypoxia during sedated endoscopy and correlate this with changes in blood pressure, cardiac rhythm, overall clinical status of the patient and type and/or stage of endoscopy.

(16) Technical Approach: Room air arterial oxygen saturation, blood pressure and heart rate will be recorded prior to, during and after intravenous sedation and endoscopy.

(17) Progress: No work has been done on this protocol in the past year. The protocol, however, should remain active as the intent of the principal investigator is still to continue and complete the protocol.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/104  (3) Status: Ongoing

(4) Title: Efficacy of Corticosteroids in the Acute Treatment of Asthma: Is Duration of Symptoms Important?

(5) Start Date: Sep 89  (6) Est Compl Date: Sep 91

(7) Principal Investigator: Thurman R. Vaughan, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy

(10) Associate Investigators: David L. Goodman, LTC, MC

(11) Key Words: asthma  corticosteroids  emergency management

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 8
d. Total Number of Subjects Enrolled to Date: 8

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if the beneficial effect of corticosteroids seen in the treatment of status asthmatics is dependent on the duration of asthmatic symptoms.

(16) Technical Approach: 120 subjects presenting to the E.R. or allergy clinic with acute episode of asthma will be studied. Subjects will receive either 125mg methylprednisolone or placebo within 30 minutes of arriving for tx. They will be divided into 2 sps - these with IRS of <24 hours duration and those with sxs for more than 24°. Spirometry and admission rate will be analyzed.

(17) Progress: Pharmacy and ER staff have been consulted and have agreed to participate in the study.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 89/105  (3) Status: Ongoing

(4) Title: Role of Blood Pressure Control in Progression of Diabetic Nephropathy and Other Microangiopathies

(5) Start Date: Dec 88  (6) Est Compl Date: Dec 93

(7) Principal Investigator: Gerald S. Kidd, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators:
    Gerald Kidd, COL, MC
    Joseph White, MAJ, MS

(11) Key Words:
    nephropathy
    diabetes

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: 
    b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 
    d. Total Number of Subjects Enrolled to Date: 
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: a) Define a level of blood pressure control in a prospective, randomized, non-blinded fashion needed to prevent or delay the progression of diabetic nephropathy and other microvascular complications of diabetes; b) determine if there is a specific advantage to either a CEI or a Ca++ channel blocker as a mode of treatment for hypertension in regard to the onset or progression of diabetic nephropathy.

(16) Technical Approach: See protocol.

(17) Progress: None. Currently awaiting FDA approval of investigational new drug, Nitrendipine. Additional coordination with other participating institutions is required before initiating this study. Awaiting funding from NIH and/or University of Colorado Health Sciences Center.

Publications and Presentations: None
Study Objective: To determine the presence of a marker for long term efficacy of immunotherapy.

Technical Approach: A. Identifiable change in sub-populations of lymphocytes with immunotherapy; B. Identification of anti-idiotypic antibodies to allergens; C. Demonstration of effect of immunotherapy on late-phase skin tests.

Progress: Delays have occurred with the development of various assays. The three areas of investigation appear to be nearly ready. We have shown an interesting non-specific adhesion of allergen to b-cells. Adhesive problem is being worked on, and we are also awaiting reagents. No new patients enrolled since last APR. The idiotypic assay appears to be working and the significance of its demonstration is under assessment. The significance of adhesion of allergen to lymphocytes is also under consideration. Stimulation of lymphocyte populations to proliferate has been achieved. Whether this is associated with adhesion or not is being studied.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/107  (3) Status: Terminated

Title: A Multicentric Observer-Plind, Randomized Study of the Safety, Efficacy and Tolerance of Cefpirome (HR-810) Versus Ceftazidime in the Treatment of Pneumonia

(5) Start Date: 1989  (6) Est Compl Date: 1991

(7) Principal Investigator: Richard E. Winn, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Pul.Dis.  (10) Associate Investigators:

(11) Key Words:

- pneumonia
- Cefpirome
- Ceftazidime

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 13 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: As per title.


(17) Progress: Cefpirome worked well, no adverse reaction. One patient died while on drug, but was heart related rather than drug related.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 89/108  Status: Ongoing

Title: Efficacy of Pentoxifylline in Treating Diabetic Impotence

Start Date: 1989  Est Compl Date: 1991

Principal Investigator: John A. Merenich, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Endocrine  Associate Investigators:

Key Words: diabetes  Clyde Roy, MAJ, MC
impotence  Nancy Pfander, MAJ, MC
pentoxifylline  William Georgitis, LTC, MC

Accumulative MEDCASE:  Est Accum OMA Cost:

Refer to Unit Summary Sheet of this Report

Study Objective: To determine if pentoxifylline is more effective than placebo in improving sexual function in non-insulin dependent diabetic men.

Technical Approach: A single center, double-blind, placebo controlled study to examine the efficacy of pentoxifylline in improving sexual function in impotent NIDDM men. Diabetic men with impotence who meet the protocol entrance criteria will be randomly assigned placebo or pentoxifylline for 12 weeks. After completion of the treatment course subjects will be reevaluated, and groups will be compared to determine beneficial effects.

Progress: No progress has been made on this study. Necessary equipment is still on order. Equipment reordered.

Publications and Presentations: None.
(1) Date: 30 Sep 90  (2) Protocol #: 89/109  (3) Status: Ongoing

(4) Title: The Effect of Percutaneous Endoscopic Gastrostomy Tube Placement on Gastric Emptying

(5) Start Date: Jan 89  (6) Est Compl Date: 1990

(7) Principal Investigator: James E. Cremins, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Int. Med.  (10) Associate Investigators:
Jeffery Dunkelberg, MAJ, MC
Stephen Freemen, LTC, MC
Scott E. Hallgren, MAJ, MC
Peter Blue, LTC, MC

(11) Key Words:
gastric emptying
gastrostomy tube

(12) Accumulative MEDCASE:* Refer to Unit Summary Sheet of this Report
(13) Est Accum OMA Cost:*

(14) a. Date, Latest IRC Review: 
       b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 2 
d. Total Number of Subjects Enrolled to Date: 2 
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To define the effect of PEG placement on gastric emptying.

(16) Technical Approach: Baseline gastric emptying studies will define subjects' status prior to PEG placement. Repeat gastric emptying studies at definite intervals post procedure will allow detection of any changes in gastric emptying. This will impact possibly on defining a standard approach to feeding these patients.

(17) Progress: To date only two patients have been enrolled who meet the inclusion criteria. However, both subjects expressed significant improvement in life by study participation, and one subject has actually gained weight while on protocol. Insertion of the PEG has allowed the two subjects who completed this protocol adequate means of maintaining nutritional status.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/110  (3) Status: Ongoing

(4) Title: Cyclic Oxygen Therapy at Rest and During Exercise

(5) Start Date: Jan 89  (6) Est Compl Date: Jun 89

(7) Principal Investigator: Ray C. Johnson, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Pul. Dis.  (10) Associate Investigators: Michael E. Perry, COL, MC

(11) Key Words: Peter Blue, COL, MC cyclic oxygen therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:

 c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 10

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if cyclic oxygenation can be used as an oxygen conservation measure. To determine physiologic correlates of efficacy.

(16) Technical Approach: A "baseline" continuous flow rate will be determined for each subject. The timing sequence and cycling flow will identify the corrected cycle flow for each subject at rest. The studies will be repeated while the subjects exercise to ascertain exercise baseline flows as a benchmark for comparison, to determine optimum timing sequences independent of resting conditions and to determine the effect of higher cycling flows.

(17) Progress: Preliminary findings indicate some people have good response to this therapy (two out of ten). The other subjects did not experience benefit. No subjects experienced adverse reactions.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/111  (3) Status: Ongoing

(4) Title: Multicenter Clinical Evaluation of Penicillin Skin Testing Materials

(5) Start Date:  (6) Est Compl Date: 

(7) Principal Investigator:  
James S. Brown, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy Svc  (10) Associate Investigators: 
Robert Ledoux, DAC

(11) Key Words:  
penicillin
minor determinants

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 70  
d. Total Number of Subjects Enrolled to Date: 148  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the optimal test reagent in assessment for anaphylactic grade sensitivity to minor determinants of penicillin.

(16) Technical Approach: Prick and intradermal skin testing.

(17) Progress: 148 patients have been studied to date. A number of individuals with a history of penicillin sensitivity have been tested and found to be positive to several of the test reagents. None of the negative controls have had positive tests. Benefits include demonstration of possible drug sensitivity. Need 50-60 persons who are history negative as controls and will be able to complete the study.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 89/112  Status: Terminated

Title: The Use of Megestrol Acetate to Treat Cachexia in Patients with Chronic Obstructive Pulmonary Disease and the Possible Improvement of Pulmonary Function

Start Date: Apr 89  Est Compl Date: 1991

Principal Investigator: James I. Meyer, CPT, MC

Facility: FAMC

Dept/Svc: MED/Pulmonary  Associate Investigators: Marin Kollef, CPT, MC  Michael E. Perry, COL, MC

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 2
d. Total Number of Subjects Enrolled to Date: 4
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e" None

Study Objective: To see if patients with COPD improve pulmonary function with wt gain 2° to using megestrol.

Technical Approach: Clinical Trial.

Progress: A total of four patients have been enrolled. Data collection is complete. Patients report improved appetite and well being. Study terminated due to insufficient patient referral.

Publications and Presentations: None
Date: 30 Sep 89  Protocol #: 89/113  Status: Terminated

Title: LCSG NC 3 Natural History Registry for Patients with Stage II Non-Small Cell Lung Cancer

Start Date:  Est Compl Date:  

Principal Investigator: Thomas Cosgriff, COL, MC

Dept/Svc: MED/Hem/Oncol  Associate Investigators:  

Key Words:  

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

Study Objective: To participate in the LCSG group protocol.


Progress: Closed.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/114  (3) Status: Ongoing

(4) Title: Response of Arthritis and Microscopic Colitis to Sulfasalazine in Rheumatoid Arthritis Patients

(5) Start Date: 1989  (6) Est Compl Date: 1992

(7) Principal Investigator: Raymond J. Enzenauer, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Rheumatology

(10) Associate Investigators:
    Sterling G. West, MD
    James Singleton, MD
    Stephen Freeman, MD
    Kenneth Sherman, MD, Ph.D.

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: May 90  b. Review Results: Approved
    c. Number of Subjects Enrolled During Reporting Period: __________
    d. Total Number of Subjects Enrolled to Date: 9 patients entered
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To evaluate the effect of sulfasalazine on both microscopic colitis and arthritis in RA.


(17) Progress: Approximately 8 total control colonoscopies with biopsy have been completed per the protocol addendum; one patient was entered onto the sulfasalazine protocol, however she discontinued her medication after less than one month due to gastrointestinal intolerance. Principal Investigator is due to PCS, Dr. West will assign a new PI.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 89/115  Status: Ongoing

Title: The Effect of Congestive Heart Failure (CHF) on the Erythrocyte Sedimentation Rate (ESR)

Start Date: Aug 89  Est Compl Date: Aug 91

Principal Investigator: Mitchell Kruger, CPT, MC

Facility: FAMC

Dept/Svc: Cardiology Svc

Associate Investigators: Raymond Enzenauer, MAJ, MC

Key Words:
- congestive heart failure
- erythrocyte sedimentation rate

Accumulative MEDCASE:*
Est Accum OMA Cost:*
Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review: 6/90  Review Results: Ongoing
Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date:
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To establish the effect of acute uncomplicated CHF on the ESR and attempt to analyze specific variables affecting the ESR in the setting of CHF.

Technical Approach: Fifty patients evaluated will be admitted for routine elective cardiac catheterization while fifty patients evaluated will be admitted for treatment of congestive heart failure. This study will analyze certain blood chemistries that are not routinely drawn for examination in patients with CHF or for routine cardiac catheterization.

Progress: Control subjects have been entered into the study. Patient's with CHF have been difficult to obtain. Many were excluded because of acute MI, some with CHF could not have appropriate labs drawn.

Publications and Presentations: None.
Title: Atrial Natriuretic Peptide (ANP) Levels in Patients With VVI Pacing With and Without Ventriculoatrial (VA) Conduction Versus Dual Chamber Pacing

Start Date: Aug 89

Principal Investigator:
John Madonna, CPT, MC

Dept/Svc: Internal Medicine

Associate Investigators:
John Van Deren, MAJ, MC

Key Words:
atrial natriuretic peptide
pacemaker syndrome

Study Objective: To obtain data which could possibly add information about the pathophysiology of Pacemaker Syndrome.

Technical Approach: To take patients who have a dual chamber pacemaker and measure serum ANP levels while they are in dual chamber pacing mode, and compare these serum ANP levels with levels obtained while these patients are in the VVI pacing mode. We will also document VA conduction while in the VVI mode and relate this phenomenon to serum ANP levels.

Progress: Protocol was administratively terminated.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 89/117  Status: Ongoing

Title: Evaluation of Thermography in the Delineation of Late Phase Skin Tests

Start Date: Sep 89  Est Compl Date: Mar 90

Principal Investigator: James Brown, COL, MC

Dept/Svc: Allergy Svc

Key Words: skin tests thermography

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review: 7 Aug 90  Review Results: approved
Number of Subjects Enrolled During Reporting Period: 6
Total Number of Subjects Enrolled to Date: 6
Adverse drug reactions: No adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: The accurate measurement of the area of involvement in the late phase reaction would enhance this parameter as a tool in studying the immunologic reaction of sensitizing substances.

Technical Approach: Skin test materials will be applied to six allergic and six non-allergic volunteers. The sites will be photographed using the thermographic camera from the time of testing until the maximal immediate reaction has been reached (usually 15-20 minutes), and then photographed hourly for six hours. All studies will be recorded on a VCR. Visual estimations of reaction size will be made by circumscribing the area of involvement with a ballpoint pen and transferring the image to paper using transparent tape.

Progress: Subjects are currently being enrolled in this recently approved study. Six subjects complete, need 2-4 more.


FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/118  (3) Status: Terminated

(4) Title: Bronchoalveolar Lavage in Intubated Patients with the Adult Respiratory Syndrome for the Evaluation of Fat Emulsion Induced Changes in Alveolar Characteristics

(5) Start Date: Aug 89  (6) Est Compl Date: Jun 90

(7) Principal Investigator: Martin Kollef, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MICU

(10) Associate Investigators:

Vishnu Reddy, LTC, MC

James Meyers, CPT, MC

(11) Key Words:
intravenous fat emulsion therapy
pulmonary abnormalities

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: 6/90  b. Review Results:

(15) Study Objective: To examine the ability of bronchoalveolar lavage (BAL) to detect changes in the chemical and histologic properties of the BAL fluid after the administration of intravenous fat emulsion therapy.

(16) Technical Approach: The triglyceride levels in the lavage fluid will be analyzed and compared to one another for ten patients before and after administration of the intralipid. The Oil Red O stains of the lavage fluid will be compared to one another and analyzed for staining within cells and for free floating fat in the fluid itself. Cell counts will be made in the lavage fluid in a standard manner.

(17) Progress: Three patients enrolled without any evidence of fat on BAC samples so the protocol was terminated. My method is not sensitive enough to find fat in BAL fluid at present time.

Publications and Presentations: None.
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>Date: 30 Sep 90</td>
</tr>
<tr>
<td>(2)</td>
<td>Protocol #: 89/119</td>
</tr>
<tr>
<td>(3)</td>
<td>Status: Ongoing</td>
</tr>
<tr>
<td>(4)</td>
<td><strong>Title:</strong> Development of a Cardiopulmonary Resuscitation (CPR) Information Sheet and Assessment of Patient and Staff Response</td>
</tr>
<tr>
<td>(5)</td>
<td>Start Date: Oct 89</td>
</tr>
<tr>
<td>(6)</td>
<td>Est Compl Date: Sep 91</td>
</tr>
<tr>
<td>(7)</td>
<td><strong>Principal Investigator:</strong> Rose Gates, MAJ, An</td>
</tr>
<tr>
<td>(8)</td>
<td><strong>Facility:</strong> FAMC</td>
</tr>
<tr>
<td>(9)</td>
<td>Dept/Svc: Hema/Oncol</td>
</tr>
<tr>
<td>(10)</td>
<td><strong>Associate Investigators:</strong> Michael Weaver, COL, MC Robert Gates, MAJ, MC</td>
</tr>
<tr>
<td>(11)</td>
<td><strong>Key Words:</strong> cardiopulmonary resuscitation do-not-resuscitate order</td>
</tr>
<tr>
<td>(12)</td>
<td>Accumulative MEDCASE:*</td>
</tr>
<tr>
<td>(13)</td>
<td>Est Accum OMA Cost:*</td>
</tr>
<tr>
<td>(14)</td>
<td>a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 219 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;</td>
</tr>
<tr>
<td>(15)</td>
<td><strong>Study Objective:</strong> a) To assess the acceptability of an information sheet on CPR to both patients and professional staff; b) To determine the attitude of patients and professional staff regarding discussion of CPR and CPR options.</td>
</tr>
<tr>
<td>(16)</td>
<td><strong>Technical Approach:</strong> A CPR information sheet and questionnaire will distributed as per objective. Discussions will be held at the time of collection of the questionnaires.</td>
</tr>
<tr>
<td>(17)</td>
<td><strong>Progress:</strong> Twenty-seven patient surveys have been completed; would like to collect approximately 25 more. Benefits subjects experience information about CPR options. Plan to amend this protocol for survey of patients with revised information sheet and more detailed patient questionnaire.</td>
</tr>
</tbody>
</table>

**Publications and Presentations:** None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 89  (2) Protocol #: 89/120A  (3) Status: Completed

(4) Title: Mediastinal Tamponade Due to Closed Thoracostomy in a Goat

(5) Start Date: Sep 1989  (6) Est Compl Date: Jan 90

(7) Principal Investigator: Marin H. Kollef, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pulmonary Dis. Svc.

(10) Associate Investigators:

(11) Key Words: tamponade thoracostomy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
   c. Number of Subjects Enrolled During Reporting Period:
   d. Total Number of Subjects Enrolled to Date:
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To document objectively in an animal model whether a closed thoracostomy tube can cause impairment in cardiac output and thus hypotension by tamponading the inferior vena cava or right ventricle.

(16) Technical Approach: The design of the study is a prospective animal model which will evaluate the above stated hypothesis.

(17) Progress: Completed.

Publications and Presentations: Publication pending approval in Chest.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/100  (3) Status: Ongoing

(4) Title: Platelet Thromboxane and Aggregation and Whole Blood Prostacyclin Synthesis in Human Thyroid Disease

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Lynn F. Abrams, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: Endocrinology

(10) Associate Investigators:
    Gerald S. Kidd, COL, MC
    John A. Merenich, MAJ, MC
    Michael T. McDermott, LTC, MC
    Chris White, MAJ, MS

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 15  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the roles of thromboxane and prostacyclin in mediating the phenomenon associated with thyroid dysfunction.

(16) Technical Approach: See protocol.

(17) Progress: Fifteen patients as of this date, no data yet.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/101  Status: Completed

Title: Study of the Efficacy of Influenza Vaccine in Chronic Lung Disease - Serologic Response and Disease Prevention

Start Date: 1989  Est Compl Date: 1990

Principal Investigator: Richard Winn, LTC, USAF, MC

Facility: FAMC

Dept/Svc: Gordon Meiklejohn, MD

Associate Investigators: SSG Kenneth Williams

Key Words: influenza vaccine serologic response

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To address influenza, vaccine serologic response and protective efficacy among patients with chronic structural lung disease in a prospective fashion.

Technical Approach: Serum will be drawn from each patient prior to vaccine administration, 4-6 weeks following vaccination and at the conclusion of influenza season.

Progress: Serologic and viral isolation studies are being performed by Dr. Meiklejohn at CU Medical Center.

Publications and Presentations: None
(4) Title: Effect of Prolonged Administration of Iodine Containing Water Purification Tablets in Man

(5) Start Date: 1990

(7) Principal Investigator: Michael T. McDermott, LTC, MC

(9) Dept/Svc: Endocrinology

(11) Key Words:

(12) Accumulative MEDCASE:*

(13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if prolonged iodine administration (3 mos) causes persistent hypothyroidism or if compensation occurs and if goiters occur.

(16) Technical Approach: Iodine containing water purification tablets (4 tabs/day, 8mg iodine/tab) will be given to 15 subjects for 3 months. Baseline studies will include thyroid hormone and TSH levels, a TRH test, a radioactive iodine uptake and thyroid ultrasound thereafter, thyroid hormone levels, TSH and TRH test will be repeated at 7, 28 and 90 days. The radioactive iodine uptake will be separated at 7 and 90 days and the thyroid ultrasound will be repeated at 90 days.

(17) Progress: None thus far. We have been unable, so far, to standardize the thyroid ultrasound measurement.

Publications and Presentations: None
The Limulus Amoebocyte Lysate Assay for the Diagnosis of Spontaneous Bacterial Peritonitis in Ascitic Fluid

Start Date: 1990
Est Compl Date: June 1991

Principal Investigator:
Kenneth E. Sherman, MAJ, MC

Facility: FAMC

Dept/Svc: Gastro.

Associate Investigators:
Stephen Freeman, LTC, MC

Key Words:
limitus
SBP

Study Objective: Determine efficacy of the limulus amoebocyte lysate assay in the early diagnosis of Gram negative spontaneous bacterial peritonitis.

Technical Approach: The limulus assay is run on peritoneal fluid obtained from patients with ascites, and then compared to standard cell count/culture definitions of SBP.

Progress: No cases of gram negative SBP have been seen since the onset of this study at this hospital. The cases examined to date were all negative by the limulus assay, as would be expected. However, several cases resulted in a negative inhibition control, indicating reaction inhibition does occur.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 90/104 (3) Status: Completed

(4) Title: Group C/Treatment Protocol: Levamisole (NSC 177023) Plus 5-Fluorouracil as an Adjuvant to Surgery for Resectable Adenocarcinoma of the Colon

NCI Protocol 89-0017

(5) Start Date: 1990 (6) Est Compl Date: 1990

(7) Principal Investigator: Patrick Judson, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Hem/Onc Svc

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To make Levamisole available to treat patients until FDA approval is obtained.

(16) Technical Approach: Per NCI protocol.

(17) Progress: Approximately 5 patients were treated. Drug recently approved by the FDA. Protocol no longer needed.

Publications and Presentations: None.
(1) Date: 30 Sep 90  (2) Protocol #: 90/105  (3) Status: Ongoing

(4) Title: Incidence and Prevalence of Hematuria in Patients on Long-Term Anticoagulation

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator:  
James A. Hasbargen, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Nephrology Svc  (10) Associate Investigators:  
Talley F. Culclasure, CPT

(11) Key Words: 
hematuria  
anticoagulation

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 180  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To assess incidence and prevalence of hematuria in anticoagulated population.

(16) Technical Approach: UA performed monthly on patients in coumadin clinic.

(17) Progress: Approximately 1200 pt/months followup.

Publications and Presentations: Abstract submitted to Army Regional ACP meeting.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/106  (3) Status: Completed

(4) Title: Self-Treatment of Anaphylaxis in an Outpatient Population

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Paul R. Sklarew, CPT, MC

(9) Dept/Svc: Allergy Svc  (10) Associate Investigators:
(11) Key Words:

David L. Goodman, LTC, MC

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 65
d. Total Number of Subjects Enrolled to Date: 65
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To study the factors which influence a physician's decision to prescribe epinephrine and a patient's decision to self inject the epinephrine.

(16) Technical Approach: I have received completed questionnaires from 65 patients who received epinephrine kits at FAMC.

(17) Progress: The study has been completed and is being prepared for presentation.

FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/107  (3) Status: Ongoing

(4) Title: A Double-Blind, Placebo-Controlled Randomized Trial of the Clinical and Hemodynamic Effects of Vasopressin in Patients with Cirrhosis and Acute Variceal Hemorrhage -- A Multi-center Study

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Michael Fisher, CPT, MC  (8) Facility: FAMC

(9) Dept/Svc: Gastro.  (10) Associate Investigators: Stephen Freeman, LTC, MC

(11) Key Words: vasopressin, variceal hemorrhage

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
   *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:
   c. Number of Subjects Enrolled During Reporting Period:
   d. Total Number of Subjects Enrolled to Date:
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Clinical: to evaluate the effect of vasopressin on the volume of variceal bleeding, early rebleeding, and death from bleeding compared to placebo. Hemodynamic: (1) to determine the relationship between the infusion rate of vasopressin, hepatic extraction of vasopressin, peripheral plasma concentration of vasopressin, and its clinical efficacy; (2) to determine whether hemodynamic tachyphylaxis occurs during prolonged infusion of vasopressin; (3) to determine whether abrupt discontinuation of vasopressin causes a rebound increase in portal pressure.

(16) Technical Approach: Multicenter, double-blind, placebo-controlled, randomized trial using a medical intensive care unit patient population.

(17) Progress: Patient accrual continues. Data analysis will be performed when the code is broken.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/108  Status: Ongoing

Title: Comparison of Impedance Plethymography, Venogram and Doppler Ultrasound in Diagnosing Deep Venous Thrombosis

Start Date: 1990  Est Compl Date:

Principal Investigator: David Kristo, CPT, MC
Associate Investigators: Marin Kollef, MAJ, MC  James Luethke, CPT, MC

Dept/Svc: Int. Med.

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:
 b. Review Results:
 c. Number of Subjects Enrolled During Reporting Period:
 d. Total Number of Subjects Enrolled to Date: 15
 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To compare IPG and doppler vs and with venogram at this facility.

Technical Approach: A blinded comparison fo the three studies.

Progress: 15 patients enrolled to date.

Presentations: None
Date: 30 Sep 90  Protocol #: 90/109  Status: Ongoing

Title: Altitude Effects on Oxygen Kinetics During Exercise in Acclimatized Fit Troops

Start Date: 1990
Est Compl Date:

Principal Investigator: Michael E. Perry, COL, MC
Associate Investigators: James Meyers, CPT, MC

Key Words: altitude, exercise, oxygen kinetics

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results: 29
Number of Subjects Enrolled During Reporting Period: 29
Total Number of Subjects Enrolled to Date: 29

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To demonstrate effects of altitude on exercise performance and oxygen kinetics in altitude-acclimatized troops.

Technical Approach: Troops stationed at altitude for a least 1 year will undergo formal exercise testing both at altitude and at sea level.

Progress: 29 subjects have completed studies at 5800 ft elevation (Ft. Carson) and -300 ft elevation (Death Valley, CA). Data indicates profound effects on ventilation parameters and also on oxygen kinetics. Data is still being analyzed for anaerobic threshold determinations as well as additional parameters of oxygen kinetics.

Publications and Presentations: Submitted, pending acceptance.
(1) Date: 30 Sep 90  (2) Protocol #: 90/110  (3) Status: Ongoing

(4) Title: Effects of Altered Calcium on Blood Pressure

(5) Start Date: 1990  (6) Est Compl Date: 1991

(7) Principal Investigator:  (8) Facility: FAMC
James A. Hasbargen, LTC, MC

(9) Dept/Svc: Nephrology Svc  (10) Associate Investigators:

(11) Key Words:
renal failure
dialysis
hypercalcemia
hypertension

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jan  
b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Establish the effect of high calcium dialysate with calcium supplementation vs low calcium dialysate without calcium supplementation on blood pressure.

(16) Technical Approach: Randomized prospective crossover study utilizing a low or high calcium dialysate bath in the correction of hypertension in patients with renal failure.

(17) Progress: Patient enrollment continues. Insufficient data for analysis at this time.

Publications and Presentations: None.
Title: Prevention of Pseudomonas Colonization by Saccharomyces boulardii or Lactobacillus Acidophilus in Antibiotic Treated Mice

Start Date: 1990

Principal Investigator: Mark J. Jarek, CPT, MC

Facility: FAMC

Dept/Svc: Pulmonary Svc

Associate Investigators:

Key Words:

Accumulative MEDCASE:* (Refer to Unit Summary Sheet of this Report)

a. Date, Latest IRC Review:

b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To prove a benefit of prophylactic administration of either Saccharomyces boulardii or Lactobacillus acidophilus in the prevention of enteric Pseudomonas colonization in mice treated with antibiotics.

Technical Approach: See protocol.

Progress: This study has never been started due to difficulties in obtaining support for maintenance of the study animals. No plans to continue it in the near future exist.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/112  Status: Ongoing

Title: Laboratory Screening to Detect Biochemical Evidence of Hemochromatosis Among Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM)

Start Date: 1990  Est Compl Date:

Principal Investigator: John A. Merenich, MAJ, MC

Facility: FAMC

Dept/Svc: Endocrine  Associate Investigators:

Key Words:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:

*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:
b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date: 320
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To provide a systemic means for all NIDDM patients at FAMC to be screened and to make physicians aware of the need for this intervention.

Technical Approach: See protocol.

Progress: 320 patients screened to date, no complications. POC is Dr. McNally and Dr. McDermott.

Publications and Presentations: None
Date: 30 Sep 90  
Protocol #: 90/113  
Status: Ongoing

Title: Effect of Cold Remedies on Metabolic Control of Noninsulin Dependent Diabetes Mellitus

Start Date: 1990  
Est Compl Date: 1991

Principal Investigator: Homer Lemar, MAJ, MC

Facility: FAMC

Dept/Svc: Endocrine

Associate Investigators:
W.J. Georgitis, LTC, MC  
Darci U. Ashley

Key Words:
- diabetes mellitus
- sucrose
- alcohol
- antitussive

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

a. Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 5  
d. Total Number of Subjects Enrolled to Date: 5  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: Determine if sugar and alcohol free cough formulas have clinically significantly fewer adverse metabolic effects inpatients with diabetes mellitus compared to standard (sugar and alcohol containing) cough formulas.

Technical Approach: Prospective crossover study in which all subjects will take both preparations in series and effects on blood sugar and lipids will be compared. Two groups of patients will be studied (well controlled and poorly controlled) in this manner.

Progress: A small number of subjects have been enrolled but have not begun the actual study.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 90/114 (3) Status: Ongoing

(4) Title: Assessment of Patient Utilities for Health Outcomes: Influence on Aspirin Prophylaxis to Prevent Myocardial Infarction

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: Cathy Ow, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Gen. Int. Med. (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 52 d. Total Number of Subjects Enrolled to Date: 52 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine what patients' utilities are for various health outcome states: (1) MI; (2) mild CVA; (3) moderate - severe CVA. Determine whether patient utilities influence decision to take ASA to prevent MI.

(16) Technical Approach: Decision analysis tree constructed using probabilities from published trials of ASA as prophylaxis against MI. Determine patient utilities by standard reference gamble interview.

(17) Progress: 52 subjects interviewed.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 90/115  Status: Ongoing

Title: Relationship of Blood Flow in Hemodialysis Access to Recirculation with Variable Blood Pump Flow

Start Date: 1990  Est Compl Date:

Principal Investigator: James Hasbargen, LTC, MC

Facility: FAMC

Dept/Svc: Nephrology  Associate Investigators: CPT Bergstrom

Key Words: recirculation access dialysis

Accumulative MEDCASE:*  Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:  Total Number of Subjects Enrolled to Date: 12  Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: Relationship between blood pump flow rate and recirculation.

Technical Approach: Measure recirculation at variable blood pump speeds.

Progress: Twelve patients enrolled, no data yet.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/116  Status: Ongoing

Title: Smoking Cessation Enhancement by Estimated Lung Age and Measured Expiratory Carbon Monoxide Levels

Start Date: 1990  Est Compl Date: 1992

Principal Investigator: Vance Bray, CPT, MC

Facility: FAMC

Dept/Svc: Int. Med.  Associate Investigators:

Key Words: smoking cessation  Ernest Degenhardt, CPT, AN

lung age

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review: Jun  b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: Evaluate the effect of patient education based upon calculated lung age and measured carbon monoxide exhalation on smoking cessation.

Technical Approach: Initial spirometry, carbon monoxide measurement and questionnaires will be repeated at 6, 12 and 18 months in groups participating in the current smoking cessation classes and groups of smokers not participating the classes to evaluate the long-term success rate of patient education.

Progress: Subjects are currently being enrolled, but no data is available for analysis at this time.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 90/117 (3) Status: Ongoing

(4) Title: The Effect of Prolonged Thyroxine Suppression Therapy on Thyroid Nodule Size, Cytology and Serum Thyroglobulin in Patients with Solitary Palpable Thyroid Lesions

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: John Merenich, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Endocrine (10) Associate Investigators:
Homer J. Lemar, MAJ, MC
Gerald S. Kidd, COL, MC
Michael McDermott, COL, MC
William Georgitis, COL, MC
Mark Larson, LTC, MC

(11) Key Words: Gerald S. Kidd, COL, MC
Michael McDermott, COL, MC
William Georgitis, COL, MC
Mark Larson, LTC, MC

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if suppressive doses of levothyroxine (documented by an 'ultrasensitive' TSH assay) reduces the size (by ultrasound) of newly discovered, biopsy "non-malignant" thyroid nodules; if response to suppression therapy differs between patients with truly uninnodal lesions VS those in whom ultrasound examination uncovers the presence of multiple nodules; if any FNA cytologic changes occur after a course of suppression therapy and the utility of serum thyroglobulin as a biochemical marker of changes in nodular size or cytology.

(16) Technical Approach: See protocol.

(17) Progress: No data yet, placebo to arrive by 1 September 90 and then the project can be started.

Publications and Presentations: None
**FAMC A.R.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<table>
<thead>
<tr>
<th>(1) Date:</th>
<th>30 Sep 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Protocol #:</td>
<td>90/118</td>
</tr>
<tr>
<td>(3) Status:</td>
<td>Ongoing</td>
</tr>
<tr>
<td>(4) Title:</td>
<td>Effect of Gymnema Sylvestre on Blood Glucose and Serum Insulin Levels</td>
</tr>
<tr>
<td>(5) Start Date:</td>
<td>1990</td>
</tr>
<tr>
<td>(6) Est Compl Date:</td>
<td></td>
</tr>
<tr>
<td>(7) Principal Investigator:</td>
<td>Lynn Abrams, CPT, MC</td>
</tr>
<tr>
<td>(8) Facility:</td>
<td>FAMC</td>
</tr>
<tr>
<td>(9) Dept/Svc:</td>
<td>Endocrine Svc</td>
</tr>
<tr>
<td>(10) Associate Investigators:</td>
<td></td>
</tr>
<tr>
<td>(11) Key Words:</td>
<td></td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td></td>
</tr>
<tr>
<td>(13) Est Accum OMA Cost:*</td>
<td></td>
</tr>
<tr>
<td>*Refer to Unit Summary Sheet of this Report</td>
<td></td>
</tr>
<tr>
<td>(14) a. Date, Latest IRC Review:</td>
<td>b. Review Results:</td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td>5</td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;</td>
<td></td>
</tr>
<tr>
<td>(15) Study Objective:</td>
<td>To investigate the acute effects of gurmar on blood glucose and insulin levels acutely and during a 7-day treatment period.</td>
</tr>
<tr>
<td>(16) Technical Approach:</td>
<td>A baseline 5-hour oral glucose tolerance test with measurement of glucose, insulin and c-peptide will be performed. Three days later the acute effect of the ingestion of 2 tablets of gurmar on glucose, insulin and c-peptide will be studied over 5 hours. Following this a 7-day period of daily ingestion of gurmar will be followed by a repeat 5-hour oral glucose tolerance test.</td>
</tr>
<tr>
<td>(17) Progress:</td>
<td>Although formal statistical evaluation of the results for the first 5 subjects has not been performed, none experience symptomatic hypoglycemia or blood sugars below 50 mg/dl. Dr. William Georgitis prepared this report for FY 90.</td>
</tr>
</tbody>
</table>

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/119  (3) Status: Ongoing

(4) Title: Epidemiological and Retrospective Analysis of Patients Consuming L-Tryptophan Containing Products

(5) Start Date: 1990  (6) Est Compl Date: 1991

(7) Principal Investigator: Harry Spaulding, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Allergy Svc  (10) Associate Investigators:

(11) Key Words: L-tryptophan eosinophilia-myalgia syndrome

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:__Jun__ b. Review Results:_______
    c. Number of Subjects Enrolled During Reporting Period:_______
    d. Total Number of Subjects Enrolled to Date:_______
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To understand the side effects of L-tryptophan ingestion and its association with eosinophilia-myalgia syndrome.

(16) Technical Approach: A review of records, a questionnaire, and selected laboratory studies will be performed. Positive results will be relayed to the subject and a generic information letter will be sent to each subject explaining the results of the overall study.

(17) Progress: No progress to date.

Publications and Presentations: None.
Title: Dose Hepatitis-B Vaccine Promote Eosinophilia, Increase Serum IgE Levels or Sensitize Recipients?

Principal Investigator: Harry Spaulding, COL, MC

Facility: FAMC

Dept/Svc: MED/Allergy Svc

Associate Investigators: David Goodman, LTC, MC

Key Words: hepatitis-B vaccine, eosinophilia, IgE

Accumulative MEDCASE:* Refer to Unit Summary Sheet of this Report

Study Objective: To determine if the standard hepatitis vaccine, in this case, Hepatvax-B, lot 074R, promotes any sensitivity, eosinophilia, or changes in total IgE to human recipients.

Technical Approach: Only patients who are receiving this first series of vaccinations and, therefore, antibody negative will be entered into the study. Prick skin testing will be performed to hepatitis vaccine, 1:10 and full strength. After 15 minutes histamine control will be added. If prick testing is negative, they will be tested intradermally to 1:100 dilution of the vaccine. Blood will be drawn for baseline determinations. Subjects will be re-evaluated after their first booster and then 6 months after the third booster was administered.

Progress: Subjects are currently being enrolled. No data is yet available.

Publications and Presentations:

167
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<table>
<thead>
<tr>
<th>(1) <strong>Date:</strong></th>
<th>30 Sep 90</th>
<th>(2) Protocol #:</th>
<th>90/121</th>
<th>(3) Status:</th>
<th>Ongoing</th>
</tr>
</thead>
<tbody>
<tr>
<td>(4) <strong>Title:</strong></td>
<td>Temporal Course of Altitude Acclimatization</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5) <strong>Start Date:</strong></td>
<td>1990</td>
<td>(6) Est Compl Date:</td>
<td>1991</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(7) <strong>Principal Investigator:</strong></td>
<td>Michael Perry, COL, MC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(8) <strong>Facility:</strong></td>
<td>Fort Sill, OK Fort Carson, CO</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(9) <strong>Dept/Svc:</strong></td>
<td>MED/Pul. Dis. Svc.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(10) <strong>Associate Investigators:</strong></td>
<td>William Annan, COL, IN Harry Dolton, Jr., LTC, FA Gerald Kidd, COL, MC John O'Connor, LTC, IN</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(11) <strong>Key Words:</strong></td>
<td>altitude effects acclimatization</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12) *<em>Accumulative MEDCASE:</em></td>
<td>Refer to Unit Summary Sheet of this Report</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(13) *<em>Est Accum OMA Cost:</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**(14)** a. Date, Latest IRC Review: Jun b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

**(15) Study Objective:** To determine the time requirement for completion of altitude-acclimatization

**(16) Technical Approach:** Subjects' anaerobic threshold will be determined using a 2-mile run and a two-part bicycle ergometer test at Ft. Sill. Arterial blood sample will be obtained. Using the same troops, the identical protocol will be carried out at Ft. Carson at 72 hrs, 1 mo, 6 mo, 9 mo 12 mo, and 18 mo after arrival for duty with the 4th ID.

**(17) Progress:** Approximately 20 subjects at Ft. Sill have undergone testing according to protocol guidelines. The same subjects are now undergoing testing at Ft. Carson.

**Publications and Presentations:** None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/122  (3) Status: Ongoing

(4) Title: Evaluation of Viral Hepatitis in Patients Infected with the Human Immunodeficiency Virus (HIV)

(5) Start Date: 1990  (6) Est Compl Date: 1990

(7) Principal Investigator: Kenneth Sherman, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Gastro.  (10) Associate Investigators:

(11) Key Words: HIV hepatitis

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jun b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To evaluate the prevalence of serologic markers of viral hepatitis including hepatitis B, hepatitis C, and hepatitis D in a military population and to determine the effect of AZT therapy on the markers of HB infection.

(16) Technical Approach: Bank sera of 220 HIV subjects will be used. Sera banked prior to AZT therapy will be studied using qualitative hepatitis B DNA probe assay. Data will be correlated to helper:suppressor status and serum markers of hepatic injury. Hepatitis C assay by ELISA will be performed on serial serum samples and at 6 month to 1 yr intervals to determine the incidence of hepatitis C in this population. Hepatitis D antibody testing will be performed in all HBsAg positive samples as well as any that may be HBV DNA positive but antigen negative on testing.

(17) Progress: Laboratory assays are being performed.

Publications and Presentations:
(1) Date: 30 Sep 90
(2) Protocol #: 90/123
(3) Status: Ongoing

(4) Title: Urinary Indices in Acute Renal Failure

(5) Start Date: 1990
(6) Est Compl Date: 1993

(7) Principal Investigator: James Hasbargen, LTC, MC
(8) Facility: FAMC

(9) Dept/Svc: MED/Gastroent.
(10) Associate Investigators:

(11) Key Words:
renal failure
serum creatinine

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jun  b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To evaluate the use of serval tests in diagnosing acute renal failure.

(16) Technical Approach: Prospective survey of serum creatinine in hospitalized patients for acute renal failure. Review of urinary diagnostic indices to include U/P creatinine, osmolality, FENA and FECL, FELI, NMR spectroscopy and transmission electron microscopy of urine as well as chart review.

(17) Progress: Patient enrollment is ongoing.

Publications and Presentations:

170
Date: 30 Sep 90  Protocol #: 90/124  Status: Ongoing

Title: The Effectiveness of Octreotide (Sandostatin*) to Prevent Pancreatitis Caused by Endoscopic Pancreato-Biliary Procedures: A Double-Blind, Randomized Study

Start Date: 1990  Est Compl Date: 1991

Principal Investigator: Michael Fisher, CPT, MC

Facility: FAMC

Dept/Svc: MED/Gastroent.

Associate Investigators:
Stephen Freeman, COL, MC
Scott Hallgren, MAJ, MC
Peter McNally, MAJ, MC

Key Words: pancreatitis octreotide

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: Jun  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To determine if administration of octreotide will decrease the risk of pancreatitis associated with endoscopic pancreato-biliary procedures and facilitate ampullary cannulation by decreasing S.O. and small bowel motility.

Technical Approach: Patients undergoing endoscopic pancreato-biliary procedures will be randomized to either a treatment or placebo group, given 5-6 hrs pre- and then immediately post procedure. After each procedure the investigators will perform an abdominal exam and interview directed toward the presence or absence of pain. Cholangiopancreatography will be done by standard method.

Progress: Patients are currently being enrolled in the study.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/125  (3) Status: Ongoing

(4) Title: SWOG 8697 Phase III Combination Chemotherapy of Predominantly Hormone Insensitive Metastatic Breast Cancer: An Evaluation of CAF versus Rotating Regimens of CAF and TSAV BH Induction Therapy Followed by Observation or Maintenance Therapy with CMF(P)TH or CMFH---Intergroup

(5) Start Date: 1990

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jun  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine most effective cancer treatment method.

(17) Progress: Open to patient accrual. No patients enrolled at FAMC.

Publications and Presentations:

172
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/126  (3) Status: Ongoing

(4) Title: SWOG 8710 Trial of Cystectomy Alone Versus Neoadjuvant M-VAC + Cystectomy in Patients with Locally Advanced Bladder Cancer, Phase III

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: __Jun__ b. Review Results:_________
c. Number of Subjects Enrolled During Reporting Period:______________
d. Total Number of Subjects Enrolled to Date:_____________________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine most effective treatment method.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:

173
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/127  (3) Status: Ongoing

(4) Title: SWOG 8737 A Phase III Study, AZQ 24 Hour Infusion Versus BCNU for Adult High Grade Gliomas (Intergroup 0093)

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jun  
    b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 
    d. Total Number of Subjects Enrolled to Date: 
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine most effective treatment method.

(17) Progress: One patient enrolled at FAMC.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/128  (3) Status: Ongoing

(4) Title: SWOG 8750 Pilot Study to Examine Cytogenetic Abnormalities in Patients with Acute Leukemia, Ancillary

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jun  b. Review Results: 
 c. Number of Subjects Enrolled During Reporting Period: 
 d. Total Number of Subjects Enrolled to Date: 
 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine most effective treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
<table>
<thead>
<tr>
<th>(1) Date: 30 Sep 90</th>
<th>(2) Protocol #: 90/129</th>
<th>(3) Status: Ongoing</th>
</tr>
</thead>
<tbody>
<tr>
<td>(4) Title: SWOG 8814 A Phase III Comparison of Adjuvant Chemoendocrine Therapy with CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients with Involved Axillary Lymph Nodes and Positive Receptors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5) Start Date: 1990</td>
<td>(6) Est Compl Date:</td>
<td></td>
</tr>
<tr>
<td>(7) Principal Investigator: Thomas Cosgriff, COL, MC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(8) Facility: FAMC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(9) Dept/Svc: MED/Hema/Oncol</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(10) Associate Investigators:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(11) Key Words:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(13) Est Accum OMA Cost:*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Refer to Unit Summary Sheet of this Report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(14) a. Date, Latest IRC Review: Jun</td>
<td>b. Review Results:</td>
<td></td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(15) Study Objective: To participate in SWOG.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(16) Technical Approach: To determine most effective treatment.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(17) Progress: Open to patient accrual, no patients enrolled at FAMC.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Publications and Presentations:
Date: 30 Sep 90  
Protocol #: 90/130  
Status: Ongoing

Title: SWOG 8899 A Prospective, Randomized Trial of Low-Dose Leucovorin + 5-FU, High-Dose Leucovorin + 5-FU, Levamisole +5-FU, or Low-Dose Leucovorin +5-FU + Levamisole Following Curative Resection in Selected Patients with Dukes' B or C Colon Cancer

Principal Investigator: Thomas Cosgriff, COL, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators:

Key Words:

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  
Review Results:  
Number of Subjects Enrolled During Reporting Period:  
Total Number of Subjects Enrolled to Date:  
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/131  (3) Status: Ongoing

(4) Title: VA Cooperative Study No. 316: Efficacy of Passive Immunization in the Prevention of Infection Due to Klebsiella Pneumoniae and Psudomonas Aeruginosa

(5) Start Date: 1990  (6) Est Compl Date: 1992

(7) Principal Investigator: William Byrne, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Inf.Dis.Svc

(10) Associate Investigators:
     Marin Kollef, MAJ, MC
     Phillip Mallory, MAJ, MC
     Thomas Cosgriff, COL, MC
     Robert Gates, LTC, MC
     Shannon Harrison, LTC, MC

(11) Key Words: IVIG

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
     *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul  
     b. Review Results: 
     c. Number of Subjects Enrolled During Reporting Period: 
     d. Total Number of Subjects Enrolled to Date: 
     e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if prophylactic administration of hyperimmune IVIG will prevent the acquisition of infection with those Klebsiella and P. aeruginosa serotypes included in the vaccine and that it will delay the onset and/or decrease the severity of infection in those patients who do become infected with these strains.

(16) Technical Approach: See protocol.

(17) Progress: OTSG approval pending.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/132  (3) Status: Ongoing

(4) Title: Prevention and Treatment of Steroid Induced Osteoporosis

(5) Start Date: 1990  (6) Est Compl Date: 1994

(7) Principal Investigator: Michael McDermott, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Endocrine

(10) Associate Investigators:
    John Merenich, MAJ, MC
    William Georgitis, LTC, MC
    James Singleton, MAJ, MC
    Sterling West, LTC, MC
    James Brown, COL, MC

(12) Accumulative MEDCASE:*
     *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul
     b. Review Results:
     c. Number of Subjects Enrolled During Reporting Period:
     d. Total Number of Subjects Enrolled to Date:
     e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Prevention and treatment of steroid induced osteoporosis.

(16) Technical Approach: Randomized controlled prospective single blind evaluation of the efficacy of a coherence therapy regimen in the prevention and treatment of steroid induced osteoporosis.

(17) Progress: Patients are currently being enrolled.

Publications and Presentations:
Date: 30 Sep 90  (2) Protocol #: 90/133  (3) Status: Ongoing

Title: The Effect of Terfenadine on Urination

Start Date: 1990  Est Compl Date: 1991

Principal Investigator: Paul Sklarew, CPT, MC

Facility: FAMC

Dept/Svc: MED/Allergy Svc

Associate Investigators:
Harry Spaulding, COL, MC
Brant Thrasher, CPT, MC
Craig Donatucci, MAJ, MC

Key Words: antihistamine urodynamics

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: Jul  
b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To determine if terfenadine alters the urinary pattern in normal, healthy men or in men with prostatic hypertrophy.

Technical Approach: Randomized crossover study with at least a one-week washout. Subjects will be skin tested prior to the initiation of the drug, after 72 hours, and after one week of treatment. Following skin testing, the urinary flow rate will be measured with a Lifetech flowmeter. Total urine volume voided, micturation time, peak or maximum flow rate and corrected maximum flow rate will be measured.

Progress: Phase I study in normal subjects completed. Seldane did not have any appreciable effects on urinary function.

Publications and Presentations: Abstracted submitted.
Date: 30 Sep 90  Protocol #: 90/134  Status: Ongoing

Title: Fibrinolytic and Thrombotic Activity in Unstable Coronary Disease

Start Date: 1990  Est Compl Date: 1991

Principal Investigator: Mark Dorogy, CPT, MC

Facility: FAMC

Dept/Svc: MED/Cardiology

Associate Investigators:
- Christopher Kozlowski, CPT, MC
- Thomas Cosgriff, COL, MC
- Bohdan Kudryk, PhD

Key Words:
- fibrinopeptide analysis
- coronary disease

Study Objective: To determine the relative contributions of thrombosis and fibrinolysis in the development of acute myocardial infarction and unstable angina.

Technical Approach: Specific markers of thrombosis and fibrinolysis will be studied. These markers are fibrinopeptide A, and two other fibrinopeptides known as B-beta-1-42 and B-beta-15-42.

Progress: Blood specimens are being accrued.

Publications and Presentations:
Date: 30 Sep 90  (2) Protocol #: 90/135  (3) Status: Ongoing

(4) Title: Comparison of Liver Biopsy Versus Noninvasive Testing Using Hepatic Ultrasound, Radionuclide Scanning, Erythrocyte Folate Levels and Methotrexate Levels for the Determination of Methotrexate-Induced Hepatotoxicity

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Michael Fisher, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Gastro

(10) Associate Investigators:
Jeffrey Dunkelberg, MAJ, MC
Stephen Freeman, COL, MC

(11) Key Words:
methotrexate
hepatotoxicity

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To correlate the findings at the time of liver biopsy with blood tests as well as images of the liver obtained by ultrasound and nuclear imaging of the effect of methotrexate on the liver.

(16) Technical Approach: See protocol.

(17) Progress: Subjects are being enrolled in the study.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 90/136 (3) Status: Ongoing

(4) Title: SWOG 8921 A Phase II Trial of Cyclophosphamide/IL-2, DTIC/IL-2 and DTIC/Cisplatin/Tamoxifen in Stage IV Melanoma

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/137  (3) Status: Ongoing

(4) Title: SWOG 8312 Megestrol Acetate and Aminoglutethimide/Hydrocortisone in Sequence or in Combination as Second-Line Endocrine Therapy of Estrogen Receptor Positive Metastatic Breast Cancer, Phase III

(5) Start Date: 1990

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul  b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/138  (3) Status: Ongoing

(4) Title: SWOG 8520 Cis-Diamminedichloroplatinum (II), Methotrexate and Bleomycin in the Treatment of Advanced Epidermoid Carcinoma of the Penis, Phase II

(5) Start Date: 1990  (6) Est Compl Date: 1991

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul  b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: One patient enrolled at FAMC.

Publications and Presentations:

185
(1) Date: 30 Sep 90  (2) Protocol #: 90/139  (3) Status: Ongoing

(4) Title: SWOG 8621 Chemo-Hormonal Therapy of Postmenopausal Receptor-Positive Breast Cancer, Phase III

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul   b. Review Results:
   c. Number of Subjects Enrolled During Reporting Period:
   d. Total Number of Subjects Enrolled to Date:
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
(4) Title: SWOG 8692 Therapy in Premenopausal Women with Advanced ER Positive or PgR Positive Breast Cancer: Surgical Oophorectomy vs the LH-RH Analog, Zoladex. Phase III Intergroup

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None
Date: 30 Sep 90  
Protocol #: 90/141  
Status: Ongoing

Title: SWOG 8711 A Study of Reproductive Function in Patients with Testicular Cancer

Start Date: 1990  
Est Compl Date: 

Principal Investigator: Thomas Cosgriff, COL, MC

Dept/Svc: MED/Hema/Oncol

Associate Investigators: 

Key Words: 

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: Jul  
b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Date: 30 Sep 90  
Protocol #: 90/142  
Status: Ongoing

Title: SWOG 8736 Treatment of Localized Non-Hodgkin's Lymphoma: Comparison of Chemotherapy (CHOP) to Chemotherapy Plus Radiation Therapy

Start Date: 1990  
Est Compl Date: 

Principal Investigator: Thomas Cosgriff, COL, MC

Dept/Svc: MED/Hema/Oncol

Key Words: 

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Date: 30 Sep 90  (2) Protocol #: 90/143  (3) Status: Ongoing

Title: SWOG 8793 Randomized Phase III Evaluation of Hormonal Therapy Vs Observation in Patients with Stage D1 Adenocarcinoma of the Prostate Following Pelvic Lymphadenectomy and Radical Prostatectomy

Start Date: 1990

Principal Investigator: Thomas Cosgriff, COL, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators:

Key Words:

Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/144  (3) Status: Ongoing

(4) Title: SWOG 8794 Treatment of Pathologic Stage C Carcinoma of the Prostate with Adjuvant Radiotherapy

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Date: 30 Sep 90 (2) Protocol #: 90/145 (3) Status: Ongoing

(4) Title: SWOG 8806 A Phase II Study of Recombinant Tumor Necrosis Factor (rTNF) in Patients with Advanced Bladder Cancer

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COl, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul b. Review Results: 

c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
(1) Date: 30 Sep 90  (2) Protocol #: 90/146  (3) Status: Ongoing

(4) Title: SWOG 8809 A Phase III Study of Alpha Interferon Consolidation Following Intensive Chemotherapy with Promace-MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:________ b. Review Results:________
c. Number of Subjects Enrolled During Reporting Period:________
d. Total Number of Subjects Enrolled to Date:________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/147  (3) Status: Ongoing

(4) Title: SWOG 8819 Central Lymphoma Repository Tissue Procurement Protocol

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
(1) Date: 30 Sep 90  
(2) Protocol #: 90/148  
(3) Status: Ongoing  

(4) Title: SWOG 8836 A Study of Chest Irradiation Plus Concurrent Daily Low-Dose Cisplatin Followed by High Dose Consolidation for Locally Advanced Non-Small Cell Lung Cancer  

(5) Start Date: 1990  
(6) Est Compl Date:  

(7) Principal Investigator:  
Thomas Cosgriff, COL, MC  

(8) Facility: FAMC  

(9) Dept/Svc: MED/Hema/Oncol  
(10) Associate Investigators:  

(11) Key Words:  

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report  

(14) a. Date, Latest IRC Review: Jul b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"  

(15) Study Objective: To participate in SWOG.  

(16) Technical Approach: To determine the most effective cancer treatment.  

(17) Progress: One patient enrolled at FAMC.  

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/149  Status: Ongoing  

Title: SWOG 8896 Intergroup Phase III Protocol for Surgical Adjuvant Therapy of Rectal Carcinoma: A Controlled Evaluation of (A), Protracted Infusion of 5-Fluorouracil as a Radiation Enhancer and (B), 5-Fluorouracil Plus Methyl-CCNU Chemotherapy  

Start Date: 1990  Est Compl Date:  

Principal Investigator: Thomas Cosgriff, COL, MC  

Facility: FAMC  

Dept/Svc: MED/Hema/Oncol  

Associate Investigators:  

Key Words:  

Study Objective: To participate in SWOG.  

Technical Approach: To determine the most effective cancer treatment.  

Progress: Open to patient accrual, no patients enrolled at FAMC.  

Publications and Presentations:
(1) Date: 30 Sep 90 (2) Protocol #: 90/150 (3) Status: Ongoing

(4) Title: SWOG 8905 Phase II/III Study of Fluorouracil (5-FU) and Its Modulation in Advanced Colorectal Cancer

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator:
Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Jul b. Review Results:__________
c. Number of Subjects Enrolled During Reporting Period:__________
d. Total Number of Subjects Enrolled to Date:__________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Title: Extrinsic Positive End-Expiratory Pressure (PEEP) Effects on Functional Residual Capacity in Normal Subjects and in Ventilated Patients Experiencing Air Trapping (AUTO-PEEP)

Status: Ongoing

Start Date: 1990

Est Compl Date: 1991

Principal Investigator: Douglas Dothager, CPT, MC

Associate Investigators:
- Marin Kollef, MAJ, MC
- Phillip Mallory, MAJ, MC
- Robert Browning, BS, DAC

Key Words: lung volume

Study Objective: To determine lung volume changes when air-pressure is added through a ventilator in patients with lung disease on ventilators.

Technical Approach: Ventilated subjects will be placed in an "iron lung" which will be used to measure lung volumes and changes in lung volumes. Computer hookup to subject will allow measurement of lung volume changes. Air pressure will be added to the ventilator a little at a time and any change in lung volumes will be measured. Blood pressure and heart rate will also be monitored.

Progress: Patient enrollment continues, and data is being accrued.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/152  Status: Ongoing

Title: Residual Renal Function in Dialysis Patients

Start Date: 1990  Est Compl Date: 1991

Principal Investigator: James Hasbargen, LTC, MC

Facility: FAMC  Dept/Svc: MED/Nephrology

Associate Investigators: Barbara Hasbargen, RN, BSN  Peter Blue, COL, MC

Key Words: dialysis  renal function

Accumulative MEDCASE:* Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: Aug       b. Review Results:      
c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: The principal objective of the study is to elucidate the relationship between modality of dialysis and residual renal function.

Technical Approach: Fifteen patients who are on hemodialysis and 15 patients who are on CAPD and approximately 6 patients that will change from one modality to the other will be studied using blood samples and renal scans.

Progress: Patients are currently being enrolled on this study which was approved in Aug '90.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 90/153  Status: Ongoing

Title: Relationship of Calcium and Glucose Metabolism on Blood Pressure

Start Date: 1990  Est Compl Date: 1991

Principal Investigator: James Hasbargen, LTC, MC

Facility: FAMC

Dept/Svc: MED/Nephrology  Associate Investigators: Joseph White, MAJ, MC

Key Words:
hypertension
calcium
glucose

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: Aug  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To allow for a more rational approach to antihypertensive therapy.

Technical Approach: Evaluate the subgroups of essential hypertensives with respect to calcium/PTH axis, vs glucose/insulin axis, vs Na/renin axis. Specifically to evaluate the relationships of Ca/PTH and the potential role of diminished insulin release and hyperglycemia in essential hypertensives.

Progress: Patients are currently being enrolled in this study which was approved in Aug '90.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/154  (3) Status: Ongoing

(4) Title: SWOG 9326 Evaluation of Combination Chemotherapy Using High Dose Ara-C in Adult Acute Leukemia and Chronic Granulocytic Leukemia in Blastic Crisis, Phase III

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:
 c. Number of Subjects Enrolled During Reporting Period:
 d. Total Number of Subjects Enrolled to Date:
 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:

201
(1) Date: 30 Sep 90 (2) Protocol #: 90/155 (3) Status: Ongoing

(4) Title: SWOG 8810 Six Courses of 5-Fluorouracil and Cis-Platinum with Correlation of Clinical and Cellular DNA Parameters in Patients with Advanced, Untreated and Unresectable Squamous Cell Carcinoma of the Head and Neck, Phase II Pilot Study

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost: *
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/156  Status: Ongoing

Title: SWOG 8812 Treatment of Limited Small Cell Lung Cancer with Concurrent Chemotherapy, Radiotherapy, with or without GM-CSF and Subsequent Randomization to Maintenance Interferon or No Maintenance

Start Date: 1990

Principal Investigator: Thomas Cosgriff, COL, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators:

Key Words: 

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 90/157 (3) Status: Ongoing

(4) Title: SWOG 8828 A Phase II Trial of Carboplatin (CBDCA) in Relapsed or Refractory Acute Myeloid Leukemia

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: ______ b. Review Results: ________
c. Number of Subjects Enrolled During Reporting Period: ______
d. Total Number of Subjects Enrolled to Date: ____________

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:

204
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/158  (3) Status: Ongoing

(4) Title: SWOG d851 A Phase III Comparison of Combination Chemotherapy (CAF) and Chemohormonal Therapy (CAF + Zoladex or CAF + Zoladex and Tamoxifen) in Premenopausal Women with Axillary Node-Positive, Receptor-Positive Breast Cancer

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Co-t:*  *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:

205
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Date:</td>
<td>30 Sep 90</td>
</tr>
<tr>
<td>(2) Protocol #:</td>
<td>90/159</td>
</tr>
<tr>
<td>(3) Status:</td>
<td>Ongoing</td>
</tr>
<tr>
<td>(4) Title:</td>
<td>SWOG 8892 A Study of Radiotherapy with or without Concurrent Cisplatin in Patients with Nasopharyngeal Cancer, Phase III</td>
</tr>
<tr>
<td>(5) Start Date:</td>
<td>1990</td>
</tr>
<tr>
<td>(6) Est Compl Date:</td>
<td></td>
</tr>
<tr>
<td>(7) Principal Investigator:</td>
<td>Thomas Cosgriff, COL, MC</td>
</tr>
<tr>
<td>(8) Facility:</td>
<td>FAMC</td>
</tr>
<tr>
<td>(9) Dept/Svc:</td>
<td>MED/Hema/Oncol</td>
</tr>
<tr>
<td>(10) Associate Investigators:</td>
<td></td>
</tr>
<tr>
<td>(11) Key Words:</td>
<td></td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td></td>
</tr>
<tr>
<td>(13) Est Accum OMA Cost:*</td>
<td></td>
</tr>
<tr>
<td>*Refer to Unit Summary Sheet of this Report</td>
<td></td>
</tr>
<tr>
<td>(14) a. Date, Latest IRC Review:</td>
<td></td>
</tr>
<tr>
<td>b. Review Results:</td>
<td></td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td></td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td></td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;</td>
<td></td>
</tr>
<tr>
<td>(15) Study Objective:</td>
<td>To participate in SWOG.</td>
</tr>
<tr>
<td>(16) Technical Approach:</td>
<td>To determine the most effective cancer treatment.</td>
</tr>
<tr>
<td>(17) Progress:</td>
<td>Open to patient accrual, no patients enrolled at FAMC.</td>
</tr>
</tbody>
</table>

**Publications and Presentations:**
Date: 30 Sep 90  Protocol #: 90/160  Status: Ongoing

Title: SWOG 8897 Phase III Comparison of Adjuvant Chemotherapy with or without Endocrine Therapy in High-Risk, Node Negative Breast Cancer Patients and a Natural History Follow-up Study in Low-Risk, Node Negative Patients

Start Date: 1990  Est Compl Date: 

Principal Investigator: Thomas Cosgriff, COL, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators: 

Key Words: 

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/161  (3) Status: Ongoing

(4) Title: SWOG 8910 Evaluation of Low Dose Continuous 5-Fluorouracil (5-FU) and Weekly Cisplatinum (CDDP) in Advanced Adeno-carcinoma of the Stomach, Phase II Pilot

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
    Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:________ b. Review Results:________
    c. Number of Subjects Enrolled During Reporting Period:________
    d. Total Number of Subjects Enrolled to Date:________
    e. Note any adverse drug reactions reported to the FDA or sponsor for
       studies conducted under an FDA-awarded IND. May be continued on a
       separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/162  Status: Ongoing

Title: SWOG 8915 A Phase II Study of 6-Thioguanine Administered as 120 Hour Continuous Infusion for Refractory or Recurrent Small Cell Carcinoma

Start Date: 1990  Est Compl Date:

Principal Investigator:  Thomas Cosgriff, COL, MC

Dept/Svc: MED/Hema/Oncol

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period:  d. Total Number of Subjects Enrolled to Date:  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/163  Status: Ongoing

Title: SWOG 8916 Evaluation of Merbarone in Pancreatic Adenocarcinoma, Phase II

Start Date: 1990  Est Compl Date:

Principal Investigator: Thomas Cosgriff, COL, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators:

Key Words:

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90   (2) Protocol #: 90/164   (3) Status: Ongoing

(4) Title: SWOG 8952 Treatment of Advanced Hodgkin's Disease - A Randomized Phase III Study Comparing ABVD vs MOPP/ABV Hybrid

(5) Start Date: 1990   (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(9) Dept/Svc: MED/Hema/Oncol   (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*   (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:______ b. Review Results:__________
    c. Number of Subjects Enrolled During Reporting Period:__________
    d. Total Number of Subjects Enrolled to Date:__________
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Date: 30 Sep 90 (2) Protocol #: 90/165 (3) Status: Ongoing

Title: SWOG 8997 A Phase III Chemotherapy of Disseminated Advanced Stage Testicular Cancer with Cisplatin Plus Etoposide with Either Bleomycin or Ifosfamide

Start Date: 1990

Principal Investigator: Thomas Cosgriff, COL, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol

Associate Investigators:

Key Words:

Accumulative MEDCASE:* (Est Accum OMA Cost:*)

Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Title: Evaluation of Allergenic Cross-Reactivity Amongst Cockroach Species

Start Date: 1990

Est Compl Date: 1992

Principal Investigator: David Goodman, LTC, MC

Facility: FAMC

Dept/Svc: MED/Allergy

Associate Investigators:
- T. Ray Vaughan, MAJ, MC
- Anthony Henry, LTC, MC
- Jeffrey Glassheim, MAJ, MC
- Robert Ledoux, BS, DAC

Key Words:
- cross-reactivity
- antigenicity
- allergenicity

Accumulative MEDCASE:

Progress:
- Newly approved study. No progress.

Study Objective:
To determine the incidence of clinical hypersensitivity to cockroach, common insects, and mites in an atopic disease population; to determine if there is significant cross reactivity among the five common cockroach pests in North America; to determine cross-reactivity among cockroach, other common indoor insect pests and mite antigens.

Technical Approach:
Animal models will be used to develop antiserum specific for cockroach and other insect species under investigation in this protocol. Prior to skin testing blood will be drawn for immunochemical analysis. Subjects will then be skin tested.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/167A  Status: Ongoing

Title: Animal Model of Physiologic PEEP (Positive End-Expiratory Pressure)

Start Date: 1990  Est Compl Date: 1991

Principal Investigator: Marin Kollef, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Pul.Dis.Svc.  Associate Investigators:

Key Words: Positive end-expiratory pressure

Associate Investigators:
Michael McCormack, CPT, MC
Michael Perry, COL, MC
Kevin Bright, CPT, MC
Michael Lepore, COL, MC

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Study Objective: To determine that physiologic PEEP does exist and that its removal will cause a decrease in lung volume, worsening gass exchange, and decrease in end-expiratory pressures of the trachea.

Technical Approach: A prospective animal model will be used to evaluate the above stated hypothesis.

Progress: None. New study approved in Sep'90.

Publications and Presentations:
Date: 30 Sep 90  
Protocol #: 90/168A  
Status: Ongoing

Title: A Histologic and Immunopathologic Study of the Skin and Internal Organs of MRL+/+ Mice

Start Date: 1990  
Est Compl Date: 1991

Principal Investigator:  
Kathleen David, MAJ, MC

Facility: FAMC  
VA Hospital, Denver

Dept/Svc: MED/Dermatology

Associate Investigators:  
Cheryl Teuton, CPT  
Lele Lee, MD  
Thomas Santoro, MD  
Pat Skavlen, DVM

Key Words:  
lupus erythematosus

Accumulative MEDCASE:  
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: __Sep__  
b. Review Results: __________
c. Number of Subjects Enrolled During Reporting Period: __________
d. Total Number of Subjects Enrolled to Date: __________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: We predict that the MRL+/+ mice will have pathologic findings similar to those reported in MRL/1pr mice, but will develop these findings in a more delayed manner. Further, we predict that the 1pr gene is not a prerequisite for autoimmune disease in the MRL mouse.

Technical Approach: This autopsy study will involve 10 animals in each age group studied, 4, 16, 32, 40, 48 and 60 weeks or approximately 60-100 animals. Blood will be obtained, and various internal organs removed for pathologic studies. We will compare our findings with those reported for MRL/1pr mice and with findings reported in humans with lupus.

Progress: New study recently approved. No progress.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/169  (3) Status: Ongoing

(4) Title: The Effect of Steroid Therapy on Recovery After Tonsillectomy

(5) Start Date: 1990  (6) Est Compl Date: 1991

(7) Principal Investigator: Glen Yoshida, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SURG/Otolaryn.

(10) Associate Investigators:

(11) Key Words:
    steroids
    tonsillectomy
    anti-inflammatory

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: Sep  
    b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 
    d. Total Number of Subjects Enrolled to Date: 
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To demonstrate the effectiveness of steroids to reduce the incidence and severity of postoperative symptoms and complications in patient undergoing tonsillectomy.

(16) Technical Approach: Twenty adult subjects will be randomized to receive either steroid or placebo intravenously at the time of surgery. A total of three doses will be given every 6 hrs. Patients will be asked to answer questions pertaining to their postoperative course at 24 hrs, 2 weeks and 2 months.

(17) Progress: No progress as stipulations for IRC approval are still pending.

Publications and Presentations:

216
Details Summary Sheet (HSCR 40-23 as amended)

1. Date: 30 Sep 90  
2. Protocol #: 90/170  
3. Status: Ongoing

4. Title: SWOG 8744 A Phase II Study of Recombinant Tumor Necrosis Factor (rTNF) in Patients with Refractory Multiple Myeloma

5. Start Date: 1990  
6. Est Compl Date:

7. Principal Investigator: Thomas Cosgriff, COL, MC

8. Facility: FAMC

9. Dept/Svc: MED/Hema/Oncol  
10. Associate Investigators:

11. Key Words:

12. Accumulative MEDCASE:*  
13. Est Accum OMA Cost:*  
   *Refer to Unit Summary Sheet of this Report

14. a. Date, Latest IRC Review:  
   b. Review Results:  
   c. Number of Subjects Enrolled During Reporting Period:  
   d. Total Number of Subjects Enrolled to Date:  
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

15. Study Objective: To participate in SWOG.

16. Technical Approach: To determine the most effective cancer treatment.

17. Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
(1) Date: 30 Sep 90  (2) Protocol #: 90/171  (3) Status: Ongoing

(4) Title: SWOG 8789 A Randomized Study of Etoposide plus Cisplatin and Etoposide Plus Carboplatin (CBDCA) in the Management of Good Risk Patients with Advanced Germ Cell Tumors

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
       *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
     c. Number of Subjects Enrolled During Reporting Period:
     d. Total Number of Subjects Enrolled to Date:
     e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:

218
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 90/172 (3) Status: Ongoing

(4) Title: SWOG 8792 A Phase III Study of Alfa-nl (Wellferon) as Adjuvant Treatment for Resectable Renal Cell Carcinoma

(5) Start Date: 1990 (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
(1) Date: 30 Sep 90  (2) Protocol #: 90/173  (3) Status: Ongoing

(4) Title: SWOG 8842 Dihydroxyazacytidine in Malignant Mesothelioma, Phase II

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC  (8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/174  Status: Ongoing

Title: SWOG 8900 A Phase II Pilot of VAD and VAD/Verapamil for Refractory Multiple Myeloma

Start Date: 1990  Est Compl Date:

Principal Investigator: Thomas Cosgriff, COL, MC

Dept/Svc: MED/Hema/Oncol  Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.
(1) Date: 30 Sep 90  (2) Protocol #: 90/175  (3) Status: Ongoing

(4) Title: SWOG 8931 Phase III Comparison of Cyclophosphamide, Doxorubicin and 5-Fluorouracil (CAF) and a 16-Week Multi-drug Regimen as Adjuvant Therapy for Patients with Hormone Receptor Negative, Node-Positive Breast Cancer

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: Thomas Cosgriff, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in SWOG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/176  Status: Ongoing

Title: SWOG 8994 Evaluation of Quality of Life in Patients with Stage C Adenocarcinoma of the Prostate Enrolled on SWOG 8794

Start Date: 1990  Est Compl Date:

Principal Investigator: Thomas Cosgriff, COL, MC  Facility: FAMC

Dept/Svc: MED/Hema/Oncol  Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*

Date, Latest IRC Review: ______  Review Results: ______

Number of Subjects Enrolled During Reporting Period: ______  Total Number of Subjects Enrolled to Date: ______

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in SWOG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations:

223
Date: 30 Sep 90  Protocol #: 90/177  Status: Ongoing

Title: National Co-operative rHu Erythropoietin Study in Patients with Chronic Renal Failure: A Phase IV Multi-center Study

Start Date: 1990  Est Compl Date: 1992

Principal Investigator: James Hasbargen, LTC, MC

Facility: FAMC

Dept/Svc: MED/Nephrology

Associate Investigators:

Key Words: renal failure  erythropoietin

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review: Sep  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: Expand the safety profile of erythropoietin in anemic patients with chronic failure. To understand the medical and social impact of erythropoietin therapy on the United States chronic renal failure population, including patients currently receiving erythropoietin and patients receiving therapy for the first time.

Technical Approach: Active study of patients currently receiving or starting on erythropoietin.

Progress: No progress. Recently approved study.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/178  Status: On

Title: The Efficacy and Safety of Orally Administered SQ 32,756 in the Treatment of Acute, Localized Non-Trigeminal Zoster in Immunocompetent Patients

Start Date: 1990  Est Compl Date: 1993

Principal Investigator: Scott Bennion, LTC, MC

Facility: FAMC

Dept/Svc: MED/Dermatology  Associate Investigators:
James Fitzpatrick, LTC, MC
Katherine David, MAJ, MC
M. Jim Schleve, LTC, MC

Key Words: herpes zoster

Accumulative MEDCASE:*  Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  Sep  

b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To assess the relative efficacy and safety of SQ 32,756 when given orally in doses of 10 mg once daily (qd) or 40 mg qd vs. placebo qd in the treatment of acute, localized, non-trigeminal zoster in immunocompetent adults.


Progress: No progress. Recently approved by IRC. NCS-OIA approval pending.

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/179  (3) Status: Ongoing

(4) Title: A Randomized Prospective Study of Clindamycin or Pyrimethamine Therapy for Prevention of Toxoplastic Encephalitis in HIV-Infected Individuals with Serologic Evidence of Latent Toxoplasma gondii Infection (CPCRA 001).

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Robert Gates, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Inf.Dis.Svc.  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: _____ b. Review Results: _____

c. Number of Subjects Enrolled During Reporting Period: _____

d. Total Number of Subjects Enrolled to Date: _____

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To evaluate clindamycin and pyrimethamine as prophylactic agents against toxoplastic encephalitis in individuals who are coinfected with HIV and latent T. gondii.

(16) Technical Approach: Multicenter, prospective, 4-arm, placebo-controlled (clindamycin, placebo for clindamycin, pyrimethamine, placebo for pyrimethamine) randomized, modified double-blind study.

(17) Progress: No progress. Recently approved by the IRC. Pending approval from HCS-CIA.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 78/20X-001  Status: Ongoing

Title: Repair of Femoral Artery by Microvascular Technique in Rabbit and Rats

Start Date:  Est Compl Date: Indefinite

Principal Investigator: James C. Johns, Jr.  MAJ, MC

Facility: FAMC

Dept/Svc: SUR/Orthopedic

Key Words: microvascular education and training

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:  Total Number of Subjects Enrolled to Date:  Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To increase microsurgical technique for orthopedic staff and residents.

Technical Approach: Perform all microvascular studies/techniques prior to human surgery.

Progress: Continued training/education for resident/interns and students. Continued maintenance of staff skills. Microvascular techniques used for vein grafts, arterial and venous anastamoses, nerve repairs, and grafts. In progress, principal investigator on temporary duty elsewhere.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 78/20X-002  (3) Status: Ongoing

(4) Title: Repair of Femoral Artery by Microvascular Technique in Rabbits and the Rat

(5) Start Date:  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Thomas E. Carter, COL, MC  (8) Facility: FAMC

(9) Dept/Svc: SUR/Neurosurgery  (10) Associate Investigators

(11) Key Words: microvascular education and training

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To increase microsurgical technique for staff and residents.

(16) Technical Approach: Perform all microvascular studies/techniques prior to human surgery.


Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date 30 Sep 90 (2) Protocol #: 78/20X-003 (3) Status: Ongoing

(4) Title: Microsurgical Training in Free Flap Transfer and Vessel and Nerve Repair Utilizing the Rabbit and Rat

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Berry E. Morton, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Training protocol.

(16) Technical Approach: See protocol.

(17) Progress: Five personnel have been trained this FY.

Publications and Presentations: None
Date: 30 Sep 90  
Protocol #: 78/201  
Status: Ongoing

Title: Clinical Study of Intraocular Lens

Start Date:  
Est Compl Date:  

Principal Investigator:  
David Pernelli, MAJ, MC

Facility:  
FAMC  
General Leonard Wood Army Community Hospital

Dept/Svc: Ophthalmology  
Associate Investigators:

Key Words:  
intraocular lens

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review: Mar  
Review Results  
Number of Subjects Enrolled During Reporting Period:  
Total Number of Subjects Enrolled to Date:  
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To establish the safety and effectiveness of intraocular lens implantation of the cataract patient. (See original protocol).

Technical Approach: Extracapsular cataract extraction with posterior chamber IOL.

Progress: In a 6-month period, 42 lenses have been implanted in aphakic subjects. Subjects have improved eyesight with no adverse reactions.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 78/201  Status: Ongoing

Title: Clinical Study of Intraocular Lens

Start Date: 1978  Est Compl Date: Indefinite

Principal Investigator: Floyd M. Cornell, LTC, MC

Facility: FAMC

Dept/Svc: SUR/Ophthalmology

Associate Investigators
MAJ Robert Enzenauer
MAJ Ricardo J. Ramirez
CPT Thomas A. Gardner

Key Words
- cataract
- aphakia

Accumulative MEDCASE:*  Est Accum OMA Cost:* 
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: 3/90  b. Review Results: Ongoing
  c. Number of Subjects Enrolled During Reporting Period: 450
  d. Total Number of Subjects Enrolled to Date: 400/year
  e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". NONE

3M, ALCON, IOLAB (PRECISION-COSMET), COBURN, CILCO, IOPEX, COPELAND, PHARMACIA INTERMEDICS, SURGIDEV, AMERICAN MEDICAL OPTICS

Study Objective: To determine postoperative visual acuity of patients receiving intraocular lens, and to compare those results with those of a control group of patients who undergo cataract surgery but do not receive an intraocular lens.

Technical Approach: Post-operative examinations include: pachymetry, keratometry and specular microscopy. Contraindications to surgery include: patients with good visual potential in only one eye, proliferative diabetic retinopathy, rubeosis irides, high axial myopia, and inadequately controlled glaucoma, Fuch's endothelial dystrophy.

Progress: Results have been excellent with over 1,000 subjects enrolled. No adverse reactions due to implants perse, continue to enjoy good results. Silicon lenses are expensive but off core and adjunct studies.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 78/201.A  Status: Ongoing

Title: Clinical Study of Intraocular Lens

Start Date:  Est Compl Date: Continuous

Principal Investigator: Monte Dirks, MAJ, MC
Facility: FAMC Munson ACH Ft. Leavenworth, KS 66027

Dept/Svc: Ophthalmology

Key Words:
cataract extraction
intraocular lens implanting

Accumulative MEDCASE: *  Est Accum OMA Cost: *
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 80
d. Total Number of Subjects Enrolled to Date: 160
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: Participation in IOL implantation to meet FDA requirements for safety and efficacy and to improve eyesight in patients having cataracts.

Technical Approach: See Protocol

Progress: Subjects are experiencing improved eyesight with decreased incidence of posterior capsular fibrosis with B-1-convex lenses. Approximately 160 lens have been implanted to date without complications.

Publications and Presentations: None
(1) Date: 30 Sep 90 (2) Protocol WU#: 78/201.C (3) Status: Ongoing

(4) Title: Clinical Study of Intraocular Lens

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Paul Kuck, MAJ, MC
(8) Facility: FAMC Irwin Army Community Hospital Ft. Riley, Kansas 66442

(9) Dept/Svc: SUR/Ophthalmology (10) Associate Investigators

(11) Key Words:
- intraocular lens

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To determine postoperative visual acuity of patients receiving intraocular lens, and compare those results with those who undergo cataract surgery without an implant. To determine the occurrence and time of postoperative ocular complications and adverse reactions for intraocular lens implant; to identify subgroups within the implant group that are risk of a particular complication.

(16) Technical Approach: After completing his residency, didactic courses, laboratory practice and assistance with an experienced surgeon, a surgeon who can perform a successful cataract surgery is then allowed to perform intraocular lens surgery. Postoperative examination includes: refraction, pachymetry, keratometry and a complete anterior and posterior segment examination. Contraindications to surgery with intraocular implants include: patients with good visual potential in only one eye, proliferative diabetic retinopathy, rubeosis irides, high axial myopia, any history of anterior or posterior uveitis. History of glaucoma would preclude the use of an anterior chamber implant.
(17) Progress: At this time no pre-market lenses are being used. Anticipate possible use of these types of lenses in the future.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 78/201.D  Status: Ongoing

Title: Clinical Study of Intraocular Lens

Start Date:  Est Compl Date:

Principal Investigator: Jeffrey L. Bezier, MAJ, MC
Facility: FAMC
Reynolds Army Hospital
Ophthalmology, Box 21
4700 Hartell Blvd.
Ft. Sill, OK 73503-6300
AV 639-0295/0296

Dept/Svc: Ophthalmology

Key Words: intraocular lens

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: 3/90  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 45-50

d. Total Number of Subjects Enrolled to Date: 160

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e" None [CILCO]

Study Objective: To determine postoperative visual acuity of patients receiving intraocular lens, and to compare those results with those of a control group of patients who undergo cataract surgery but do not receive an intraocular lens.

Technical Approach: Post-operative examinations include: visual acuity testing and keratometry. Contraindications to surgery include: proliferative diabetic retinopathy, rubeosis irides. Implanting CILCO lens now, but also authorized to implant Precision Cosmet, 3M, Alcon, and IOLAB.

Progress: Cataract surgery with the intraocular lens implantation has been satisfactory with no unusual post operative complications to date.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 78/201.E  Status: Ongoing

Title: Clinical Study of Intraocular Lens

Start Date:  Est Compl Date: Indefinite

Principal Investigator: Charles E. Aronson, COL, MC  Facility: FAMC
Evans Army Community Hospital
ATTN: EENT Clinic
Ft. Carson, CO 80913-5207
AV 691-7450

Dept/Svc: Ophthalmology  Associate Investigators: Horace Gardner, M.D.

Key Words:
- intraocular lens

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review: 3/90  Review Results:
Number of Subjects Enrolled During Reporting Period: 200
Total Number of Subjects Enrolled to Date: 200
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e" None [COBURN]

Study Objective: Participation in IOL implantation.

Technical Approach: See protocol.

Progress: Lens center well, none needed repositioned or removed. No evidence of prolonged inflammation other than normal healing process. No unusual complications.

Publications and Presentations: None
Title: Microvascular Arterial and Venous Anastomosis in Laboratory Rats

Principal Investigator: Michael J. Raife
COL, MC

Associate Investigators:
- Thomas A. Jones, MAJ, MC
- Craig Donatucci, MAJ, MC
- Ronald Sutherland, CPT, MC
- James B. Thrasker, CPT, MC
- Karl Kreder, MAJ, MC
- Timothy A. Moses, CPT, MC

Study Objective: To develop and maintain microvascular skills.

Technical Approach: Microsurgical exercises of increasing complexity will be performed under anesthesia.

Progress: The protocol has been valuable in teaching microsurgical techniques.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol WU#: 86/200A  (3) Status: Ongoing

(4) Title: Treatment of Urinary Tract Trauma in the Porcine Animal Model

(5) Start Date: 1986  (6) Est Compl Date: Indefinite

(7) Principal Investigator:
Michael J. Raife, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Urology Svc

(10) Associate Investigators
James B. Thrasher, CPT, MC
Thomas A. Jones, MAJ, MC
Ronald Sutherland, CPT, MC
Karl Kreder, MAJ, MC
Craig Donatucci, MAJ, MC
Timothy A. Moses, CPT, MC

(11) Key Words:
renal trauma
renovascular surgery
bladder augmentation and substitution

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To provide an opportunity for urologists in training to develop expertise in the surgical techniques which are useful in the management of urinary tract trauma, to include renovascular surgery, renal autotransplantation, and use of various types of bowel segments for augmentation or substitution.

(16) Technical Approach: Animals are subjected, under anesthesia, to simulated urinary tract trauma. Various surgical procedures are performed to allow resident training in management of these situations.

(17) Progress: This is an important teaching protocol for urology.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 86/209A  Status: Terminated

Title: Effects of Nonsteroidal Anti-inflammatory Agents on Tendon Healing

Start Date:  Est Compl Date:

Principal Investigator: R. Todd Hockenbury, CPT, MC

Facility: FAMC  Dept/Svc: SUR/Orthopedics

Key Words: tendon healing  non-steroidal  anti-inflammatory agent

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:
Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date:
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To determine if NSAID's effect heal rate of strength in rat tendon model.

Technical Approach: Suture tendon laceration followed by haling with and without NSAID's.

Progress: More detailed literature review indicates that similar studies have already been done.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 87/202  Status: Ongoing

Title: Improving Cancer Management Through the Tumor Conference

Start Date:  Est Compl Date: 1989-1990

Principal Investigator: Jeffrey R. Clark, COL, MC

Facility: FAMC


Associate Investigators
Daniel T. Tell, MAJ, MC
Harris W Hollis, Jr., LTC, MC

Key Words: Harris W Hollis, Jr., LTC, MC

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 51

Total Number of Subjects Enrolled to Date: 851
e. Note any adverse drug reactions reported to the FDA or sponsor for
studies conducted under an FDA-awarded IND. May be continued on a
separate sheet, and designated as "(14)e".

Study Objective: FAMC Tumor Board will be one of 22 in the state
where in a randomized controlled fashion, multifaceted educational inter-
vention (maintaining a randomly selected control group) will be in-
roduced. The hypothesis is: Given emphasis on stimulating case
presentations in a concert of patient management decision making, tumor
boards can function as key elements in patient care and medical educa-
tion.

Technical Approach: The first 6 months will be baseline evaluation
of tumor boards as they now exist. Then an interventional education
package is randomly introduced to half the boards over one year and im-
pact is seen. the other half receive no intervention. A crossover of
intervention will occur after one year for one year's time. Then, six
months of final analysis and recommendation made to NCI.

Progress: Data is being collected through 31 Aug 90, then this data
which was collected over the last two years will be analyzed.

Publications and Presentations: None

241
Date: 30 Sep 90  Protocol #: 87/203  Status: Ongoing

Title: Comparison of Thermography and Standard Techniques for Detection, Diagnosis and Tracing of Disorders Marked by Altered Patterns of Peripheral Blood Flow

Start Date:  Est Compl Date: 6/92

Principal Investigator: Richard A. Sherman, MAJ, MS

Facility: FAMC

Dept/Svc: SUR/Orthopedics

Associate Investigators

Key Words: thermography, pain

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: 6/90  b. Review Results: Ongoing

Number of Subjects Enrolled During Reporting Period: 54

Total Number of Subjects Enrolled to Date: 145

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To determine the optimal utilization of thermography in clinical evaluation of the vascular status of the affected area for patients with orthopedic related pain disorders.

Technical Approach: We will make thermographic recordings of groups of ten subjects having one of the following conditions each time they come to Orthopedic Clinic from the initial diagnostic appointment through post-resolution follow-up: Frostbite, Charcot Joints, Carpal Tunnel Syndrome, Fibrositis, Sympathetic Distrophy and Peripheral Neuropathy, Pre-amputation preparation, and Prediction of Bed Sore Formation. The clinical evaluations will not be related to the thermographic evaluations until the subject has completed participation in the study.

Progress: This study is going smoothly but there are too few subjects in each group to determine the effectiveness of thermography for any of the groups begun to date. We have determined that videothermography is not a good way to track carpal tunnel syndrome, but is good for tracking reflex dystrophy.

Publications: None

Presentations: Thermography and Carpal Tunnel Syndrome. Presented to the Barnard Series at the University of Colorado Health Science Center, 1990.
Title: Mechanism Based Treatments of Phantom Limb Pain

Start Date: 1987

Est Compl Date: 1990

Principal Investigator:
Richard A. Sherman, MAJ, MS

Facility: FAMC

Dept/Svc: SURG/Orthopedics

Associate Investigators

Key Words:
phantom limb pain
treatments

Accumulative MEDCASE:

Est Accum OMA Cost:
*Refer to Unit Summary Sheet of this Report.

Study Objective: To demonstrate the effectiveness of treatments for burning phantom limb pain.

Technical Approach: We will treat four groups of ten amputees each with the same six interventions. The amputees will be grouped by the description of their phantom pain. We will work with those describing their phantom pain as (1) only burning, (2) only cramping, (3) mixed cramping and burning, and (4) shooting / stabbing / shocking. Before treatment begins, there will be a three week baseline in which each amputee will be interviewed and stump muscle tension and heat outflow patterns will be recorded. Each amputee will receive each treatment for one month unless side effects force withdrawal. Treatment months will alternate with three week "washout" periods to permit phantom pain to return to baseline. The treatments will be: (1) topical application of nitroglycerine for mainly venous-side vasodilatative effects, (2) trental to reduce blood viscosity so more blood can reach tissues in the stump having compromised vascular beds, (3) Nifedipine as a Calcium channel blocker for its known peripheral vasodilatative effects, (4) Cyclobenzaprine for its ability to reduce spasms of local origin without interfering with muscle function, (5) muscle tension recognition and relaxation training for its proven ability to reduce microspasms and
tension related to intensification of phantom pain, and (6) body surface temperature recognition and control training for its ability to help people control vasodilation of peripheral vessels while under stress. Subjects will be recorded the same way they were during the baseline at each session to permit objective verification of physiological changes. They will come to the clinic every other week during treatments. At the end of the last treatment, there will be another three week baseline. Following the final baseline, the treatment which proved most effective, if any, will be continued for one year. Subjects will be recorded at monthly intervals. If no treatments are effective, subjects will still be followed for one year but will be recorded at six and twelve months.

(17) Progress: Virtually all patients were cured or helped substantially to the point where no more medication is required.

Publications:


Presentations:

Date: 30 Sep 90  Protocol #: 87/205  Status: Ongoing

Title: Etiology of Low Back Pain Due to Muscle Tension

Start Date: 1987  Est Compl Date: 1990

Principal Investigator: Richard A. Sherman, MAJ, MS

Facility: FAMC

Dept/Svc: Orthopedics

Associate Investigators:
- David Hahn, LTC, MC
- Timothy Young, MD, Augusta, VAMC
- Robert Rodinelli, Ph.D., Denver, VAMC
- Bertram Rothschild, Ph.D., Denver, VAMC
- John Arena, Ph.D., Augusta, VAMC

Key Words:
- low back pain
- environmental recording
- surface EMG

Accumulative MEDCASE:*  Refer to Unit Summary Sheet of this Report.

Est Accum OMA Cost:*

Date, Latest IRC Review: 6/90  Review Results: Approved
Number of Subjects Enrolled During Reporting Period: 5
Total Number of Subjects Enrolled to Date: 20

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To determine the relationship between (a) the intensity and duration of work, (b) patterns of muscle tension, and (c) onset of low back pain. To determine whether patterns of muscle tension occurring during normal daily activities are different among people with (a) chronic low back pain, (b) intermittent pain, and (c) no pain. To determine relationships between patterns of muscle tension observed among relatively young active duty soldiers with intermittent low back pain and relatively older veterans with intermittent and chronic low back pain of muscle tension origin. To determine whether simple preventive measures can decrease intensity and frequency of episodes of pain by changing response patterns of low back muscle tension.

Technical Approach: We will do two week long, continuous muscle tension, activity, and pain recordings of relatively young active duty soldiers with duties ranging from strenuous to sedentary who are either
pain free, report intermittent low back pain due to muscle tension, or report almost continuous low back pain due to muscle tension. We will do similar recordings of relatively older veterans having similar activity patterns and similar back pain problems. If we are able to identify abnormal patterns, we will provide people who clearly show these patterns with behaviorally oriented muscle control treatments or mild muscle relaxants in order to determine the effect of these interventions on muscle contractions patterns and pain.

(17) Progress: No problems have been encountered. When they are pain free, subjects who frequently report low back pain have low back muscle patterns similar to subjects who virtually never report low back pain. When experiencing low back pain, these subjects have very different patterns than pain free subjects. EMG increases prior to onset of low back pain. Funding from MRDC and staff has been hired, significant delays due to hiring freeze.

Publications:


Sherman R, Arena J, Searle J: Development of an ambulatory recorder for evaluation of muscle tension related to low back pain and fatigue in soldier's normal environments. Accepted, Military Medicine, 1990.

Presentations:


Date: 30 Sep 90  Protocol #: 87/206  Status: Ongoing

Title: Evaluation of Psychophysiological Ways to Assess Chronic Low Back Pain

Start Date: 1987  Est Compl Date: 6/91

Principal Investigator: Richard A. Sherman, MAJ, MS  John G. Arena, Ph.D.
Facility: FAMC  Augusta, VAMC

Dept/Svc: Clin. Invstgn.

Key Words: low back pain  thermography  surface EMG  MMPI

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 38
d. Total Number of Subjects Enrolled to Date: 130
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

Study Objective: To test the effectiveness of paraspinal surface EMG, the MMPI, videothermography, physical examination, and standard diagnostic procedures for ascertaining objective data concerning the patient's actual low back pain intensity and underlying physical problems.

Technical Approach: We completed process of performing paraspinal surface EMG and videothermographic recordings of at least 360 subjects with low back pain of six diagnostic categories and who hurt most while in one of six different positions (6 x 6 cell design with ten subjects in a group). Each subject is being recorded four times: Twice while their pain intensity is the same and twice while it varies up or down from the two similar recordings. Thus, each subject is recorded at between two and three pain intensities. This provides data on change with time while pain is constant. All of these subjects are given a modified version of the MMPI designed to differentiate between psychological factors and changes in responses due to presence or absence of low back pain. Each subject is also given a complete orthopedic physical examination and any standard diagnostic procedures not already well documented is done.
Progress: Thermography is usually able to pick up low back disorders independently diagnosed as being related to nerve problems but is not sensitive to pain due to muscle tension in the low back. Surface EMG is sensitive in the opposite way. When the two tests are used together, they are very efficient at quickly and noninvasively determining the physiological cause of the back pain.

The recorder portion of this study has been completed. The MMPI portion is proceeding according to the approved addendum.

Publications:


Presentations:


Date: 30 Sep 90 (2) Protocol #: 87/207 (3) Status: Ongoing

(4) Title: Determination of Mechanisms of Phantom Limb Pain: Phase 2

(5) Start Date: 1987 (6) Est Compl Date: 1990

(7) Principal Investigator: Richard A. Sherman, MAJ, MS

(9) Dept/Svc: Orthopedics

(10) Associate Investigators
    Michael D. Getter, MAJ, MC
    Timothy Young, MD, Augusta, VAMC
    Robert Rodinelli, MD, Ph.D., Denver, VAMC
    Jeffrey Ginther, MAJ, MC

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results: 
     c. Number of Subjects Enrolled During Reporting Period: 24
     d. Total Number of Subjects Enrolled to Date: 24
     e. Note any adverse drug reactions reported to the FDA or sponsor for
        studies conducted under an FDA-awarded IND. May be continued on a
        separate sheet, and designated as "(14)e". None

(15) Study Objective: To use MRI, nerve recording, and other techniques
to monitor veteran and active duty amputees who report shocking, shoot-
ing, and stabbing descriptors of phantom limb pain while they are ex-
periencing various intensities of pain in order to ascertain the
physiological changes which are related to changes in pain intensity.

(16) Technical Approach: We will carry out the pilot for a full proposal
in which we would record groups of twenty active duty or veteran am-
putees four times. In the pilot, only two amputees from each group will
participate. Two of the recordings will be at one particular pain in-
tensity while the other two will be at two different intensities. This
will permit factoring changes due to time from "hose due to changes in
pain intensity. Each subject will be recorded at about weekly intervals
but the exact timing will have to depend on when their pain intensity
changes. The groups will consist of two amputees with (1) only stabbing
phantom pain, (2) only shooting phantom pain, (3) only shocking phantom-
pain, (4) a combination of all three (which is common), and (5) no phan-
tom pain. The fifth group of amputees without phantom pain is necessary
to further evaluate changes which occur in the normal stump over time so we can differentiate them from abnormal changes. We know from our experience in Phase I of this study that twenty is the minimum number of amputees we can have in a group due to normal physiological variability and in variability in reporting pain intensity. However, two per group will give us an idea of whether the following techniques are likely to show any differences at all. We propose to use MRI to record overall stump anatomy, plethysmography to record swelling and internal stump pressure, and signals from the neuroma to record responses to mechanical and other stimuli. Because of its invasive nature, we will carry out only one nerve signal study from the stump. For subjects who report phantom pain, we will perform the test on a day when they report the maximum phantom pain they usually experience. We will compare the results of this recording with those from pain free amputees. Due to its cost, we will do MRI recordings of only one subject per pilot group. Two MRI's will be done for each pilot subject. One will be while the subject is as pain free as they get and the other will be while they are experiencing the most pain they generally expect.

(17) Progress: Four amputees experiencing numerous acute episodes of cramping phantom pain had the surface muscle tension in their residual limbs recorded. They pressed a button during episodes of phantom pain. Temporal relationships between initiation of episodes and spasms in the limb were established. Spasms precede start of pain by more than reaction time so cause the phantom pain. FY 90, no new patients or progress.

Publications:


Presentations:

Date: 30 Sep 90
Protocol #: 88/20x-003
Status: Ongoing

Title: Evaluation of the Goat as a Model for Bone Grafting Studies

Start Date:
Est Compl Date:

Principal Investigator:
David B. Hahn, LTC, MC

Facility: FAMC

Dept/Svc: Orthopedics

Associate Investigators:
Richard Sherman, MAJ, MS
Ross M. Wilkins, MD

Key Words: Presbyterian Hospital

Study Objective: The overall objective is to determine the suitability of the goat as a model for studies on bone grafting.

Technical Approach: See protocol

Progress: We created 2cm defects in ulna in three goats. The goats were radiographed at three week intervals. Two out of three went on to heal their defects, thus bone grafts were not performed. We feel it is necessary to create a model that would consistently result in non-union. Plans are to do another preparatory study. Study in progress, principal investigator on temporary duty elsewhere.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 88/20x-004  Status: Ongoing

Title: Development of an Animal Model for the Study of Anterior Cruciate Ligament Repairs

Start Date:  Est Compl Date: 

Principal Investigator:  Facility: FAMC
Steven D. Pals, CPT, MC

Dept/Svc: Orthopedic Surgery  Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date:
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective:

Technical Approach:

Progress: Resident on rotation. Gone from FAMC for the summary period. No progress.

Publications and Presentations:

253
(1) Date: 30 Sep 90   (2) Protocol #: 88/200   (3) Status: Ongoing

(4) Title: ALCON Surgical Intraocular Lens Study

(5) Start Date:   (6) Est Compl Date:

(7) Principal Investigator: Floyd M. Cornell, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Ophthalmology

(10) Associate Investigators
    Jonathan Stock, MAJ, MC
    Ricardo J. Ramirez, MAJ, MC
    Robert W. Enzenauer, LTC, MC
    Thomas A. Gardner, CPT, MC
    Margaret B. Lisecki, CPT, MC
    Joseph E. O'Boyle, CPT, MC
    Robert W. Weller, CPT, MC
    William Walton, CPT, MC
    Roger K. George, CPT, MC

(11) Key Words: intraocular lens

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:__________  b. Review Results:__________
    c. Number of Subjects Enrolled During Reporting Period:__________ 11
    d. Total Number of Subjects Enrolled to Date:__________25
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Adjunctive study with FDA for intraocular lenses used following cataract extraction.

(16) Technical Approach: Intraocular lenses are implanted into the anterior segment of the eye following cataract extraction either as a primary procedure or as a secondary procedure.

(17) Progress: All lenses in place are doing well. No adverse reactions.

Publications and Presentations: None
Date: 30 Sep 90  
Protocol #: 88/201A  
Status: Ongoing  

Title: Use of Goats for Training in Advanced Trauma Life Support  
Start Date: 1988  
Est Compl Date: Indefinite  
Principal Investigator: Stephen M. Fall, COL, MC  
Facility: FAMC  
Dept/Svc: SUR/Cardiothoracic  
Associate Investigators: Dick R. Smith, COL, MC  
Key Words:  

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.  

Date, Latest IRC Review:  
Review Results:  
Number of Subjects Enrolled During Reporting Period:  
Total Number of Subjects Enrolled to Date:  
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".  

Study Objective: To conduct training courses in Advanced Trauma Life Support (ATLS).  
Technical Approach: See protocol  
Progress: 32 ATLS provider/instructors trained this calendar year.  
Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

<table>
<thead>
<tr>
<th>Date</th>
<th>Protocol #</th>
<th>Status</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Sep 90</td>
<td>88/202</td>
<td>Ongoing</td>
<td>A Comparison of Clinical Features of Ulnar Nerve Compression at the Elbow Before and After Medial Epicondylectomy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Start Date:</th>
<th>Est Compl Date:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1989</td>
<td>1990</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Principal Investigator:</th>
<th>Facility:</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Bizousky, CPT, MC</td>
<td>FAMC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dept/Svc:</th>
<th>Associate Investigators</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUR/Orthopedics</td>
<td>James C. Johns, MAJ, MC</td>
</tr>
<tr>
<td></td>
<td>Douglas Hemmler, CPT, MC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Key Words:</th>
</tr>
</thead>
<tbody>
<tr>
<td>nerve compression</td>
</tr>
<tr>
<td>conduction velocity</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Accumulative MEDCASE:*</th>
<th>Est Accum OMA Cost:*</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Refer to Unit Summary Sheet of this Report.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>a. Date, Latest IRC Review:</th>
<th>b. Review Results:</th>
<th>c. Number of Subjects Enrolled During Reporting Period:</th>
<th>d. Total Number of Subjects Enrolled to Date:</th>
<th>e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>21</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Objective:</th>
<th>Technical Approach:</th>
<th>Progress:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assess results of medial epicardylectomy in the treatment of cubital tunnel syndrome.</td>
<td>Comparison of pregoperative and postoperative and electrical parameters.</td>
<td>Approximately 21 patients have undergone the procedure of medial epicardylectomy. Clinical impression is that operation is working well. No adverse reactions recorded. Data continues to be collected.</td>
</tr>
</tbody>
</table>

Publications and Presentations: None
(1) Date: 30 Sep 90 (2) Protocol #: 88/203 (3) Status: Ongoing

(4) Title: Evaluation of Current Nasal Surgical Techniques Used to Improve Nasal Obstruction (Subjective and Objective) Utilizing Anterior Rhinometric Techniques

(5) Start Date: 1988 (6) Est Compl Date: 1992

(7) Principal Investigator: Michael L. Lepore, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: SUR/Otolyn/Hd&NkSur. (10) Associate Investigators

(11) Key Words:
    rhinomanometry
    nasal obstruction
    nasal surgery

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: ____________  b. Review Results: ____________
    c. Number of Subjects Enrolled During Reporting Period: ____________
    d. Total Number of Subjects Enrolled to Date: ____________
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: (a) to utilize anterior rhinometric principles in the pre-op assessment of patients prior to nasal surgery, (b) to utilize anterior rhinometric principles in the post-op evaluation of patients who have had either septoplasty surgery and/or total nasal septal reconstructive surgery (opened or closed), and (c) to determine, utilizing anterior rhinomanometric techniques, if the unobstructive nasal cavity after nasal surgery (opened or closed) is significantly altered at the expense of correcting the pre-op obstructive side, and is this subjectively noted by the patient to the point of causing secondary obstructive symptoms, of any degree on the unobstructive side which will be objectively measured.

(16) Technical Approach: Measurements of nasal airflow utilizing anterior rhinomanometry will be performed before surgery and after surgery.
at definite periods. Correlation will be made between the various surgical procedures and the measured test results to note if any significant alterations on the unobstructed side have resulted from the surgical procedures.

(17) Progress: This protocol has not been started due to multiple administrative problems and inability to set aside the appropriate research time because of lack of staff. It is hopeful, that when my operation is stable, I will be able to begin my endeavors. I would appreciate having the project open, so when I am able to begin, I will not have any particular delays.

Publications and Presentations: None
Title: An Analysis of the Effect of Nonsteroidal Anti-Inflammatory Medications on Regeneration of Articular Cartilage in New Zealand White Rabbits Treated by Intermittent Active Motion and Continuous Passive Motion

(5) Start Date: (6) Est Compl Date: 1990

(7) Principal Investigator: Alexander Pruitt, MAJ, MC
    Anthony W. Colpini, MAJ, MC

(9) Dept/Svc: SUR/Orthopedics

(10) Associate Investigators
    Joe K. Ozaki, COL, MC
    Cris Myers, CPT, MC

(11) Key Words:
    articular cartilage regeneration
    continuous passive motion
    nonsteroidal anti-inflammatory

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:_________ b. Review Results:_________
    c. Number of Subjects Enrolled During Reporting Period:_________
    d. Total Number of Subjects Enrolled to Date:_________
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The object of this protocol is to determine whether non-steroidal anti-inflammatory medications have an effect upon the regeneration of articular cartilage in rabbit knees. We are also attempting to delineate whether two separate nonsteroidal anti-inflammatories have different effects on regenerative of articular cartilage treated with continuous passive motion.

(16) Technical Approach: The rabbit knees will be arthrotonized and pieces of the articular cartilage will be moved and the knees will be closed, and then the rabbits will either be put on continuous passive motion on one leg and active intermittent motion on the other, after both arthrotomies. Then they will be reoperated at 4, 8 & 12 weeks, and one group will get no nonsteroidal, one group will get Piroxicam, one group will get Acetylsalicylic acid.

(17) Progress: Project terminated, was never started as resident left.

Publications and Presentations: None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

1. **Date:** 30 Sep 90
2. **Protocol #:** 88/208
3. **Status:** Completed

4. **Title:** A Retrospective Analysis of the Incidence of Pseudarthrosis in Posterior Spine Fusion Done Between 1971 and 1986, at St. Anthony's Hospital and Denver Children's Hospital

5. **Start Date:**
6. **Est Compl Date:**

7. **Principal Investigator:**
   - Alexander Pruitt, MAJ, MC
   - John A. Odom, MD

8. **Facility:** FAMC
   - Lakewood Clinic, Denver, CO

9. **Dept/Svc:** SUR. Orthopedic
10. **Associate Investigators**
    - John L. Brugman, LTC, MC

11. **Key Words:**

12. **Accumulative MEDCASE:**
13. **Est Accum OMA Cost:**
    *Refer to Unit Summary Sheet of this Report.*

14. **a. Date, Latest IRC Review:**
    **b. Review Results:**
    **c. Number of Subjects Enrolled During Reporting Period:**
    **d. Total Number of Subjects Enrolled to Date:**
    **e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

15. **Study Objective:** The purpose of this study is to evaluate those patients with pseudarthrosis and compare them with an age, sex, and diagnosed matched group of controls who also underwent posterior spine fusion but did not develop pseudarthrosis. We propose to evaluate the contributions of several factors which may effect the incidence of pseudarthrosis in these patients.

16. **Technical Approach:** See protocol.

17. **Progress:** Data is currently being put into the computer. Charts are still being reviewed. Project completed. No significant information derived. No further plans for progression, presentation or publications.

**Publications and Presentations:** None

260
Date: 30 Sep 89  Protocol #: 88/209  Status: Ongoing

Title: A Comparison of Percutaneous Repair Versus Open Repair of Achilles Tendon Ruptures

Start Date:  Est Compl Date: 1990

Principal Investigator: R. Todd Hockenbury, CPT, MC

Facility: FAMC

Dept/Svc: SUR/Orthopedics  Associate Investigators
James C. Johns, MAJ, MC
Rick Wilkerson, MAJ, MC

Key Words:
achilles tendon ruptures
percutaneous repair of achilles tendon ruptures

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: (a) To compare the clinical results of percutaneous repair to open repair of achilles tendon rupture and to investigate the complications and long-term outcome of these techniques. (b) To compare the initial repair strengths of these techniques.

Technical Approach: Patients are now being randomized into 2 separate groups and surgery is being performed. The cadaver study is completed.

Progress: Only 4 additional patients enrolled.
Publications:

"A Biomechanical Comparison of Percutaneous Versus Open Repair of Achilles Tendon Defects" (Submitted for publication, Journal of Foot and Ankle Surgery).

Presentations:


"A Biomechanical Comparison of Percutaneous Versus Open Repair of Achilles Tendon Defects" Presented: Rocky Mountain Chapter Meeting of the Western Orthopedic Society Barnard Lecture Competition. February 1988, and was selected as one of the five finalist papers.
Date: 30 Sep 90  Protocol #: 88/210A  Status: Completed

Title: Delayed Repair of Traumatic Intratemporal Facial Nerve Palsy in the Pig

Start Date:  Est Compl Date: 

Principal Investigator: David M. Barrs, COL, MC

Facility: FAMC

Dept/Svc: SUR/Otolaryngology

Associate Investigators:

Key Words:
traumatic facial palsy
nerve graft

Accumulative MEDCASE:*  Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date:
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: a. Determine optimal timing for facial nerve repair following temporal bone trauma; b. measure effect of stretch injury to facial nerve in cerebellopontine angle; c. refine direct facial nerve stimulation technique in the temporal bone; and d. develop an animal model for facial nerve study in the temporal bone.

Technical Approach: The facial nerve is cut in the temporal bone and nerve grafted at intervals from immediately to three months after trauma. Histologic and electrophysiologic examinations will determine differences in return of function for different times of repair.

Progress: Protocol is completed. Dr. Barrs received an honorable mention at the Triologic Society meeting.

Publications and Presentations: A thesis for the American Laryngological, Rhinological, and Otological Society has been completed and forwarded September 5, 1989. If accepted, the thesis will probably be broken into two separate publications due to its length. Several other publications may also be written concerning the electrophysiologic testing. This was presented at the Triologic Society and will be published in the future.

263
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/211  (3) Status: Terminated

(4) Title: Double Blind Crossover Study of Cyclobenzaprine Versus Placebo in Patients with Primary Fibrositis: Correlation of Symtomatic Versus Thermographic Criteria of Improvement

(5) Start Date: Jan '90  (6) Est Compl Date: June '90

(7) Principal Investigator: Robert A. Coe, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: SURG/Orthopedic

(10) Associate Investigators:
    Alexander Pruitt, MAJ, MC
    Richard A. Sherman, MAJ, MS
    Douglas Hemler, MAJ, MC
    Sterling West, COL, MC

(11) Key Words:
    fibrositis
    flexeril
    thermography

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: _______ b. Review Results: _______
    c. Number of Subjects Enrolled During Reporting Period: _______
    d. Total Number of Subjects Enrolled to Date: _______
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The objectives of this study are to compare Flexeril versus Placebo in the treatment of fibrositis, and to evaluate how subjective improvement of either drug or placebo corresponds to normalization of the thermogram.

(16) Technical Approach: Forty patients will be randomized to either the placebo or Flexeril (30mg qhs) group for a seven week period. Pain logs will be used by the subjects. PIs will assess subjects using subject interview, MMPI, pain log, physical exam and thermogram. After a one month washout period, the subjects will be crossed over.

(17) Progress: Protocol was withdrawn and terminated.

Publications and Presentations: None
Date: 30 Sep 90

Protocol #: 88/212

Status: Terminated

Title: Prevention of Nosocomial Pneumonia and Gastroduodenal Ulcer Prevention in Mechanically-Ventilated Patients

Start Date: Oct 89

Est Compl Date: Oct 92

Principal Investigator: Phillip L. Mallory, II, MAJ, MC

Facility: FAMC

Dept/Svc: SURG/Intensive Care

Associate Investigators:
- Kevin Dwyer, MD
- Brant Thrasher, MD
- William Marx, MAJ, MC

Key Words: Nosocomial pneumonia, gastroduodenal ulcer

Accumulative MEDCASE:

Est Accum OMA Cost:

Refer to Unit Summary Sheet of this Report

Study Objective: To decrease the incidence of pneumonia (nosocomial) in mechanically ventilated patients receiving antiulcer prophylaxis.

Technical Approach: 4 groups of patients will be sequentially assigned to high, low, and moderate risk (based on APACHE score) to receive either Cimetidine and antacids; Cimetidine, antacids, Tobramycin, Polymyxin B, Amphotericin; Famotidine or Sulcralfate; GI bleeding will be noted; routine cultures will be performed.

Progress: No progress as of this date. Medical Research and Development Command recently funded this project. FY 90, no progress as of this date so will terminate the protocol.

Publications and Presentations: None

265
Date: 30 Sep 90  Protocol #: 88/213  Status: Ongoing

Title: Investigational Plan for the Clinical Study of Silicone Intraocular Lenses Sponsored by Allergan Medical Optics

Start Date:  Est Compl Date:

Principal Investigator: Floyd M. Cornell, COL, MC

Facility: FAMC

Dept/Svc: SURG/Ophthalmology

Key Words: silicone IOL

Associate Investigators:
- Robert W. Enzenauer, LTC, MC
- Thomas A. Gardner, MAJ, MC
- Jonathan Stock, MAJ, MC
- William Walton, CPT, MC
- Ricardo J. Ramirez, MAJ, MC

Accumulative MEDCASE:*  Est Accum OMA Cost:*  Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:
Number of Subjects Enrolled During Reporting Period: 0
Total Number of Subjects Enrolled to Date: 0
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: The objective of this study is to establish the safety and efficacy of the silicone intraocular lens according to FDA regulations.

Technical Approach: The technical approach is the standard surgical method of cataract extraction and lens implantation to treat visually disabling cataracts.

Progress: Although no patients have been enrolled to date, we anticipate beginning patient enrollment during the period November 1989 through October 1989.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 88/214  Status: Ongoing

Title: Clinical Investigation of Intraocular Lenses in Minors  Sponsored by COBURN Optical IND, Inc/Storz Ophthalmics Inc.

Start Date: 1988  Est Compl Date: Indefinite

Principal Investigator: Floyd Cornell, COL, MC

Dept/Svc: SURG/Ophthalmology  Associate Investigators: Robert W. Enzenauer, LTC, MC

Key Words: minors IOL cataract extraction

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Study Objective: The purpose of this study is to evaluate the safety and efficacy of intraocular lenses in children.

Technical Approach: Patients are selected based on inability to utilize spectacles, contact lenses, or the use of epikeratoplasty. Only posterior chamber lenses are utilized. The lenses are placed in the capsular bag when available, into the ciliary sulcus when appropriate, or sutured into place when sulcus fixation is otherwise not achievable.

Progress: There have been two patients enrolled because of traumatic cataracts, two patients enrolled because of irregular astigmatism and/or lack of iris support. All patients were enrolled because of cataract formation to one degree or another as a result of trauma. All patients are achieving their preoperative best corrected visual acuity and having no adverse reactions to the lens implant.

Publications and Presentations: None

267
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol WU#: 88/215  (3) Status: Ongoing

(4) Title: Continuous Environmental Recording of Activity, Headache, and Muscle Contraction Level Among Subjects with Tension, Migraine or No Headache

(5) Start Date: 1988  (6) Est Compl Date: 1992

(7) Principal Investigator: Richard A. Sherman, MAJ, MS

(8) Facility: FAMC

(9) Dept/Svc: Orthopedics

(10) Associate Investigators

Richard Calkins, COL, MC
David Hahn, LTC, MC
Crystal Sherman,

(11) Key Words: headache, muscle tension, environmental recording

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 
   b. Review Results:
   c. Number of Subjects Enrolled During Reporting Period: 2
   d. Total Number of Subjects Enrolled to Date: 10
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: To determine relationships between motion, muscle tension in the frontal and trapezius muscles, and onset and intensity of headaches among subjects recorded in their normal environments.

(16) Technical Approach: Subjects wear a small EMG and motion recorder during all working hours for one week. They keep an hourly log of types and activity and pain intensity while wearing the recorder.

(17) Progress: The patterns of muscle tension and movement were virtually identical for all back pain subjects during pain free periods and for the pain free control. The subjects with back pain almost always showed increases in muscle tension preceding increases in pain and decreases preceding decreases in pain. All six headache subjects showed relationships in which both stress and upper back muscle tension increased prior to increases in headache intensity and decreased prior to decreases in pain. Trial results indicate that changes in muscle tension precede changes in pain so are causative rather than reactive.

Minimal progress this fiscal year due to lack of manpower. Protocol will be restarted after the end of the hiring freeze.
Publications: None

Study Objective: This training protocol is to attain and maintain proficiency in microvascular surgical repair of small nerves and blood vessels. The femoral artery and nerve of the rat is well suited for this type of study.

Technical Approach: See protocol.

Progress: The maintenance of microvascular proficiency has been accomplished. Each year new residents are provided basic skills in their training. Twenty hours of training was received for two personnel.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 89/202  Status: Ongoing

Title: The Effect of Harvesting the Central One-third of the Patellar Tendon and Reapproximating the Medial and Lateral Edges of Patellofemoral Joint Mechanics in Cadavers

Start Date: 1989  Est Compl Date: 1990

Principal Investigator: Richard A. Schaefer, CPT, MC
Associate Investigators: Scott D. Gillogly, MAJ, MC  Alexander Pruitt, MAJ, MC

Dept/Svc: SURG/Orthopedics
Key Words: arthroscopy anterior cruciate ligament

Study Objective: To determine differences in patellofemoral joint contact area and pressure resulting from two standard treatments after harvesting the central third of the patellar tendon for ACL reconstruction (suturing versus not suturing the cut edges).

Technical Approach: The radiographic and patellofemoral joint contact area and pressure changes in cadavers pre- and post harvesting the central one-third of the patellar tendon will be investigated.

Progress: No progress.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/203  (3) Status: Ongoing

(4) Title: Rates of Occurrence of Simultaneous and Independent Low Back Pain and Headache Among Patients with and without Chronic Pain

(5) Start Date: 1989  (6) Est Compl Date: 1991

(7) Principal Investigator: Richard A. Sherman, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SURG/Orthopedics

(10) Associate Investigators:
    John G. Arena, Ph.D.
    Jeffrey R. Ginther, MAJ, MC
    Melissa Damiano, M.S.

(11) Key Words: low back pain, tension headache, incidence

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 44 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the temporal relationships between the above pain problems among subjects with and without chronic pain.

(16) Technical Approach: Survey deers eligible people with and without pain while they are waiting for appointment at FAMC.

(17) Progress: No results yet as surveys are still being distributed. Study has been stopped by the hiring freeze.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/204  (3) Status: Completed

(4) Title: Incidence of Multiresistance in Serial Gram-Negative Isolates from ICU's

(5) Start Date: 1989  (6) Est Compl Date: 1989

(7) Principal Investigator: Phillip Mallory, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SURG/SICU

(10) Associate Investigators:
    Jeffrey R. Clark, COL, MC
    Harris W. Hollis, Jr., LTC, MC
    Leo A. Andron, LTC, MS
    William H. Marx, MAJ, MC

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: __________  b. Review Results: __________
    c. Number of Subjects Enrolled During Reporting Period: __________
    d. Total Number of Subjects Enrolled to Date: __________
    e. Note any adverse drug reactions reported to the FDA or sponsor for
       studies conducted under an FDA-awarded IND. May be continued on a
       separate sheet, and designated as "(14)e"

(15) Study Objective: The objective is to develop an antibiotogram for
    the SICU.

(16) Technical Approach: Specimens will be analyzed using Merck, Sharp
    & Dohme protocol.

(17) Progress: No specimens were studied.

Publications and Presentations: None

273
(1) Date: 30 Sep 90  (2) Protocol #: 89/205A  (3) Status: Ongoing

(4) Title: Correlation of the Vocal Fold Vibratory Pattern to the Post Operative Surgical Wound in the Porcine Model

(5) Start Date: 

(6) Est Compl Date: 

(7) Principal Investigator: Vincent D. Eusterman, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: SURG/Otolaryngology

(10) Associate Investigators: Don B. Blakeslee, RET, COL

(11) Key Words:

(12) Accumulative MEDCASE:* 

(13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: 

b. Review Results: 

c. Number of Subjects Enrolled During Reporting Period: 

d. Total Number of Subjects Enrolled to Date: 

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Study was delayed due to equipment purchase. Awaiting equipment which as been ordered by contracting.

Publications and Presentations:

274
Date: 30 Sep 90  Protocol #: 89/206A  Status: Completed

Title: The Effect of Liposuction on Myocutaneous Flaps in the Yucatan Micro Pig

Start Date:  Est Compl Date:

Principal Investigator: Terence R. Woods, MAJ, MC

Facility: FAMC

Dept/Svc: SURG/Otolaryngology  Associate Investigators: Michael L. Lepore, COL, MC

Key Words: swine  liposuction  myocutaneous flaps

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To determine the effect of the timing of liposuction on the viability of the cutaneous portion of trapezius myocutaneous axial flaps created on the Yucatan Micro Pig.

Technical Approach: See protocol

Progress: This project is completed. We are awaiting Pathology's review of the biopsies before any formal evaluation of our results. The project was completed in May 1990.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/207  (3) Status: Ongoing

(4) Title: Etiology and Progression of Acute Muscle Tension Related Low Back Pain Occurring During Sustained Activity Including Combat Training Exercises

(5) Start Date: 1989  (6) Est Compl Date: Sep 1992

(7) Principal Investigator: Richard A. Sherman, MAJ, MS
(8) Facility: FAMC

(9) Dept/Svc: SURG/Orthopedics
(10) Associate Investigators:
    David Hahn, LTC, MC
    Jeffrey R. Ginther, MAJ, MC
    John G. Arena, Ph.D.

(11) Key Words:
    low back pain
    EMG

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: 4/50  b. Review Results: Ongoing
    c. Number of Subjects Enrolled During Reporting Period: 8
    d. Total Number of Subjects Enrolled to Date: 8
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Determine the etiology and progression of acute muscle tension related low back pain occurring during sustained activity including combat training exercises.

(16) Technical Approach: Use ambulatory recorders to make second by second records of bilateral surface paraspinall EMG and back movement as well as hourly back pain and fatigue rating entries for 20 hours per day while subjects function in their normal environment.

(17) Progress: All equipment has been purchased and tested. Staff has been hired and trained. The study is underway.

Publications and Presentations: None.

276
<table>
<thead>
<tr>
<th>(1) Date:</th>
<th>30 Sep 90</th>
<th>(2) Protocol #:</th>
<th>89/209</th>
<th>(3) Status:</th>
<th>Terminated</th>
</tr>
</thead>
<tbody>
<tr>
<td>(4) Title:</td>
<td>Clinical Investigation of the Synthes Spinal Internal Fixator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5) Start Date:</td>
<td>1989</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(6) Est Compl Date:</td>
<td>1992</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(7) Principal Investigator:</td>
<td>David B. Hahn, LTC, MC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(8) Facility:</td>
<td>FAMC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(9) Dept/Svc:</td>
<td>SURG/Orthopedics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(10) Associate Investigators:</td>
<td>Michael Getter, MAJ, MC</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(11) Key Words:</td>
<td>spinal fixator</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(13) Est Accum OMA Cost:*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(14) a. Date, Latest IRC Review:</td>
<td>6/90</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Review Results:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(15) Study Objective:</td>
<td>To verify the improved results of the surgical management of spinal fractures, that has been reported in Europe, with the use of the Synthes spinal internal fixator.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(16) Technical Approach:</td>
<td>Phase II clinical trial to meet FDA requirements for release of this investigational new medical device.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(17) Progress:</td>
<td>Terminated</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Publications and Presentations:</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

277
Date: 30 Sep 90  Protocol #: 89/210  Status: Ongoing

Title: Use of Body Surface Heat Patterns for Predicting and Evaluating Acute Lower Extremity Pain Among Soldiers

Start Date: Oct 89  Est Compl Date: Sep 92

Principal Investigator: Richard Sherman, MAJ, MS

Facility: FAMC

Dept/Svc: Orthopedic Svc

Associate Investigators:
Allyn Woerman, LTC, PT
Kent Karstetter, CPT, MC

Key Words: Ft. Sill, OK
thermography
lower extremity pain
surface temperature

Accumulative MEDCASE:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: 6/90  b. Review Results: Ongoing
 c. Number of Subjects Enrolled During Reporting Period: 11
 d. Total Number of Subjects Enrolled to Date: 11
 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To provide immediate, on-site diagnosis of stress fractures in the lower extremities of active duty soldiers using a comparison of high technology videothermography and bone scan with filed viable contact thermography and surface temperature probes.

Technical Approach: Phase I) Use videothermography and standard physical evaluations to establish baselines for trainees initially entering service at Ft. Sill, OK. Repeat thermograms will be performed on all trainees reporting to the troop medical clinic for treatment of pain in their knees, lower legs, and feet. Thermography will be performed on a matched group of trainees who come in to the clinic for other problems. This will permit differentiation of changes which occur among most trainees from pathological changes.

Phase II) Compare videothermograms, contact thermograms, bone scad and other recordings of 100 trainees and 100 relatively senior soldiers suspected of having stress fractures with similar evaluations of matched controls to establish the efficacy of low technology contact thermography for evaluation of stress fractures.

Progress: All equipment has been purchased. Staff has been hired and trained and the study is underway.

Publications and Presentations: None.
(1) Date: 30 Sep 90  (2) Protocol #: 89/211  (3) Status: Ongoing

(4) Title: Randomization Study of Transurethral Resection of the Prostate vs Balloon Dilation of the Prostate for Symptomatic Benign Prostatic Hyperplasia in Men

(5) Start Date: Sep 89  (6) Est Compl Date: Sep 90

(7) Principal Investigator: Craig Donatucci, MAJ, MC
   Karl Kreder, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Urology Svc

(10) Associate Investigators: Michael Raife, COL, MC

(11) Key Words: transurethral resection of prostate (TURP)
     balloon dilation of prostate (BDP)

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
     *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: 6/90  b. Review Results:
     c. Number of Subjects Enrolled During Reporting Period:
     d. Total Number of Subjects Enrolled to Date: 39
     e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the effectiveness of balloon dilation of the prostate (BDP) to TURP in moderately symptomatic men over 45 who suffer from benign prostatic hyperplasia (BPH).

(16) Technical Approach: This is a multi-center, two-arm, randomized study to examine the efficacy of BDP in improving symptoms of urinary outlet obstruction and urinary flow in men with symptomatic BPH, and compare and contrast the results with those of men undergoing TURP. Men with urinary outlet obstruction who need TURP and meet the protocol entrance criteria will be randomly assigned to TURP or BDP. After operation the patients will be followed for 1 year to determine improvement in symptoms, urinary flow parameters and post void residual urines. Groups will be compared to determine whether any beneficial effects from BDP have occurred.

(17) Progress: First patient underwent TUP 11/89 - to complete 1-yr. follow-up in 11/90.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 90/20x-001  Status: Ongoing

Title: Evaluation of the Goat as a Model for ACL Reconstruction  Fixation Studies

Start Date:  Est Compl Date:

Principal Investigator: R. Todd Hockenbury, CPT, MC  Scott D. Gillogly, MAJ, MC

Facility: FAMC  Dept/Svc: Surgery/Ortho

Associate Investigators: Steven Pals, CPT, MC

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:

Number of Subjects Enrolled During Reporting Period:

Total Number of Subjects Enrolled to Date:

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: The overall objective is to determine the suitability of the goat as a model for ACL reconstruction.

Technical Approach: Three goats will be anesthetized and open ACL reconstruction will be performed on one of the hindlegs, using a different graft fixation technique on each goat. Following surgery the goats will be housed in Bldg 610 in large animal enclosures, which permit the animals full freedom of movement. No postoperative immobilization will be used. They will be euthanatized at one week postop and the knee will be harvested and subjected to biomechanical and histologic testing.

Progress: Progress report is due October 90.

Publications and Presentations: None.
Title: Comparison of ACL Graft Fixation Techniques in a Goat Model

Start Date: 1990

Principal Investigator: Scott D. Gillogly, MAJ, MC

Associate Investigators: Todd Hockenbury, CPT, MC

Study Objective: To determine which of three standard ACL graft fixation techniques provides the best graft fixation in reconstruction of the anterior cruciate ligament utilizing the central one-third of the patellar tendon.

Technical Approach: See protocol.

Progress: Data from the testing of Groups I and II under this protocol has been completed. Requested purchase of sufficient goats to support completion of protocol. The requested goats would allow completion of the testing of Group III.

Publications and Presentations: Accepted for presentation for FY 91.
Use of Tetrograde Cardioplegia in the Pig Model

Start Date: 1990

Principal Investigator: Thomas Gaines, MAJ, MC

Facility: FAMC

Dept/Svc: Cardiothor. Surg.

Associate Investigators:

Key Words:

Accumulative MEDCASE:*

Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  
Review Results:  
Number of Subjects Enrolled During Reporting Period:  
Total Number of Subjects Enrolled to Date:  
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective:

Technical Approach:

Progress: New study and will be reported on in Nov 90.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: 90/202  Status: Ongoing

Title: Non-Surgical Treatment of Morton's Neuroma with Injection of Vitamin B-12/Lidocaine/Solumedrol Combination

Start Date: 1990  Est Compl Date: 1992

Principal Investigator: Paul Spezia, CPT, MC

Facility: FAMC

Dept/Svc: Orthopedic

Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: The aim of the first phase is to determine whether the injection produces good enough results with a sufficient percent of the patients to be worth giving as a simple first try prior to offering surgery.

Technical Approach: Our plan is to inject a combination of 0.5cc of lidocaine, 0.5cc solumedrol, and 0.5cc of vitamin B-12 into the interdigital neuroma of all patients in a series of two injections.

Progress: The study injection works as a temporary measure at the 90-day followup. Long-term effects cannot yet be determined as the one-year followup data is pending.

Publications and Presentations: Presentation in 1989 at the Barnard Residents's competition.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/203  (3) Status: Ongoing

(4) Title: Synovial and Serum Keratan Sulfate Levels and Their Correlation with Arthroscopically Determined Articular Damaged Chronically Deficient Cruciate Ligament Knees

(5) Start Date: 1990  (6) Est Compl Date: 1993

(7) Principal Investigator: Paul Spezia, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: Orthopedic

(10) Associate Investigators: Scott Gillogly

(11) Key Words: keratan sulfate arthroscopic cruciate deficient

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 18  
d. Total Number of Subjects Enrolled to Date: 18  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine if there is a correlation between keratan sulfate and cruciate deficient knees as determined by arthroscopy and bone scan.

(16) Technical Approach: No significant data.

(17) Progress: Currently 36 samples, ongoing harvesting.

Publications and Presentations: None

284
(1) Date: 30 Sep 90  (2) Protocol #: 90/204  (3) Status: Ongoing

(4) Title: A Clinical Comparison of a Hydroxylapatite Coated Versus Porous Coated Total Hip Implant for Use in Arthritic Human Hips

(5) Start Date: 1990  (6) Est Compl Date: Sep 91

(7) Principal Investigator: Edward Lisecki, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Orthopedics

(10) Associate Investigators:
      James Wolfe, CPT, MC
      Frederick Coville, COL (RET)

(11) Key Words: hydroxyapatite

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 29
    d. Total Number of Subjects Enrolled to Date: 29
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Compare results of two porous ingrowth hip components to improve amount of ingrowth, thereby, reduce the need for revisions.


(17) Progress: Hip scores on hydroxy apatite hips is consistently higher than the non HA coated hip.

Publications and Presentations: None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<table>
<thead>
<tr>
<th>(1) Date</th>
<th>30 Sep 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Protocol #:</td>
<td>90/205A</td>
</tr>
<tr>
<td>(3) Status:</td>
<td>Completed</td>
</tr>
<tr>
<td>(4) Title:</td>
<td>Investigation of the Radiology and Anatomy of the Origin of the Anterior Cruciate Ligament</td>
</tr>
<tr>
<td>(5) Start Date:</td>
<td>1990</td>
</tr>
<tr>
<td>(6) Est Compl Date:</td>
<td></td>
</tr>
<tr>
<td>(7) Principal Investigator:</td>
<td>Brent McIntosh, MAJ, MC</td>
</tr>
<tr>
<td>(8) Facility:</td>
<td>FAMC</td>
</tr>
<tr>
<td>(9) Dept/Svc:</td>
<td>Orthopedics</td>
</tr>
<tr>
<td>(10) Associate Investigators:</td>
<td></td>
</tr>
<tr>
<td>(11) Key Words:</td>
<td></td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td></td>
</tr>
<tr>
<td>(13) Est Accum OMA Cost:*</td>
<td></td>
</tr>
<tr>
<td></td>
<td>*Refer to Unit Summary Sheet of this Report</td>
</tr>
<tr>
<td>(14) a. Date, Latest IRC Review:</td>
<td></td>
</tr>
<tr>
<td>b. Review Results:</td>
<td></td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td></td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td></td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;</td>
<td></td>
</tr>
<tr>
<td>(15) Study Objective:</td>
<td>To establish accurate anatomic and radiologic correlation of the origin of the anterior cruciate ligament.</td>
</tr>
<tr>
<td>(16) Technical Approach:</td>
<td>See protocol.</td>
</tr>
<tr>
<td>(17) Progress:</td>
<td>The study has been completed, awaiting report from Ft. Leavenworth.</td>
</tr>
<tr>
<td>Publications and Presentations:</td>
<td>None</td>
</tr>
</tbody>
</table>

286
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

1. **Date:** 30 Sep 90  
2. **Protocol #:** 90/206  
3. **Status:** Ongoing

4. **Title:** Pilot Trial of Potentiating Normal Healing of Stress Fractures Using Pulsing Electromagnetic Fields

5. **Start Date:** 1990

6. **Est Compl Date:**

7. **Principal Investigator:** Kent Karstetter, CPT, MC
8. **Facility:** FAMC Reynolds ACH, Ft. Sill, OK

9. **Dept/Svc:** Orthopedics
10. **Associate Investigators:**
    - Allyn Woerman, LTC, MC
    - Richard Sherman, MAJ, MS

11. **Key Words:**
    - stress fractures
    - pulsing magnetic fields

12. **Accumulative MEDCASE:**
*Refer to Unit Summary Sheet of this Report*

13. **Est Accum OMA Cost:**

14. **a. Date, Latest IRC Review:**
    **b. Review Results:**
    **c. Number of Subjects Enrolled During Reporting Period:**
    **d. Total Number of Subjects Enrolled to Date:**
    **e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

15. **Study Objective:** To demonstrate that a full study of pulsing magnetic fields is warranted for treatment of stress fractures.

16. **Technical Approach:** Double-blind, placebo controlled study. Electrical stimulators will be used in half of the subjects.

17. **Progress:** No progress, funding pending.

Publications and Presentations: None
Date: 30 Sep 90  (2) Protocol #: 90/207A  (3) Status: Ongoing

(4) Title: Patellar Tendon Healing and Strength Following Patellar Tendon Autograft Harvest in Goats

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: David Bizousky, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: Orthopedics

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:
     c. Number of Subjects Enrolled During Reporting Period:
     d. Total Number of Subjects Enrolled to Date:
     e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: See protocol.

(16) Technical Approach: See protocol.


Publications and Presentations: None
Date: 30 Sep 90 (2) Protocol #: 90/208A (3) Status: Ongoing

(4) Title: Development of an Implanted, Hydroxyapatite Coated, Titanium Limb Prosthetic Through Tests in Tissue Culture, Then in Goats, and Finally in Humans

(5) Start Date: 1990 (6) Est Compl Date: 1992

(7) Principal Investigator: Richard Sherman, MAJ, MS

(9) Dept/Svc: Orthopedics (10) Associate Investigators:

(11) Key Words: percutaneous implant prosthetic amputees goats

(13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To test a percutaneous implant in a goat model to evaluate long term (a) infection through the skin - implant interface, (b) strength of the interface, and (c) ability of the goat to walk on the implanted prosthesis.

(16) Technical Approach: Tissue culture will be used to refine methods for evaluating tissue growth into the prosthesis. A goat model will be used to test which combination of coatings and materials give the best skin adhesion with the least infection and formation of fistulas. The optimal combination will be used to produce a percutaneously implanted prosthetic which will be implanted into several goats to test the above objective.

(17) Progress: None.

Publications and Presentations: None.
(1) Date: 10 Sep 90  (2) Protocol #: 90/209  (3) Status: Ongoing

(4) Title: Reliability of Psychophysiological Measures Used to Evaluate Pain

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Richard Sherman, MAJ, MS  (8) Facility: FAMC

(9) Dept/Svc: SURG/Ortho  (10) Associate Investigators:

   John Arena, Ph.D.
   Carson Henderson, Psy.D.
   Richard Calkins, COL, MC
   Kimford Meador, MD
   Jeffrey Ginter, MD

(11) Key Words:

   chronic pain
   psychophysiological responses
   comprehensive assessment

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
   *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:       b. Review Results:
     c. Number of Subjects Enrolled During Reporting Period:
     d. Total Number of Subjects Enrolled to Date:
     e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: to evaluate the test/retest reliability of several commonly used psychophysiological measures when used with patients and controls.

(16) Technical Approach: Three groups of chronic low back pain subjects, two groups of tension headache and 75 age-matched controls will be assessed five times. The pain groups will be seen three times when at no or low pain levels and twice when at high pain levels. The assessments will consist of the standard six position measurement of surface EMG patterns, standard psychophysiological evaluations and cold presser test.

(17) Progress: To date no progress pending funding. This is a VA-DoD grant application which cannot be performed unless it is funded.

Publications and Presentations: None.

290
Date: 30 Sep 90  Protocol #: 90/210  Status: Ongoing

Title: Effectiveness of Treatments for Reflex Sympathetic Dystrophy

Start Date:  Est Compl Date:

Principal Investigator:  Facility: FAMC
Richard Sherman, MAJ, MS

Dept/Svc: SURG/Ortho  Associate Investigators:

Key Words:  Douglas Hemler, MAJ, MC
reflex sympathetic dystrophy  Kent Karstetter, MAJ, MC
erve block  Muhammad Shaukat, LTC, MC
corticosteroids  Mary Brinkman, MAJ, RPT
physical therapy  Darlene Mullon, MAJ, MC
Robert Ketchum, COL, MC

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for 
studies conducted under an FDA-awarded IND. May be continued on a 
separate sheet, and designated as "(14)e"

Study Objective: To determine the most effective of the standard 
treatments for reflex sympathetic dystrophy.

Technical Approach: After standard workup and videothermography, 
subjects will be randomized to one of the three standard treatments-- 
corticosteroids, multiple nerve blocks or vigorous physical therapy. 
Patients will be followed at 3-mo intervals for one year. If there is 
no improvement, the patient will be randomized to one of the remaining 
treatments.

Progress: Patients are currently being enrolled on this study 
which was approved in Aug 90.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/211A  (3) Status: Ongoing

(4) Title: Effects of Coumadin and Methotrexate on Bone Ingrowth and Fixation in Hydroxyl Apatite Coated Porous Implants in a Goat

(5) Start Date:  

(6) Est Compl Date:  

(7) Principal Investigator:  
James Wolff, CPT, MC

(8) Facility:  
FAMC

(9) Dept/Svc:  
SURG/Ortho

(10) Associate Investigators:  
Edward Lisecki, MAJ, MC  
Stephen Cook, Ph.D.

(11) Key Words:  
coumadin  
methotrexate  
bone ingrowth  
hydroxyl apatite implants

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To quantify the biomechanical histological effects of coumadin and methotrexate on bone ingrowth and fixation strength of porous coated implants.

(16) Technical Approach: Thirty-six adult goats will be randomized to treatment groups 1-6. Of the coumadin and methotrexate animals, one will be given the medication beginning one month prior to surgery and the other will not receive the medication until the day of surgery. Five transcortical rods will be placed in the femur. Each rod is coated for half its length so each acts as its own comparison control. Specimens will be collected, radiographed and prepared for biomechanical and histological evaluation from 3 to 104 weeks postoperatively.

(17) Progress: No progress, LACUC approved in Sep 90.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/212A  Status: Ongoing

Title: The Evaluation of Bone Ingrowth in Hydroxyl Apatite and in Non-Hydroxylapatite Porous Implants in a Goat

Start Date:  Est Compl Date: 

Principal Investigator: Richard Schaefer, CPT, MC

Facility: FAMC

Dept/Svc: SURG/Ortho  Associate Investigators: Edward Lisecki, MAJ, MC
Stephen Cook, PhD
Jerome Weidel, MD

Key Words: bone ingrowth implants

Accumulative MEDCASE:* Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Study Objective: To quantify the biomechanical and histological effects of hydroxyl apatite on bone growth into porous-coated implants.

Technical Approach: The following parameters will be evaluated in a weight loaded goat hip: (a) the interface attachment shear strength and stiffness; (b) rate of development of interfacial strength and stiffness; (c) the amount, rate and organization of bone ingrowth.

Progress: No progress, LACUC approved Sep 90.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/213  Status: Ongoing

Title: Eaton Trapezial Implant Long-Term Follow-up

Start Date:  Est Compl Date:

Principal Investigator:  Facility: FAMC
Phillip Deffer, CPT, MC

Dept/Svc: SURG/Ortho  Associate Investigators:
(10) Associate Investigators:
James Johns, MAJ, MC
Frank Scott, MD

Key Words:  eaton trapezial implant

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:
Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date:
Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To demonstrate through long-term follow-up that the Eaton trapezial implant provides a strong, stable, mobile and useful thumb without significant complications.

Technical Approach: Retrospective analysis of postoperative records; subjective questionnaire; clinical exam; radiographic evaluation to look for evidence of implant failure, osseous changes or arthritic progression.

Progress: No progress, newly approved study.

Publications and Presentations: None
<table>
<thead>
<tr>
<th>(1) Date: 30 Sep 90</th>
<th>(2) Protocol #: 77/300</th>
<th>(3) Status: Ongoing</th>
</tr>
</thead>
<tbody>
<tr>
<td>(4) Title: Immunologic Disorders in Children and Adults. I. Correlation of Immune Function in the Immunodeficiency State. II. Correlation of Immune Function of Leukemia and other Childhood Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5) Start Date: 1977</td>
<td>(6) Est Compl Date: Open-Ended</td>
<td></td>
</tr>
<tr>
<td>(7) Principal Investigator: Robert S. Stewart, MAJ, MS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(8) Facility: FAMC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(9) Dept of Clin Investigation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(10) Associate Investigators Shannon M. Harrison, LTC, MC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(11) Key Words: immunologic diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(13) Est Accum OMA Cost:*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>*Refer to Unit Summary Sheet of this Report.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(14) a. Date, Latest IRC Review: Oct 87 b. Review Results: Ongoing c. Number of Subjects Enrolled During Reporting Period: 199 d. Total Number of Subjects Enrolled to Date: 1328 e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(15) Study Objective: Existing specialized immunochemical procedures will be consolidated into a registered protocol for use on a consultative basis by the FAMC hospital staff.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(16) Technical Approach: Serum gammapathics evaluated by SPEP, IEP, and rate nephelometry. Lymphocyte phenotyping, DNA analysis, and neutrophil activation potential by flow cytometry. Lymphocyte activation determined by quantitative mitogenesis.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(17) Progress: We continue to provide specialized immunological evaluations and testing with this protocol.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Presentations:


Publications:

Date: 30 Sep 90  Protocol #: 82/302  Status: Ongoing

Title: The Evaluation of Recently Introduced, Commercially Available Clinical Microbiology Products for Possible Use in the FAMC Diagnostic Microbiology Laboratory

Start Date: FY 84  Est Compl Date: Ongoing

Principal Investigator: Pari L. Morse

Facility: FAMC

Dept of Clin Investigation

Associate Investigators

Key Words:
- microbiology
- microbiological techniques

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: 5/90  Review Results:
Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date:
Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To evaluate introduced products which are of interest to the Microbiology Service, Department of Pathology, FAMC, but which cannot adequately be evaluated within the laboratory due to time, personnel, and monetary constraints. This evaluation will include cost effectiveness, ease of use, reproducibility and speed.

Technical Approach: A separate protocol will be designed for each product evaluated.

Progress: FY 90 - Evaluation of a kit for the measurement of Beta 2 Microglobulin in sera. This has been useful in the evaluation of HIV patients. Evaluation of a ELISA kit (ortho) for the measurement of antibody to hepatitis C (formerly non-A, non-B). Testing of this kit is still underway, but it appears useful in current hepatitis and HIV patients. Evaluation of a western blot kit (CHIRON-RIBA) for the measurement of antibody to Hepatitis C in sera. This kit appears to be more specific than the ELISA. Further testing is required.
Presentations:


Publications:

# Early Identification of Borrelia burgdorferi Antibody in Human Sera

**Date:** 30 Sep 90  
**Protocol #:** 86/300  
**Status:** Ongoing

**Title:** Early Identification of Borrelia burgdorferi Antibody in Human Sera

**Start Date:** 1986  
**Est Compl Date:**

**Principal Investigator:** Leo A. Andron, LTC, MS

**Dept of Clin Investigation:**

**associate Investigators:**

**Key Words:** borbrelia, lyme disease, spirochete

**Study Objective:** To develop a sensitive and specific screening assay to detect human IgM directed against B. burgdorferi. The procedure proposed here will determine if the avidin-biotin system can detect IgM antibody bound to B. burgdorferi on nitrocellulose paper (NCP).

**Technical Approach:** Preliminary studies confirmed that the probes currently available against IgG are more sensitive and much more specific than the anti IgM probes. A new IFA kit using the FIAX fluorometer system that detects IgG/IgM antibodies to *B. burgdorferi* was found to have the best sensitivity and specificity of currently available commercial kits.

**Progress:** Tests for Ab to tick antigens and direct tests for *B. burgdorferi* antigens are in planning stages.

**Publications and Presentations:** None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

1. **Date:** 30 Sep 90  
2. **Protocol #:** 88/30X  
3. **Status:** Ongoing

4. **Title:** Veterinarian and Veterinary Support Personnel Training in Emergency Care Procedures for Laboratory Animals

5. **Start Date:** Jul 88  
6. **Est Compl Date:** Ongoing

7. **Principal Investigator:**  
   Ron E. Banks, MAJ, VC

8. **Facility:** FAMC

9. **Dept/Svc:** DCI

10. **Associate Investigators:**  
    Terrie R. Clark

11. **Key Words:**  
    laboratory animals  
    emergency procedures  
    veterinary personnel training

12. **Accumulative MEDCASE:**  
    *Refer to Unit Summary Sheet of this Report

13. **Est Accum OMA Cost:**

14. **a. Date, Latest IRC Review:** N/A  
    **b. Review Results:**  
    **c. Number of Subjects Enrolled During Reporting Period:**  
    **d. Total Number of Subjects Enrolled to Date:**  
    **e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"**

15. **Study Objective:** To provide veterinary resources personnel training in routine and emergency medical procedures in government owned animals.

16. **Technical Approach:** See Protocol.

17. **Progress:** No animals used under this protocol, to date. Fortunately, we have been able to conduct training on animals being terminated for other research protocols.

**Publications and Presentations:** None
(4) Title: The Effect of the Topical Application of Minoxidil on Hair Growth in the "Nude" Mouse

(17) Progress: Histologic evaluations have been made and all technical work has been completed.

Publications and Presentations: None
Date: 30 Sep 90  (2) Protocol #: 89/301  (3) Status: Ongoing

(4) Title: Biology of Cutaneous Lupus: I Skin Lesion Examination

(5) Start Date: 1989  (6) Est Compl Date: 1991

(7) Principal Investigator:
Scott Bennion, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Dept Clin Investgn

(10) Associate Investigators:

(11) Key Words:
lupus erythmatosus
immunofluorescence
icam

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:

f. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 20

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine whether systemic lupus erythematosus, discoid lupus erythematosus, and subacute lupus erythematosus can be differentiated by specific auto-antibody binding patterns in the skin using immunofluorescent staining techniques.

(16) Technical Approach: Direct immunofluorescence, immunoperoxidase staining, H&E histology.

(17) Progress: In addition to the original IF studies we have been performing on the specimens, we are studying the tissue for the presence of intracellular adhesion molecule. This molecule is thought by many to be important in the trafficking of inflammatory cells through the epidermis.
Publications: 2 papers in progress - 3 abstracts given.

Presentations: Western Regional Meeting of the American Federation of Clinical Research.
National Meeting of the Society of Investigative Dermatology.
National Meeting of the American College of Rheumatology.
Poster presentation at the annual meeting of the American Society of Dermatopathology.
FAMC A.P.R. (RC: MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/302  (3) Status: Ongoing

(4) Title: Biology of Cutaneous Lupus: II Characterization of Autoantigens and Autoantibodies in Lupus

(5) Start Date: 1989  (6) Est Compl Date: 1992

(7) Principal Investigator: Scott Bennion, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: Dept Clin Investgn
(10) Associate Investigators:
      Charles F. Ferris, MAJ, MS
      Lela Lee, MD, UCHSC

(11) Key Words: neonatal lupus erythematosus autoantigens autoantibodies Ro

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:__________b. Review Results:__________
c. Number of Subjects Enrolled During Reporting Period:__________
d. Total Number of Subjects Enrolled to Date:__________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The major objectives of this project are to characterize the autoantigens and autoantibodies involved in neonatal lupus erythematosus (NLE) and subacute cutaneous lupus erythematosus (SCLE) and to determine if certain characteristics of the autoantigens or autoantibodies can be related to the major clinical findings in these diseases.

(16) Technical Approach: Immunoblotting technique, cloning of Ro, rabbit immunization with Ro to attempt to produce animal model.

(17) Progress: It has been found that the La RNA-binding antigen is present in greater quantities in neonatal than in adult tissues. (These studies were done using antisera from patients who were from the Univ. of Colorado Medical Center.) There have been no direct benefits to the human subjects.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 89/303 (3) Status: Ongoing

(4) Title: Biology of Cutaneous Lupus: III The Study of the Effects of Ultraviolet Light on the Skin of Lupus Erythematosus Patients

(5) Start Date: 1989 (6) Est Compl Date: 1992

(7) Principal Investigator:
Scott Bennion, LTC, MC
Lela Lee, MD

(8) Facility: FAMC
UCHSC

(9) Dept/Svc: Dept Clin Investgn

(10) Associate Investigators:

(11) Key Words:
ultraviolet light
cutaneous lupus

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To investigate and better correlate the cutaneous lupus subsets with their respective responses to ultraviolet light to be performed by phototesting patients with systemic lupus erythematosus (SLE), discoid lupus erythematosus (DLE) and subacute cutaneous lupus erythematosus (SCLE) then analyzing tissue and serologic specimens.

(16) Technical Approach: UV exposure followed by immunfluorescent.

(17) Progress: No progress. Currently we are having difficulty in determining the appropriate dosage of UV light. We are utilizing one patient who is at the UCHSC to adjust the area and time of UV light exposure. Until we feel comfortable with the UV dosage we are not going to begin a large study.

Publications and Presentations: None

306
(1) Date: 30 Sep 90  (2) Protocol #: 89/304  (3) Status: Ongoing

(4) Title: Evaluation of the Protofluor-Z as a Screening Tool for Lead Intoxication in Children

(5) Start Date: 30 Aug 89  (6) Est Compl Date: 30 Aug 91

(7) Principal Investigator: Joseph C. White, MAJ, MS

(8) Facility: FAMC

(9) Dept/Svc: Dept Clin Invstgn

(10) Associate Investigators: COL Askold Mosijczuk

(11) Key Words: blood lead, heated graphite atomizaion, atomic absorption

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 1000

d. Total Number of Subjects Enrolled to Date: 1400

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The objective is to reduce the cost of blood lead screening by placing hematofluorometers in a clinic setting. Only samples that fail the screening criteria need be analyzed further for anemia or lead intoxication.

(16) Technical Approach: Blood lead assayed by the gold standard method: atomic absorption, then results compared with hematofluorometers measuring ZPP.

(17) Progress: 1000 samples assayed by a; 800 samples assayed by hematofluorometer; methods developed for both instruments; survey certification complete in March, 1990. CDH portion complete. Army participation open.


**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 90  
(2) Protocol #: 90/300  
(3) Status: 

(4) Title: Videx (2', 3'dideoxyinosine, ddI) Treatment IND Protocol No. 454-999-001 (Bristol-Myers Co)

(5) Start Date: 1990  
(6) Est Compl Date: 1991

(7) Principal Investigator:  
Robert H. Gates, LTC, MC

(8) Facility: FAMC

(9) Dept/Svc: DCI/MDI

(10) Associate Investigators:  
Shannon M. Harrison, LTC, MC  
William R. Byrne, LTC, MC  
Rowland N. Hannon, PA-C/IDS

(11) Key Words:  
HIV therapy  
anti-retroviral therapy  
reverse transcriptase inhibitor

(12) Accumulative MEDCASE:*  
*Refer to Unit Summary Sheet of this Report

(13) Est Accum OMA Cost:*

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 1  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Treatment with ddi in patients with severe ARC or AIDS who clinically deteriorate on Zidovudine therapy and cannot participate in NIAID phase II study.

(16) Technical Approach: Study design is an open label salvage treatment using 2', 3' dideoxyinosine (ddi), in patients with advanced HIV disease. These patients are followed in the Infectious Disease Clinic at Fitzsimons Army Medical Center, and treated according to protocol, and in coordination with the sponsor.

(17) Progress: To date, one patient has been treated with ddi on this protocol. This patient has noted improved energy, appetite, and sense of well-being. A laboratory improvement in the CD4 helper cell count has been noted. This patient remains clinically stable, without obvious adverse side effects. This patient has returned to work full-time.

Publications and Presentations: None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<table>
<thead>
<tr>
<th>(1) Date:</th>
<th>30 Sep 90</th>
<th>(2) Protocol #:</th>
<th>90/301</th>
<th>(3) Status:</th>
<th>Ongoing</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(4) Title:</th>
<th>Videx (2', 3'dideoxyinosine, ddI) Open Label Study Protocol No. 454-999-002 (Bristol-Myers Co)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(5) Start Date:</th>
<th>1990</th>
<th>(6) Est Compl Date:</th>
<th>1991</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(7) Principal Investigator:</th>
<th>Robert H. Gates, LTC, MC</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(8) Facility:</th>
<th>FAMC</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(9) Dept/Svc:</th>
<th>DCI</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(10) Associate Investigators:</th>
<th>Shannon M. Harrison, LTC, MC</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(11) Key Words:</th>
<th>HIV therapy, anti-retroviral therapy, reverse transcriptase inhibitor</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(12) Accumulative MEDCASE:*</th>
<th>(13) Est Accum OMA Cost:*</th>
</tr>
</thead>
<tbody>
<tr>
<td>*Refer to Unit Summary Sheet of this Report</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(14) a. Date, Latest IRC Review:</th>
<th></th>
<th>b. Review Results:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot; Peripheral neuropathy, which developed in one subject, was reported to the sponsor.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(15) Study Objective:</th>
<th>Treatment with ddi in patients with severe ARC or AIDS who clinically deteriorate on Zidovudine therapy and cannot participate in NIAID phase II study.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(16) Technical Approach:</th>
<th>Study design is an open label salvage treatment using 2', 3' dideoxyinosine (ddi), in patient with advanced HIV disease. These patients are followed in the Infectious Disease Clinic at Fitzsimons Army Medical Center, and treated according to protocol, and in coordination with the sponsor.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(17) Progress:</th>
<th>To date, one patient has been treated with ddi. This patient as noted above, had the drug discontinued secondary to peripheral neuropathy. This peripheral neuropathy has improved greatly off drug.</th>
</tr>
</thead>
</table>

Publications and Presentations: None

309
Two Advanced Trauma Life Support (ATLS) exercises were conducted during the year, using eight goats in the training of 40 staff physicians in the emergency management of casualties. 80-plus hours of training were provided, requiring 100 hours of support by Animal Resources Service personnel for planning, preparation, pre-op anesthesia induction, surgical preps, anesthesia monitoring, circulating, and cleanup.

Two pigs were used by the Urology Service in the training of two staff physicians and three residents in the management of renal trauma. Forty-five hours of training were received, requiring thirty hours of support by Animal Resources Service personnel.

Two kittens were used by the Neonatology Service for the training of 18 members of their staff in methods of resuscitation, which included endotracheal intubation and chest tube placement. Forty-five hours of training were received, requiring 12 hours of support by Animal Resources Service personnel.

Fifty-six rats were utilized in support of microsurgery training in the re-anastomosis of small vessels, providing 180-plus hours of training to 19 staff surgeons and residents. Orthopedic Surgery Service conducted 26 sessions; Plastic Surgery Service, 19; Urologic Surgery Service, nine; and Otolaryngology Service, two. Support of this training by Animal Resources Service personnel totalled nearly 270 hours, administering and monitoring anesthesia, surgical preps, cleanup, and instrument cleaning and resterilization.

Ten enlisted members of Emergency Medicine Service, in MOS 91A, 91B, or 91C, were trained in suturing techniques. Training consisted of an overview of operating room procedure, including aseptic technique, operating room rules of etiquette, instruction in the surgical hand scrub, and gowning and gloving, and hands-on experience in dry and wet labs. Training was conducted on two days and utilized ten rats. Thirty-plus hours of training were received, requiring fifty-plus hours of support by Animal Resources Service personnel.

One exercise was conducted in "Resuscitation of Newborn" for the American College of Obstetricians and Gynecologists/Indian Health Service Postgraduate Course in Obstetrics, Gynecology and Neonatology. Ninety physicians and nurses received 135 hours of training in methods of resuscitation and endotracheal intubation, using 16 kittens and requiring sixty hours of support by Animal Resources Service personnel.
One goat was utilized under the Animal Resources Service training protocol for the training and evaluation of skills of personnel of this service. Four people participated in the exercise, including the staff veterinarian, two 91T animal specialists, and the 91D operating room specialist, receiving 36 hours of training. Preparation and cleanup contributed an additional 12 hours.

Cost of Training

<table>
<thead>
<tr>
<th>Exercise</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATLS Exercises</td>
<td>$375/animal x 8 animals = $ 3,000</td>
</tr>
<tr>
<td>In-service Training</td>
<td>375/animal x 1 animal = 375</td>
</tr>
<tr>
<td>Renal Trauma Exercises</td>
<td>290/animal x 2 animals = 580</td>
</tr>
<tr>
<td>Kitten Intubation, FAMC</td>
<td>270/animal x 2 animals = 540</td>
</tr>
<tr>
<td>Kitten Intubation, IHS</td>
<td>51/animal x 16 animals = 816</td>
</tr>
<tr>
<td>Rat Microsurgery</td>
<td>117/animal x 56 animals = 6,552</td>
</tr>
<tr>
<td>Suture Labs (Rats)</td>
<td>15/animal x 10 animals = 150</td>
</tr>
<tr>
<td></td>
<td><strong>$12,013</strong></td>
</tr>
</tbody>
</table>

There were no high school students trained during the year under the memorandum of agreement with Aurora Public Schools T.H. Pickens Technical Center.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90

(2) Protocol #: 80/351

(3) Status: Ongoing

(4) Title: Section A: Master Protocol for Phase II Drug Studies in the Treatment of Advanced Recurrent Pelvic Malignancies

GOG 26 A

(5) Start Date: 4/14/86

(6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: _4/90_ 

b. Review Results: 

c. Number of Subjects Enrolled During Reporting Period: 

d. Total Number of Subjects Enrolled to Date: 

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: Ongoing

Publications and Presentations: Multiple by GOG, none by FAMC.

313
Date: 30 Sep 90
Protocol #: 80/352
Status: Ongoing

Title: Section C: A Phase II Trial of CIS-Platinum GOG 26 C

Start Date: 4/27/77
Est Compl Date: Unknown

Principal Investigator:
Mark E. Potter, MAJ, MC

Facility: FAMC

Dept of OB-GYN

Key Words:
pelvic neoplasms

Accumulative MEDCASE:*  *Refer to Unit Summary Sheet of this Report.
Est Accum OMA Cost:

Date, Latest IRC Review: 4/90
Review Results: Approved
Number of Subjects Enrolled During Reporting Period: 0
Total Number of Subjects Enrolled to Date: 3

Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol

Progress: Three patients; one partial remission. No serious adverse reactions.

Publications and Presentations: Multiple by GOG, none by FAMC.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 80/359  (3) Status: Ongoing

(4) Title: Section S: A Phase II Trial of VM26
        GOG 26

(5) Start Date: 7/9/84  (6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
     *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 4/90  b. Review Results: Approved
     c. Number of Subjects Enrolled During Reporting Period: 0
     d. Total Number of Subjects Enrolled to Date: 4
     e. Note any adverse drug reactions reported to the FDA or sponsor for
        studying under an FDA-awarded IND. May be continued on a separate
        sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study
     of cancer.

(16) Technical Approach: See protocol

(17) Progress: Four patients, three progressive disease, 1 stable. No
     adverse reactions.

Publications and Presentations: Multiple by GOG.

315
Date: 30 Sep 90    Protocol #: 80/378    Status: Ongoing

Title: Ovarian Tumors of Low Malignant Potential: A Study of the Natural History and a Phase II Trial of Melphalan and Secondary Treatment with Cisplatin in Patients with Progressive Disease

GOG 72

Start Date: 12/20/83    Est Compl Date: Unknown

Principal Investigator: Mark E. Potter, MAJ, MC

Facility: FAMC

Dept of OB-GYN

Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*    Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: 4/90 b. Review Results: Approved
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 3
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol

Progress: Three patients, surgical-pathological study only, no adverse effects.

Publications and Presentations: None
Date: 30 Sep 90
Protocol #: 80/379
Status: Completed

Title: Early Stage I Vulvar Cancer Treated with Ipsilateral Superficial Inguinal Lymphadenectomy and Modified Radical Hemivulvectomy (Phase III)

Start Date: 10/17/83
Est Compl Date: Unknown

Principal Investigator:
Mark E. Potter, MAJ, MC

Facility: FAMC

Dept of OB-GYN

Key Words:
pelvic neoplasms

Accumulative MEDCASE:* *Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: 4/90
Review Results_Completed
Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date:

Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol

Progress: Closed, no patients.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 80/380  (3) Status: Ongoing

(4) Title: A Clinical Pathologic Study of Primary Malignant Melanoma of the Vulva Treated by Modified Radical Hemivulvectomy GOG 73

(5) Start Date: 11/1/83  (6) Est Compl Date: 1990

(7) Principal Investigator:  
Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept of OB-GYN

(10) Associate Investigators

(11) Key Words:
pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  4/90  b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol

(17) Progress: No patients entered.

Publications and Presentations: None

318
Date: 30 Sep 90  Protocol #: 82/35X-001  Status: Terminated

Title: Repair of Femoral Artery and Fallopian Tube of Rabbit and Rat

Start Date:  Est Compl Date:

Principal Investigator: Edward G. Lundblad, COL, MC

Facility: FAMC

Dept of OB-GYN Associate Investigators

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:  Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective:

Technical Approach:

Progress: No response for request of progress.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 83/351  Status: Terminated

Title: Danazol in the Treatment of Premenstrual Syndrome

Start Date: 1985  Est Compl Date: 1989

Principal Investigator: Diane C. Garrow, CPT, MS

Facility: FAMC

Dept of OB-GYN  Associate Investigators
Edward Lundblad, COL, MC

Key Words:

pms  therapy

Accumulative MEDCASE:*  Est Accum OMA Cost: *
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:
Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date: 5
Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To determine if Danazol is effective in treating symptoms of pre-menstrual syndrome.

Technical Approach: A double-blind, cross-over, placebo study in which patients who have documented PMS are treated for 2 months with Danazol and 2 months with placebo. While being treated, patients keep a diary of their symptoms.

Progress: No progress.

Title: A Randomized Comparison of Hydroxyurea Versus 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy in Patients with Stages II-B, III and IV-A Carcinoma of the Cervix and Negative Para-Ap.rt Nodes

(5) Start Date: 

(6) Est Compl Date: 

(7) Principal Investigator: 
Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators:

(11) Key Words: 

(12) Accumulative MEDCASE:* 
(13) Est Accum OMA Cost:* 
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG group in the study of malignancies.

(16) Technical Approach: See protocol.

(17) Progress: Completed.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 87/353  (3) Status: Ongoing

(4) Title: Evaluation of Cisplatin, Etoposide, and Bleomycin Induction Followed by Vincristine, Dactinomycin and Cyclophosphamide Consolidation in Advanced Ovarian Germ Cell Tumors

GOG 90

(5) Start Date: 9/18/86  (6) Est Compl Date: 1991

(7) Principal Investigator: Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: MED/Hema/Oncol

(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 4/90  b. Review Results: Approved
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None

322
Date: 30 Sep 90  Protocol #: 87/354  Status: Ongoing

Title: Randomized Clinical Trial for the Treatment of Women with Selected Stage IAI & IAii & IBii Ovarian Cancer (Phase III) GOG 95

Start Date: 9/22/86  Est Compl Date: 1994

Principal Investigator: Mark E. Potter, MAJ, MC

Facility: FAMC

Dept/Svc: MED/Hema/Oncol  Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: 4/90  b. Review Results: Approved
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Ongoing, no patients.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 87/356  (3) Status: Completed

(4) Title: 'A Phase III Randomized Study of Cyclophosphamide and Cisplatin in Patients with Suboptimal Stage III and State IV Epithelial Ovarian Carcinoma Comparing Intensive and Non-Intensive Schedules

GOG 97

(5) Start Date: 12/1/86  (6) Est Compl Date: 1990

(7) Principal Investigator: Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 4/90  b. Review Results: Completed

c. Number of Subjects Enrolled During Reporting Period: 4

d. Total Number of Subjects Enrolled to Date: 7

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Seven patients; 1 complete response, 3 alive with no evidence of disease; 5 dead of disease. No adverse reactions.

Publication... and Presentations: None
Date: 30 Sep 90  Protocol #: 87/358  Status: Ongoing

Title: Evaluation of Intraperitoneal Chromic Phosphate After Negative Second-Look Laparotomy in Ovarian Carcinoma

GOG 93

Start Date: 6/1/87  Est Compl Date: 1992

Principal Investigator: Mark E. Potter, MAJ, MC

Dept/Svc: OB-GYN

Associate Investigators

Key Words: pelvic neoplasms

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: 4/90  Review Results: Approved
Number of Subjects Enrolled During Reporting Period: 0
Total Number of Subjects Enrolled to Date: 0

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Ongoing, no patients.

Publications and Presentations: None
I AMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 87/359  (3) Status: Ongoing

(4) Title: Adjunctive Radiation Therapy in Intermediate Risk Endometrial Carcinoma

GOG 99

(5) Start Date: 6/1/87  (6) Est Compl Date: 1991

(7) Principal Investigator:  (8) Facility: FAMC
Mark E. Potter, MAJ, MC

(9) Dept/Svc: OB-GYN  (10) Associate Investigators

(11) Key Words:
pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 4/90  b. Review Results: Approved
  c. Number of Subjects Enrolled During Reporting Period: 0
  d. Total Number of Subjects Enrolled to Date: 0
  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/350  (3) Status: Ongoing

(4) Title: Radiation Therapy vs No Further Therapy in Selected Patients with Stage IB Invasive Carcinoma of the Cervix

GOG 92

(5) Start Date: 3/9/88  (6) Est Compl Date: 1992

(7) Principal Investigator:
Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators

(11) Key Words:
pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: __4/90__  b. Review Results: _Approved_
   c. Number of Subjects Enrolled During Reporting Period: ____0_____
   d. Total Number of Subjects Enrolled to Date: ____0_____
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/351  (3) Status: Ongoing

4) Title: A Phase II Study of the Treatment of Stage III and IV Disease of Advanced Endometrial Carcinoma and All Stages of Papillary Serious Carcinoma and Clear Cell Carcinoma of the Endometrium with Total Abdominal Radiation Therapy

GOG 94

(5) Start Date: 12/22/86  (6) Est Compl Date: 1990

(7) Principal Investigator: Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators

(11) Key Words:
pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 4/90  b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 88/355  (3) Status: Ongoing

(4) Title: Intraperitoneal (SWOG8501) Intraperitoneal Cis-Platinum and Cyclophosphamide IV vs Intravenous Cis-Platinum and Cyclophosphamide IV in Patients with Optimal Stage III Ovarian Cancer

GOG 104

(5) Start Date: 6/15/88  (6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB-GYN

(10) Associate Investigators

(11) Key Words: pelvic neoplasms

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: 4/90 b. Review Results: Approved
c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date: 0
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None other than expected.

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None
Date: 30 Sep 90  
Protocol #: 88/358  
Status: Ongoing

Title: Monoclonal Antibody Against Free Beta HCG to Predict Development of PGTD in patients with Hydaticiform Mole  
GOG #100

Start Date: 1/88  
Est Compl Date: 1/92

Principal Investigator: Mark E. Potter, MAJ, MC

Facility: FAMC  
Dept/Svc: GYN-ONC Svc

Publications and Presentations: None

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol.

Progress: Ongoing, no patients.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 88/359  Status: Ongoing


Start Date: 1/4/88  Est Compl Date: Unknown

Principal Investigator: Mark E. Potter, MAJ, MC

Facility: FAMC

Dept/Svc: OB-GYN

Associate Investigators: Francis J. Major, COL, MC

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: 4/90  Review Results: Approved

Number of Subjects Enrolled During Reporting Period: 0

Total Number of Subjects Enrolled to Date: 0

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the GOG group in the study of malignancies.

Technical Approach: See Protocol

Progress: Ongoing, no patients.

Publications and Presentations: None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

(1) Date: 30 Sep 90  
(2) Protocol #: 88/360  
(3) Status: Ongoing

(4) Title: A Phase II Trial of hydroxurea, DTIC and VP-16 in Patients with Advanced Uterine Sarcomas

(5) Start Date: 3/7/88  
(6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN  
(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: 4/90  
b. Review Results: Approved  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The objective is to participate in the GOG group in the study of malignancies.

(16) Technical Approach: See protocol

(17) Progress: Ongoing, no patients.

Publications and Presentations: None
(1) Date: 30 Sep 90  
(2) Protocol #: 89/350  
(3) Status: Completed  

(4) Title: A Phase II Trial of Echinomycin (NSC#E526417) in Patients with Advanced Squamous Cell Carcinoma of the Cervix  
GOG 76H  

(5) Start Date: Aug 89  
(6) Est Compl Date:  

(7) Principal Investigator:  
Mark E. Potter, MAJ, MC  

(8) Facility: FAMC  

(9) Dept/Svc: Gynecology (GYN)  

(10) Associate Investigators:  

(11) Key Words:  
echinomycin  

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report  

(14) a. Date, Latest IRC Review: 4/90  
b. Review Results: Completed  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"  

(15) Study Objective: Evaluation of the efficacy and safety of echinomycin in the treatment of patients with advanced squamous cell carcinoma of the cervix.  

(16) Technical Approach: This is a non-randomized study; all patients will be treated identically.  

(17) Progress: Closed, no patients.  
Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

<table>
<thead>
<tr>
<th>(1) Date:</th>
<th>30 Sep 90</th>
</tr>
</thead>
<tbody>
<tr>
<td>(2) Protocol #:</td>
<td>89/351</td>
</tr>
<tr>
<td>(3) Status:</td>
<td>Ongoing</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(4) Title:</th>
<th>A Phase II Trial of VP-16 in Patients with Advanced or Recurrent Uterine Sarcoma</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>GOG 87D</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(5) Start Date:</th>
<th>Aug 89</th>
</tr>
</thead>
<tbody>
<tr>
<td>(6) Est Compl Date:</td>
<td>1994</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(7) Principal Investigator:</th>
<th>Mark Potter, MAJ, MC</th>
</tr>
</thead>
<tbody>
<tr>
<td>(8) Facility:</td>
<td>FAMC</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(9) Dept/Svc:</th>
<th>OB/GYN</th>
</tr>
</thead>
<tbody>
<tr>
<td>(10) Associate Investigators:</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(11) Key Words:</th>
<th>VP-16, uterine sarcoma</th>
</tr>
</thead>
</table>

| (12) Accumulative MEDCASE:* | |
|-----------------------------| |
| (13) Est Accum OMA Cost:* | |

*Refer to Unit Summary Sheet of this Report

<table>
<thead>
<tr>
<th>(14) a. Date, Latest IRC Review:</th>
<th>4/90</th>
</tr>
</thead>
<tbody>
<tr>
<td>b. Review Results:</td>
<td>Approved</td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td>0</td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td>0</td>
</tr>
<tr>
<td>e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as &quot;(14)e&quot;</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>(15) Study Objective:</th>
<th>To identify active drugs against each of the two major types of sarcomas which have a high recurrence rate and against which combination chemotherapy has not been effective. VP-16 has been included because it has been shown to have elicited some response in a very small sample and the data suggest the need for study in previously untreated patients.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(16) Technical Approach:</th>
<th>This is a non-randomized study which will involve treating an average sample size of 30 evaluable patients per drug. This method allows for rapid replacement of ineffective agents.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>(17) Progress:</th>
<th>No patients have been enrolled at FAMC to date.</th>
</tr>
</thead>
</table>

Publications and Presentations: None.
(4) Title: A Phase II Evaluation of Preoperative Chemoradiation for Patients with Advanced Vulvar Cancer
   GOG 101

(15) Study Objective: To determine if using preoperative chemoradiotherapy will obviate the need for pelvic exenteration in patients with advanced vulvar cancer; will its use allow less extensive surgical resection without compromising survival or cure.

(16) Technical Approach: All patients will be treated with split-course radiotherapy to the primary lesion as well as chemotherapy. Only patients with positive groin nodes will receive additional radiotherapy to the groin and pelvic nodes. Four to eight weeks after radiotherapy is completed, all patients will have surgical resection of the primary tumor plus bilateral groin node dissection.

(17) Progress: No FAMC patients enrolled to date on this recently approved protocol.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/353  (3) Status: Completed

(4) Title: A Phase II Study of Intraperitoneal Administration of Cisplatin (NSC#119875) and Recombinant Alpha 2 Interferon in Residual Ovarian Carcinoma

GOG 102C

(5) Start Date: Aug 89  (6) Est Compl Date:

(7) Principal Investigator: Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN  (10) Associate Investigators:

(11) Key Words:
cisplatin
interferon
ovarian carcinoma

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: 4/90 b. Review Results: Completed
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To test the effectiveness of these two drugs used in combination when there has been a partial response to Cisplatin as determined by second-look surgery.

(16) Technical Approach: All patients accepted for inclusion in this study will receive the above-named drugs. Any dosage modifications will be based on the type and degree of toxicity, if any, and is carefully defined in the body of the protocol.

(17) Progress: Closed, no patients.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/354   (3) Status: Ongoing

(4) Title: A Randomized Study of Doxorubicin vs Doxorubicin Plus Cisplatin in Recurrent Endometrial Adenocarcinoma Previously Diagnosed as Primary Stage III or IV (Phase III)  
GOG 107

(5) Start Date: Aug 89  (6) Est Compl Date: 6/92

(7) Principal Investigator: Mark Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: OB/GYN  
(10) Associate Investigators:

(11) Key Words: doxorubicin  
cisplatin  
endometrial adenocarcinoma

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: 4/90  b. Review Results: Ongoing  
c. Number of Subjects Enrolled During Reporting Period: 0  
d. Total Number of Subjects Enrolled to Date: 0  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine whether the addition of cisplatin to doxorubicin offers significant improvement in the frequency of objective response, in the duration of progression-free interval and the length of survival as compared with the administration of doxorubicin alone.

(16) Technical Approach: Patients will be randomized to one of the two regimens and will be treated until the maximum tolerated dose of doxorubicin is reached or until there is progression of disease.

(17) Progress: No FAMC patients enrolled.

Publications and Presentations: None.
Date: 30 Sep 90       Protocol #: 89/355       Status: Ongoing

Title: Intraperitoneal Administration of Cisplatin (NSC#119875) and Etoposide (VP-16) (NSC #141540) in Patients with Residual Ovarian Carcinoma (Phase II)

Start Date: 1989       Est Compl Date: 2/91

Principal Investigator: Mark Potter, MAJ, MC

Facility: FAMC

Dept/Svc: OB-GYN

Key Words: cisplatin, etoposide, carcinoma

Accumulative MEDCASE:*       Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review: 4/90       Review Results: Ongoing

Number of Subjects Enrolled During Reporting Period: 0

Total Number of Subjects Enrolled to Date: 0

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To test the effectiveness of these two drugs used in combination when there has been a partial response to Cisplatin as determined by second-look surgery.

Technical Approach: 200 mgm/M2 of Etoposide and 100 mgm/M2 of Cisplatin every 4 weeks for six doses.

Progress: No patients enrolled at FAMC.

Publications and Presentations: None

338
Date: 30 Sep 90  Protocol #: 89/356  Status: Ongoing

Title: Intraperitoneal Administration of Alpha Recombinant Interferon (aIFN) in Residual Ovarian Carcinoma (Phase II)  GOG 102F

Start Date: 1989  Est Compl Date: 2/91

Principal Investigator: Mark Potter, MAJ, MC

Facility: FAMC

Dept/Svc: OB-GYN

Associate Investigators:

Key Words: Interferon carcinoma

Study Objective: To test the effectiveness of this agent when it is administered directly into the area where the tumor is localized when there has been a partial response to Cisplatin.

Technical Approach: 50x106 units of Interferon administered IP in 250ml NS after 1750 ml dialysate solution is given IP via the IP catheter. Therapy is given weekly for 12 weeks.

Progress: No patients enrolled at FAMC.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/350  Status: Ongoing

Title: Ifosfamide and the Uroprotector Mesna, with or without Cisplatin, in Patients with Advanced or Recurrent Mixed Mesodermal Tumors of the Uterus

GOG 108

Start Date: 1990  Est Compl Date: 10/93

Principal Investigator: Mark Potter, MAJ, MC

Facility: FAMC

Dept/Svc: OB/GYN

Associate Investigators:

Key Words:

Accumulative MEDCASE:  Est Accum OMA Cost:
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date: 0
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol.

Progress: New study, not yet open.

Publications and Presentations: None
(1) Date: 30 Sep 90 (2) Protocol #: 90/351 (3) Status: Ongoing

(4) Title: A Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy vs Radiation Therapy Alone in Selected Patients with Stage 1A-2, 1B or 2A Carcinoma of the Cervix Following Radical Hysterectomy and Node Dissection

GOG 109

(5) Start Date: 1990 (6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC

(9) Dept/Svc: GYN-ONC Svc

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 0 d. Total Number of Subjects Enrolled to Date: 0 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG protocol in the study of Cancer.

(16) Technical Approach: See protocol.

(17) Progress: New study, not yet open.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/352  (3) Status: Ongoing

(4) Title: A Phase II Trial of Didemnin B in Patients with Advanced Pelvic Malignancies

GOG #26EE

(5) Start Date: 1990  (6) Est Compl Date: Unknown

(7) Principal Investigator:  (8) Facility: FAMC
Mark E. Potter, MAJ, MC

(9) Dept/Svc: GYN-ONC Svc  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date: 0
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14, "

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol.

(17) Progress: Ongoing, no patients.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 90/353  Status: Ongoing

Title: A Phase II Trial of Fazarabine in Patients with Advanced/Recurrent Pelvic Malignancies
GOG 26GG

Start Date: 1990  Est Compl Date: Undetermined

Principal Investigator: Mark E. Potter, MAJ, MC

Facility: FAMC

Dept/Svc: GYN-ONC Svc

Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date: 0

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol.

Progress: Ongoing, no patients.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 90/354  Status: Ongoing

Title: A Phase II Trial of 5-Fluorouracil and Leucovorin in Advanced Metastatic or Recurrent Pelvic Malignancies

GOG #26HH

Start Date: 1990  Est Compl Date: Undetermined

Principal Investigator: Mark E. Potter, MAJ, MC

Dept/Svc: GYN-ONC Svc

Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date: 0
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol.

Progress: New study, no patients.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/355  (3) Status: Ongoing

(4) Title: Intraperitoneal Administration of Cisplatin (NSC#119875) and Thiotepa in Residual Ovarian Carcinoma

GOG 102G

(5) Start Date: 1990  (6) Est Compl Date: Unknown

(7) Principal Investigator: Mark E. Potter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: GYN-ONC Svc

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: ________ b. Review Results: ________
c. Number of Subjects Enrolled During Reporting Period: _____0_____
d. Total Number of Subjects Enrolled to Date: ___________0_________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the GOG protocol in the study of cancer.

(16) Technical Approach: See protocol.

(17) Progress: New study not yet started.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 90/356  Status: Ongoing

Title: A Phase III Randomized Study of Cyclophosphamide (NSC#26271) and Cisplatin (NSC#19875) Versus Taxol (NSC#125973) and Cisplatin (NSC#119875) in patients with Suboptimal Stage III and Stage IV Epithelial Ovarian Carcinoma

GOG 111

Start Date: 1990  Compl Date: Unknown

Principal Investigator: Mark E. Potter, MAJ, MC

Dept/Svc: GYN-ONC Svc

Associate Investigators: 

Key Words: 

Accumulative MEDCASE:*  Est Accum OMA Cost:* 

*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 0 
d. Total Number of Subjects Enrolled to Date: 0 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in the GOG protocol in the study of cancer.

Technical Approach: See protocol.

Progress: New study, no patients.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 78/40X-001  Status: Ongoing

Title: Use of Laboratory Animals (Cats) to Teach Medical Skills

Start Date:  
Est Compl Date:  

Principal Investigator:  Beverly A. Anderson, MAJ, MC  
Facility:  FAMC

Dept of Pediatrics  
Associate Investigators  
John P. Kinsella, MAJ, MC

Key Words:  

Accumulative MEDCASE:  Est Accum OMA Cost:  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 2  
d. Total Number of Subjects Enrolled to Date: 10  
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: Teaching protocol.

Technical Approach: See protocol.

Progress: Annual laboratory exercise continues to be successful in teaching intubation/chest tube placement skills to Pediatric House Officers. This remains an excellent model for teaching skills.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 82/403  (3) Status: Ongoing

(4) Title: Rare Tumor Protocol for Childhood Solid Tumor Malignancies, Ancillary
POG 7799

(5) Start Date:  (6) Est Compl Date: 

(7) Principal Investigator:  (8) Facility: FAMC
Askold D. Mosijczuk, COL, MC

(9) Dept of Pediatrics  (10) Associate Investigators
(11) Key Words:  
drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 0 
d. Total Number of Subjects Enrolled to Date: 2 
e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: Two patients have been registered at FAMC, one pt. with superficial melanoma of the eye is continuing to do well, in complete remission. The other patient, a newborn with metastatic undifferentiated sarcoma of the face has died. The study remains open for new patient entry.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 82/414  Status: Ongoing

Title: NWTS Long Term Follow-Up Study: A Non-therapeutic Study
POG 8158

Start Date:  Est Compl Date: 

Principal Investigator:  Facility: FAMC
Askold Mosijczuk, COL, MC

Dept/Svc: Pediatrics  Associate Investigators

Key Words: drug therapy

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 0
d. Total Number of Subjects Enrolled to Date: 0
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the P group in the study of pediatric malignancies.

Technical Approach: See Protocol

Progress: No patients have been entered at Fitzsimons, the study remains open to new patient registrations.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 82/420  (3) Status: Ongoing

(4) Title: Intergroup Rhabdomyosarcoma Study III
          POG 8451

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  Askold Mosijczuk, COL, MC
(8) Facility:  FAMC

(9) Dept/Svc: Pediatrics  (10) Associate Investigators

     Dr. Clark
     Dr. Reddy
     Dr. Henderson
     Dr. Bodlien

(11) Key Words:  drug therapy

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
     *Refer to Unit Summary Sheet of this Report.

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: Four patients have been entered at FAMC. The first patient has relapsed with metastatic disease after having completed the prescribed two years of chemotherapy and has died. Another patient, who entered in 1987 achieved complete remission status of his undifferentiated sarcoma of the pelvis region, but has subsequently died of overwhelming sepsis as a result of severe myelosuppression from chemotherapy; another patient entered in October 1986 had pulmonary metastases of chest and died on 10 July 1990. The other patient who was entered in 1988 with nasopharyngeal rhabdomyosarcoma is currently in complete remission status having completed chemotherapy. The study remains open to new patient entry.

Publications and Presentations: None
Title: Prevalence of Endometriosis Externa in Adolescent Women Complaining of Severe Dysmenorrhea

Start Date: 1983

Principal Investigator: David W. Wells, COL, MC

Facility: FAMC

Dept of Pediatrics

Key Words: endometriosis dysmenorrhea

Study Objective: An epidemiologic survey of young women will document the prevalence of symptomatic endometriosis externa in a middle class primary care population of adolescent women complaining of dysmenorrhea. This prevalent figure will tell the health care provider how alert he has to be to this condition.

Technical Approach: This retrospective stage of epidemiologic survey is designed to isolate by questionnaire those young women who might have endometriosis and subject them to laparoscopy.

Progress: No progress has been made on this protocol since the departure of the original principal investigator.

Publications and Presentations: None
(1) Date: 30 Sep 90 (2) Protocol #: 86/403 (3) Status: Completed

(4) Title: Prophylactic Intravenous Immunoglobulin for Infections in High Risk Neonates

(5) Start Date: March 86 (6) Est Compl Date: 1989

(7) Principal Investigator: C. Gilbert Frank, LTC, MC

(8) Facility: FAMC

(9) Dept of Pediatrics

(10) Associate Investigators

(11) Key Words: high risk neonates prophylactic IVIG

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 21 d. Total Number of Subjects Enrolled to Date: 4423 e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To evaluate in a double blind manner the effectiveness compared to an albumin placebo of IVIG preventing infectious disease and/or reducing morbidity and mortality in the high risk neonate.

(16) Technical Approach: < 2,000g, < 34 wks gestation are eligible for the study. Routine evaluations and therapy will be given as necessary to all infants. IgG antibody titers will be drawn pre and post infusion as well as at 1, 2, and 8 weeks. The incidence of infection as well as mortality and morbidity will be evaluated.

(17) Progress: An FDA advisory panel reviewed study data and recommeded conclusion of the study and analysis and publication of results. Data collection was completed in July 1989 and additional study material returned to Sandoz per protocol. Study presently in evaluation stage.

Abstracts and presentations "Intravenous Immunoglobulin Therapy of Neonatal Sepsis" and "Intravenous Immunoglobulin Prophylaxis of Late-Onset Septicemia in Neonates", Society for Pediatric Research meeting, Anaheim, CA, May 90.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 86/408 (3) Status: Ongoing

(4) Title: Laboratory Classification in Acute Lymphoid Leukemia of Childhood (ALinC 14C) Phase III
POG 8600

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Askold Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept of Pediatrics

(10) Associate Investigators
Dr. Reddy
Dr. Bodlien
Dr. Henderson

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:__________ b. Review Results:__________
c. Number of Subjects Enrolled During Reporting Period: 2
d. Total Number of Subjects Enrolled to Date:__________ 8

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: During the past fiscal year, two new patients have been entered on study. Eight patients at FAMC are on this study. One of those patients was entered at Walter Reed and transferred here. Another patient was entered at Keesler AFB, transferred here and subsequently transferred to Prince Charles Hospital in Salt Lake City, Ut. Since this is a laboratory classification study, there is no toxicity. The study is ongoing and is open to new pt. entry. One of the patients (MP) entered on study one year ago has a unique ALL phenotype. The patient has markers of T-cell ALL as well as being Philadelphia chromosome positive. This is a new finding in the protocol and in the Pediatric Oncology Group. The study is ongoing and is open to new patient entry.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 86/410  Status: Ongoing

Title: ALinC #14: Evaluation of Treatment Regimens in Acute Lymphoid Leukemia of Childhood (ALinC#14) - A Pediatric Oncology Group Phase III Study

POG 8602

Principal Investigator: Askold Mosijczuk, COL, MC

Associate Investigators
Dr. Reddy
Dr. Bouilen
Dr. Henderson

Key Words: drug therapy

Accumulative MEDCASE:*  Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report.

Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

Technical Approach: See Protocol

Progress: There are currently eight patients on this study. One of the 8 patients on study was entered at Walter Reed and transferred to FAMC. This patient has subsequently transferred to Roswell Park Memorial Institute in Buffalo, New York. Another patient was entered at Keesler AFB, transferred here and recently transferred to Prince Charles Hospital. Responsibility for POG data will remain with Dr. Mosijczuk. A previous patient diagnosed at FAMC has subsequently been transferred to Travis Air Force Base and continues on protocol with information being related periodically to principal investigator at Fitzsimons. Significant toxicity in two of the 8 patients has included severe myelosuppression, septicemia in one patient, secondary to high-dose Methotrexate and high-dose Ara-C chemotherapy as per protocol. Otherwise, patients are tolerating therapy well and all remain in complete remission status, some having completed treatment. The study remains open for new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 87/401  (3) Status: Ongoing

(4) Title: Combined Therapy and Restaging in the Treatment of Stages I, IIA, and IIIA Hodgkin's Disease in Pediatric Patients, A Pediatric Oncology Group Phase III Study
POG 8625/26

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Askold D. Mosijczuk, COL, MC

(9) Dept/Svc: PED/Hema/Oncol  (10) Associate Investigators
(11) Key Words:  Dr. Reddy
drug therapy  Dr. Bodlien

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: One patient has been entered at FAMC. The patient achieved complete remission status and is currently doing well, having completed all therapy as per protocol. No unusual toxicities have been encountered. The study remains open to new patient entry.

Publications and Presentations: None
Title: Randomized Phase II Study of Carboplatin (CBCDA) vs. CHIP in Treatment of Children with Progressive or Recurrent Brain Tumor

POG 8638

Start Date: (6) Est Compl Date: 

Principal Investigator: (8) Facility: FAMC  
Askold D. Mosijczuk, COL, MC

Dept/Svc: PED/Hema/Oncol (10) Associate Investigators  
Dr. Carter  
Dr. REddy  
Dr. Bodlien

Accumulative MEDCASE:* (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review:__________ b. Review Results:__________  
c. Number of Subjects Enrolled During Reporting Period:__________  
d. Total Number of Subjects Enrolled to Date: 1  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

Technical Approach: See Protocol

Progress: One patient, a 14-year-old girl with recurrent pontine glioma was entered on this study in November of 1986. The patient is currently off chemotherapy, doing well with stable disease. Toxicity has been limited to moderate myelosuppression. The study is closed to new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 87/404 (3) Status: Ongoing

(4) Title: A Study of Childhood Soft Tissue Sarcomas (STS) Other than Rhabdomyosarcoma and Its Variants, A Pediatric Oncology Group Phase III Study

POG 8653/54

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Askold D. Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: PED/Hema/Oncol (10) Associate Investigators
Dr. Clark
Dr. Reddy
Dr. Bodlien

(11) Key Words: drug therapy

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:__________ b. Review Results:__________
c. Number of Subjects Enrolled During Reporting Period:__________
d. Total Number of Subjects Enrolled to Date:__________
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

(16) Technical Approach: See Protocol

(17) Progress: No patients have been entered at Fitzsimons. The study remains open to new patient entry.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 87/405  Status: Completed

Title: Front Loading Chemotherapy in Children with Increased Risk Medulloblastoma
POG 8695

Principal Investigator: Askold D. Mosijczuk, COL, MC
Associate Investigators:
- Dr. Carter
- Dr. Reddy
- Dr. Bodlien
- Dr. Henderson

Key Words: drug therapy

Start Date:  Est Compl Date:

Facility: FAMC

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review:  Review Results:
Number of Subjects Enrolled During Reporting Period:
Total Number of Subjects Enrolled to Date: 1

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. Might be continued on a separate sheet, and designated as "(14)e".

Study Objective: The objective is to participate in the POG group in the study of pediatric malignancies.

Technical Approach: See Protocol

Progress: One patient was entered at FAMC in April of 1987. The patient suffered severe grade IV myelosuppression secondary to the high-dose Cyclophosphamide as per protocol but recovered. However, during subsequent radiation therapy, the patient developed severe bone marrow hypoplasia lasting for two months but eventually recovered and refused further radiation therapy. He is currently off study, and is alive with recurrent tumor. Nationally, 39 patients have been entered on protocol. 30 patients are evaluable for response. Of these, the following post chemotherapy responses have been documented prior to radiation therapy: CR 10 patients, PR 5 patients, SD (stable disease) 17 patients, progressive disease 4 patients. Most important toxicity has been severe myelosuppression due to the high dose Cyclophosphamide which is expected. Although there have been 2-3 week delays in radiation therapy because of the myelosuppression, most patients have been able to complete chemotherapy and radiation as intended. The study is closed to new patient entry.

360
Publications and Presentations:

Dr. Mosijczuk presented an update on the status of the study at the Annual UCHSC Pediatric Hematology Seminar in Aspen, Colorado on March 31, 1989.

Dr. Mosijczuk presented an update on the status of the study at the Semi-annual Pediatric Oncology Group Meeting in Clearwater, Florida, April 1989.

Dr. Mosijczuk presented a poster abstract of the protocol results at the International Pediatric Neuro-Oncology meeting in Seattle, Washington on 2 June 1989.

Dr. Mosijczuk presented an update on the study at the semi-annual Pediatric Oncology Meeting, Orland, FL, April 1990.
Title: Effects of Oral Contraceptive Agents on Coagulation Parameters in the Adolescent Patient

Study Objective: To assess if the newer oral contraceptive agents used today have effects on the levels of clotting factors in adolescent patients (specifically Factor VIII, PT, PTT, fibrinogen, Antithromb III, and protein C).

Technical Approach: Patients have the above studies measured at baseline, then 3 months, 6 months and one year after being on oral contraceptives.

Progress: Currently in process of analyzing data on computer patients to assess any trends. Following patients already enrolled but not entering any new patients until stats on current patients are analyzed. Statistics revealed difference between smokers and nonsmokers in SATI III and fibrinogen. Completed study.

Publications and Presentations: Presented but not published.
Date: 30 Sep 90  
Protocol #: 87/408  
Status: Terminated

Title: Efficacy of Prophylactic Anti-Migraine Therapy in the Adolescent Therapy Patient - A Double Blinded Study

Start Date:  
Est Compl Date:

Principal Investigator:  
Sharon Freeman, LTC, MC

Facility: FAMC

Dept/Svc: PED/Adolescent Med.  
Associate Investigators  
MAJ Miller, MD  
LTC Dorsett, MD  
Michael G. Schaffrinna, CPT, MC

Key Words:  
migraine headaches  
verapamil

Accumulative MEDCASE:*  
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: 6/90  
b. Review Results: Terminated  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: Determine efficacy of prophylactic verapamil in a double blinded study in adolescent migraine sufferers. At the same time this study would establish a per kilogram dose for younger adolescents.

Technical Approach: Patients will be evaluated at entry for the diagnosis of migraine headaches with a frequency per history of at least two events per month. Presence of organic disease will be evaluated via physical and laboratory evaluation. If no contraindications to verapamil exist then enrollment will occur. Over the next two months no medications will be given. The patient will see two different neurologists who will again evaluate them and fill out an interval history sheet. If both concur with the diagnosis, the patient will be randomly assigned by the pediatric pharmacy to receive either verapamil or placebo for two months. The patient will be seen every month for evaluation of therapy. At the end of two months, they will have a 7 day washout period. Then they will take the counterpart placebo or verapamil depending on which they were initially assigned. They will again take the drug for two months at which time the study will be completed.

Progress: No progress was made due to inability to obtain the placebo. No publications or presentations.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/400  (3) Status: Ongoing

(4) Title: T Cell#3 Protocol - A Pediatric Oncology Group Phase III Study

POG 8704

(5) Start Date: Dec 1987  (6) Est Compl Date: 1990

(7) Principal Investigator: Askold D. Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics  (10) Associate Investigators

B. Vishnu Reddy, LTC, MC
Randal Henderson, MAJ, MC
John M. Bodliien, CPT, MS

(11) Key Words:
T cell ALL

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:
 b. Review Results:
 c. Number of Subjects Enrolled During Reporting Period:
 d. Total Number of Subjects Enrolled to Date: 1
 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: The one patient entered at FAMC (MP) is an eight-year-old girl who presented with an extremely high white count at diagnosis (852,000) and was found to have T-cell ALL. The patient responded well to initial leukopheresis and chemotherapy according to protocol. She relapsed 8 months from diagnosis and died. Toxicity has been the expected severe myelosuppression. The study remains open for new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/401  (3) Status: Completed

(4) Title: Stage D NBL #3: Treatment of Stage D Neuroblastoma in Children > 365 Days at Diagnosis

POG 8741/42

(5) Start Date: Dec 1987  (6) Est Compl Date: 1990

(7) Principal Investigator: Askold D. Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators

B. Vishnu Reddy, LTC, MC
Randal Henderson, MAJ, MC
John M. Bodlien, CPT, MS
Jeffrey R. Clark, COL, MC

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: No patients have been entered at FAMC on this study. The study is closed to new patient entry.

Publications and Presentations: None

365
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/402  (3) Status: Ongoing
(4) Title: The Effectiveness of Phase II Agents in Untreated Metastatic Osteosarcoma (MOS) or Unresectable Primary Osteosarcoma vs Previously Treated Recurrent Osteosarcoma POG 8759
(5) Start Date: Dec 1987  (6) Est Compl Date: 1990
(7) Principal Investigator: Askold D. Mosijczuk, COL, MC
(8) Facility: FAMC
(9) Dept/Svc: Pediatrics
(10) Associate Investigators
B. Vishnu Reddy, LTC, MC
David Hahn, LTC, MC
John M. Bodlien, CPT, MS
Jeffrey R. Clark, COL, MC
(11) Key Words: phase II agents in untreated or recurrent osteosarcoma
(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.
(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".
(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.
(16) Technical Approach: See protocol
(17) Progress: No patients have been entered at FAMC on this study. The study remains open for patient entry.

Publications and Presentations: None
(1) Date: 30 Sep 90  
(2) Protocol #: 88/403  
(3) Status: Completed

(4) Title: Evaluation of Response and Toxicity of Ifosfamide and VP-16-213 in Children with Resistant Malignant Tumors POG 8763

(5) Start Date: Dec 1987  
(6) Est Compl Date: 1990

(7) Principal Investigator:  
Askold D. Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics  
(10) Associate Investigators  
John M. Bodlien, CPT, MS

(11) Key Words:  
ifosfamide  
VP-16

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period: 2  
d. Total Number of Subjects Enrolled to Date: 3  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". ONE PATIENT WAS STARTED ON TREATMENT ACCORDING TO PROTOCOL ON A COMPASSIONATE BASIS FROM THE NCI. HE IS NOT OFFICIALLY ENTERED ON PROTOCOL.

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: Three patients have been entered at FAMC on this study. Patient (PA) has had progressive tumors and died. Patient (DS) had recurrent osteosarcoma and showed no response on this study and died. Patient (NO) with recurrent metastatic hepatoblastoma, developed sudden coma after only one dose of Ifosfamide. This was due to a silent cerebral metastasis. Patient recovered and was taken off study. Study recently closed to new patient entry.

Publications and Presentations: None
Title: Ceftriaxone vs Amoxicillin/Clavulanate for Initial Empirical Therapy of Occult Bacteremia in Children

Start Date: 1989  Est Compl Date: 1991

Principal Investigator: Frederic W. Bruhn, COL, MC

Dept/Svc: Pediatrics

Key Words: bacteremia Ceftriaxone Clavulanate

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: To determine if one of the antibiotic regimens used for the emperic therapy of occult bacteremia will be more effective in preventing serious complications.

Technical Approach: See protocol.

Progress: Patient enrollment ongoing, 180 nationwide/2 at FAMC; preliminary data shows both therapies effective.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/405A  (3) Status: Ongoing

(4) Title: Macromolecular Absorption in the Post-Asphyxiated Small Intestine of the Adult Rat

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Kevin J. Kelly, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics  (10) Associate Investigators

(11) Key Words: macromolecular absorption asphyxial injury

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date: 48
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: This protocol will attempt to demonstrate the mechanism of movement of whole protein macromolecules through small intestinal absorptive cells which have been subjected to an asphyxial injury, as compared to controls.

(16) Technical Approach: No new experimental techniques have been introduced. The animals are still anesthetized and subjected to laparotomy, as previously approved. The intestinal sacs constructed post-removal are now subjected to a new experimental variable. They are being incubated in the same nutrient media as previously described with the addition of a metabolic inhibitor 2.4 dinitrophenol. This will attempt to determine active vs. passive transport.

369
Progress: To date, 48 animals have been used to expand the N values of both the control and experimental groups. To date, we have data on 16 gut sacs per group. It is very apparent that the experimental groups transport whole protein at a rate three times greater than the control groups. In addition, the metabolic inhibitor experiments preliminarily demonstrate total cessation of transport in both the experimental and control groups suggesting an active transport mechanism in both. These findings need to be confirmed in a larger sample of control and experimental animals as well as by light and electron microscopic evaluation. Once these experiments are completed, the gut sacs need to be then incubated from rats that have been pre-treated with therapeutic doses of theophylline. The sacs will then be exposed to the non-absorbable carbohydrate lactulose. No new data for FY 90.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/408A  (3) Status: Ongoing

(4) Title: The Effect of Human/Animal Interaction on Stress Levels During Outpatient Pediatric Oncology Visits

(5) Start Date:

(6) Est Compl Date: 1992

(7) Principal Investigator:
Mary Woolverton, MSW
Terri R. Clark, CPT, VC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators
Askold Mosijczuk, COL, MC

(11) Key Words:
animal interaction
stress reduction

(12) Accumulative MEDCASE:* *Refer to Unit Summary Sheet of this Report.

(13) Est Accum OMA Cost:*

(14) a. Date, Latest IRC Review: 5/90  b. Review Results: Ongoing
   c. Number of Subjects Enrolled During Reporting Period:
   d. Total Number of Subjects Enrolled to Date: 12
   e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: a. Does the presence and interaction with animals during outpatient treatment visits have any measurable effect on the patient's stress level as measured by blood pressure and fingertip temperature; b. Does the presence and interaction with animals during outpatient treatment visits have any measurable effect on the patient's anxiety level (as measured by behavioral questionnaires) or discomfort as measured by the visual analog pain scale).

(16) Technical Approach: Blood pressure, temperature and questionnaire will be used to evaluate stress levels in study subject.

(17) Progress: A total of 12 patients have been entered into the study. Due to investigators' time constraints we have not been able to gather data as projected. Hope is to start enrolling patients in fall of 1990.

Publications and Presentations: None

371
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 88/409 (3) Status: Terminated

(4) Title: The Correlation of Perinatal Events with Neonatal Morbidity: A Scoring System

(5) Start Date: Oct 88 (6) Est Compl Date: Oct 90

(7) Principal Investigator: Brian S. Carter, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: PED/Neonatal

(10) Associate Investigators: C. Gilbert Frank, LTC, MC

(11) Key Words:
    neonatal morbidity
    scoring system

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period: 200
    d. Total Number of Subjects Enrolled to Date: 3000
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To test the hypothesis that the combination of 3 commonly used means of fetal and neonatal assessment (fetal heart-rate tracings, umbilical arterial base deficit, and the 5 min. Apgar score) when combined in a scoring system can allow for the prediction of neonatal morbidity in the first 28 days of life.

(16) Technical Approach: A prospective, observational study. Enrollment is by chart review on all near-term (> 36 weeks gest.) newborns that had umbilical cord blood drawn in the delivery room, and were monitored in utero. Scores are assigned and the clinical courses observed for outcome.

(17) Progress: Due to lack of interest the protocol became inactive in December 1989. As the Labor & Delivery service at FAMC experienced a decline in the number of births of prospective eligible study patients since the initiation of the protocol an alternate Labor & Delivery service was identified and is currently being studied.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 89/400  Status: Ongoing

Title: Protocol for Second Induction and Maintenance in Childhood Acute Lymphoblastic Leukemia (SIMAL #5)

POG 8710

Principal Investigator: Askold Mosijczuk, COL, MC

Facility: FAMC

Dept/Svc: PEDS/Hemo/Oncol

Associate Investigators:
Dr. Reddy
Dr. Bodliien

Key Words: Dr. Bodliien

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: 
 b. Review Results: 
 c. Number of Subjects Enrolled During Reporting Period: 
 d. Total Number of Subjects Enrolled to Date: 
 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

Technical Approach: See protocol

Progress: No patients have been entered at FAMC.

Publications and Presentations: None
Date: 30 Sep 90 (2) Protocol #: 89/401A (3) Status: Ongoing

Title: An Observational Study on the Response of Children to the Presence of a Stuffed Animal VS a Live Animal During a Neuromuscular Exam

Start Date: 1988 (6) Est Compl Date: 1990

Principal Investigator: Mary Woolverton, MSW
Terri R. Clark, CPT, VC

Dept/Svc: PEDS/EFMP

Facility: FAMC

Associate Investigators:
David Hahn, LTC, MC

Key Words:
animal interaction
stress reduction

Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:

b. Review Results:

c. Number of Subjects Enrolled During Reporting Period: 10

d. Total Number of Subjects Enrolled to Date: 36

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: By introducing an interaction with an animal we may be able to decrease anxiety and lessen the apprehension associated with potentially uncomfortable hospital visits.

Technical Approach: See protocol

Progress: Children seen in neuromuscular clinic are introduced first to a large white stuffed rabbit and later a dog/or cat to see how it effects their stress level during their physical exam in the clinic. This is documented on films and by independent observation. A total of 26 patients have been observed. This study is being actively pursued with more patients enrolled each month as they qualify by age and mental capacity. Children who have been to the clinic and around the animals now ask for them as soon as they come in.

Publications and Presentations: 3 presentations.
(1) Date: 30 Sep 90  (2) Protocol #: 89/402  (3) Status: Completed

(4) Title: Newborn Informed Consent Study

(5) Start Date: 1989  (6) Est Compl Date: 1991

(7) Principal Investigator: C. Gilbert Frank, LTC, MC
(8) Facility: FAMC

(9) Dept/Svc: PEDS/Newborn Svc
(10) Associate Investigators:
     Brian Carter, CPT, MC
     Patti Paige, MAJ, AN

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:
    b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Evaluation of parental understanding of procedures and counseling performed following admission of their infant to the Newborn Intensive Care Unit.

(16) Technical Approach: Interview technique by single investigator with correlation of interview information with the medical record.

(17) Progress: Patient enrollment and parent interviews are complete. Data accumulation phase complete. Anticipate interpretation to begin in the summer of 1990.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 89/403A  Status: Ongoing

Title: Effect of Inflammation in Chronic Pneumonia in Rats Due to Pseudomonas Aeruginosa—Medication by Bacterial Exoproducts

Start Date:  Est Compl Date:

Principal Investigator: LeRoy M. Graham, MAJ, MC

Facility: FAMC

Dept/Svc: PEDS/Pulmonary

Associate Investigators:
- Michael L. Vasil, PhD
- Norbert F. Voelkel, MD
- Kurt R. Stenmark, MD

Key Words: pneumonia pseudomonas aeruginosa rats

Accumulative MEDCASE:*  Est Accum OMA Cost:* 
*Refer to Unit Summary Sheet of this Report

Study Objective: To establish an animal model for cystic fibrosis using rats.

Technical Approach: See protocol

Progress: Equipment being manufactured/purchased. Clinical duties have precluded work on this project to date. It is anticipated work may begin in the next 6 months.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90   (2) Protocol #: 89/404   (3) Status: Ongoing

(4) Title: Randomized Study of Intensive Chemotherapy (MOPP/ABVD) + or - Low Dose Total Nodal Radiation Therapy in the Treatment of Stages IIB, IIIA-2, IIIB, IV Hodgkin's Disease in Pediatric Patients

POG 8725

(5) Start Date:  

(6) Est Compl Date:  

(7) Principal Investigator: Askold Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: PEDS/Hemo/Oncol

(10) Associate Investigators:
    Dr. Reddy
    Dr. Clark
    Dr. Henderson
    Dr. Bodlien

(11) Key Words: Dr. Clark  Dr. Henderson  Dr. Bodlien

(12) Accumulative MEDCASE:*  

(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  
    b. Review Results:  
    c. Number of Subjects Enrolled During Reporting Period:  
    d. Total Number of Subjects Enrolled to Date:  
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: No patients have been entered at FAMC.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/405  (3) Status: Ongoing

(4) Title: Clonidine Treatment of Constitutional Delay of Growth and Puberty--A Prospective Double Blind Study

(5) Start Date: Sep 89  (6) Est Compl Date: Mar 92

(7) Principal Investigator: Robert Slover, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: PEDS/Adol Med

(10) Associate Investigators:
    Linda Brantner, CPT, MC
    Linda Ikle, PhD

(11) Key Words:
    growth delay
    clonidine

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: _5/90_  b. Review Results:_Ongoing_
    c. Number of Subjects Enrolled During Reporting Period:_
    d. Total Number of Subjects Enrolled to Date:_
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine whether chronic oral clonidine therapy is effective when compared to placebo in accelerating linear growth in constitutionally delayed pre-pubertal pediatric and adolescent patients.


(17) Progress: Dr. Brantner who originally submitted the protocol has moved to Tyler AMC. I plan to start enrolling patients.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/406  (3) Status: Completed

(4) Title: A Phase I Study of Hyperfractionation Radiation in Brain Stem Glioma in Children

POG 8495

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
   Askold Mosijczuk, COL, MC

(9) Dept/Svc: PEDS\Hema/Oncol  (10) Associate Investigators:
    Dr. Carter

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: ________ b. Review Results: ________
    c. Number of Subjects Enrolled During Reporting Period: ________
    d. Total Number of Subjects Enrolled to Date: ________ 3
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in the POG protocol in the study of pediatric malignancies.

(16) Technical Approach: See protocol

(17) Progress: Three patients have been entered at FAMC. 2 patients with classic signs of high grade pontine glioma responded initially but subsequently relapsed. Another patient with symptoms consistent with low grade pontine glioma continues to do well two years after completing radiation treatment. Study is closed for new patient entry.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/407  (3) Status: Ongoing

(4) Title: Baby Development Follow-up Network Project

(5) Start Date:  (6) Est Compl Date: Dec 90

(7) Principal Investigator: Beverly A. Anderson, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: PEDS/Newborn

(10) Associate Investigators:
    Majorie Feinberg EFMP
    C. Gilbert Frank, MD

(11) Key Words: developmental evaluation
     high risk infants

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date: 7
    e. Note any adverse drug reactions reported to the FDA or sponsor for
       studies conducted under an FDA-awarded IND. May be continued on a
       separate sheet, and designated as "(14)e"

(15) Study Objective: Developmental evaluation of all infants with
    birth weight of 1,000 to 1,500 grams who are Colorado residents.

(16) Technical Approach: The examinations will be done at 36-40 weeks
    post-conceptual age and eight months corrected age by physical or
    occupational therapists with at least one year experience in the Newborn
    Nursery who have been given special training sessions for this project.

(17) Progress: The infants enrolled in the followup study have
    continued to receive both medical and developmental evaluations
    routinely and per protocol. The occupational/physical therapists have
    been allowed to utilize current testing materials in a controlled manner
    and the communication between health care givers and the families of
    this high risk population has been optimized.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 89/408  Status: Ongoing

Title: Comparison of Cotinine Hair and Saliva Analysis in the Determination of Passive and Active Cigarette Smoking Exposure in Adolescents

Start Date: Oct 89  Est Compl Date: 6/91

Principal Investigator: Neil Goodman, CPT, MC

Facility: FAMC

Dept/Svc: Pediatrics

Associate Investigators:
Joseph White, MAJ, MS
Ian Stewart, M.S.

Key Words: cigarette smoke exposure  passive smoking

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Study Objective: To determine if commercially available EIA techniques for detecting cotinine correlate with historical survey to determine if the values accurately reflect the smoking history.

Technical Approach: Small amounts of hair and saliva will obtained for EIA assay of cotinine from an adolescent population. A self-administered questionnaire detailing history of passive and active smoking over the preceding 3 months will also be given.

Progress: Assay method for cotinine in hair has been developed and is extremely sensitive and reliable. This is the first such assay that will allow cotinine measurement from hair via a monoclonal antibody technique. Subject sampling will begin in Aug 90. Initial publication of assay technique is being sought at this time.

Publications and Presentations: None at present time.
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

1. **Date:** 30 Sep 90  
2. **Protocol #:** 90/400  
3. **Status:** Terminated

4. **Title:** A Treatment IND for Retrovir Brand Zidovudine (AZT) Therapy of Pediatric Patients with HIV Disease (TX 304-IND-33,760)

5. **Start Date:** 1990  
6. **Est Compl Date:**

7. **Principal Investigator:** Shannon M. Harrison, LTC, MC

8. **Facility:** FAMC

9. **Dept/Svc:** DCI/PEDS

10. **Associate Investigators:**

11. **Key Words:**

12. **Accumulative MEDCASE:**

13. **Est Accum OMA Cost:**

*Refer to Unit Summary Sheet of this Report*

14. a. **Date, Latest IRC Review:**

   b. **Review Results:**

   c. **Number of Subjects Enrolled During Reporting Period:**

   d. **Total Number of Subjects Enrolled to Date:**

   e. **Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

15. **Study Objective:**

16. **Technical Approach:**

17. **Progress:** This protocol was cancelled.

**Publications and Presentations:**

382
Date: 30 Sep 90  Protocol #: 90/401  Status: Ongoing

Title: Experience with Multiple Doses of Survanta in Premature Infants

Start Date: 1990  Est Compl Date: Indefinite

Principal Investigator: John Kinsella, MAJ, MC

Facility: FAMC

Dept/Svc: Neonatal/PEDS

Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: Treatment IND; surfactant therapy for premature infants with hyaline membrane disease.

Technical Approach: Surfactant is instilled through the endotracheal tube; up to four doses may be given as indicated by respiratory status.

Progress: No progress.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/402A  Status: Ongoing

Title: Training for Pediatricians in Emergency Procedures

Start Date: 1990  Est Compl Date: Indefinite

Principal Investigator: John Kinsella, MAJ, MC

Facility: FAMC

Dept/Svc: Neonatal/PEDS

Associate Investigators:

Key Words:

Accumulative MEDCASE:  Est Accum OMA Cost:

*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:

Total Number of Subjects Enrolled to Date:

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded TNID. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To train pediatricians in invasive emergency procedures.

Technical Approach: Goat, swine, and rabbits are to be used for training in intubation, femoral venous and arterial cutdown procedures, thoracostomy tube placement, and percutaneous jugular venous catheter placement.

Progress: First training course is to be scheduled for Fall 1990.

Publications and Presentations: None

384
Date: 30 Sep 90  Protocol #: 90/403A  Status: Ongoing

Title: Studies of the Hemodynamic Consequences of Partial Cardiopulmonary Bypass in the Lamb

Start Date: 1990  Est Compl Date:

Principal Investigator: John Kinsella, MAJ, MC

Facility: FAMC

Dept/Svc: Neonatal/PEDS  Associate Investigators: Adam A Rosenberg, MD

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To study the distribution of blood flow during partial cardiopulmonary bypass in lambs.

Technical Approach: Blood flow will be measured using microspheres during control period and at two levels of cardiopulmonary bypass (50 and 100 ml/kg/min).

Progress: This protocol is scheduled for funding in FY 91.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/404  Status: Completed

Title: Revision of Bayley Scales of Infant Development

Start Date: 1990  Est Compl Date:

Principal Investigator: Linda Ikle, Ph.D.

Facility: FAMC

Dept/Svc: Excep. Fam. Mbr/PEDS

Associate Investigators:

Key Words: bayley scales human infants

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 60
d. Total Number of Subjects Enrolled to Date: 60
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: The primary objective of this study is to assist the psychological corporation in the restandardization of the bayley scales of infant development by providing critical feedback of the tryout version of the revised instrument and by providing approximately 50 subjects whose data will contribute to the development of the revised version of the scale.

Technical Approach: See protocol.

Progress: We have completed the protocol on the subjects whom we arranged to do for the psychological corporation. All data has been mailed in. Payments for subjects will probably all be disbursed by the end of September by T.P.C. Our portion of this nationwide study is complete. We are considering being involved in the standardization trials next year.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/405  (3) Status: Ongoing

(4) Title: Followup of the NICU Graduate in Military Medical Facilities

(5) Start Date: 1990  (6) Est Compl Date: 1991

(7) Principal Investigator: Beverly Anderson, MAJ, MC

(8) Facility: FAMC

(9) Dept/Svc: Newborn/PEDS

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: 
 c. Number of Subjects Enrolled During Reporting Period: 123
 d. Total Number of Subjects Enrolled to Date: 123
 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Surveillance of NICU graduates in military medical facilities.

(16) Technical Approach: Information retrieved through questionnaire sent to every military facility serving a pediatric population.

(17) Progress: Information from questionnaire is currently being assessed.

Publications and Presentations: None
(4) Title: POG 8788 Intergroup Rhabdomyosarcoma Study IV: A Pilot Study for Clinical Group III Disease

(7) Principal Investigator: Askold Mosijczuk, COL, MC

(9) Dept/Svc: PEDS

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90    (2) Protocol #: 90/407    (3) Status: Ongoing

(4) Title: POG 8821 AML#3: Intensive Multiagent Therapy vs Autologous Bone Marrow Transplant Early in 1st CR for Children with Acute Myelocytic Leukemia

(5) Start Date:    (6) Est Compl Date:

(7) Principal Investigator: Askold Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics    (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*    (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:    b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 90/408  (3) Status: Ongoing

(4) Title: POG 8823/24 Recombinant Alpha Interferon in Childhood Chronic Myelogenous Leukemia

(5) Start Date:  

(6) Est Compl Date:  

(7) Principal Investigator: Askold Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/409  Status: Ongoing

Title: POG 8827 Treatment of Children with Hodgkin's Disease in Relapse - Phase I

Start Date:  Est Compl Date:

Principal Investigator: Askold Mosijczuk, COL, MC
Facility: FAMC

Dept/Svc: Pediatrics

Associate Investigators:

Key Words:

Accumulative MEDCASE:  Est Accum OMA Cost:  
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:  
Number of Subjects Enrolled During Reporting Period:  
Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective:  To participate in POG.

Technical Approach:  To determine the most effective cancer treatment.

Progress:  Open to patient accrual, no patients entered at FAMC.

Publications and Presentations:  None
(1) Date: 30 Sep 90 (2) Protocol #: 90/410 (3) Status: Ongoing

(4) Title: POG 8829 A Protocol for a Case-Control Study of Hodgkin's Disease in Childhood: A Non-Therapeutic Study

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: (8) Facility: FAMC
Askold Mosijczuk, COL, MC

(9) Dept/Svc: Pediatrics (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/411  Status: Ongoing

Title: POG 8832 Pre-XRT Cisplatin and Ara-C for Children with Imcompletely Resected Supratentorial Malignant Brain Tumors

Start Date:  Est Compl Date:

Principal Investigator: Askold Mosijczuk, COL, MC

Facility: FAMC

Dept/Svc: Pediatrics  Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:  Total Number of Subjects Enrolled to Date:

Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in POG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None
**Date:** 30 Sep 90  
**(2)** Protocol #: 90/412  
**(3)** Status: Ongoing  

**(4)** Title: **POG 8850 Evaluation of Vincristine, Adriamycin, Cyclophosphamide, and Dactinomycin with or without the Addition of Ifosfamide and Etoposide in the Treatment of Patients with Newly Diagnosed Ewing's Sarcoma or Primitive Neuroectodermal Tumor of Bone**  

**(5)** Start Date:  
**(6)** Est Compl Date:  

**(7)** Principal Investigator:  
Askold Mosijczuk, COL, MC  

**(8)** Facility: FAMC  

**(9)** Dept/Svc: Pediatrics  

**(10)** Associate Investigators:  

**(11)** Key Words:  

**(12)** Accumulative MEDCASE:*  
**(13)** Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report  

**(14)** a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"  

**(15)** Study Objective: To participate in POG.  

**(16)** Technical Approach: To determine the most effective cancer treatment.  

**(17)** Progress: Open to patient accrual, no patients enrolled at FAMC.  

Publications and Presentations: None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 amended)**

(1) Date: 30 Sep 90  
(2) Protocol #: 90/413  
(3) Status: Ongoing

(4) Title: POG 8889 Intergroup Rhabdomyosarcoma Study-IV Pilot Study for Clinical Group IV Disease

(5) Start Date:  
(6) Est Compl Date:

(7) Principal Investigator:  
Askold Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Pediatrics  
(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  
(13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  
b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, no patients enrolled at FAMC.  
Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 90/414  Status: Ongoing

Title: POG 8828 Late Effects of Treatment of Hodgkin's Disease: A Pediatric Oncology Group Non-Therapeutic Study

Start Date:  Est Compl Date:  

Principal Investigator: Askold Mosijczuk, COL, MC  Facility: FAMC

Dept/Svc: Pediatrics  Associate Investigators:  

Key Words:  

Accumulative MEDCASE:*  Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report  

a. Date, Latest IRC Review:  b. Review Results:  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date:  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To participate in POG.

Technical Approach: To determine the most effective cancer treatment.

Progress: Open to patient accrual, no patients enrolled at FAMC.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 90/415  (3) Status: Ongoing

(4) Title: POG 8650 National Wilms' Tumor Study - 4 (NWTS-4), A Pediatric Hematology-Oncology Group Phase III Study

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Askold Mosijczuk, COL, MC

(8) Facility:  FAMC

(9) Dept/Svc: Pediatrics  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To participate in POG.

(16) Technical Approach: To determine the most effective cancer treatment.

(17) Progress: Open to patient accrual, one patient enrolled at FAMC.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/450  (3) Status: Completed

(4) Title: Evaluation of the Available Plasma Separator Tubes for Storage of Patient Specimens

(5) Start Date: 1989  (6) Est Compl Date:

(7) Principal Investigator: Alan F. Weir, CPT, MS

(8) Facility: FAMC

(9) Dept/Svc: Pathology  (10) Associate Investigators: Margaret Zakroff, MT

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the difference between the current method and the newer serum separator tubes and the length of time serum can be stored using the new serum separator tubes.

(16) Technical Approach: See protocol.

(17) Progress: Data has been collected and is being evaluated. Manuscript will be submitted upon completion of evaluation of data.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 80/602  (3) Status: Ongoing

(4) Title: I.V. Administration of 131-I-6-B Iodomethyl norcholesterol (NP-59) for Adrenal Evaluation and Imaging

(5) Start Date: 1980  (6) Est Compl Date: Indefinite

(7) Principal Investigator: Peter W. Blue, COL, MC

(8) Facility: FAMC

(9) Dept of Radiology/Nuc.Med.  (10) Associate Investigators

(11) Key Words:
adosterone
adrenal glands

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review: Sep 89  b. Review Results: Ongoing
    c. Number of Subjects Enrolled During Reporting Period: 1
    d. Total Number of Subjects Enrolled to Date: 31
    e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: Clinical evaluation of NP-59 as a diagnostic agent for the detection of adrenal cortical disorders and as a potential scanning agent for detecting structural abnormalities of the adrenal medulla.

(16) Technical Approach: Each patient will be studied while taking Lugol's or SSKI to protect thyroid. Some patients will have adrenal function suppressed with Dexamethasone. Following a 2 millicurie dose of NP-59, each patient will be scanned at day 3 and possibly day 5 and 7.

(17) Progress: No studies were performed this period. One negative study performed.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 88/600  Status: Terminated

Title:  a. The Usefulness of MRI and Transrectal Ultrasound in the Staging of Prostatic Cancer: Comparison to 1mm Whole Gland Mounts.  b. Artifacts and Variants of the Normal Prostate Seen by MRI and Transrectal Ultrasound: Comparison to 1mm Whole Gland Mounts

Start Date: 1988  Est Compl Date: 1989

Principal Investigator:  Kenneth D. Hopper, MAJ, MC  Daniel Horne, LTC, MC  David Thickman, MD  Gary Miller, MD  Gail Weingast, MD  Michael Manco-Johnson, MD

Facility:  FAMC  UCHSC  UCHSC  UCHSC  UCHSC

Dept of Radiology  Associate Investigators

Key Words:

Edward Pienkos, LTC, MC  Steve Parker, MAJ, MC  Merlyn Gibson, MAJ, MC  Jerry Sims, LTC, MC

Accumulative MEDCASE:*  Est Accum OMA Cost:*

a. Date, Latest IRC Review:  b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 42

e. Note any adverse drug reactions reported to the FDA or sponsor for studying under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

Study Objective: Within the past two years, the usefulness of transrectal ultrasound and MRI in the diagnosis and staging of prostatic cancer has been well demonstrated. There are numerous artifacts and variants within the prostate as seen with these two modalities, however, which are poorly understood. In addition, no study evaluating the efficacy of transrectal ultrasound and MRI in prostate cancer has compared the radiographic findings with histological mounts of the entire gland. We intend to correlate the results of the MRI and transrectal ultrasound to 1mm whole gland mounts in order to better understand the aforementioned artifacts/variants as well as tumor extension.

Technical Approach: See original protocol.
(17) Progress: Terminated due to PCS of principal investigators and budget exhaustion.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 88/601  Status: Ongoing

Title: Body Fat Determination by Dual Photon Absorptiometry

Start Date: 1988  Est Compl Date: Indefinite

Principal Investigator: Peter W. Blue, COL, MC

Dept of Radiology/Nuc.Med.  Associate Investigators

Key Words:
  absorptiometry
  body fat

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

a. Date, Latest IRC Review: 89  b. Review Results: Ongoing
   c. Number of Subjects Enrolled During Reporting Period:
   d. Total Number of Subjects Enrolled to Date: approx.
   e. Note any adverse drug reactions reported to the FDA or sponsor for
      studying under an FDA-awarded IND. May be continued on a separate
      sheet, and designated as "(14)e".

Study Objective: To evaluate body fat composition by absorptiometry
   and other current modalities.

Technical Approach: Each patient will be studied by four methods
   and the methods compared.

Progress: No progress. To date funding is not available.

Publications and Presentations: None
**Study Objective:** The intent of the study is to objectively compare the renal serum clearance of each of the agents in the most optimally controlled environment possible, the individual patient. In this manner, the claims of the manufacturer can be established or refuted and the best agent determined.

**Technical Approach:** The subjects will be categorized into normal (total serum bilirubin of less than 2.0), and four groups of abnormal (greater than 2.0, 5.0, 10.0 and 20.0). Each patient will then be given the minimal suggested dose (4 millicures to 10 millicuries) and renal and hepatic clearances will be calculated. Hepatobiliary scans will also be performed on the patients with each agent. The abnormal group with bilirubins greater than 20 will receive the mebrofenin first followed by the disofenin to assess for competitive binding interference.

**Progress:** Projects has not started yet, no patients have been tested.

**Publications and Presentations:** None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 89/602 (3) Status: Ongoing

(4) Title: The Utility of the Bard "Biopty" Gun in the Breast: Correlation with Surgical Excisional Specimens

(5) Start Date: 1988 (6) Est Compl Date: 1990

(7) Principal Investigator: James Leuthke, CPT, MC

(8) Facility: FAMC

(9) Dept/Svc: Radiology

(10) Associate Investigators: Steve H. Parker, MAJ, MC

(11) Key Words: Jeffrey Lovin, CPT, MC

breast biopsy

Wayne Yakes, MAJ, MC

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: 105 e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To ascertain the accuracy of breast biopsies performed with the Bard "Biopty" biopsy gun utilizing stereotaxic mammographic and ultrasonographic guidance.

(16) Technical Approach: As outlined in objective.

(17) Progress: Results indicate that Bard "biopty" gun produces specimens as good as surgical biopsy.

Publications and Presentations: Abstract to be presented at the Radiological Society of North America 75th Annual Meeting, 26 Nov-1 Dec 89, Chicago, IL, and to be published in Radiology.
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(1)</td>
<td>Date: 30 Sep 90</td>
</tr>
<tr>
<td>(2)</td>
<td>Protocol #: 80/650</td>
</tr>
<tr>
<td>(3)</td>
<td>Status: Ongoing</td>
</tr>
<tr>
<td>(4)</td>
<td>Title: A Study of Hemoglobin and of Red Cell Metabolism in the American Opossum (Didelphis virginiana)</td>
</tr>
<tr>
<td>(5)</td>
<td>Start Date: 1980</td>
</tr>
<tr>
<td>(6)</td>
<td>Est Compl Date: Indefinite</td>
</tr>
<tr>
<td>(7)</td>
<td>Principal Investigator: Nicholas C. Bethlenfalvay, MD</td>
</tr>
<tr>
<td>(8)</td>
<td>Facility: FAMC</td>
</tr>
<tr>
<td>(9)</td>
<td>Dept/Svc: Primary Care</td>
</tr>
<tr>
<td>(10)</td>
<td>Associate Investigators: J.E. Lima</td>
</tr>
<tr>
<td>(11)</td>
<td>Key Words: opossums marsupial erythrocytes purine metabolism</td>
</tr>
<tr>
<td>(12)</td>
<td>Accumulative MEDCASE:*</td>
</tr>
<tr>
<td>(13)</td>
<td>Est Accum OMA Cost:*</td>
</tr>
</tbody>
</table>

*Refer to Unit Summary Sheet of this Report

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>(14)</td>
<td>a. Date, Latest IRC Review:</td>
</tr>
<tr>
<td></td>
<td>b. Review Results:</td>
</tr>
<tr>
<td></td>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
</tr>
<tr>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td></td>
</tr>
</tbody>
</table>
| e. | Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

| (15) | Study Objective: An inquiry into the energy metabolism of opossum erythrocytes (glucose, purines and pyrimidines) and factors involved which maintain cell viability and function. |
| (16) | Technical Approach: Radiolabelled purine and pyrimidinenucleosides, bases and glucose are provided to red cells in-vitro and synthetic/catabolic pathways are determined with the aid of HPLC/radiochromatography. |
| (17) | Progress: Study results to date: In contrast to human red cells, opossum RBC effectively salvage hypoxanthine for the production of ATP and GTP (J. Cell Physiol. 1990). Formate and AICA are also incorporated into ATP and GTP indicating that the last steps of de-novo nucleotide synthesis is active in these cells (Comp. Biochem. Physiol., 1990). |
Progress - continued

The amounts of NAD are directly proportional to intra cellular ATP concentrations in opossum red cells. In the presence of glutamine, both nicotinic acid and nicotinamide are substrates for the synthesis of NAD, indicating the presence of nicotinamide deamidase in these cells. This enzyme is not active in human red cells under physiologic conditions.

Collaborative Efforts:

1. Division of Clinical Pharmacology, Department of Medicine, Brown University, Providence, RI - Isoenzymes of adenosine deaminase (40,000 and 100,000 Dalton species) were isolated from red cells, plasma, spleen and liver of D. virginiana. Their activities in these tissues, and their kinetic constants (Km and Vmax) to adenosine and deoxyadenosine were determined. A paper is in preparation for publication.

2. Department of Biology, Federal University of Santa Catarina, Florianopolis, Brasil - Purine nucleotide patterns of red cells of D. marsupialis and of D. albiventris have been determined. D. marsupialis, from which D. virginiana has evolved, does not have detectable deoxy ATP in its erythrocytes suggesting interesting genetic and evolutionary possibilities. A paper is in preparation for publication.

3. Department of Pharmacology, University of Columbia-Missouri, Columbia, MO - Cation transport in red cells of D. virginiana containing ATP/dATP, or dATP alone is being investigated. Membrane Na, K, Mg and Ca ATPase(s) are also being investigated using ATP and dATP as substrates.

4. Department of Physiology, University of New England, Armidale, Australia - A study of red cell nucleotide patterns and cation ATPase(s) of small Australian marsupialia is intended to commence in the Spring of 1991.

Abstracts of two papers will be submitted for consideration for presentation at the 7th International Symposium on Purine and Pyrimidine Metabolism in Man, Bournemouth, England, July 1991.

Publications:


Presentations: None
Date: 30 Sep 90  Protocol #: 87/650  Status: Terminated

Title: Clonal Fidelity of Erythroid Lineage in Dyserythropoiesis: An Inquiry Into Ultrastructure

Start Date: 1987  Est Compl Date: Indefinite

Principal Investigator: N.C. Bethlenfalvay, MD  V.V. Reddy, LTC, MC

Associate Investigators: C.F. Ferris, MAJ, MS  D.B. Mercill

Key Words: dyserythropoiesis  ultrastructure  x-ray microanalysis

Study Objective: To investigate the aspects of ultrastructural components of erythroid precursors to include elemental composition of these components for determination of their role on erythroid maturation, morphology, the process of erythroid denucleation, and functional differentiation in various dyserythropoietic states.

Technical Approach: Burst forming erythroid colonies will be grown in semi-solid tissue-culture media. Bursts will be isolated, fixed, embedded and evaluated by electron microscopy and concurrent x-ray microanalysis of metallic cellular inclusions.

Progress: Growth of erythroid colonies and of bursts was never achieved, project was therefore terminated.

Publications and Presentations: None
Date: 30 Sep 90  
Protocol #: 86/700A  
Status: Ongoing

Title: Introduction of Suturing Techniques Using Outbred Adult Rats

Start Date:  
Est Compl Date: Indefinite

Principal Investigator: LTC Debra J. Walker

Facility: FAMC  
Dept/Svc: Nursing

Key Words: suture techniques training

Accumulative MEDCASE:* 
Est Accum OMA Cost:*  
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: 11/89  
b. Review Results: Ongoing  
c. Number of Subjects Enrolled During Reporting Period:  
d. Total Number of Subjects Enrolled to Date: 17  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: To instruct selected department of nursing personnel to properly suture traumatic lacerations, to establish and maintain a sterile field during the suturing procedure, to cleanse traumatic lacerations, to instruct the patient to manage the wound and facilitate healing, and to correctly remove suture when healing is complete.

Technical Approach: Students are detailed to perform at least 1 successful suturing episode under direct supervision of an Emergency Medical Service staff physician to validate learning and clinical competence. Once certified, suturing activities become a part of the staff members' scopes of nursing practice. Skills are revalidated annually to ensure continued competence.

Progress: Seventeen department of nursing personnel have completed the protocol during reporting period. All have been subsequently certified to perform basic suturing techniques in the FAMC Emergency Medical Service. No clinical practice deficiencies have been observed/reported which would indicate a problem with the revised protocol.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/700  (3) Status: Completed

(4) Title: A Study of the Clinical Nurse Specialist in the AMEDD

5) Start Date: 1988  (6) Est Compl Date: 1989

(7) Principal Investigator: A.J. Frelin, COL, AN  (8) Facility: FAMC

(9) Dept/Svc: Nursing  (10) Associate Investigators
(11) Key Words: role development

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:  b. Review Results:  c. Number of Subjects Enrolled During Reporting Period:
    d. Total Number of Subjects Enrolled to Date:
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e".

(15) Study Objective: The purpose of this descriptive study is to explore the role of the clinical nurse specialist (CNS) as implemented by the ANC from the perspective of the CNSs now in practice as well as the Nurse Managers where the roles are or could be implemented. (a) to describe the role of the CNS in HSC from the perspective of the practicing CNSs; (b) to describe the role of the CNS in HSC as perceived by ANC officers who rate/senior rate them and by Chiefs of Nursing Departments; (c) to compare the perceptions of these groups regarding role implementation; (d) to describe a normative profile of the ANC officer practicing in the CNS role and (e) to assess potential for the future implementation of this specialty in the ANC.

(16) Technical Approach: Each group will be surveyed using a written mailed survey instrument constructed for this purpose. Data analysis will be directed to describing the role and the normative characteristics of those practicing in the role.

(17) Progress: Principal data collection and analysis has been completed.

Presentations: Presented: 6th Annual Research Conference sponsored by the VA Medical Center and University of Utah, 17 Feb 89.

Publications: Accepted for publication in CNS, Fall 1990.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/700  (3) Status: Ongoing

(4) Title: A Pilot Study: A Comparison of Subarachnoid Block Anesthesia with Tetracaine and Epidural Anesthesia with Lidocaine and the Effects on the Umbilical Artery Acid-Base Results and Five Minute Apgar Scores of Neonates Following Uncomplicated Cesarean Section

(5) Start Date: 1990  (6) Est Compl Date:

(7) Principal Investigator: William Gillis, CPT, AN

(8) Facility: FAMC

(9) Dept/Svc: Anesthesia/Nursing

(10) Associate Investigators:
    Arthur Brehn, CPT, An
    Arthur Bryson, CPT, An
    Jenifer Crawford, CPT, An
    John Wong, CPT, AN

(11) Key Words:
    subarachnoid block
    epidural anesthesia
    apgar scores
    cesarean section
    umbilical artery acid-base

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: 
    c. Number of Subjects Enrolled During Reporting Period: 20 
    d. Total Number of Subjects Enrolled to Date: 20 
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". None

(15) Study Objective: Via a process of random selection compare 2 groups of 10 patients, 1 group to receive subarachnoid block anesthetic the other an epidural anesthetic for cesarean section, and compare the 5 min. apgar scores and umbilical artery acid-base results from the infants of the two groups.

(16) Technical Approach: Refer to "6.c. Evaluations" of the protocol.

(17) Progress: We have recently completed our subject data gathering and are compiling the data in preparation for statistical analysis.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/701  (3) Status: Ongoing

(4) Title: Assessment of Post Myocardial Infarction Patients
           Learning Needs During Hospitalization and Post Discharge

(5) Start Date:  (6) Est Compl Date:  

(7) Principal Investigator:  (8) Facility:  FAMC
    Greg Cannon, ILT, AN

(9) Dept/Svc: NURSING  (10) Associate Investigators:  

(11) Key Words:  

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
     *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:________  b. Review Results:________
     c. Number of Subjects Enrolled During Reporting Period:________
     d. Total Number of Subjects Enrolled to Date:________
     e. Note any adverse drug reactions reported to the FDA or sponsor for
        studies conducted under an FDA-awarded IND. May be continued on a
        separate sheet, and designated as "(14)e"

(15) Study Objective: To determine the priority of learning needs of
       the cardiac patient.

(16) Technical Approach: Utilize questionnaire developed by Peggs S.
       Gerard, RN, MS.

(17) Progress: Performed study to satisfy requirements for graduation
       from coronary care nursing course.

Publications and Presentations: None
**FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)**

<table>
<thead>
<tr>
<th>(1) Date:</th>
<th>30 Sep 90</th>
<th>(2) Protocol #:</th>
<th>90/702</th>
<th>(3) Status:</th>
<th>Ongoing</th>
</tr>
</thead>
<tbody>
<tr>
<td>(4) Title:</td>
<td>The Impact of Practice at Fitzsimons Army Medical Center Upon Registered Nurses Professional Role Conception</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(5) Start Date:</td>
<td></td>
<td>(6) Est Compl Date:</td>
<td>1992</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(7) Principal Investigator:</td>
<td>A.J. Frelin, COL, AN</td>
<td>(8) Facility:</td>
<td>FAMC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(9) Dept/Svc:</td>
<td>Nursing</td>
<td>(10) Associate Investigators:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(11) Key Words:</td>
<td>registered nurses</td>
<td>role conception</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(12) Accumulative MEDCASE:*</td>
<td></td>
<td>(13) Est Accum OMA Cost:*</td>
<td>*Refer to Unit Summary Sheet of this Report</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(14) a. Date, Latest IRC Review:</td>
<td></td>
<td>b. Review Results:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Number of Subjects Enrolled During Reporting Period:</td>
<td></td>
<td>d. Total Number of Subjects Enrolled to Date:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(15) Study Objective:</td>
<td>a) Compare the role conception of neophyte RNs upon their assignment to FAMC and one year after assignment. b) Compare the role conception of experienced RNs upon their assignment to FAMC and one year after assignment. c) Assess similarities and dissimilarities between the two groups. d) Evaluate especially items of role discrepancy among all groups with the intent of making decisions regarding possible system changes which could decrease role conflict and impact positively on retention.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(16) Technical Approach:</td>
<td>Comparative study using questionnaires distributed over an 18-month period.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(17) Progress:</td>
<td>Recently approved study, no progress to date.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Publications and Presentations:</td>
<td>None</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

417
**Date:** 30 Sep 90 | **Protocol #:** 90/750 | **Status:** Ongoing

**Title:** Onset-to-Onset Difference Between the Median Motor Nerve and the Anterior Interosseous Nerve Using a Common Stimulation at the Antebubital Fossae

**Start Date:** 1990 | **Est Compl Date:**

**Principal Investigator:**
Douglas Hemler, MAJ, MC

**Facility:** FAMC

**Dept/Svc:** Phy. Med.

**Associate Investigators:**

**Key Words:**

**Accumulative MEDCASE:**

**Est Accum OMA Cost:**

*Refer to Unit Summary Sheet of this Report

**a.** Date, Latest IRC Review: 
**b.** Review Results: 
**c.** Number of Subjects Enrolled During Reporting Period: 
**d.** Total Number of Subjects Enrolled to Date: 
**e.** Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

**Study Objective:** To mathematically define the temporal relationship between the anterior interosseous nerve and the median nerve.

**Technical Approach:** Volunteers with no known neurologic pathology will be used. Stimulation by standard surface electrodes with cathode placement medial to the biceps tendon at the flexion crease of the antebubital fossae. Standard adjustment of the stimulus to achieve maximal responses from the Abductor Pollicis Brevis and Pronator Quadratus is performed.

**Progress:** Fifteen subjects have been studied. Current data is insufficient for analysis.

**Publications and Presentations:** None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/751  (3) Status: Completed

(4) Title: The Frequency that Physicians Recommend Aerobic Exercise for Patients with Rheumatoid Arthritis

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
C.L. Lewis, CPT, SP

(9) Dept/Svc: Occupational Therapy  (10) Associate Investigators:

(11) Key Words:
aerobic exercise
rheumatoid arthritis

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:   b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:   d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: The purpose of this study is to determine if aerobic exercise is recommended by physicians for patients with rheumatoid arthritis.

(16) Technical Approach: One hundred and sixty-five military physicians were surveyed using a written mailed questionnaire developed for this purpose. The study looked at the frequency and percentages that physicians recommended aerobic exercise for patients with RA, the exercise modes recommended, the benefits and contraindications of aerobic exercise for RA patients, the tests recommended prior to starting an exercise program, and the method of explaining the exercise program to the patient.

(17) Progress: Principal data collection has been completed. Analysis of the data is ongoing.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 83/902A  Status: Ongoing

Title: Training Study, Emergency Medical Procedures

Start Date: 1982  Est Compl Date: Ongoing

Principal Investigator: Mark A. Larsen, COL, MC


Dept of Emerg Med & Vet Svc

Key Words: emergency medical services

Accumulative MEDCASE:  Est Accum OMA Cost:

*Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:

Number of Subjects Enrolled During Reporting Period: 78

Total Number of Subjects Enrolled to Date: 85

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: This project is a refresher/teaching course in emergency medicine operative procedures. It is conducted on a monthly basis for EMS physicians and PAs'.

Technical Approach: Under general anesthesia animals are subjected to common emergency medicine operative procedures including venous cutdown, peritoneal lavage, chest tube insertion, and thorocotomy with aortic cross clamp with cardiac laceration repair. At the end of the exercise, the animals are disposed of by lethal injection.

Progress: Training program, good utilization and training continues.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 88/900  (3) Status: Ongoing

(4) Title: IOLAB Investigational Plan for the Clinical Study of Intraocular Lenses

(5) Start Date: 8/87  (6) Est Compl Date: Indefinite

(7) Principal Investigator: David Pernelli, MAJ, MC
(8) Facility: FAMC
   Fort Leonard Wood, MO
   65473-5700

(9) Dept/Svc: Ophthalmology Svc

(10) Associate Investigators

(11) Key Words:
IOL (posterior chamber)

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report.

(14) a. Date, Latest IRC Review:__________ b. Review Results:__________
c. Number of Subjects Enrolled During Reporting Period: 21
d. Total Number of Subjects Enrolled to Date: 46
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e". N/A

(15) Study Objective: To establish the safety and effectiveness of intraocular lens implantation of the cataract patient.

(16) Technical Approach: Extracapsular cataract extraction with PC IOL secondary intraocular lens (IOL) implants.

(17) Progress: No adverse effects noted to date.

Publications and Presentations: None

423
Date: 30 Sep 90  Protocol #: 88/901  Status: Ongoing

Title: Coburn Intraocular Lens Study AT GLWACH

Start Date: 8/87  Est Compl Date: Indefinite

Principal Investigator: David Perenelli, MAJ, MC
Facility: FAMC

Dept/Svc: Ophthalmology Svc

Associate Investigators

Key Words:
IOL (anterior chamber)

Accumulative MEDCASE:*  Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report.

Study Objective: To establish the safety and effectiveness of intraocular lens implantation of the cataract patient.

Technical Approach: Secondary intraocular lens implant.

Progress: No adverse effects noted to date.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/900  (3) Status: Ongoing

(4) Title: Evaluation of a Phase I *Coxiella burnetii* Vaccine (IND 610) for Immunization Against Q Fever

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
   Steven White, LTC, MC  US Army Health Clinics
   Dugway Proving Grounds
   Dugway, Utah 84022

(9) Dept/Svc:  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
    *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review:  b. Review Results:
    c. Number of Subjects Enrolled During Reporting Period: 21
    d. Total Number of Subjects Enrolled to Date: 21
    e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Surveillance program to protect high risk workers.


(17) Progress: Endpoint of this study has not been reached.

Publications and Presentations: None
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: 89/901 (3) Status: Ongoing

(4) Title: Continued Evaluation of the Safety and Effectiveness of Venezuelan Equine Encephalomyelitis Vaccine, TC-83 Live, Attenuated, NDBR-102, Lot 4 in At-Risk Personnel IND 142

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Steven White, LTC, MC Director of Health Services US Army Health Clinic, DPG

(9) Dept/Svc: (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 20 d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Surveillance program to protect high risk workers.


(17) Progress: Endpoint of this study has not been reached. No new enrollments authorized.

Publications and Presentations: None

426
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 89/902  (3) Status: Ongoing

(4) Title: Evaluation of New Lots of Tularemia Vaccine, Protocol B: Comparative Assessment of *Francisella tularensis* Vaccine, Live, NDBR 101, IND 157

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator: Steven White, LTC, MC  (8) Facility: FAMC
Dugway Proving Grounds
US Army Health Clinic

(9) Dept/Svc:  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period: 20
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Surveillance program to protect high risk workers.


(17) Progress: Endpoint of this study has not been reached. No new enrollments authorized.

Publications and Presentations: None
Date: 30 Sep 90  Protocol #: 89/903  Status: Ongoing

Title: Evaluation of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated. Protocol B: Continued Assessment of the Safety and Effectiveness of Venezuelan Equine Encephalomyelitis Vaccine, Inactivated, Lot C-84-6, TSI-GSD 205 as a Booster in At-Risk Personnel, IND 914

Start Date:  Est Compl Date:

Principal Investigator: Steven White, LTC,MC  Facility: FAMC Director of Health Services DPG

Dept/Svc:  Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: 20 d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective: Surveillance program to protect high risk workers.

Technical Approach: Administered by U.S. Army Research Institute for Infectious Disease.

Progress: Endpoint of this study has not been reached. No new enrollments for this reporting period.

Publications and Presentations: None
(1) Date: 30 Sep 90  (2) Protocol #: 89/904  (3) Status: Ongoing

(4) Title: Use of the Sixteen Personality Factor Questionnaire to Predict Susceptibility to Occupational Stress Among US Army Recruiters

(5) Start Date: Aug 89  (6) Est Compl Date: Aug 90

(7) Principal Investigator:
   John Kaicher, CPT, MC

(8) Facility:
   FAMC
   US Army Health Clinic
   Ft. Sheridan, IL

(9) Dept/Svc:

(10) Associate Investigators:
   Peter Orris, MD, MPH and
   Robert Moretti, PhD,
   Northwestern University
   Medical School
   Walter Teachout, CPT, MS, FAMC

(11) Key Words:
   occupational stress
   Army recruiters
   personality factors

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
   *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To determine a mechanism to identify those soldiers who are predisposed to disabling occupational stress problems, considerable psychopathological morbidity and its attendant costs.

(16) Technical Approach: To determine the validity of the 16PF to predict Army Recruiters predisposed to occupational stress related psychological and behavioral problems.

(17) Progress: To date 180 subjects were tested. Enrollment will continue through the end of September 1990.

Publications and Presentations: None.
(1) Date: 30 Sep 90 (2) Protocol #: 89/905 (3) Status: Completed

(4) Title: Comparative Evaluation of Jet Injected PPD Based on the Mantoux Response in Initial Entry Training Soldiers

(5) Start Date: Oct 89 (6) Est Compl Date: Jul 90

(7) Principal Investigator: Linda J. Andersen MAJ, AN Ft. Leonard Wood, MO

(8) Facility: FAMC

(9) Dept/Svc: Immunization Clinic

(10) Associate Investigators:

(11) Key Words: TB testing

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To directly compare the jet-injected intradermal PPD to the standard Mantoux method for detection of TB exposure among IET soldiers at Fort Leonard Wood, MO.

(16) Technical Approach: Phase I) Jet injected response is compared to the Mantoux response in a convenience sample of known positive Mono-Vaccs assessing for the sensitivity and specificity against the gold standard. Phase II) Jet injected PPD is administered simultaneously with the Mono-Vacc to soldiers of unknown Mono-Vacc response and is evaluated as the single process of determining TB exposure among the IET soldiers at FLW.

(17) Progress: I completed the study as principal investigator after CPT Luther PCS'd. All data has been mailed to her at her new duty station.

Publications and Presentations: None.
Date: 30 Sep 90  Protocol #: 90/900  Status: Ongoing

Title: Iron Deficiency Anemia in 11-14 Month Old Infants at 6,000 Feet (1830m) Elevation. A Study to Evaluate the Response to a Therapeutic Trial of Iron

Start Date:  Est Compl Date:

Principal Investigator: Steve Lang, MAJ, MC
Facility: FAMC
Family Practice

Dept/Svc: Ft. Carson  Associate Investigators:

Key Words:

Accumulative MEDCASE:  Est Accum OMA Cost:  
*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results: 
c. Number of Subjects Enrolled During Reporting Period: 
d. Total Number of Subjects Enrolled to Date: 
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as 

Study Objective: To determine whether one year old infants at higher altitudes are more likely than children at sea level to be iron deficient.

Technical Approach: Hemoglobin response in healthy 11-14 month old infants living at altitude to 3-month oral iron treatment will be assessed using a HemoCue hemoglobin measuring instrument.

Progress: None to date, due to recent assignment of principal investigator to long-term TDY.

Publications and Presentations: None.
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: 90/950A  (3) Status: Ongoing

(4) Title: Postgraduate Course on Obstetric, Neonatal, and Gynecologic Care. Resuscitation of the Newborn Utilizing Young Cats

(5) Start Date:  (6) Est Compl Date:  

(7) Principal Investigator: To be announced.  (8) Facility: FAMC

(9) Dept/Svc:  (10) Associate Investigators:  

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:* *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: To provide a live, realistic animal model for teaching the life-saving skill of neonatal endotracheal intubation to Indian Health Service (IHS) personnel newly assigned to remote Service Units where successful resuscitation of asphyxiated infants may depend on their ability to intubate.

(16) Technical Approach: Animal models will be used to teach the skills of neonatal endotracheal intubation and bag and mask ventilation.

(17) Progress: This is a recurring post graduate course, the yearly outline will determine the principal and associate investigator and the number of course attendees.

Publications and Presentations: None.
EMERGENCY USE PROTOCOLS
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: EU-89-1  (3) Status: Completed

(4) Title: POG 8633/34 Treatment of Children Less than Three Years of Age with Malignant Brain Tumors Using Postoperative Chemotherapy and Delayed Irradiation.

(5) Start Date: 1989  (6) Est Compl Date: 

(7) Principal Investigator: Askold Mosijczuk, COL, MC

(8) Facility: FAMC

(9) Dept/Svc: Ped Hem-Onc

(10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date: 1

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: Patient treatment with NCI approved protocol.

(16) Technical Approach: See protocol.

(17) Progress: Closed to patient accrual.

Publications and Presentations: None.
| (1) Date: | 30 Sep 90 |
| (2) Protocol #: | EU-89-2 |
| (3) Status: | Ongoing |
| (4) Title: | POG 8743 |
| (5) Start Date: | 1989 |
| (6) Est Compl Date: | |
| (7) Principal Investigator: | Askold Mosijczuk, COL, MC |
| (8) Facility: | FAMC |
| (9) Dept/Svc: | Ped Hem-Onc |
| (10) Associate Investigators: | |
| (11) Key Words: | |
| (12) Accumulative MEDCASE:* | |
| (13) Est Accum OMA Cost:* | |
| (14) a. Date, Latest IRC Review: | |
| b. Review Results: | |
| c. Number of Subjects Enrolled During Reporting Period: | |
| d. Total Number of Subjects Enrolled to Date: | 1 |
| e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e" | |
| (15) Study Objective: | Treatment study for stage IV neuroblastoma sponsored by NCI. |
| (16) Technical Approach: | See protocol. |
| (17) Progress: | Open to patient accrual. One patient enrolled at FAMC. Clinically doing well, stable disease. |

Publications and Presentations: NA
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #:  (3) Status: Completed
(4) Title: Compassionate Enrollment in POG 8696/97

(5) Start Date: 1989  (6) Est Compl Date:

(7) Principal Investigator: COL Askold Mosijczuk

(8) Facility: FAMC

(9) Dept/Svc:  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: b. Review Results: c. Number of Subjects Enrolled During Reporting Period: d. Total Number of Subjects Enrolled to Date: e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Closed to patient accrual. One patient entered. Achieved a complete response after chemo but relapsed 6 months later and was taken off the study.

Publications and Presentations:

436
Date: 30 Sep 90  Protocol #: One  Status: Completed

Title: Compassionate/One Time Use Protocol - Ribovirin (2-wk course)

Start Date:  Est Compl Date:

Principal Investigator: Dr. Byrne

Facility: FAMC

Dept/Svc:  Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review:  b. Review Results:
c. Number of Subjects Enrolled During Reporting Period:
d. Total Number of Subjects Enrolled to Date:
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective:

Technical Approach:

Progress: Compassionate/one time use protocol (2-wk course).

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90  (2) Protocol #: Two  (3) Status: Completed

(4) Title:
Tc99m Antimony - Trisulfide Colloid

(5) Start Date:  (6) Est Compl Date:

(7) Principal Investigator:  (8) Facility: FAMC
Fortenbury

(9) Dept/Svc:  (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:*  (13) Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: ______  b. Review Results: ______  
c. Number of Subjects Enrolled During Reporting Period: ______ 
d. Total Number of Subjects Enrolled to Date: ______  
e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective:

(16) Technical Approach:

(17) Progress:  Completed.

Publications and Presentations:
Date: 30 Sep 90

Protocol #: Three

Status: Terminated

Title: Itraconazole

Start Date:

Est Compl Date:

Principal Investigator: Jerry Pluss, MAJ, MC

Facility: FAMC

Dept/Svc:

Associate Investigators:

Key Words:

Accumulative MEDCASE:* (13) Est Accum OMA Cost:*

*Refer to Unit Summary Sheet of this Report

a. Date, Latest IRC Review: b. Review Results:

c. Number of Subjects Enrolled During Reporting Period:

d. Total Number of Subjects Enrolled to Date:

e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective:

Technical Approach:

Progress: Drug discontinued in patient.

Publications and Presentations:
Date: 30 Sep 90  Protocol #: Four  Status: Terminated

Title: POG 8751

Start Date:  Est Compl Date:

Principal Investigator: Askold Mosijczuk, COL, MC

Facility: FAMC

Dept/Svc:  Associate Investigators:

Key Words:

Accumulative MEDCASE:*  Est Accum OMA Cost:*  *Refer to Unit Summary Sheet of this Report

Date, Latest IRC Review:  Review Results:  Number of Subjects Enrolled During Reporting Period:  Total Number of Subjects Enrolled to Date:  Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

Study Objective:

Technical Approach:

Progress:

Publications and Presentations:
FAMC A.P.R. (RCS MED 300) Detail Summary Sheet (HSCR 40-23 as amended)

(1) Date: 30 Sep 90 (2) Protocol #: Five (3) Status: Completed

(4) Title: Intravenous Ciprofloxacin

(5) Start Date: (6) Est Compl Date:

(7) Principal Investigator: Byrne (8) Facility: FAMC

(9) Dept/Svc: (10) Associate Investigators:

(11) Key Words:

(12) Accumulative MEDCASE:* (13) Est Accum OMA Cost:*
   *Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: ______ b. Review Results: ______
    c. Number of Subjects Enrolled During Reporting Period: ______
    d. Total Number of Subjects Enrolled to Date: ______
    e. Note any adverse drug reactions reported to the FDA or sponsor for
       studies conducted under an FDA-awarded IND. May be continued on a
       separate sheet, and designated as "(14)e"

(15) Study Objective:

(16) Technical Approach:

(17) Progress: Course completed.

Publications and Presentations:

441
(1) Date: 30 Sep 90 (2) Protocol #: Six (3) Status: Completed

(4) Title: Strontium Chloride Sr-89

(5) Start Date: __________________________ (6) Est Compl Date: __________________________

(7) Principal Investigator: Fortenbury
(8) Facility: FAMC

(9) Dept/Svc: __________________________ (10) Associate Investigators: __________________________

(11) Key Words: __________________________

(12) Accumulative MEDCASE:* __________________________ (13) Est Accum OMA Cost:* __________________________
*Refer to Unit Summary Sheet of this Report

(14) a. Date, Latest IRC Review: __________________________ b. Review Results: __________________________
  c. Number of Subjects Enrolled During Reporting Period: __________________________
  d. Total Number of Subjects Enrolled to Date: __________________________
  e. Note any adverse drug reactions reported to the FDA or sponsor for studies conducted under an FDA-awarded IND. May be continued on a separate sheet, and designated as "(14)e"

(15) Study Objective: __________________________

(16) Technical Approach: __________________________

(17) Progress: One time only.

Publications and Presentations: __________________________
INVESTIGATORS INDEX
<table>
<thead>
<tr>
<th>NAME</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abrams, L.F.</td>
<td>147, 165</td>
</tr>
<tr>
<td>Andersen, L.</td>
<td>430</td>
</tr>
<tr>
<td>Andersen, P.A.</td>
<td>69, 88</td>
</tr>
<tr>
<td>Anderson, B.</td>
<td>348, 353, 380, 387</td>
</tr>
<tr>
<td>Andron, L.A.</td>
<td>78, 94, 169, 273, 300</td>
</tr>
<tr>
<td>Anman, W.</td>
<td>168</td>
</tr>
<tr>
<td>Arena, J.</td>
<td>246, 248, 272, 276, 290</td>
</tr>
<tr>
<td>Aronson, C.E.</td>
<td>237</td>
</tr>
<tr>
<td>Ashley, D.D.</td>
<td>159, 169</td>
</tr>
<tr>
<td>Asp, A.</td>
<td>93</td>
</tr>
<tr>
<td>Atchley, S.H.</td>
<td>112</td>
</tr>
<tr>
<td>Banks, R.E.</td>
<td>301</td>
</tr>
<tr>
<td>Barber, J.</td>
<td>362</td>
</tr>
<tr>
<td>Barrett, J.R.</td>
<td>100</td>
</tr>
<tr>
<td>Barrs, D.M.</td>
<td>262</td>
</tr>
<tr>
<td>Bennion, S.</td>
<td>40, 42, 111, 225, 303, 305, 306</td>
</tr>
<tr>
<td>Bergstrom,</td>
<td>162</td>
</tr>
<tr>
<td>Bethlenfalvay, N.C.</td>
<td>408, 411</td>
</tr>
<tr>
<td>Bezier, J.L.</td>
<td>236</td>
</tr>
<tr>
<td>Bianchi, A.M.</td>
<td>127</td>
</tr>
<tr>
<td>Bizousky, D.</td>
<td>256, 288</td>
</tr>
<tr>
<td>Blakeslee, D.B.</td>
<td>274</td>
</tr>
<tr>
<td>Blue, P.</td>
<td>71, 77, 103, 122, 128, 135, 136, 199, 401, 404</td>
</tr>
<tr>
<td>Brantner, L.</td>
<td>378</td>
</tr>
<tr>
<td>Bray, V.</td>
<td>108, 163</td>
</tr>
<tr>
<td>Brehn, A.</td>
<td>415</td>
</tr>
<tr>
<td>Bright, K.</td>
<td>214</td>
</tr>
<tr>
<td>Brinkman, M.</td>
<td>291</td>
</tr>
<tr>
<td>Brown, J.S.</td>
<td>131, 137, 143, 179</td>
</tr>
<tr>
<td>Brugman, J.L.</td>
<td>260</td>
</tr>
<tr>
<td>Bruhn, F.W.</td>
<td>368</td>
</tr>
<tr>
<td>Bryson, A.</td>
<td>415</td>
</tr>
<tr>
<td>Bunker, D.</td>
<td>159</td>
</tr>
<tr>
<td>Burgess, D.B.</td>
<td>307</td>
</tr>
<tr>
<td>Byrne, W.R.</td>
<td>78, 178, 226, 308, 309</td>
</tr>
<tr>
<td>Calkins, R.</td>
<td>268, 290</td>
</tr>
<tr>
<td>Campbell, R.L.</td>
<td>105</td>
</tr>
<tr>
<td>Cannon, G.</td>
<td>416</td>
</tr>
<tr>
<td>Caras, W.E.</td>
<td>133</td>
</tr>
<tr>
<td>Carter, B.</td>
<td>372, 375</td>
</tr>
<tr>
<td>Carter, T.</td>
<td>229</td>
</tr>
<tr>
<td>Casserly, J.</td>
<td>78</td>
</tr>
<tr>
<td>Clark, J.R.</td>
<td>93, 241, 273</td>
</tr>
<tr>
<td>Clark, T.</td>
<td>301, 371, 374</td>
</tr>
<tr>
<td>Cobb, P.W.</td>
<td>114</td>
</tr>
</tbody>
</table>
Coe, R.A. -------------------------- 264
Colpini, A.W. ---------------------- 259
Cook, S. --------------------------- 289,292,293,405
Copeland, T. ------------------------ 44
Cornell, F.M. ----------------------- 232,254,266,267
Corpe, R.S. ------------------------- 283
Cosgriff, T. ------------------------- 53,54,56,58,59,60,61,63,64, 72,74,79,80,81,82,83,84,85, 92,95,96,103,114,119,125,139, 172-177,178,181,183-197, 201,212,217-223

Coulter, S. --------------------------- 111
Coville, F. ------------------------- 285
Cravero, J. -------------------------- 431
Crawford, J. ------------------------- 415
Cremins, J.E. ------------------------ 135
Crosby, B.L. ------------------------- 67
Cruz-Saez, J.A. ---------------------- 42
Culclosure, T.F. ---------------------- 152

Damiano, M. ------------------------- 272
David, K. --------------------------- 40,215,225
Davis, R.C. -------------------------- 120
Deffer, P. -------------------------- 289,294
Dengenhardt, E. --------------------- 163
Dirks, M. ---------------------------- 233
Dolton, H. --------------------------- 168
Donatucci, C. ------------------------ 180,238,239,279
Dorogy, M. -------------------------- 112,181
Dorsett ------------------------------- 363
Dothager, D. ------------------------- 122,146,198
Dunkelberg, J. ----------------------- 129,135,182
Dwyer, A.P. -------------------------- 216
Dwyer, K. ---------------------------- 263,265,277

Enzenauer, R.J. ---------------------- 140,141
Enzenauer, R.W. ---------------------- 232,254,266,267
Eusterman, V.D. ---------------------- 274

Fall, S. ----------------------------- 255
Feinberg, M. ------------------------- 380
Ferris, C.F. -------------------------- 39,50,73,302,305,411
Fisher, M. --------------------------- 154,171,182
Fitzpatrick, J.E. --------------------- 111,225,302
Fortenberry, E.J. --------------------- 86
Frank, C.G. --------------------------- 353,372,375,380
Freeman, S. -------------------------- 129,135,140,150,154,169, 171,182,363
Frelin, A.J. -------------------------- 414,417

445
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kaicher, J.</td>
<td>429</td>
</tr>
<tr>
<td>Karstitter, K.</td>
<td>278, 283, 287, 291</td>
</tr>
<tr>
<td>Kelly, K.J.</td>
<td>369</td>
</tr>
<tr>
<td>Ketchum, R.</td>
<td>291</td>
</tr>
<tr>
<td>Kidd, G.S.</td>
<td>32, 34, 36, 37, 46, 71, 77, 86, 90, 93, 100, 103, 128, 131, 134, 147, 164, 168</td>
</tr>
<tr>
<td>Kinsella, J.P.</td>
<td>348, 383, 384, 385</td>
</tr>
<tr>
<td>Kollef, M.H.</td>
<td>133, 138, 144, 146, 155, 158, 178, 198, 214</td>
</tr>
<tr>
<td>Kreder, K.</td>
<td>238, 239, 279</td>
</tr>
<tr>
<td>Kozlowski, C.</td>
<td>181</td>
</tr>
<tr>
<td>Kristo, D.</td>
<td>155</td>
</tr>
<tr>
<td>Kruger, M.</td>
<td>141</td>
</tr>
<tr>
<td>Kuck, P.</td>
<td>234</td>
</tr>
<tr>
<td>Kudryk, B.</td>
<td>181</td>
</tr>
<tr>
<td>Lang, S.</td>
<td>431</td>
</tr>
<tr>
<td>Lanier, D.</td>
<td>114</td>
</tr>
<tr>
<td>Larsen, M.A.</td>
<td>164</td>
</tr>
<tr>
<td>Larsen, L.V.</td>
<td>117</td>
</tr>
<tr>
<td>Lawrence, S.P.</td>
<td>129</td>
</tr>
<tr>
<td>Ledoux, R.A.</td>
<td>67, 137, 213</td>
</tr>
<tr>
<td>Lee, L.</td>
<td>215, 305, 306</td>
</tr>
<tr>
<td>Lemar, H.J.</td>
<td>160, 164</td>
</tr>
<tr>
<td>Lepore, M.L.</td>
<td>214, 257, 275</td>
</tr>
<tr>
<td>LeSueur, C.</td>
<td>62</td>
</tr>
<tr>
<td>Leuthke, J.</td>
<td>155, 406</td>
</tr>
<tr>
<td>Lewis, C.L.</td>
<td>429</td>
</tr>
<tr>
<td>Lima, J.</td>
<td>408</td>
</tr>
<tr>
<td>Lin, E.</td>
<td>134, 419</td>
</tr>
<tr>
<td>Lisecki, M.B.</td>
<td>254, 285, 289, 292, 293</td>
</tr>
<tr>
<td>Lovin, J.</td>
<td>406</td>
</tr>
<tr>
<td>Lundblad, E.</td>
<td>319, 320</td>
</tr>
<tr>
<td>Maco-Johnson, M.</td>
<td>402</td>
</tr>
<tr>
<td>Madonna, J.</td>
<td>142</td>
</tr>
<tr>
<td>Mallory, P.L.</td>
<td>198, 263, 265, 273</td>
</tr>
<tr>
<td>Manier, S.M.</td>
<td>71</td>
</tr>
<tr>
<td>Marx, W.H.</td>
<td>263, 265, 273</td>
</tr>
<tr>
<td>McCormack, M.</td>
<td>214</td>
</tr>
<tr>
<td>McDermott, M.T.</td>
<td>34, 36, 37, 48, 52, 65, 71, 77, 86, 90, 93, 100, 103, 128, 147, 149, 159, 164, 179</td>
</tr>
<tr>
<td>McIntosh, B.R.</td>
<td>286</td>
</tr>
<tr>
<td>McNauley, P.J.</td>
<td>159, 171</td>
</tr>
<tr>
<td>Meador, K.</td>
<td>290</td>
</tr>
<tr>
<td>Meiklejohn, G.</td>
<td>148</td>
</tr>
<tr>
<td>Mercill, D.B.</td>
<td>73, 111, 289, 411</td>
</tr>
<tr>
<td>Merenich, J.</td>
<td>77, 93, 100, 134, 147, 159, 164, 179</td>
</tr>
<tr>
<td>Meyers, J.I.</td>
<td>138, 144, 156</td>
</tr>
</tbody>
</table>

447
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miles, F.W.</td>
<td>105</td>
</tr>
<tr>
<td>Miller, G.</td>
<td>402</td>
</tr>
<tr>
<td>Moretti, R.</td>
<td>429</td>
</tr>
<tr>
<td>Morse, P.L.</td>
<td>298</td>
</tr>
<tr>
<td>Morton, B.E.</td>
<td>230</td>
</tr>
<tr>
<td>Moses, T.A.</td>
<td>238, 239</td>
</tr>
<tr>
<td>Mullon, D.</td>
<td>291</td>
</tr>
<tr>
<td>Myers, C.</td>
<td>259</td>
</tr>
<tr>
<td>Negron, F.</td>
<td>77</td>
</tr>
<tr>
<td>Nelson, H.S.</td>
<td>48</td>
</tr>
<tr>
<td>Nordstrom, D.</td>
<td>69</td>
</tr>
<tr>
<td>O'Barr, T.P.</td>
<td>73, 302</td>
</tr>
<tr>
<td>O'Connell, M.A.</td>
<td>75</td>
</tr>
<tr>
<td>O'Connor, J.</td>
<td>168</td>
</tr>
<tr>
<td>Odom, J.A.</td>
<td>260</td>
</tr>
<tr>
<td>Orris, P.</td>
<td>429</td>
</tr>
<tr>
<td>Ow, C.L.</td>
<td>97, 161</td>
</tr>
<tr>
<td>Ozaki, J.K.</td>
<td>259</td>
</tr>
<tr>
<td>Paige, P.</td>
<td>375</td>
</tr>
<tr>
<td>Pals, S.D.</td>
<td>253, 280</td>
</tr>
<tr>
<td>Parker, S.</td>
<td>402, 406</td>
</tr>
<tr>
<td>Pernelli, D.P.</td>
<td>231, 423, 424</td>
</tr>
<tr>
<td>Perry, M.E.</td>
<td>77, 122, 136, 138, 156, 168, 214</td>
</tr>
<tr>
<td>Pfander, N.</td>
<td>127, 134</td>
</tr>
<tr>
<td>Potter, M.E.</td>
<td>313-318, 321-326, 327-332, 333-346</td>
</tr>
<tr>
<td>Pruitt, A.</td>
<td>259, 260, 264, 271</td>
</tr>
<tr>
<td>Raife, M.J.</td>
<td>238, 239, 279, 402</td>
</tr>
<tr>
<td>Ramirez, R.J.</td>
<td>232, 254, 266</td>
</tr>
<tr>
<td>Reddy, V.</td>
<td>101, 144, 159, 362, 411</td>
</tr>
<tr>
<td>Rodinelli, R.</td>
<td>243, 246, 250</td>
</tr>
<tr>
<td>Rosenberg, A.A.</td>
<td>385</td>
</tr>
<tr>
<td>Rothschild, B.</td>
<td>246</td>
</tr>
<tr>
<td>Roy, C.R.</td>
<td>134</td>
</tr>
<tr>
<td>Rush, P.</td>
<td>362</td>
</tr>
<tr>
<td>Santoro, T.</td>
<td>215</td>
</tr>
<tr>
<td>Schaefer, R.A.</td>
<td>271, 293</td>
</tr>
<tr>
<td>Schaffrinna, M.G.</td>
<td>363</td>
</tr>
<tr>
<td>Schleve, M.M.</td>
<td>40, 225</td>
</tr>
<tr>
<td>Scott, F.</td>
<td>294</td>
</tr>
<tr>
<td>Shanefield, C.</td>
<td>62</td>
</tr>
<tr>
<td>Shaukat, M.</td>
<td>291</td>
</tr>
<tr>
<td>Sherman, K.</td>
<td>140, 150, 169</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Simcic, K.</td>
<td>100</td>
</tr>
<tr>
<td>Sims, J.</td>
<td>402</td>
</tr>
<tr>
<td>Singleton, J.D.</td>
<td>88,115,140,179</td>
</tr>
<tr>
<td>Sjoberg, R.J.</td>
<td>32,100</td>
</tr>
<tr>
<td>Skavlen, P.</td>
<td>215</td>
</tr>
<tr>
<td>Sklarew, P.R.</td>
<td>104,153,180</td>
</tr>
<tr>
<td>Slover, R.</td>
<td>378</td>
</tr>
<tr>
<td>Spaulding, H.S.</td>
<td>166,167,180</td>
</tr>
<tr>
<td>Spezia, P.</td>
<td>283,284</td>
</tr>
<tr>
<td>Staggars, N.</td>
<td>414</td>
</tr>
<tr>
<td>Stenmark, K.R.</td>
<td>376</td>
</tr>
<tr>
<td>Stewart, I.B.</td>
<td>381</td>
</tr>
<tr>
<td>Stewart, R.S.</td>
<td>132,296</td>
</tr>
<tr>
<td>Stock, J.</td>
<td>254,266</td>
</tr>
<tr>
<td>Sutherland, R.</td>
<td>238,239</td>
</tr>
<tr>
<td>Szefler, S. J.</td>
<td>48</td>
</tr>
<tr>
<td>Tell, D.T.</td>
<td>55,56,241</td>
</tr>
<tr>
<td>Tessier, S.</td>
<td>300</td>
</tr>
<tr>
<td>Teuton, C.</td>
<td>215</td>
</tr>
<tr>
<td>Thickman, D.</td>
<td>402</td>
</tr>
<tr>
<td>Thrasher, J.B.</td>
<td>180,238,239,263,265</td>
</tr>
<tr>
<td>Travis, P.S.</td>
<td>157</td>
</tr>
<tr>
<td>Truxal, A.R.</td>
<td>52</td>
</tr>
<tr>
<td>Tyler, H.N.</td>
<td>128,404</td>
</tr>
<tr>
<td>Urry, L.</td>
<td>111</td>
</tr>
<tr>
<td>VanDeren, J.M.</td>
<td>120,129,142</td>
</tr>
<tr>
<td>Vasil, M.L.</td>
<td>376</td>
</tr>
<tr>
<td>Voelmeck, W.</td>
<td>416</td>
</tr>
<tr>
<td>Vollkel, N.F.</td>
<td>376</td>
</tr>
<tr>
<td>Vaughan, R.</td>
<td>44,48,75,104,109,117,126,130,213</td>
</tr>
<tr>
<td>Walden, T.</td>
<td>71</td>
</tr>
<tr>
<td>Walker, D.J.</td>
<td>413</td>
</tr>
<tr>
<td>Walton, W.</td>
<td>254,266</td>
</tr>
<tr>
<td>Ward, F.</td>
<td>112</td>
</tr>
<tr>
<td>Wartofsky, L.</td>
<td>52</td>
</tr>
<tr>
<td>Weaver, M. J.</td>
<td>97,116,145,163</td>
</tr>
<tr>
<td>Weber, R.W.</td>
<td>132,143</td>
</tr>
<tr>
<td>Weidel, J.</td>
<td>293</td>
</tr>
<tr>
<td>Weingast, G.</td>
<td>402</td>
</tr>
<tr>
<td>Weir, A.</td>
<td>399</td>
</tr>
<tr>
<td>Weller, R.W.</td>
<td>254</td>
</tr>
<tr>
<td>Wells, D.W.</td>
<td>352</td>
</tr>
<tr>
<td>West, S.G.</td>
<td>62,69,88,115,140,179,264</td>
</tr>
<tr>
<td>Weston, W.</td>
<td>111</td>
</tr>
<tr>
<td>White, J.C.</td>
<td>131,147,200,307,381</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>---------------</td>
<td>---------------</td>
</tr>
<tr>
<td>White, S.</td>
<td>425, 428</td>
</tr>
<tr>
<td>Wilkerson, P.</td>
<td>261</td>
</tr>
<tr>
<td>Wilkins, R.M.</td>
<td>252</td>
</tr>
<tr>
<td>Williams, K.</td>
<td>148</td>
</tr>
<tr>
<td>Williams, R.F.</td>
<td>42</td>
</tr>
<tr>
<td>Winn, R.</td>
<td>99, 133, 148</td>
</tr>
<tr>
<td>Woerman, A.</td>
<td>278, 287</td>
</tr>
<tr>
<td>Wolfe, J.</td>
<td>285</td>
</tr>
<tr>
<td>Wolff, J.</td>
<td>292</td>
</tr>
<tr>
<td>Wong, J.</td>
<td>415</td>
</tr>
<tr>
<td>Woods, T.R.</td>
<td>275</td>
</tr>
<tr>
<td>Woolverton, M.</td>
<td>371, 374</td>
</tr>
<tr>
<td>Yakes, W.</td>
<td>406</td>
</tr>
<tr>
<td>Yoshidja, G.</td>
<td>270</td>
</tr>
<tr>
<td>Young, T.</td>
<td>243, 246, 248, 250</td>
</tr>
<tr>
<td>Zakroff, M.</td>
<td>399</td>
</tr>
<tr>
<td>KEY WORDS</td>
<td>Page</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>absorptiometry</td>
<td>404</td>
</tr>
<tr>
<td>access</td>
<td>162</td>
</tr>
<tr>
<td>acclimatization</td>
<td>168</td>
</tr>
<tr>
<td>achilles tendon rupture</td>
<td>261</td>
</tr>
<tr>
<td>adosterone</td>
<td>401</td>
</tr>
<tr>
<td>adrenal glands</td>
<td>401</td>
</tr>
<tr>
<td>aerobic exercise</td>
<td>420</td>
</tr>
<tr>
<td>age</td>
<td>163</td>
</tr>
<tr>
<td>alcohol</td>
<td>160</td>
</tr>
<tr>
<td>allergens</td>
<td>67</td>
</tr>
<tr>
<td>allergenicity</td>
<td>213</td>
</tr>
<tr>
<td>altitude</td>
<td>156</td>
</tr>
<tr>
<td>effects</td>
<td>168,431</td>
</tr>
<tr>
<td>amputees</td>
<td>289</td>
</tr>
<tr>
<td>angina pectoris</td>
<td>120</td>
</tr>
<tr>
<td>animal interaction</td>
<td>371,374</td>
</tr>
<tr>
<td>anterior cruciate ligament</td>
<td>271</td>
</tr>
<tr>
<td>arthroscopy</td>
<td>271</td>
</tr>
<tr>
<td>anticoagulation</td>
<td>152</td>
</tr>
<tr>
<td>antigenicity</td>
<td>213</td>
</tr>
<tr>
<td>antihistamine</td>
<td>104,180</td>
</tr>
<tr>
<td>antiinflammatory agent</td>
<td>216</td>
</tr>
<tr>
<td>antiretroviral therapy</td>
<td>308,309</td>
</tr>
<tr>
<td>antitussive</td>
<td>160</td>
</tr>
<tr>
<td>aphakia</td>
<td>232</td>
</tr>
<tr>
<td>apgar scores</td>
<td>415</td>
</tr>
<tr>
<td>army recruiters</td>
<td>429</td>
</tr>
<tr>
<td>arthroscopic cruciate deficient</td>
<td>28</td>
</tr>
<tr>
<td>articular cartilage regeneration</td>
<td>259</td>
</tr>
<tr>
<td>asphyxial injury</td>
<td>369</td>
</tr>
<tr>
<td>asthma</td>
<td>109,130</td>
</tr>
<tr>
<td>asymptomatic HIV</td>
<td>94</td>
</tr>
<tr>
<td>atrial natriuretic peptide</td>
<td>142</td>
</tr>
<tr>
<td>atomic absorption</td>
<td>307</td>
</tr>
<tr>
<td>autoantibodies</td>
<td>305</td>
</tr>
<tr>
<td>autoantigens</td>
<td>305</td>
</tr>
<tr>
<td>bacteremia</td>
<td>368</td>
</tr>
<tr>
<td>baird biopty gun</td>
<td>406</td>
</tr>
<tr>
<td>balloon dilition of prostate</td>
<td>279</td>
</tr>
<tr>
<td>basal cell CA</td>
<td>39,40,50</td>
</tr>
<tr>
<td>bayley scales</td>
<td>386</td>
</tr>
<tr>
<td>bladder augmentation and substitution</td>
<td>239</td>
</tr>
<tr>
<td>blood lead</td>
<td>307</td>
</tr>
<tr>
<td>body fat</td>
<td>404</td>
</tr>
</tbody>
</table>

452
<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone density</td>
<td>34,103,128</td>
</tr>
<tr>
<td>Ingrowth</td>
<td>292,293</td>
</tr>
<tr>
<td>Borrelia</td>
<td>300</td>
</tr>
<tr>
<td>Breast biopsy</td>
<td>406</td>
</tr>
<tr>
<td>Calcium</td>
<td>77,86,200</td>
</tr>
<tr>
<td>Calcitonin deficiency</td>
<td>34</td>
</tr>
<tr>
<td>Carbohydrate</td>
<td>32</td>
</tr>
<tr>
<td>Cardiopulmonary resuscitation</td>
<td>145</td>
</tr>
<tr>
<td>Cataract</td>
<td>232</td>
</tr>
<tr>
<td>Extraction</td>
<td>233,267</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>368</td>
</tr>
<tr>
<td>Cesarean section</td>
<td>415</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>63,79</td>
</tr>
<tr>
<td>Chronic pain</td>
<td>290</td>
</tr>
<tr>
<td>Cigarette smoking exposure</td>
<td>381</td>
</tr>
<tr>
<td>Clavulanate</td>
<td>368</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>226</td>
</tr>
<tr>
<td>Clonidine</td>
<td>378</td>
</tr>
<tr>
<td>Clotting factors</td>
<td>362</td>
</tr>
<tr>
<td>Comprehensive assessment</td>
<td>290</td>
</tr>
<tr>
<td>Congestive heart failure</td>
<td>141</td>
</tr>
<tr>
<td>Cognitive, moral &amp; faith development</td>
<td>105</td>
</tr>
<tr>
<td>Continuous passive motion</td>
<td>259</td>
</tr>
<tr>
<td>Contract vs noncontract</td>
<td>127</td>
</tr>
<tr>
<td>COPD</td>
<td>126</td>
</tr>
<tr>
<td>Coronary disease</td>
<td>181</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>126,130,291</td>
</tr>
<tr>
<td>Coumadin</td>
<td>163,292</td>
</tr>
<tr>
<td>Cross reactivity</td>
<td>213</td>
</tr>
<tr>
<td>Cutaneous lupus</td>
<td>396</td>
</tr>
<tr>
<td>Cyclic oxygen therapy</td>
<td>136</td>
</tr>
<tr>
<td>Cyclosporin</td>
<td>52</td>
</tr>
<tr>
<td>D-dimer</td>
<td>112</td>
</tr>
<tr>
<td>D-penicillamine</td>
<td>115</td>
</tr>
<tr>
<td>Development evaluations</td>
<td>380</td>
</tr>
<tr>
<td>Diabetes</td>
<td>131,134</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>160</td>
</tr>
<tr>
<td>Dialysis</td>
<td>157,162,199</td>
</tr>
<tr>
<td>Disofen</td>
<td>405</td>
</tr>
<tr>
<td>Do not resuscitate order</td>
<td>145</td>
</tr>
<tr>
<td>Drug induced lupus</td>
<td>88</td>
</tr>
<tr>
<td>Drug sensitivity</td>
<td>75</td>
</tr>
<tr>
<td>Drug therapy</td>
<td>53-61, 64, 72, 74, 80-85</td>
</tr>
<tr>
<td></td>
<td>92,95,96,119,349-351</td>
</tr>
<tr>
<td></td>
<td>355-361,364-367</td>
</tr>
<tr>
<td>Dyserythropoiesis</td>
<td>411</td>
</tr>
<tr>
<td>Dysmenorrhea</td>
<td>352</td>
</tr>
</tbody>
</table>

453
<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>eaton trapezial implant</td>
<td>294</td>
</tr>
<tr>
<td>emergency medical services</td>
<td>422</td>
</tr>
<tr>
<td>emergency procedures</td>
<td>301</td>
</tr>
<tr>
<td>management</td>
<td>130</td>
</tr>
<tr>
<td>emg</td>
<td>276</td>
</tr>
<tr>
<td>endometriosis</td>
<td>352</td>
</tr>
<tr>
<td>endoscopy</td>
<td>129</td>
</tr>
<tr>
<td>environmental recording</td>
<td>246,268</td>
</tr>
<tr>
<td>eosinophilia</td>
<td>167</td>
</tr>
<tr>
<td>myalgia syndrome</td>
<td>166</td>
</tr>
<tr>
<td>epidural anesthesia</td>
<td>415</td>
</tr>
<tr>
<td>erythrocytes sedimentation rate</td>
<td>141</td>
</tr>
<tr>
<td>erythropoietin</td>
<td>224</td>
</tr>
<tr>
<td>estrogen</td>
<td>73</td>
</tr>
<tr>
<td>exercise</td>
<td>156</td>
</tr>
<tr>
<td>eye disease</td>
<td>52</td>
</tr>
<tr>
<td>fibrin monomer</td>
<td>112</td>
</tr>
<tr>
<td>fibrinopeptide analysis</td>
<td>181</td>
</tr>
<tr>
<td>fibrositis</td>
<td>264</td>
</tr>
<tr>
<td>flexeril</td>
<td>264</td>
</tr>
<tr>
<td>food hypersensitivity</td>
<td>44</td>
</tr>
<tr>
<td>gastric emptying</td>
<td>135</td>
</tr>
<tr>
<td>gastroduodenal ulcer</td>
<td>263,265</td>
</tr>
<tr>
<td>gastrostomy tube</td>
<td>135</td>
</tr>
<tr>
<td>glucose</td>
<td>200</td>
</tr>
<tr>
<td>goats</td>
<td>289</td>
</tr>
<tr>
<td>gonadal dysgenesis</td>
<td>36,37</td>
</tr>
<tr>
<td>gonadotropins</td>
<td>36</td>
</tr>
<tr>
<td>gram-negative shock</td>
<td>99</td>
</tr>
<tr>
<td>gram-negative sepsis</td>
<td>99</td>
</tr>
<tr>
<td>growth delay</td>
<td>378</td>
</tr>
<tr>
<td>ha-Ia, monoclonal antibody</td>
<td>99</td>
</tr>
<tr>
<td>headaches</td>
<td>268</td>
</tr>
<tr>
<td>heated graphite atomization</td>
<td>307</td>
</tr>
<tr>
<td>hematuria</td>
<td>152</td>
</tr>
<tr>
<td>hepatitis</td>
<td>169</td>
</tr>
<tr>
<td>b vaccine</td>
<td>167</td>
</tr>
<tr>
<td>hepatotoxicity</td>
<td>182</td>
</tr>
<tr>
<td>herpes zoster</td>
<td>225</td>
</tr>
<tr>
<td>high risk neonates</td>
<td>353</td>
</tr>
<tr>
<td>infants</td>
<td>380</td>
</tr>
<tr>
<td>hip fracture</td>
<td>90</td>
</tr>
<tr>
<td>histones</td>
<td>88</td>
</tr>
<tr>
<td>HIV virus</td>
<td>78</td>
</tr>
<tr>
<td>infection</td>
<td>226</td>
</tr>
<tr>
<td>therapy</td>
<td>308,309</td>
</tr>
<tr>
<td>HLA antigens</td>
<td>62</td>
</tr>
</tbody>
</table>
human infants ............... 386
humanistic qualities .... 97
hydroxyapatite ........... 285
implants .................. 292
hypercalciemia ........... 157
hypersensitivity ...... 67
hypertension ............. 108, 157, 200
hyperthyroidism ......... 32, 48
hypothyroidism .......... 36, 37, 46, 48
hypoxia .................. 129
icam ..................... 303
ige ......................... 167
immunofluorescence ...... 303
immunologic diseases ... 296
immunotherapy ........... 132
implants ................. 293
impotence ......... 134
incidence ............. 272
infants ............. 431
intraocular lens .......... 231, 234, 236, 237, 254
implanting .............. 233
intravenous fat emulsion therapy 144
iodine .................. 100
iol ....................... 267, 423, 424
iron deficiency .......... 431
IVIG .................... 178
keratin .................. 42
sulfate .................. 284
laboratory animals ....... 301
limulus .................. 150
liposuction ............. 275
locus of control ....... 127
low back pain .......... 246, 248, 272, 276
lower extremity pain ... 278
l-tryptophan ............ 166
lung ...................... 163
volume ................. 198
lupus erythematosus .... 62, 215, 303
lyme disease .......... 300
macromolecular absorption 369
malignant melanoma ..... 73
marsupial ............... 408
mebrofenin .............. 405
mechanisms ............... 250
mediators ............... 44
medical residents ....... 97
MMPI .................. 248
methotrexate ........................................ 109, 115, 182, 292
methylprednisolone.......................... 48
microbiological techniques.................. 298
microbiology........................................ 298
microsurgery...................................... 238
microvascular education & training ....... 228, 229
migraine ................................................ 44
  headaches........................................... 363
minor ................................................. 267
minor determinants............................. 137
monoclonal antibody......................... 99
morton's neuroma............................... 283
muscle tension.................................... 268
myocutaneous flaps.............................. 275

nasal obstruction.................................. 257
nasal surgery...................................... 257
neonatal lupus erythematosus............... 305
neonatal morbidity.............................. 372
nephropathy......................................... 131
nerve block........................................ 291
graft.................................................. 262
nifedipine........................................... 65, 108
nifedipine GITS.................................... 120
non-insulin dependent diabetes.............. 127
non-steroidal....................................... 240, 259
nosocomial pneumonia.......................... 263, 265
nude mice.......................................... 50
obstructive lung disease...................... 126
occupational stress............................. 429
octreotide.......................................... 171
opossum............................................. 408
oral contraceptives agents................... 362
orem's self-care model....................... 127
osteocalcium....................................... 103
osteoporosis....................................... 34, 90, 179
oxygen kinetics................................... 156
pacemaker syndrome............................ 142
pain................................................... 242
pancreatitis........................................ 171
passive smoking.................................. 381
peak bone mass.................................... 128
pelvic neoplasms................................... 313-318, 322-326, 327-332, 333-346
penicillin.......................................... 137
pentoxifylline..................................... 134
percutaneous implant........................... 289
tendon ruptures.................................... 261
personality factors............................. 429
<table>
<thead>
<tr>
<th>Term</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>phantom limb pain treatments</td>
<td>243</td>
</tr>
<tr>
<td>treatments</td>
<td></td>
</tr>
<tr>
<td>phenindamine</td>
<td>104</td>
</tr>
<tr>
<td>physical therapy</td>
<td>291</td>
</tr>
<tr>
<td>pituitary</td>
<td>36</td>
</tr>
<tr>
<td>pms</td>
<td>320</td>
</tr>
<tr>
<td>pneumonia</td>
<td>376</td>
</tr>
<tr>
<td>pollen</td>
<td>67</td>
</tr>
<tr>
<td>positive end expiratory pressure</td>
<td>214</td>
</tr>
<tr>
<td>prednisone</td>
<td>52</td>
</tr>
<tr>
<td>procainamide</td>
<td>88</td>
</tr>
<tr>
<td>progesterone</td>
<td>73</td>
</tr>
<tr>
<td>prophylactic IVIG</td>
<td>353</td>
</tr>
<tr>
<td>prostaglandins synthetics</td>
<td>461</td>
</tr>
<tr>
<td>prosthetic</td>
<td>289</td>
</tr>
<tr>
<td>pseudomonas aeruginosa</td>
<td>376</td>
</tr>
<tr>
<td>psychophysiological responses</td>
<td>290</td>
</tr>
<tr>
<td>psycho-social-spiritual</td>
<td>105</td>
</tr>
<tr>
<td>pulmonary abnormalities</td>
<td>144</td>
</tr>
<tr>
<td>purine metabolism</td>
<td>408</td>
</tr>
<tr>
<td>pulsing magnetic fields</td>
<td>287</td>
</tr>
<tr>
<td>rats</td>
<td>376</td>
</tr>
<tr>
<td>reactive arthritis</td>
<td>69</td>
</tr>
<tr>
<td>receptors</td>
<td>73</td>
</tr>
<tr>
<td>recirculation</td>
<td>162</td>
</tr>
<tr>
<td>reflex sympathetic dystrophy</td>
<td>291</td>
</tr>
<tr>
<td>registered nurses</td>
<td>417</td>
</tr>
<tr>
<td>reiter's disease</td>
<td>69</td>
</tr>
<tr>
<td>renal clearance</td>
<td>405</td>
</tr>
<tr>
<td>failure</td>
<td>157, 170, 224</td>
</tr>
<tr>
<td>function</td>
<td>199</td>
</tr>
<tr>
<td>trauma</td>
<td>239</td>
</tr>
<tr>
<td>renovascular surgery</td>
<td>239</td>
</tr>
<tr>
<td>retinoids</td>
<td>40</td>
</tr>
<tr>
<td>reverse transcriptase inhibitor</td>
<td>308, 309</td>
</tr>
<tr>
<td>ro</td>
<td>305</td>
</tr>
<tr>
<td>role conception</td>
<td>417</td>
</tr>
<tr>
<td>development</td>
<td>414</td>
</tr>
<tr>
<td>rheumatoid arthritis</td>
<td>115, 420</td>
</tr>
<tr>
<td>rhinomanometry</td>
<td>257</td>
</tr>
<tr>
<td>SBP</td>
<td>150</td>
</tr>
<tr>
<td>scoring system</td>
<td>372</td>
</tr>
<tr>
<td>serum creatinine</td>
<td>170</td>
</tr>
<tr>
<td>silent ischemia</td>
<td>120</td>
</tr>
<tr>
<td>silicone iol</td>
<td>266</td>
</tr>
<tr>
<td>skin test</td>
<td>143</td>
</tr>
<tr>
<td>smoking cessation</td>
<td>163</td>
</tr>
<tr>
<td>spinal fixator</td>
<td>261, 277</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>457</td>
</tr>
</tbody>
</table>
spirochete........................................ 300
steroid ........................................... 179,216
dependent ........................................ 109
stress fractures .................................. 287
subarachnoid block............................... 415
sucrose ........................................... 160
surface EMG........................................ 246,248
temperature ........................................ 278
suture techniques training...................... 413
swine ............................................. 275
tamponade ......................................... 146
tb testing .......................................... 430
tendon healing ...................................... 240
tension headache ................................... 272
theophylline ........................................ 48,65,86
therapy ............................................. 320
thermography ....................................... 143,242,248,264,278
thromboembolic disorders ....................... 362
thoracostomy ....................................... 146
thyroid function tests............................ 71,100
gland .............................................. 71
hormones .......................................... 34
disease ............................................ 71
tonsillectomy ....................................... 216
toxoplasmic encephalitis ......................... 226
transplantation ..................................... 50
transurethral resection of prostate ............ 279
traumatic facial palsy ............................. 262
ultrastructure ...................................... 411
ultraviolet light .................................. 306
umbilical artery acid-base ....................... 415
unstable coronary artery disease ............... 112
urodynamics ....................................... 180
variceal hemorrhage ................................ 154
vasopressin ........................................ 154
verapamil .......................................... 363
veterinary personnel training .................. 301
vitamin b-12 ...................................... 283
d .................................................... 86
vitamin d rifampin ................................ 77
deficiency ......................................... 77
water electrolyte balance ....................... 46
imbalance .......................................... 46
water purification tablets....................... 100
x-ray microanalysis ............................... 411
ZDV ............................................... 94
DISTRIBUTION LIST

2 Copies
Commander
US Army Medical Research Command
Fort Detrick, ATTN: SGRD-AJ
Frederick, MD 21701

2 Copies
Commander
US Army Medical Research Command
Fort Detrick, ATTN: SGRD-HR
Frederick, MD 21701

12 Copies
Defense Documentation Center
ATTN: DDC-TCA, Cameron Station
Alexandria, Va 22314

2 Copies
Commander
HQ, US Army Health Services Command
ATTN: HSHN-I
Fort Sam Houston, TX 78234-6060

1 Copy
Superintendent
Academy of Health Sciences, US Army
ATTN: AHS-COM
Fort Sam Houston, TX 78234-6000

1 Copy
Each US Army Medical Center